0001593034-16-000082.txt : 20161108 0001593034-16-000082.hdr.sgml : 20161108 20161108121335 ACCESSION NUMBER: 0001593034-16-000082 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 98 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161108 DATE AS OF CHANGE: 20161108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Endo International plc CENTRAL INDEX KEY: 0001593034 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36326 FILM NUMBER: 161980500 BUSINESS ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 353-1-268-2000 MAIL ADDRESS: STREET 1: MINERVA HOUSE, SIMMONSCOURT ROAD STREET 2: BALLSBRIDGE CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Endo International Ltd DATE OF NAME CHANGE: 20131203 FORMER COMPANY: FORMER CONFORMED NAME: Sportwell Ltd DATE OF NAME CHANGE: 20131126 10-Q 1 endp-9302016x10q.htm 10-Q 9.30.2016 Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________________
FORM 10-Q
_______________________________
(Mark One)
x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2016
OR
o    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM              TO
Commission file number: 001-36326
____________________________________________________________________________________________
ENDO INTERNATIONAL PLC
(Exact Name of Registrant as Specified in Its Charter)
____________________________________________________________________________________________
Ireland
68-0683755
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
 
 
First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland
Not applicable
(Address of Principal Executive Offices)
(Zip Code)
011-353-1-268-2000
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
The NASDAQ Global Market, The Toronto Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
None
____________________________________________________________________________________________
Indicate by check whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x    No   o
Indicate by check whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes x     No   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
x
Accelerated filer
o
 
 
 
 
Non-accelerated filer
o  (Do not check if a smaller reporting company)
Smaller reporting company
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    YES  o    NO   x
Indicate the number of shares outstanding of each of the issuer’s classes of ordinary shares, as of the latest practical date.
Ordinary shares, $0.0001 par value
Number of ordinary shares outstanding as of
November 1, 2016
:
222,876,797




ENDO INTERNATIONAL PLC

INDEX
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



FORWARD-LOOKING STATEMENTS
Statements contained or incorporated by reference in this document contain information that includes or is based on “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements, including estimates of future revenues, future expenses, future net income and future net income per share, contained in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which is included in this document, are subject to risks and uncertainties. Forward-looking statements include the information concerning our possible or assumed results of operations. We have tried, whenever possible, to identify such statements by words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “projected,” “forecast,” “will,” “may,” or similar expressions. We have based these forward-looking statements on our current expectations and projections about the growth of our business, our financial performance, and the development of our industry. Because these statements reflect our current views concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in Part II, Item 1A of this document and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, as supplemented and amended by risk factors previously disclosed by us in Part II, Item 1A under the caption “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, and as otherwise enumerated herein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained or incorporated by reference in this document.
We do not undertake any obligation to update our forward-looking statements after the date of this document for any reason, even if new information becomes available or other events occur in the future, except as may be required under applicable securities law. You are advised to consult any further disclosures we make on related subjects in our reports filed with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval. Also note that, under the caption “Risk Factors” in Part II, Item 1A of this document and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, as supplemented and amended by the risk factors previously disclosed by us in Part II, Item 1A under the caption “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, we provide a cautionary discussion of the risks, uncertainties and possibly inaccurate assumptions relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We note these factors for investors as permitted by Section 27A of the Securities Act and Section 21E of the Exchange Act. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this to be a complete discussion of all potential risks or uncertainties.

i

PART I. FINANCIAL INFORMATION
Item 1.        Financial Statements
ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share data)
 
September 30,
2016
 
December 31,
2015
ASSETS
 
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
561,577

 
$
272,348

Restricted cash and cash equivalents
275,745

 
585,379

Marketable securities
—

 
34

Accounts receivable
669,815

 
1,014,808

Inventories, net
624,302

 
752,493

Prepaid expenses and other current assets
75,568

 
55,052

Income taxes receivable
40,429

 
735,901

Assets held for sale (NOTE 3)
—

 
36,522

Total current assets
$
2,247,436

 
$
3,452,537

MARKETABLE SECURITIES
2,361

 
3,855

PROPERTY, PLANT AND EQUIPMENT, NET
671,618

 
675,624

GOODWILL
7,411,620

 
7,299,354

OTHER INTANGIBLES, NET
6,975,578

 
7,828,942

DEFERRED INCOME TAXES
3,733

 
10,423

OTHER ASSETS
371,156

 
79,601

TOTAL ASSETS
$
17,683,502

 
$
19,350,336

LIABILITIES AND SHAREHOLDERS’ EQUITY
 
 
 
CURRENT LIABILITIES:
 
 
 
Accounts payable
$
306,096

 
$
347,503

Accrued expenses
945,412

 
1,162,612

Current portion of legal settlement accrual
1,280,785

 
1,606,726

Current portion of long-term debt
124,250

 
328,705

Income taxes payable
5,759

 
8,551

Liabilities held for sale (NOTE 3)
—

 
20,215

Total current liabilities
$
2,662,302

 
$
3,474,312

DEFERRED INCOME TAXES
178,271

 
871,040

LONG-TERM DEBT, LESS CURRENT PORTION, NET
8,170,618

 
8,251,657

LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION, NET
—

 
549,098

OTHER LIABILITIES
621,450

 
236,253

COMMITMENTS AND CONTINGENCIES (NOTE 12)


 


SHAREHOLDERS’ EQUITY:
 
 
 
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued
49

 
43

Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 222,859,941 and 222,124,282 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively
22

 
22

Additional paid-in capital
8,733,360

 
8,693,385

Accumulated deficit
(2,350,425
)
 
(2,341,215
)
Accumulated other comprehensive loss
(332,145
)
 
(384,205
)
Total Endo International plc shareholders’ equity
$
6,050,861

 
$
5,968,030

Noncontrolling interests
—

 
(54
)
Total shareholders’ equity
$
6,050,861

 
$
5,967,976

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
$
17,683,502

 
$
19,350,336

See Notes to Condensed Consolidated Financial Statements.

1

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
TOTAL REVENUES
$
884,335

 
$
745,727

 
$
2,768,761

 
$
2,195,021

COSTS AND EXPENSES:
 
 
 
 
 
 
 
Cost of revenues
557,472

 
442,459

 
1,878,395

 
1,265,583

Selling, general and administrative
186,735

 
163,221

 
558,160

 
529,290

Research and development
44,885

 
21,327

 
137,166

 
58,208

Litigation-related and other contingencies, net
18,256

 
—

 
28,715

 
19,875

Asset impairment charges
93,504

 
923,607

 
263,080

 
1,000,850

Acquisition-related and integration items
19,476

 
(27,688
)
 
80,201

 
51,177

OPERATING LOSS FROM CONTINUING OPERATIONS
$
(35,993
)
 
$
(777,199
)
 
$
(176,956
)
 
$
(729,962
)
INTEREST EXPENSE, NET
112,184

 
96,446

 
340,896

 
250,196

LOSS ON EXTINGUISHMENT OF DEBT
—

 
40,909

 
—

 
41,889

OTHER (INCOME) EXPENSE, NET
(2,866
)
 
50,091

 
402

 
62,589

LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX
$
(145,311
)
 
$
(964,645
)
 
$
(518,254
)
 
$
(1,084,636
)
INCOME TAX EXPENSE (BENEFIT)
46,185

 
(160,939
)
 
(627,807
)
 
(340,528
)
(LOSS) INCOME FROM CONTINUING OPERATIONS
$
(191,496
)

$
(803,706
)

$
109,553


$
(744,108
)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)
(27,423
)
 
(246,782
)
 
(118,747
)
 
(632,624
)
CONSOLIDATED NET LOSS
$
(218,919
)
 
$
(1,050,488
)
 
$
(9,194
)
 
$
(1,376,732
)
Less: Net income (loss) attributable to noncontrolling interests
—

 
(46
)
 
16

 
(153
)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC
$
(218,919
)
 
$
(1,050,442
)
 
$
(9,210
)
 
$
(1,376,579
)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
 
 
 
 
 
 
 
Continuing operations
$
(0.86
)
 
$
(3.84
)
 
$
0.49

 
$
(3.96
)
Discontinued operations
(0.12
)
 
(1.18
)
 
(0.53
)
 
(3.36
)
Basic
$
(0.98
)
 
$
(5.02
)
 
$
(0.04
)
 
$
(7.32
)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—DILUTED:
 
 
 
 
 
 
 
Continuing operations
$
(0.86
)
 
$
(3.84
)
 
$
0.49

 
$
(3.96
)
Discontinued operations
(0.12
)
 
(1.18
)
 
(0.53
)
 
(3.36
)
Diluted
$
(0.98
)
 
$
(5.02
)
 
$
(0.04
)
 
$
(7.32
)
WEIGHTED AVERAGE SHARES:
 
 
 
 
 
 
 
Basic
222,767

 
209,274

 
222,579

 
188,085

Diluted
222,767

 
209,274

 
223,060

 
188,085

See Notes to Condensed Consolidated Financial Statements.

2

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (UNAUDITED)
(In thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
CONSOLIDATED NET LOSS
 
 
$
(218,919
)
 
 
 
$
(1,050,488
)
 
 
 
$
(9,194
)
 
 
 
$
(1,376,732
)
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net unrealized gain (loss) on securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain (loss) arising during the period
$
152

 
 
 
$
(403
)
 
 
 
$
(855
)
 
 
 
$
1,311

 
 
Less: reclassification adjustments for (gain) loss realized in net loss
(6
)
 
146

 
—

 
(403
)
 
(6
)
 
(861
)
 
—

 
1,311

Foreign currency translation (loss) gain:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign currency (loss) gain arising during the period
(6,195
)
 
 
 
(84,952
)
 
 
 
$
52,959

 
 
 
$
(208,299
)
 
 
Less: reclassification adjustments for loss realized in net loss
—

 
(6,195
)
 
25,715

 
(59,237
)
 
—

 
52,959

 
25,715

 
(182,584
)
OTHER COMPREHENSIVE (LOSS) INCOME
 
 
$
(6,049
)
 
 
 
$
(59,640
)
 
 
 
$
52,098

 
 
 
$
(181,273
)
CONSOLIDATED COMPREHENSIVE (LOSS) INCOME
 
 
$
(224,968
)
 
 
 
$
(1,110,128
)
 
 
 
$
42,904

 
 
 
$
(1,558,005
)
Less: Net income (loss) attributable to noncontrolling interests
 
 
—

 
 
 
(46
)
 
 
 
16

 
 
 
(153
)
Less: Other comprehensive income (loss) attributable to noncontrolling interests
 
 
—

 
 
 
(32
)
 
 
 
38

 
 
 
(581
)
COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC
 
 
$
(224,968
)
 
 
 
$
(1,110,050
)
 
 
 
$
42,850

 
 
 
$
(1,557,271
)
See Notes to Condensed Consolidated Financial Statements.

3

ENDO INTERNATIONAL PLC
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
Nine Months Ended September 30,
 
2016
 
2015
OPERATING ACTIVITIES:
 
 
 
Consolidated net loss
$
(9,194
)
 
$
(1,376,732
)
Adjustments to reconcile consolidated net loss to Net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
716,332

 
381,952

Inventory step-up
99,099

 
122,714

Share-based compensation
44,567

 
48,537

Amortization of debt issuance costs and discount
21,483

 
16,440

Provision for bad debts
6,264

 
1,970

Deferred income taxes
(613,318
)
 
(335,171
)
Net loss on disposal of property, plant and equipment
4,639

 
1,785

Change in fair value of contingent consideration
24,790

 
(83,605
)
Loss on extinguishment of debt
—

 
41,889

Prepayment penalty on long-term debt
—

 
(17,496
)
Asset impairment charges
284,409

 
1,244,672

Gain on sale of business and other assets
(791
)
 
(13,550
)
Changes in assets and liabilities which (used) provided cash:
 
 
 
Accounts receivable
342,012

 
(220,973
)
Inventories
22,215

 
(31,823
)
Prepaid and other assets
(289,631
)
 
(30,568
)
Accounts payable
(35,406
)
 
(1,767
)
Accrued expenses
(616,361
)
 
211,970

Other liabilities
(250,746
)
 
(238,048
)
Income taxes payable/receivable
693,014

 
100,372

Net cash provided by (used in) operating activities
$
443,377

 
$
(177,432
)
INVESTING ACTIVITIES:
 
 
 
Purchases of property, plant and equipment
(88,087
)
 
(50,944
)
Proceeds from sale of intellectual property and property, plant and equipment
2,578

 
—

Acquisitions, net of cash acquired
(30,394
)
 
(7,514,425
)
Proceeds from sale of marketable securities and investments
34

 
347

Proceeds from notes receivable
—

 
17

Patent acquisition costs and license fees
(19,206
)
 
—

Proceeds from sale of business, net
4,108

 
1,588,779

Increase in restricted cash and cash equivalents
(588,455
)
 
(533,441
)
Decrease in restricted cash and cash equivalents
898,288

 
549,171

Net cash provided by (used in) investing activities
$
178,866

 
$
(5,960,496
)

4

 
Nine Months Ended September 30,
 
2016
 
2015
FINANCING ACTIVITIES:
 
 
 
Proceeds from issuance of notes
—

 
2,835,000

Proceeds from issuance of term loans
—

 
2,800,000

Principal payments on notes
—

 
(499,875
)
Principal payments on term loans
(76,000
)
 
(459,626
)
Proceeds from draw of revolving debt
—

 
300,000

Repayments of revolving debt
(225,000
)
 
(300,000
)
Principal payments on other indebtedness, net
(4,634
)
 
(8,931
)
Repurchase of convertible senior subordinated notes
—

 
(247,760
)
Sale of AMSH Inc. mandatorily redeemable preferred shares
—

 
60,000

Deferred financing fees
(500
)
 
(114,440
)
Payment for contingent consideration
(23,807
)
 
(20,264
)
Tax benefits of share awards
—

 
19,878

Payments of tax withholding for restricted shares
(10,532
)
 
(15,268
)
Exercise of options
1,952

 
25,068

Issuance of ordinary shares related to the employee stock purchase plan
4,010

 
3,328

Issuance of ordinary shares
—

 
2,300,000

Payments related to the issuance of ordinary shares
—

 
(66,956
)
Cash buy-out of noncontrolling interests
—

 
(39,608
)
Net cash (used in) provided by financing activities
$
(334,511
)
 
$
6,570,546

Effect of foreign exchange rate
$
1,497

 
$
(5,260
)
NET INCREASE IN CASH AND CASH EQUIVALENTS
$
289,229

 
$
427,358

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
272,348

 
408,753

CASH AND CASH EQUIVALENTS, END OF PERIOD
$
561,577

 
$
836,111

SUPPLEMENTAL INFORMATION:
 
 
 
Cash received from income taxes, net
$
702,786

 
$
49,832

Cash paid into Qualified Settlement Funds for mesh legal settlements
$
587,782

 
$
526,785

Cash paid out of Qualified Settlement Funds for mesh legal settlements
$
898,288

 
$
509,563

Other cash distributions for mesh legal settlements
$
5,561

 
$
16,312

SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Purchases of property, plant and equipment financed by capital leases
$
716

 
$
4,234

Accrual for purchases of property, plant and equipment
$
2,201

 
$
2,719

Acquisition financed by ordinary shares
$
—

 
$
2,844,969

Repurchase of convertible senior subordinated notes financed by ordinary shares
$
—

 
$
625,483

See Notes to Condensed Consolidated Financial Statements.

5

ENDO INTERNATIONAL PLC
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2016

NOTE 1. BASIS OF PRESENTATION
The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary to a fair statement of the Company’s financial position as of September 30, 2016 and the results of our operations and our cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2015 was derived from the audited financial statements.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our,” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.
Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on branded and generic pharmaceuticals.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2015.
NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017 and the Company currently plans to adopt it on January 1, 2018. In March and April 2016, the FASB issued ASU No. 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” and ASU No. 2016-10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” respectively, which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which amends certain narrow aspects of Topic 606. The Company is currently evaluating the impact of these standards on the Company’s consolidated results of operations and financial position, including possible transition alternatives.
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” (ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively and early application is permitted. The Company is currently evaluating the impact of ASU 2015-11 on the Company’s consolidated results of operations and financial position.
In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company’s consolidated results of operations and financial position.

6

In March 2016, the FASB issued ASU No. 2016-09 “Improvements to Employee Share-Based Payment Accounting” (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (a) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (b) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (c) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (d) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation, (e) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (f) electing whether to account for forfeitures of share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-09 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on the Company’s consolidated results of operations and financial position.
In August 2016, the FASB issued ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments” (ASU 2016-15). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-15 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-15 on the Company’s consolidated statement of cash flows.
In October 2016, the FASB issued ASU No. 2016-16 “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company is currently evaluating the impact of ASU 2016-16 on the Company’s consolidated results of operations and financial position.
NOTE 3. DISCONTINUED OPERATIONS AND HELD FOR SALE
American Medical Systems
On February 24, 2015, the Company’s Board of Directors (Board of Directors) approved a plan to sell the Company’s American Medical Systems Holdings, Inc. (AMS) business, which comprised the entirety of our former Devices segment. The AMS business was comprised of the Men’s Health and Prostate Health business as well as the Women’s Health business (referred to herein as Astora). On August 3, 2015, the Company sold the Men’s Health and Prostate Health business to Boston Scientific Corporation (Boston Scientific) for $1.65 billion, with $1.60 billion paid upfront in cash and $50.0 million in cash contingent on Boston Scientific achieving certain product revenue milestones in the Men’s Health and Prostate Health business in 2016.
In addition to selling the Men’s Health and Prostate Health business in 2015, as of December 31, 2015 and continuing into 2016, the Company was actively pursuing a sale of the Astora business with the Company in active negotiations with multiple potential buyers. The majority of the remaining assets and liabilities of the AMS business, which were related to the Astora business, were classified as held for sale in the Consolidated Balance Sheet as of December 31, 2015 in the Company’s Form 10-K filed with the Securities and Exchange Commission on February 29, 2016. Certain of AMS’s assets and liabilities, primarily with respect to its product liability accrual related to vaginal mesh cases, the related Qualified Settlement Funds and certain intangible and fixed assets, were not classified as held for sale based on management’s expectation that these assets and liabilities would remain with the Company.
On February 24, 2016, the Board of Directors resolved to wind down the Company’s Astora business as it did not align with the Company’s strategic direction and to reduce the additional exposure to mesh-related product liability. The Company conducted a wind down process to transition physicians to alternative products during the first quarter of 2016. The Company ceased business operations of Astora on March 31, 2016 and exited its AMS business. As a result, as of March 31, 2016 and periods thereafter, the remaining assets and liabilities of the AMS business, which were related to the Astora business, were no longer classified as held for sale in the Condensed Consolidated Balance Sheets. In accordance with applicable accounting guidance, the Company also reclassified the Astora assets and liabilities previously presented as held for sale as of December 31, 2015 to held and used on its Condensed Consolidated Balance Sheets.
The operating results of the AMS business are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented.

7

The following table provides the operating results of the Discontinued operations, net of tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Revenue
$
387

 
$
43,705

 
$
30,101

 
$
282,310

Litigation related and other contingencies, net
$
17,705

 
$
—

 
$
20,155

 
$
273,752

Asset impairment charges
$
—

 
$
2,200

 
$
21,328

 
$
224,953

Gain on sale of business
$
—

 
$
13,550

 
$
—

 
$
13,550

Loss from discontinued operations before income taxes
$
(27,309
)
 
$
(18,775
)
 
$
(118,633
)
 
$
(506,275
)
Income tax expense
$
—

 
$
228,007

 
$
—

 
$
126,349

Discontinued operations, net of tax
$
(27,309
)
 
$
(246,782
)
 
$
(118,633
)
 
$
(632,624
)
As a result of the Astora wind down initiative announced in the first quarter of 2016, the Company incurred asset impairment charges of $21.3 million during the nine months ended September 30, 2016. See below for discussion of our material wind down initiatives.
The following table provides the Depreciation and amortization and Purchases of property, plant and equipment of AMS for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash flows from discontinued operating activities:
 
 
 
Net loss
$
(118,633
)
 
$
(632,624
)
Depreciation and amortization
$
—

 
$
11,555

Net cash used in discontinued investing activities:
 
 
 
Purchases of property, plant and equipment
$
(138
)
 
$
(2,182
)
Astora Restructuring
The Astora wind down process includes a restructuring initiative implemented during the three months ended March 31, 2016, which includes the reduction of the Astora workforce consisting of approximately 250 employees. Under this restructuring initiative, separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.
As a result of the Astora restructuring initiative, the Company incurred expenses of $1.8 million and $68.4 million during the three and nine months ended September 30, 2016, respectively, consisting of employee separation, retention and other benefit-related costs, asset impairment charges, contract termination charges and other general restructuring costs. There were no restructuring expenses related to this initiative during the three and nine months ended September 30, 2015. The Company anticipates there will be additional pre-tax restructuring expenses of $2.4 million related to employee separation, retention and other benefit-related costs, contract termination charges and other restructuring costs. The majority of these actions have been completed as of September 30, 2016 and substantially all cash payments will be made by the end of 2016. These restructuring costs are included in Discontinued operations in the Condensed Consolidated Statements of Operations.
A summary of expenses related to the Astora restructuring initiative is included below for the three and nine months ended September 30, 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
Employee separation, retention and other benefit-related costs
$
715

 
$
22,181

Asset impairment charges
—

 
21,328

Contract termination charges
769

 
10,569

Other wind down costs
285

 
14,315

Total
$
1,769

 
$
68,393


8

The liability related to the Astora restructuring initiative totaled $16.1 million as of September 30, 2016 and is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Contract Termination Charges
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
—

 
$
—

 
$
—

 
$
—

Expenses
22,181

 
10,569

 
7,778

 
40,528

Cash distributions
(13,393
)
 
(5,743
)
 
(5,276
)
 
(24,412
)
Liability balance as of September 30, 2016
$
8,788

 
$
4,826

 
$
2,502

 
$
16,116

NOTE 4. RESTRUCTURING
U.S. Generic Pharmaceuticals Restructuring
2015 U.S Generic Pharmaceuticals Restructuring
In connection with the acquisition of Par Pharmaceutical Holdings, Inc. and its subsidiaries (together herein Par) on September 25, 2015, we implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning the Company’s U.S. Generic Pharmaceuticals segment sales, sales support, management activities and staffing, which resulted in separation benefits to certain U.S. Generic Pharmaceuticals employees. The cost reduction initiatives included a reduction in headcount of approximately 6% of the U.S. Generic Pharmaceuticals workforces. Under this restructuring initiative (the 2015 U.S. Generic Pharmaceuticals restructuring initiative), separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.
As a result of the 2015 U.S. Generic Pharmaceuticals restructuring initiative, the Company incurred restructuring expenses of $0.6 million and $5.2 million during the three and nine months ended September 30, 2016, respectively, consisting of employee separation, retention and other benefit-related costs. The Company does not anticipate any further additional pre-tax restructuring expenses related to employee separation, retention and other benefit-related costs. These actions are expected to be completed by October 31, 2016, with substantially all cash payments made by the end of 2016. In addition, the Company anticipates there will be additional pre-tax restructuring expenses of approximately $4.9 million related to accelerated depreciation on certain assets. These restructuring costs are allocated to the U.S. Generic Pharmaceuticals segment, and are primarily included in Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the 2015 U.S. Generic Pharmaceuticals restructuring initiative totaled $10.0 million and $17.9 million at September 30, 2016 and December 31, 2015, respectively. At September 30, 2016, this liability is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
17,914

Expenses
5,229

Cash distributions
(13,114
)
Liability balance as of September 30, 2016
$
10,029

2016 U.S Generic Pharmaceuticals Restructuring
As part of the ongoing U.S. Generic Pharmaceuticals integration efforts, in May 2016 we announced a restructuring initiative to optimize our product portfolio and rationalize our manufacturing sites to expand product margins (the 2016 U.S. Generic Pharmaceuticals restructuring initiative). These measures include certain cost savings initiatives, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility. On October 31, 2016, we entered into a definitive agreement to sell the Charlotte, North Carolina facility for proceeds of $14 million, subject to purchase price adjustments as defined in the agreement. The Company expects to record an impairment charge during the fourth quarter of 2016 of approximately $10 million related to fixed assets associated with the sale. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions.

9

As a result of the 2016 U.S. Generic Pharmaceuticals restructuring initiative, the Company has incurred total restructuring expenses of $159.5 million through September 30, 2016 and expects to incur additional restructuring-related expenses of approximately $30 million consisting of accelerated depreciation, employee separation, retention and other benefit-related costs and certain other charges. The Company anticipates these actions will be completed by September 2017, with substantially all cash payments made by the end of 2017. Under this restructuring initiative, separation costs will be expensed ratably over the requisite service period, if any.
Restructuring charges of $13.3 million and $159.5 million recorded during the three and nine months ended September 30, 2016, respectively, consisted of certain intangible asset impairment charges of $100.3 million and charges to increase excess inventory reserves of $33.3 million during the nine months ended September 30, 2016, charges relating to employee separation, retention and other benefit-related costs of $7.0 million and $13.4 million, accelerated depreciation of $3.4 million and $6.8 million and other charges of $3.0 million and $5.7 million during the three and nine months ended September 30, 2016, respectively. These charges are included in the U.S. Generic Pharmaceuticals segment, and are included in Asset impairment charges, Cost of revenues, and Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative totaled $8.1 million at September 30, 2016 and is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to the accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
—

Expenses
13,398

Cash payments
(5,274
)
Liability balance as of September 30, 2016
$
8,124

Auxilium Restructuring
In connection with the acquisition of Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals LLC hereafter referred to as Auxilium) on January 29, 2015, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning our sales, sales support, management activities and staffing, which included separation benefits to former Auxilium employees, in addition to the closing of duplicative facilities. The cost reduction initiatives included a reduction in headcount of approximately 40% of the former Auxilium workforce. For former Auxilium employees that agreed to continue employment with the Company for a merger transition period, the separation costs payable upon completion of their retention period were expensed over their respective retention period. The Company does not anticipate there will be additional material pre-tax restructuring expenses related to this initiative. The Company anticipates that substantially all employee separation, retention and other benefit-related costs cash payments relating to this initiative will be made by the end of 2016. The remainder of the cash payments will be made over the remaining lease term of Auxilium’s former corporate headquarters in Chesterbrook, Pennsylvania. These restructuring costs are included in the U.S. Branded Pharmaceuticals segment, and are primarily included in Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the Auxilium restructuring initiative totaled $5.9 million and $12.3 million at September 30, 2016 and December 31, 2015, respectively, and is included in Accrued expenses and Other liabilities in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
5,353

 
$
6,910

 
$
12,263

Cash distributions
(5,174
)
 
(1,143
)
 
(6,317
)
Liability balance as of September 30, 2016
$
179

 
$
5,767

 
$
5,946

NOTE 5. ACQUISITIONS
For each of the acquisitions described below, except for Auxilium, Par and Aspen Holdings, the estimated fair values of the net assets acquired are provisional as of September 30, 2016 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements. Accordingly, the measurement of the assets acquired and liabilities assumed may change upon finalization of the Company’s valuations and completion of the purchase price allocations, all of which are expected to occur no later than one year from the respective acquisition dates.

10

Auxilium Pharmaceuticals, Inc.
On January 29, 2015 (the Auxilium Acquisition Date), the Company acquired all of the outstanding shares of common stock of Auxilium, a fully integrated specialty biopharmaceutical company emerging as a leader in the men’s healthcare sector with a strategically focused product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas, in a transaction valued at $2.6 billion. The Company believed that Auxilium would be highly complementary to its branded pharmaceuticals business with significant opportunities to leverage Auxilium’s leading presence in men’s health, as well as the Company’s R&D capabilities and financial resources, to accelerate the growth of Auxilium’s XIAFLEX® and its other products.
The operating results of Auxilium are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and the operating results from the Auxilium Acquisition Date are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015.
The Company recognized no acquisition-related transaction costs associated with the Auxilium acquisition during the nine months ended September 30, 2016. The Company recognized acquisition-related transaction costs associated with the Auxilium acquisition during the nine months ended September 30, 2015 totaling $23.1 million. These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Condensed Consolidated Statements of Operations.
The amounts of Auxilium Revenue and Net loss included in the Company’s Condensed Consolidated Statements of Operations from and including January 29, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
237,807

Net loss attributable to Endo International plc
$
(257,597
)
Basic and diluted net loss per share
$
(1.37
)
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on January 1, 2015 for the nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
Revenue
$
2,218,596

Net loss attributable to Endo International plc
$
(1,395,162
)
Basic and diluted net loss per share
$
(7.42
)
These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Auxilium to reflect factually supportable adjustments that give effect to events that are directly attributable to the Auxilium acquisition assuming the Auxilium acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $1.1 million for the nine months ended September 30, 2015. In addition, the adjustments include additional intangible amortization, net of tax, which would have been charged assuming the Company’s estimated fair value of the intangible assets. The adjustment to the amortization expense for the nine months ended September 30, 2015 increased the expense by $6.2 million.
Acquisition of Par Pharmaceutical Holdings, Inc.
On September 25, 2015 (Par Acquisition Date), the Company acquired Par, a specialty pharmaceutical company that develops, licenses, manufactures, markets and distributes innovative and cost-effective pharmaceuticals with a focus on high-barrier-to-entry products and first-to-file or first-to-market opportunities, for total consideration of $8.14 billion, including the assumption of Par debt. The consideration included the Company’s 18,069,899 ordinary shares valued at $1.33 billion.

11

The operating results of Par are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016. The amounts of Par Revenue and Net loss attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including September 25, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
23,413

Net loss attributable to Endo International plc
$
(17,441
)
Basic and diluted net loss per share
$
(0.09
)
The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date, including measurement period adjustments since the fair values presented in the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016, (in thousands):
 
September 25, 2015
 
Measurement period adjustments
 
September 25, 2015
(As adjusted)
Cash and cash equivalents
$
215,612

 
$
—

 
$
215,612

Accounts and other receivables
530,664

 
(13,755
)
 
516,909

Inventories
330,406

 
(1,849
)
 
328,557

Prepaid expenses and other current assets
31,124

 
—

 
31,124

Deferred income tax assets, current
14,652

 
30,176

 
44,828

Property, plant and equipment
256,293

 
4,744

 
261,037

Intangible assets
3,627,000

 
(154,500
)
 
3,472,500

Other assets
8,477

 
—

 
8,477

Total identifiable assets
$
5,014,228

 
$
(135,184
)
 
$
4,879,044

Accounts payable and accrued expenses
$
551,614

 
$
(511
)
 
$
551,103

Deferred income tax liabilities
1,093,779

 
(44,961
)
 
1,048,818

Other liabilities
16,057

 
2,556

 
18,613

Total liabilities assumed
$
1,661,450

 
$
(42,916
)
 
$
1,618,534

Net identifiable assets acquired
$
3,352,778

 
$
(92,268
)
 
$
3,260,510

Goodwill
4,782,876

 
92,268

 
4,875,144

Net assets acquired
$
8,135,654

 
$
—

 
$
8,135,654

Our measurement period adjustments for Par were complete as of September 30, 2016. As a result of the measurement period adjustments recorded above, the Company recorded a reduction of $3.8 million of expense, $3.1 million related to the amortization of intangible assets and $0.7 million related to the amortization of inventory step-up, during the nine months ended September 30, 2016. There were no adjustments of expense recorded during the three months ended September 30, 2016.

12

The valuation of the intangible assets acquired and related amortization periods are as follows:
 
Valuation (in millions)
 
Amortization period (in years)
Developed Technology:
 
 
 
Vasostrict®
$
556.0

 
8
Aplisol®
312.4

 
11
Developed - Other - Non-Partnered (Generic Non-Injectable)
230.4

 
7
Developed - Other - Partnered (Combined)
164.4

 
7
Nascobal®
118.3

 
9
Developed - Other - Non-Partnered (Generic Injectable)
116.4

 
10
Other
517.9

 
9
Total
$
2,015.8

 
 
In Process Research & Development (IPR&D):
 
 
 
IPR&D 2019 Launch
$
401.0

 
n/a
IPR&D 2018 Launch
283.8

 
n/a
Ezetimibe
147.6

 
n/a
IPR&D 2016 Launch
133.3

 
n/a
Ephedrine Sulphate
128.6

 
n/a
Neostigmine vial
118.6

 
n/a
Other
243.8

 
n/a
Total
$
1,456.7

 
n/a
Total other intangible assets
$
3,472.5

 
n/a
The fair values of the developed technology and IPR&D assets were estimated using a discounted present value income approach. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company used cash flows discounted at rates ranging from 9% to 10.5%, which were considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions.
The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, the assembled workforce of Par and other factors. At the acquisition date, approximately $34.2 million of goodwill was expected to be deductible for income tax purposes.
Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets and inventory step-up.
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on January 1, 2015 for the three and nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
 
 
Revenue
$
1,053,654

 
$
3,194,413

Net loss attributable to Endo International plc
$
(1,084,031
)
 
$
(1,475,667
)
Basic and diluted net loss per share
$
(5.18
)
 
$
(7.85
)

13

These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Par to reflect factually supportable adjustments that give effect to events that are directly attributable to the Par acquisition assuming the Par acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $4.9 million and $11.7 million for the three and nine months ended September 30, 2015, respectively. In addition, the adjustments include additional intangible amortization, net of tax, that would have been charged assuming the Company’s estimated fair value of the intangible assets. An adjustment to the amortization expense for the three and nine months ended September 30, 2015 increased the expense by $44.8 million and $129.2 million, respectively.
Aspen Holdings
On October 1, 2015, the Company acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutic areas from a subsidiary of Aspen Pharmacare Holdings Ltd, a leading publicly-traded South African company that supplies branded and generic products in more than 150 countries, and from GlaxoSmithKline plc (GSK) for total consideration of approximately $135.6 million (the Aspen Asset Acquisition). The transaction expanded the Company’s presence in South Africa.
The fair values of the net identifiable assets acquired totaled $127.8 million, resulting in goodwill of $7.8 million, which was assigned to our International Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Aspen Asset Acquisition includes $118.4 million of intangible assets to be amortized over an average life of approximately 19 years, and inventory of $9.4 million. Our measurement period adjustments for Aspen Holdings were complete as of September 30, 2016.
The operating results of the Aspen Asset Acquisition are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016. There are no results included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015.
Pro forma results of operations have not been presented because the effect of the Aspen Asset Acquisition was not material.
Voltaren® Gel
The Company had exclusive U.S. marketing rights to Voltaren® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. (the 2008 Voltaren® Gel Agreement). On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement (the 2015 Voltaren® Gel Agreement) whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren® Gel and to launch an authorized generic of Voltaren® Gel effective July 1, 2016. Pursuant to the 2015 Voltaren® Gel Agreement, the former 2008 Voltaren® Gel Agreement expired on June 30, 2016 in accordance with its terms.
The Company is accounting for this transaction as a business combination as of the effective date in accordance with the relevant accounting literature. The Company acquired the product for consideration of $158.6 million, consisting of an upfront payment of $16.2 million and contingent cash consideration with an acquisition-date fair value of $142.4 million. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. See Note 10. License and Collaboration Agreements for further discussion of the License and Supply Agreement.
The preliminary fair values of the net identifiable assets acquired totaled approximately $159 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Voltaren® Gel acquisition includes approximately $159 million of identifiable developed technology intangible assets to be amortized over an average life of approximately 7 years.
The operating results of Voltaren® Gel under business combination accounting effective July 1, 2016 are included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2016. The results included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2015 were accounted for under the previous license and supply agreement, which was not treated as a business combination. The Consolidated Balance Sheets as of September 30, 2016 reflects the acquisition of Voltaren® Gel, effective July 1, 2016.
Other Acquisition
In addition to the business combinations disclosed above, the Company acquired the rights to commercialize a developed technology asset, which is being treated as a business combination. The asset was acquired during the third quarter of 2016 and was not individually material. Total consideration for this business combination was $19.7 million, consisting of an upfront payment of $14.2 million, deferred consideration with respect to acquired inventory of $1.0 million and contingent cash consideration with acquisition-date fair value of $4.5 million. The fair value of the net identifiable intangible asset acquired totaled $18.2 million.

14

NOTE 6. SEGMENT RESULTS
The reportable business segments in which the Company operates are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals and (3) International Pharmaceuticals. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income (loss) from continuing operations before income tax, which we define as loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; excess costs that will be eliminated pursuant to integration plans; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; certain non-cash interest expense; litigation-related and other contingent matters; gains or losses from early termination of debt activities; foreign currency gains or losses on intercompany financing arrangements; and certain other items that the Company believes do not reflect its core operating performance.
Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated.” The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate costs.
U.S. Branded Pharmaceuticals
Our U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as our urology and men’s health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm®, OPANA® ER, Voltaren® Gel, Percocet®, BELBUCA™, Aveed®, Supprelin® LA, and XIAFLEX®, among others.
U.S. Generic Pharmaceuticals
Our U.S. Generic Pharmaceuticals segment focuses on a differentiated product portfolio including high barrier-to-entry products, first-to-file or first-to-market opportunities, which are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.
International Pharmaceuticals
Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women’s health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs.

15

The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net revenues to external customers:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
279,843

 
$
304,778

 
$
876,998

 
$
905,198

U.S. Generic Pharmaceuticals
533,691

 
367,933

 
1,682,439

 
1,063,221

International Pharmaceuticals (1)
70,801

 
73,016

 
209,324

 
226,602

Total net revenues to external customers
$
884,335

 
$
745,727

 
$
2,768,761

 
$
2,195,021

 
 
 
 
 
 
 
 
Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
131,615

 
$
156,897

 
$
422,816

 
$
484,758

U.S. Generic Pharmaceuticals
$
228,717

 
$
177,961

 
$
655,453

 
$
507,507

International Pharmaceuticals
$
22,077

 
$
18,961

 
$
64,446

 
$
54,729

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
In 2015, we realigned certain costs amongst our International Pharmaceuticals segment, U.S. Branded Pharmaceuticals segment and Corporate unallocated costs based on how our chief operating decision maker reviews segment performance. As a result of this realignment, certain expenses included in our consolidated adjusted income (loss) from continuing operations before income tax for the three and nine months ended September 30, 2015 have been reclassified among our various segments to conform to current period presentation. The net impact of these reclassification adjustments increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $0.6 million and $7.5 million, respectively, with an offsetting $8.1 million decrease to International Pharmaceuticals segment costs for the three months ended September 30, 2015 and increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $1.7 million and $21.0 million respectively, with an offsetting $22.7 million decrease to International Pharmaceuticals segment costs for the nine months ended September 30, 2015.
There were no material revenues from external customers attributed to an individual country outside of the United States during the three and nine months ended September 30, 2016 or 2015.

16

The table below provides reconciliations of our consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Total consolidated loss from continuing operations before income tax
$
(145,311
)
 
$
(964,645
)
 
$
(518,254
)
 
$
(1,084,636
)
Corporate unallocated costs (1)
159,123

 
137,180

 
473,933

 
363,298

Amortization of intangible assets
211,548

 
121,503

 
636,061

 
333,759

Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans
14,208

 
42,919

 
111,787

 
131,783

Upfront and milestone payments to partners
1,770

 
9,261

 
5,875

 
14,063

Separation benefits and other cost reduction initiatives (2)
9,782

 
22,669

 
70,412

 
70,256

Impact of Voltaren® Gel generic competition
—

 
—

 
(7,750
)
 
—

Acceleration of Auxilium employee equity awards at closing
—

 
—

 
—

 
37,603

Certain litigation-related charges, net (3)
18,256

 
—

 
28,715

 
19,875

Asset impairment charges (4)
93,504

 
923,607

 
263,080

 
1,000,850

Acquisition-related and integration items (5)
19,476

 
(27,688
)
 
80,201

 
51,177

Loss on extinguishment of debt
—

 
40,909

 
—

 
41,889

Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Foreign currency impact related to the remeasurement of intercompany debt instruments
(114
)
 
(5,693
)
 
1,558

 
(23,991
)
Other, net
167

 
(10,484
)
 
(2,903
)
 
(6,153
)
Total segment adjusted income from continuing operations before income tax
$
382,409

 
$
353,819

 
$
1,142,715

 
$
1,046,994

__________
(1)
Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of $(9.0) million and increases of excess inventory reserves of $24.3 million during the three and nine months ended September 30, 2016, respectively, primarily related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative. The adjustment for the three months ended September 30, 2016 resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of $14.8 million and $30.0 million and other restructuring costs of $3.9 million and $16.1 million were recorded for the three and nine months ended September 30, 2016, respectively. Amounts in the comparable 2015 periods include employee separation costs of $20.8 million and $58.1 million, respectively, and a $7.9 million charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium’s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and Selling, general and administrative expense in our Condensed Consolidated Statements of Operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
These amounts include charges for Litigation-related and other contingencies, net as further described in Note 12. Commitments and Contingencies.
(4)
Asset impairment charges primarily relate to charges to write down intangible assets as further described in Note 9. Goodwill and Other Intangibles and goodwill impairment charges recorded during the third quarter of 2015.
(5)
Acquisition-related and integration items include costs directly associated with previous acquisitions of $7.9 million and $55.4 million for the three and nine months ended September 30, 2016, respectively, compared to $52.6 million and $134.8 million for the comparable 2015 periods. In addition, during the three and nine months ended September 30, 2016, there is a charge for changes in fair value of contingent consideration of $11.6 million and $24.8 million, respectively. During the three and nine months ended September 30, 2015, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of $80.3 million and $83.6 million, respectively.
Interest income and expense are considered corporate items and included in Corporate unallocated. Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

17

NOTE 7. FAIR VALUE MEASUREMENTS
Financial Instruments
The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds are structured to maintain the fund’s net asset value at $1.00 per unit, which assists in providing adequate liquidity upon demand by the holder. Money market funds pay dividends that generally reflect short-term interest rates. Thus, only the dividend yield fluctuates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.
Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
•
Level 1—Quoted prices in active markets for identical assets or liabilities.
•
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Marketable Securities
Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015.
At the time of purchase, we classify our marketable securities as either available-for-sale securities or trading securities, depending on our intent at that time. Available-for-sale and trading securities are carried at fair value with unrealized holding gains and losses recorded within other comprehensive income or net income, respectively. The Company reviews unrealized losses associated with available-for-sale securities to determine the classification as a “temporary” or “other-than-temporary” impairment. A temporary impairment results in an unrealized loss being recorded in other comprehensive income. An impairment that is viewed as other-than-temporary is recognized in net income. The Company considers various factors in determining the classification, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the issuer or investee, and the Company’s ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.
Equity and Cost Method Investments
As of September 30, 2016, the Company has investments that it accounts for using the equity or cost method of accounting totaling $9.1 million. The Company divested a joint venture investment owned through its Litha subsidiary during the three months ended March 31, 2016. The Company classified this joint venture investment as Assets held for sale as of December 31, 2015 in its Condensed Consolidated Balance Sheets.
With respect to its other equity or cost method investments, which are included in Other Assets in the Company’s Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015, the Company did not recognize any other-than-temporary impairments. The Company considered various factors, including the operating results of its equity method investments and the lack of an unrealized loss position on its cost method investments.
Acquisition-Related Contingent Consideration
The fair value of contingent consideration liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.

18

Recurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2016
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant 
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Time deposits
—

 
100,091

 
—

 
100,091

Equity securities
2,361

 
—

 
—

 
2,361

Total
$
67,861

 
$
100,091

 
$
—

 
$
167,952

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
108,778

 
$
108,778

Acquisition-related contingent consideration—long-term
—

 
—

 
177,019

 
177,019

Total
$
—

 
$
—

 
$
285,797

 
$
285,797

At September 30, 2016, money market funds include $40.5 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 12. Commitments and Contingencies for further discussion of our product liability cases.
 
Fair Value Measurements at Reporting Date using:
December 31, 2015
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Equity securities
3,889

 
—

 
—

 
3,889

Total
$
55,034

 
$
—

 
$
—

 
$
55,034

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
65,265

 
$
65,265

Acquisition-related contingent consideration—long-term
—

 
—

 
78,237

 
78,237

Total
$
—

 
$
—

 
$
143,502

 
$
143,502

At December 31, 2015, money market funds include $51.1 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 12. Commitments and Contingencies for further discussion of our product liability cases.
Fair Value Measurements Using Significant Unobservable Inputs
The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Beginning of period
$
135,796

 
$
189,082

 
$
143,502

 
$
46,005

Amounts acquired
146,866

 
47,900

 
146,866

 
214,435

Amounts settled
(8,121
)
 
(13,094
)
 
(30,242
)
 
(21,668
)
Transfers (in) and/or out of Level 3
—

 
—

 
—

 
—

Measurement period adjustments
—

 
(78
)
 
—

 
(11,634
)
Changes in fair value recorded in earnings
11,585

 
(80,277
)
 
24,790

 
(83,605
)
Effect of currency translation
(329
)
 
(1,210
)
 
881

 
(1,210
)
End of period
$
285,797

 
$
142,323

 
$
285,797

 
$
142,323


19

The fair value measurement of the contingent consideration obligations was determined using risk-adjusted discount rates ranging from 3.0% to 22.0%. Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition related contingent consideration are included in Accrued expenses and Other liabilities, respectively, in our Condensed Consolidated Balance Sheets.
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2016 by acquisition (in thousands):
 
Balance as of December 31, 2015
 
Acquisitions
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2016
Qualitest acquisition
$
1,137

 
$
—

 
$
(1,137
)
 
$
—

 
$
—

Sumavel acquisition
631

 
—

 
(631
)
 
—

 
—

Auxilium acquisition
26,435

 
—

 
2,203

 
(9,787
)
 
18,851

Lehigh Valley Technologies, Inc. acquisitions
97,003

 
—

 
24,686

 
(19,389
)
 
102,300

Voltaren Gel® acquisition
—

 
142,355

 
(2,905
)
 
—

 
139,450

Other
18,296

 
4,511

 
2,574

 
(185
)
 
25,196

Total
$
143,502

 
$
146,866

 
$
24,790

 
$
(29,361
)
 
$
285,797

The following is a summary of available-for-sale securities held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
(Losses) 
 
Fair Value
September 30, 2016
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Total included in cash and cash equivalents
$
25,012

 
$
—

 
$
—

 
$
25,012

Total included in restricted cash and cash equivalents
$
40,488

 
$
—

 
$
—

 
$
40,488

Equity securities
$
—

 
$
—

 
$
—

 
$
—

Total other short-term available-for-sale securities
$
—

 
$
—

 
$
—

 
$
—

Equity securities
$
1,766

 
$
595

 
$
—

 
$
2,361

Long-term available-for-sale securities
$
1,766

 
$
595

 
$
—

 
$
2,361


 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains 
 
Gross
Unrealized
(Losses)
 
Fair Value
December 31, 2015
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Total included in cash and cash equivalents
$
3

 
$
—

 
$
—

 
$
3

Total included in restricted cash and cash equivalents
$
51,142

 
$
—

 
$
—

 
$
51,142

Equity securities
$
24

 
$
10

 
$
—

 
$
34

Total other short-term available-for-sale securities
$
24

 
$
10

 
$
—

 
$
34

Equity securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855

Long-term available-for-sale securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855


20

Nonrecurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis as of September 30, 2016 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2016
 
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Assets:
 
 
 
 
 
 
 
Certain Astora property, plant and equipment (NOTE 3)
$
—

 
$
—

 
$
—

 
$
(5,041
)
Certain U.S. Generics Pharmaceuticals property, plant and equipment
—

 
—

 
649

 
(4,448
)
Certain U.S. Branded Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
—

 
(72,814
)
Certain U.S. Generic Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
45,966

 
(169,576
)
Certain International Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
5,324

 
(16,243
)
Certain Astora intangible assets (NOTE 3)
—

 
—

 
—

 
(16,287
)
Total
$
—

 
$
—

 
$
51,939

 
$
(284,409
)
NOTE 8. INVENTORIES
Inventories consist of the following at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Raw materials (1)
$
195,830

 
$
210,038

Work-in-process (1)
111,437

 
177,821

Finished goods (1)
317,035

 
364,634

Total
$
624,302

 
$
752,493

(1) The components of inventory shown in the table above are net of allowance for obsolescence.
Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX® inventory, is classified as long-term inventory and is not included in the table above. At September 30, 2016 and December 31, 2015, $32.6 million and $24.9 million, respectively, of long-term inventory was included in Other assets in the Condensed Consolidated Balance Sheets.
The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch, when it is reasonably certain, based on management’s judgment of reasonably certain future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made once the Company (or its third party development partners) has filed an Abbreviated New Drug Application (ANDA) that has been acknowledged by the U.S. Food and Drug Administration (the FDA) as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be cleared. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the generic drug product being considered, and accordingly, the time frame within which the determination is made varies from product to product. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, or a delay in commercialization, or other potential factors. As of September 30, 2016 and December 31, 2015, the Company had approximately $25.3 million and $12.0 million, respectively, in inventories related to generic products that were not yet available to be sold.

21

NOTE 9. GOODWILL AND OTHER INTANGIBLES
Goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2016 were as follows (in thousands):
 
Carrying Amount
 
U.S. Branded Pharmaceuticals
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Balance as of December 31, 2015:
 
 
 
 
 
 
 
Goodwill
$
1,676,276

 
$
5,789,934

 
$
592,424

 
$
8,058,634

Accumulated impairment losses
(673,500
)
 
—

 
(85,780
)
 
(759,280
)
Balance as of December 31, 2015
$
1,002,776

 
$
5,789,934

 
$
506,644

 
$
7,299,354

Measurement period adjustments
16,518

 
75,750

 
1,366

 
93,634

Effect of currency translation on gross balance
—

 
—

 
19,732

 
19,732

Effect of currency translation on accumulated impairment
—

 
—

 
(1,100
)
 
(1,100
)
Balance as of September 30, 2016:
 
 
 
 
 
 
 
Goodwill
$
1,692,794

 
$
5,865,684

 
$
613,522

 
$
8,172,000

Accumulated impairment losses
(673,500
)
 
—

 
(86,880
)
 
(760,380
)
 
$
1,019,294

 
$
5,865,684

 
$
526,642

 
$
7,411,620


22

Other Intangible Assets
The following is a summary of other intangible assets held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
Cost basis:
Balance as of December 31, 2015
 
Acquisitions
(1)
 
Impairments
(2)
 
Other
(3)
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Total indefinite-lived intangibles
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
676,867

 
$
—

 
$
—

 
$
(211,147
)
 
$
—

 
$
465,720

Customer relationships (weighted average life of 15 years)
11,318

 
—

 
(3,460
)
 
(7,858
)
 
—

 
—

Tradenames (weighted average life of 12 years)
7,537

 
—

 
—

 
—

 
(127
)
 
7,410

Developed technology (weighted average life of 12 years)
6,731,573

 
148,891

 
(216,194
)
 
123,618

 
24,263

 
6,812,151

Total definite-lived intangibles (weighted average life of 12 years)
$
7,427,295

 
$
148,891

 
$
(219,654
)
 
$
(95,387
)
 
$
24,136

 
$
7,285,281

Total other intangibles
$
9,170,175

 
$
34,691

 
$
(274,754
)
 
$
(233,843
)
 
$
26,730

 
$
8,722,999

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2015
 
Amortization
 
Impairments
 
Other
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(508,225
)
 
$
(37,142
)
 
$
—

 
$
211,147

 
$
—

 
$
(334,220
)
Customer relationships
(7,858
)
 
—

 
—

 
7,858

 
—

 
—

Tradenames
(6,544
)
 
(66
)
 
—

 
—

 
19

 
(6,591
)
Developed technology
(818,606
)
 
(598,853
)
 
—

 
13,201

 
(2,352
)
 
(1,406,610
)
Total definite-lived intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Total other intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Net other intangibles
$
7,828,942

 
 
 
 
 
 
 
 
 
$
6,975,578

__________
(1)
Includes intangible assets acquired through the acquisition of Voltaren® Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX®, offset by measurement period adjustments relating to the Par acquisition.
(2)
Includes the impairment of certain intangible assets of our U.S. Generic Pharmaceuticals segment of $169.6 million, our U.S. Branded Pharmaceuticals segment of $72.8 million, our International Pharmaceuticals segment of $16.2 million and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately $16.3 million, which is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016. See Note 3. Discontinued Operations and Held for Sale for further information relating to the Astora wind down.
(3)
Includes the removal of approximately $221.9 million of fully amortized intangible assets relating to expired or terminated licensing agreements in our U.S. Branded Pharmaceuticals segment, including the 2008 Voltaren® Gel agreement, described in Note 10. License and Collaboration Agreements, NatestoTM, described in Note 5. Acquisitions of our Annual Report on Form 10-K for the year ended December 31, 2015, and STENDRA®, described in Note 10. Goodwill and Other Intangibles of our Annual Report on Form 10-K for the year ended December 31, 2015. In addition, $10.0 million of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&D assets of $138.5 million were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.

23

Amortization expense for the three and nine months ended September 30, 2016 totaled $211.5 million and $636.1 million, respectively. Amortization for the three and nine months ended September 30, 2015 totaled $121.5 million and $333.8 million, respectively. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2015 is as follows (in thousands):
2016
$
824,062

2017
$
725,659

2018
$
637,623

2019
$
575,060

2020
$
546,598

Changes in the gross carrying amount of our other intangibles for the nine months ended September 30, 2016 were as follows (in thousands):
 
Gross Carrying Amount
December 31, 2015
$
9,170,175

Capitalization of payments relating to XIAFLEX®
12,008

Voltaren® Gel acquisition
159,000

Other acquisitions
18,183

Sale of certain International Pharmaceuticals intangible assets
(1,959
)
Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(72,814
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(169,576
)
Impairment of certain International Pharmaceuticals intangible assets
(16,077
)
Impairment of certain Astora intangible assets
(26,318
)
Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)
(154,500
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(221,853
)
Effect of currency translation
26,730

September 30, 2016
$
8,722,999

Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.
Goodwill
Given the significant decline in the Company’s stock price, the Company initiated an interim goodwill impairment analysis of our U.S. Branded and U.S. Generics reporting units during the second quarter of 2016. We estimated the fair value of our reporting units through an income approach using a discounted cash flow model. Our discounted cash flow models are highly reliant on various assumptions, including estimates of future cash flows (including long-term growth rates), discount rate, and expectations about variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for our interim goodwill impairment tests ranged from 8.5% to 9.0%, depending on the overall risk associated with the particular reporting units and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. As a result of this interim analysis, the Company determined that the estimated fair value of our U.S. Branded and U.S. Generics reporting units exceeded their estimated net book value; therefore, an impairment charge was not required for the three months ended June 30, 2016.
Intangible Assets
U.S. Generic Pharmaceuticals Segment
During the three months ended March 31, 2016 and June 30, 2016, the Company identified certain market and regulatory conditions impacting the commercial potential of certain indefinite and definite-lived intangible assets in our U.S. Generic Pharmaceuticals segment. Accordingly, we tested these assets for impairment and determined that the carrying value of certain of these assets was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges of $29.3 million and $40.0 million during the first and second quarters of 2016, respectively. In addition, during the first quarter of 2016, the Company recognized pre-tax, non-cash asset impairment charges of $100.3 million related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects. See Note 4. Restructuring for discussion of our material restructuring initiatives.

24

U.S. Branded Pharmaceuticals Segment
As a result of unfavorable formulary changes and generic competition for sumatriptan, the Company has experienced a downturn in the performance of its Sumavel® DosePro® product, a needle-free delivery system for sumatriptan acquired from Zogenix, Inc. in 2014. As a result of this underperformance, the Company concluded during the third quarter of 2016 that an impairment assessment was required to evaluate the recoverability of Sumavel® DosePro®. After performing this assessment, we recorded a pre-tax, non-cash impairment charge of $72.8 million during the three months ended September 30, 2016, representing a full impairment of the intangible asset.
International Pharmaceuticals Segment
During the three months ended September 30, 2016, the Company determined that it would not pursue commercialization of a product in certain international markets. Accordingly, we tested the definite-lived intangible asset associated with this product for impairment and determined that the carrying value was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charge of $16.2 million during the third quarter of 2016.
NOTE 10. LICENSE AND COLLABORATION AGREEMENTS
Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.
The Company and its subsidiaries are generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. In addition, these agreements generally require our subsidiaries to pay royalties on sales of the products arising from these agreements. These agreements generally permit termination by our subsidiaries with no significant continuing obligation.
Novartis AG, Novartis Consumer Health, Inc. and Sandoz, Inc.
The Company had exclusive U.S. marketing rights to Voltaren® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. Effective March 1, 2015, Novartis Consumer Health, Inc. assigned the 2008 Voltaren® Gel Agreement to its affiliate, Sandoz, Inc. On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement, the 2015 Voltaren® Gel Agreement, whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren® Gel and the exclusive right to launch an authorized generic of Voltaren® Gel, effective July 1, 2016. Pursuant to the 2015 Voltaren® Gel Agreement, the former 2008 Voltaren® Gel Agreement expired on June 30, 2016 in accordance with its terms. The 2015 Voltaren® Gel Agreement became effective on July 1, 2016 and is accounted for as a business combination as of the effective date. Refer to Note 5. Acquisitions for further information. The initial term of the 2015 Voltaren® Gel Agreement will expire on June 30, 2023 with an automatic extension of the term for one year thereafter unless a written notice of non-extension is provided at least six months in advance of termination. Voltaren® Gel royalties incurred during the nine months ended September 30, 2016 and 2015 were $13.9 million and $22.5 million, respectively.
Under the 2008 Voltaren® Gel Agreement, which was effective through June 30, 2016, the Company agreed (i) to make certain guaranteed minimum annual royalty payments beginning in the fourth year of the 2008 Voltaren® Gel Agreement (2008 Guaranteed Minimum Annual Royalty Payment), (ii) to expend a minimum amount of annual advertising and promotional expenses (A&P Expenditures) on the commercialization of Voltaren® Gel and (iii) to perform a minimum number of face-to-face one-on-one discussions with physicians and other health care practitioners (Details), each subject to certain limitations set forth in the 2008 Voltaren® Gel Agreement, including the requirement that a third party generic equivalent product not be launched. Under the 2015 Voltaren® Gel Agreement, the Company agreed to make certain guaranteed minimum annual royalty payments (2015 Guaranteed Minimum Annual Royalty Payment) subject to certain limitations set forth in the 2015 Voltaren® Gel Agreement, including the requirement that a third party generic equivalent product is not launched. In March 2016, Amneal Pharmaceuticals LLC (Amneal) launched a generic equivalent of Voltaren® Gel and, therefore, the Company’s obligations to make the 2008 Guaranteed Minimum Annual Royalty Payment, to expend A&P Expenditures and to perform Details for the remainder of the term of the 2008 Voltaren® Gel Agreement terminated as of the date of the launch of the generic equivalent product by Amneal. In addition, the Company’s obligation to make the 2015 Guaranteed Minimum Annual Royalty Payment also terminated.
XIAFLEX® Out-license Agreement
We were party to an out-licensing agreement with Actelion Pharmaceuticals Ltd. (Actelion) to develop, supply and commercialize XIAFLEX® in Canada and Australia. On July 1, 2016, the parties mutually agreed to terminate the collaboration for Canada and agreed upon certain transition services to be provided by Actelion until approval of the transfer of the drug identification number by the regulatory authority in Canada to the Company. For Australia, the collaboration agreement remains in effect until a new agreement is finalized. In consideration for the rights returned to the Company by Actelion, Endo made a cash payment of $5.5 million in July 2016. This transaction was treated as an asset acquisition.

25

NOTE 11. DEBT
The following table presents the carrying amounts of the Company’s total indebtedness at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
7.25% Senior Notes due 2022
$
400,000

 
$
(11,284
)
 
$
400,000

 
$
(12,535
)
5.75% Senior Notes due 2022
700,000

 
(9,026
)
 
700,000

 
(10,088
)
5.375% Senior Notes due 2023
750,000

 
(9,585
)
 
750,000

 
(10,511
)
6.00% Senior Notes due 2023
1,635,000

 
(25,481
)
 
1,635,000

 
(27,694
)
6.00% Senior Notes due 2025
1,200,000

 
(21,287
)
 
1,200,000

 
(22,713
)
Term Loan A Facility Due 2019
962,500

 
(10,221
)
 
1,017,500

 
(13,831
)
Term Loan B Facility Due 2022
2,779,000

 
(44,803
)
 
2,800,000

 
(49,900
)
Revolving Credit Facility
—

 
—

 
225,000

 
—

Other debt
55

 
—

 
134

 
—

Total long-term debt, net
$
8,426,555

 
$
(131,687
)
 
$
8,727,634

 
$
(147,272
)
Less current portion, net
124,250

 
—

 
328,705

 
—

Total long-term debt, less current portion, net
$
8,302,305

 
$
(131,687
)
 
$
8,398,929

 
$
(147,272
)
The total fair value of the Company’s Total long-term debt at September 30, 2016 and December 31, 2015, was $8.0 billion and $8.6 billion, respectively.
The fair value of the Company’s long-term debt is estimated using the quoted market prices for the same or similar debt issuances. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.
Credit Facility
On April 4, 2016, the Company paid down the revolving credit facility in the amount of $225.0 million. As of September 30, 2016, we have $997.4 million of remaining credit available through the revolving credit facilities.
The Company’s credit agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on capital expenditures, asset sales, mergers and acquisitions, indebtedness, liens, dividends, investments and transactions with the Company’s affiliates. As of September 30, 2016, we were in compliance with all such covenants.
NOTE 12. COMMITMENTS AND CONTINGENCIES
Manufacturing, Supply and Other Service Agreements
Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. These contracts include agreements with Novartis Consumer Health, Inc., Novartis AG, and Sandoz, Inc. (collectively, Novartis), Teikoku Seiyaku Co. Ltd. (Teikoku), Noramco, Inc. (Noramco), Grünenthal GmbH (Grünenthal), Sharp Corporation, UPS Supply Chain Solutions, Inc. and Jubilant HollisterStier Laboratories LLC (JHS). If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have an adverse effect on our business, financial condition, results of operations and cash flows.
In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.

26

Significant changes made during the nine months ended September 30, 2016 to the agreements listed above and included within our Annual Report on Form 10-K for the year ended December 31, 2015 are as follows:
Noramco, Inc.
Pursuant to the terms of the Company’s 2012 agreement with Noramco, the Company made payments to Noramco during the nine months ended September 30, 2016 and 2015 totaling $27.3 million and $31.2 million, respectively. These payments are recorded in Cost of revenues in our Condensed Consolidated Statements of Operations. In July 2016, the Company sent a notice of non-renewal to Noramco which will result in the agreement being terminated as of April 2017. The Company is not subject to any penalties as a result of this termination.
Jubilant HollisterStier Laboratories LLC
During the second quarter of 2016, we entered into a new agreement with JHS (JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX® bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS agreement is three years, with automatic renewal provisions thereafter for subsequent one-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX® from JHS each year, unless JHS is unable to supply XIAFLEX® within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were not material for any of the periods presented.
Legal Proceedings and Investigations
We and certain of our subsidiaries are involved in various claims, legal proceedings, internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including those relating to product liability, intellectual property, regulatory compliance and commercial matters. These and other matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material either individually or in the aggregate, we will disclose such matters. While we cannot predict the outcome of these proceedings and we intend to defend vigorously our position, an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows.
As of September 30, 2016, our reserve for loss contingencies totaled $1.28 billion, of which $1.20 billion relates to our product liability accrual for vaginal mesh cases. We had previously announced that we had reached master settlement agreements with several of the leading plaintiffs’ law firms to resolve claims relating to vaginal mesh products sold by our AMS subsidiary. The agreements were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.
Product Liability
We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain of our products and the products of our subsidiaries. These matters are described below in more detail.
We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability matters are or may be covered in whole or in part under our product liability insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our product liability insurance policies will likely be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.
Vaginal Mesh Cases. In October 2008, the FDA issued a Public Health Notification (October 2008 Public Health Notification) regarding potential complications associated with transvaginal placement of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The notification provides recommendations and encourages physicians to seek specialized training in mesh procedures, to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications.

27

In July 2011, the FDA issued an update to the October 2008 Public Health Notification regarding mesh to further advise the public and the medical community of the potential complications associated with transvaginal placement of surgical mesh to treat POP and SUI. In the July 2011 update, the FDA stated that adverse events are not rare. Furthermore, the FDA questioned the relative effectiveness of transvaginal mesh as a treatment for POP as compared to non-mesh surgical repair. The July 2011 notification continued to encourage physicians to seek specialized training in mesh procedures, to consider and to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications. In January 2016, the FDA issued a statement reclassifying surgical mesh for transvaginal POP repair from Class II to Class III. Surgical mesh for SUI repair remains a Class II device.
In January 2012, the FDA ordered manufacturers of transvaginal surgical mesh used for POP and of single incision mini-slings for urinary incontinence, such as our AMS subsidiary, to conduct post-market safety studies and to monitor adverse event rates relating to the use of these products. AMS received a total of 19 class-wide post-market study orders regarding its pelvic floor repair and mini-sling products; however, the FDA agreed to place 16 of these study orders on hold for a variety of reasons. AMS commenced three of these post-market study orders; however, in connection with the wind down of the Astora business, it notified the FDA of its termination of these studies. The FDA has confirmed closure of these studies.
Since 2008, we and certain of our subsidiaries, including AMS and/or Astora, have been named as defendants in multiple lawsuits in the U.S. in various state courts and in a multidistrict litigation (MDL) in the Southern District of West Virginia (MDL No. 2325), in Canada, where various class action and individual complaints are pending, and in other countries alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. Plaintiffs in these suits allege various personal injuries including chronic pain, incontinence and inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.
We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other settlement agreements regarding settling up to approximately 49,000 filed and unfiled mesh claims handled or controlled by the participating counsel for an aggregate total of approximately $2.8 billion. These MSAs, which were executed at various times since June 2013, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault by us or any of our subsidiaries. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of Qualified Settlement Funds (QSFs) into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation thresholds requiring participation by the majority of claims represented by each law firm party to the MSA. If certain participation thresholds are not met, then we will have the right to terminate the settlement with that law firm. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are included in restricted cash and cash equivalents in the Condensed Consolidated Balance Sheets.
Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and a dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant shall represent and warrant that liens, assignment rights or other claims that are identified in the claims administration process have been or will be satisfied by the individual claimant. The amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlement, shall be kept confidential by all parties and their counsel.
We expect that valid claims under the MSAs will continue to be settled. However, we intend to vigorously contest pending and future claims that are invalid, for which settlement is not able to be reached or that are in excess of the maximum claim amounts under the MSAs. We are currently aware of approximately 8,000 asserted claims and unasserted claims, which we believe are likely to be asserted, that have not been accrued for because we lack sufficient information to determine whether any potential loss is probable. In addition to these asserted and unasserted claims, which we believe are likely to be asserted, there may be other claims asserted in the future. It is currently not possible to estimate the number or validity of any such future claims.
In order to evaluate whether a claim is probable of a loss, we must obtain and evaluate certain information pertaining to each individual claim, including but not limited to the following items: the name and social security number of the plaintiff, evidence of an AMS implant, the date of implant, the date the claim was first asserted to AMS, the date that plaintiff’s counsel was retained, and most importantly, medical records establishing the injury alleged. Without access to at least this information and the opportunity to evaluate it, we are not in a position to determine its validity or whether a loss is probable. Further, the timing and extent to which we obtain this information and our evaluation thereof, is often impacted by items outside of our control, including, without limitation, the normal cadence of the litigation process and the provision of claim information to us by plaintiff’s counsel.

28

We will continue to monitor the situation, and, if appropriate, we will make further adjustments to our product liability accrual based on new information. We intend to continue exploring all options as appropriate in our best interests, and depending on developments, there is a possibility that we will suffer adverse decisions or verdicts of substantial amounts, or that we will enter into additional monetary settlements. Any unfavorable outcomes as a result of such litigation or settlements with respect to any asserted or unasserted claims could have a material adverse effect on our business, financial condition, results of operations and cash flows.
As of the date of this report, we believe that the current product liability accrual includes all known claims for which liability is probable and estimable.
The following table presents the changes in the vaginal mesh QSFs and product liability balance during the nine months ended September 30, 2016 (in thousands):
 
Qualified Settlement Funds
 
Product Liability
Balance as of December 31, 2015
$
578,970

 
$
2,086,176

Additional charges
—

 
19,505

Cash contributions to Qualified Settlement Funds
587,782

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(898,288
)
 
(898,288
)
Cash distributions to settle disputes
—

 
(5,561
)
Other
456

 
—

Balance as of September 30, 2016
$
268,920

 
$
1,201,832

The entire portion of the $1.20 billion liability amount shown above is classified as Current portion of legal settlement accrual in the September 30, 2016 Condensed Consolidated Balance Sheets. Charges related to vaginal mesh product liability for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.
We expect to fund the payments under all current settlement agreements over the course of 2016 and 2017. As the funds are disbursed out of the QSFs from time to time, the product liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the product liability accrual and decrease cash and cash equivalents.
In addition, we have been contacted regarding a civil investigation that has been initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and have subsequently received additional subpoenas from other states. We are currently cooperating with this investigation. At this time, we cannot predict or determine the outcome of this investigation or reasonably estimate the amount or range of amounts of fines or penalties, if any, that might result from a settlement or an adverse outcome from this investigation.
Testosterone Cases. We and certain of our subsidiaries, including Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), along with other pharmaceutical manufacturers, have been named as defendants in lawsuits alleging personal injury resulting from the use of prescription medications containing testosterone, including Fortesta® Gel, Delatestryl®, Testim®, TESTOPEL® and Striant®. Plaintiffs in these suits allege various personal injuries, including pulmonary embolism, stroke and other vascular and/or cardiac injuries and seek compensatory and/or punitive damages, where available. In June 2014, an MDL was formed to include claims involving all testosterone replacement therapies filed against EPI, Auxilium, and other manufacturers of such products, and certain transferable cases pending in federal court were coordinated in the Northern District of Illinois as part of MDL No. 2545. In addition to the federal cases filed against EPI and Auxilium that have been transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545, litigation has also been filed against EPI in the Court of Common Pleas Philadelphia County and in certain other state courts. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545. However, we cannot predict the timing or outcome of any such litigation, or whether any such additional litigation will be brought against us. We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest. As of November 1, 2016, approximately 1,140 cases are currently pending against us; some of which may have been filed on behalf of multiple plaintiffs.
In November 2015, the U.S. District Court for the Northern District of Illinois entered an order granting defendants’ motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL®. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the District Court granted plaintiffs’ motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing.

29

In November 2014, a civil class action complaint was filed in the Northern District of Illinois against EPI, Auxilium, and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payors that had paid for certain testosterone products, alleging that the marketing efforts of EPI, Auxilium, and other defendant manufacturers with respect to certain testosterone products constituted racketeering activity in violation of 18 U.S.C. §1962(c), and other civil Racketeer Influenced and Corrupt Organizations Act claims. Further, the complaint alleges that EPI, Auxilium, and other defendant manufacturers violated various state consumer protection laws through their marketing of certain testosterone products and raises other state law claims. In March 2015, defendants filed a motion to dismiss the complaint and plaintiffs responded by filing amended complaints. In February 2016, the District Court granted in part and denied in part defendants’ motion to dismiss. The District Court declined to dismiss plaintiffs’ claims for conspiracy to commit racketeering activity in violation of 18 U.S.C. §1962(d) and claims for negligent misrepresentation. In April 2016, plaintiffs filed a third amended complaint, which defendants moved to dismiss in June 2016. In August 2016, the court denied the motion to dismiss and we filed a response to the third amended complaint in September 2016. In October 2015, a similar civil class action complaint was filed against EPI and other defendant manufacturers in the Northern District of Illinois. Similar litigation may be brought by other plaintiffs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any, but we will explore all options as appropriate in our best interest.
Unapproved Drug Litigation
In September 2013, the State of Louisiana filed a Petition for Damages against certain of our subsidiaries, EPI and Generics Bidco I, LLC, and over 50 other pharmaceutical companies alleging the defendants or their subsidiaries marketed products that were not approved by the FDA. See State of Louisiana v. Abbott Laboratories, Inc., et al., C624522 (19th Jud. Dist. La.). The State of Louisiana sought damages, fines, penalties, attorneys’ fees and costs under various causes of action. In October 2015, the District Court ordered judgment for defendants on their exception for no right of action. The State of Louisiana appealed that decision and in October 2016, the Louisiana Court of Appeals, First Circuit, issued a decision affirming the dismissal as to certain counts and reversing the dismissal as to others.
We intend to contest the above case vigorously and to explore other options as appropriate in our best interest. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against us. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.
Opioid-Related Litigations, Subpoenas and Document Requests
In June 2014, Corporation Counsel for the City of Chicago filed suit in Illinois state court against multiple defendants, including our subsidiaries, Endo Health Solutions Inc. (EHSI) and EPI, for alleged violations of city ordinances and other laws relating to defendants’ alleged opioid sales and marketing practices. In June 2014, the case was removed to the U.S. District Court for the Northern District of Illinois. In December 2014, defendants moved to dismiss the Amended Complaint and in May 2015, the District Court issued an order granting that motion in part, dismissing the case as to EHS and EPI. In August 2015, plaintiff filed its Second Amended Complaint against multiple defendants, including EPI and EHSI. In November 2015, defendants moved to dismiss the Second Amended Complaint. In September 2016, the District Court granted in part and denied in part defendants’ motions to dismiss and provided plaintiff an opportunity to amend its complaint. Plaintiff filed the third amended complaint in October 2016.
In May 2014 and in June 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, against multiple defendants, including our subsidiaries EHSI and EPI. The complaint asserts violations of California’s statutory Unfair Competition and False Advertising laws, as well as asserting a claim for public nuisance, based on alleged misrepresentations in connection with sales and marketing of opioids, including OPANA®. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), abatement, an injunction, and attorneys’ fees and costs. Defendants, which include our subsidiaries, filed various motions attacking the pleadings, including one requesting that the Superior Court refrain from proceeding under the doctrines of primary jurisdiction and equitable abstention. That motion was granted in August 2015, and the case has been stayed pending further proceedings and findings by the FDA. In June 2016, plaintiffs filed a motion to lift the stay and to amend the complaint. Defendants, included EHSI and EPI, opposed that motion. Following a hearing in July 2016, the court provided plaintiffs an opportunity to seek leave to file another amended complaint. In August 2016, plaintiffs filed a renewed motion to lift the stay and amend the complaint. In October 2016, the court granted, in part, plaintiffs’ renewed motion to lift the stay and the plaintiffs filed their third amended complaint.
In December 2015, a lawsuit was filed in the Chancery Court of the First Judicial District of Hinds County, Mississippi by the State of Mississippi against multiple defendants, including our subsidiaries EHSI and EPI. The complaint alleges violations of Mississippi’s Consumer Protection Act and various other claims arising out of defendants’ alleged opioid sales and marketing practices. Plaintiff seeks declaratory relief, restitution, civil penalties, abatement, an injunction, and attorneys’ fees and costs. In March 2016, defendants moved to dismiss the complaint.

30

In September 2014, our subsidiaries EHSI and EPI received a Request for Information from the State of Tennessee Office of the Attorney General and Reporter seeking documents and information regarding the sales and marketing of opioids, including OPANA® ER. We are currently cooperating with the State of Tennessee Office of the Attorney General and Reporter in this investigation.
In August 2015, our subsidiaries EHSI and EPI received a subpoena from the State of New Hampshire Office of the Attorney General seeking documents and information regarding the sales and marketing of opioids, including OPANA® ER. We were cooperating with the State of New Hampshire Office of the Attorney General in its investigation until we learned that it was being assisted in the investigation by outside counsel hired on a contingent fee basis. The New Hampshire Attorney General initiated an action in the Superior Court for the State of New Hampshire to enforce the subpoena despite this contingent fee arrangement, and we (along with other companies that had received similar subpoenas) responded by filing a motion for protective order to preclude the use of contingent fee counsel. In addition, we filed a separate motion seeking declaratory relief. In March 2016, the Superior Court granted the motion for protective order on the grounds that the contingent fee agreement was invalid as ultra vires and that the office of the Attorney General had acted outside of its statutory authority in entering into the agreement with the contingent fee counsel. In April 2016, both the New Hampshire Attorney General and the companies that received subpoenas from the New Hampshire Attorney General, including EHSI and EPI, appealed, in part, the March 2016 Superior Court order to the New Hampshire Supreme Court. Those appeals are pending. In April 2016, the New Hampshire Attorney General also entered into a new agreement with outside counsel. In response, the companies that received a subpoena from the New Hampshire Attorney General, including EHSI and EPI, moved to enforce a part of the protective order issued by the Superior Court in March 2016 that is not being appealed by EHSI and EPI. That motion was denied in August 2016.
In March 2016, EHSI and EPI received a Civil Investigative Demand (CID) from the Department of Justice (DOJ) for the State of Oregon seeking documents and information regarding the sales and marketing of OPANA® ER. We are currently cooperating with the State of Oregon in its investigation.
In August 2016, the County of Suffolk, New York filed suit in New York state court against multiple defendants, including our subsidiaries, EHSI and EPI, for alleged violations of state false and deceptive advertising and other statutes, public nuisance, common law fraud, and unjust enrichment based on opioid sales and marketing practices. The County of Suffolk is seeking compensatory damages, interest, costs, disbursements, punitive damages, treble damages, penalties and attorneys’ fees.
With respect to the litigations brought on behalf of the City of Chicago, the People of the State of California, the State of Mississippi and the County of Suffolk, we intend to contest those matters vigorously. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Antitrust Litigation and Investigations
Multiple direct and indirect purchasers of Lidoderm® have filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd., Teikoku Pharma USA, Inc. (collectively, Teikoku) and Actavis plc and certain of its subsidiaries (collectively, Actavis), which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries (collectively, Teva) from Allergan plc (Allergan). Certain of these actions have been asserted on behalf of classes of direct and indirect purchasers, while others are individual cases brought by one or more alleged direct or indirect purchasers. The complaints in these cases generally allege that EPI, Teikoku and Actavis (now Teva) entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. Some of the complaints also allege that Teikoku wrongfully listed the ‘529 patent in the Orange Book as related to Lidoderm®, that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of Lidoderm®. The cases allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2) and various state antitrust and consumer protection statutes as well as common law remedies in some states. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees.
The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order in April 2014 transferring these cases as In Re Lidoderm Antitrust Litigation, MDL No. 2521, to the U.S. District Court for the Northern District of California. In June 2016, motions for class certification were filed on behalf of classes of direct and indirect purchasers, and EPI, Teikoku and Actavis filed oppositions to those motions in September 2016. Trial is currently scheduled to begin in 2017. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of California as tag-along actions to In Re Lidoderm Antitrust Litigation.

31

Multiple direct and indirect purchasers of OPANA® ER have filed cases against our subsidiaries EHSI and EPI, and other pharmaceutical companies, including Penwest Pharmaceuticals Co., which we subsequently acquired, and Impax Laboratories Inc. (Impax), all of which have been transferred and coordinated for pretrial proceedings in the Northern District of Illinois by the Judicial Panel on Multidistrict Litigation. Some of these cases have been filed on behalf of putative classes of direct and indirect purchasers, while others have been filed on behalf of individual retailers or health care benefit plans. These cases generally allege that the agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA® ER and EPI’s introduction of the re-formulation of OPANA® ER violated antitrust laws. The complaints allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), various state antitrust and consumer protection statutes, as well as state common law. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the District Court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the District Court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers have also filed amended complaints. The defendants successfully moved to dismiss the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. We cannot predict whether or not additional cases similar to those described above will be filed by other plaintiffs or the timing or outcome of any such litigation.
In February 2014, our subsidiary, EPI received a CID (the February 2014 CID) from the U.S. Federal Trade Commission (the FTC). The FTC issued a second CID to EPI in March 2014 (the March 2014 CID). The February 2014 CID requested documents and information concerning EPI’s settlement agreements with Actavis and Impax settling the OPANA® ER patent litigation, EPI’s Development and Co-Promotion Agreement with Impax, and its settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of OPANA® ER and Lidoderm®. The March 2014 CID requested documents and information concerning EPI’s acquisition of U.S. Patent No. 7,852,482 (the ‘482 patent), as well as additional information concerning certain litigation relating to, and the marketing and sales of OPANA® ER. The FTC also issued subpoenas for investigational hearings (similar to depositions) to our employees and former employees. In March 2016, the FTC filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania against us and our subsidiary EPI, as well as against Allergan, Actavis, Impax and Teikoku, alleging generally that the settlement agreements with Actavis, Impax, respectively, constituted, in whole or part, unfair methods of competition in violation Section 5(a) of the FTC Act, 15 U.S.C. § 45(a). The FTC also alleges that one provision of the agreement with Actavis violated Section 7 of the Clayton Act, 15 U.S.C. § 18. The complaint seeks injunctive and declaratory relief and other remedies, including restitution and disgorgement. In June 2016, we joined in the defendants’ motion to sever OPANA® ER-related claims from the Lidoderm®-related claims. In July 2016, a motion to dismiss was filed on behalf of all defendants. In October 2016, the District Court granted the defendants’ motion to sever the claims ordering the FTC to file lawsuits for the OPANA® ER-related claims separately from the Lidoderm®-related claims. The District Court also denied the defendants’ motion to dismiss as moot. Subsequently in October 2016, the FTC voluntarily sought to dismiss their case against us without prejudice. We filed two separate lawsuits relating to OPANA® ER-related claims and Lidoderm®-related claims, with Impax and Watson, respectively, in October 2016 seeking declaratory judgment on the merits of the case.
We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these matters, if any, but will explore all options as appropriate in our best interest.
In November 2014, EPI received a CID from the State of Florida Office of the Attorney General issued pursuant to the Florida Antitrust Act of 1980, Section 542.28 and seeking documents and other information concerning EPI’s settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Lidoderm®.
In February 2015, EHSI and EPI received a CID for Production of Documents and Information from the State of Alaska Office of Attorney General issued pursuant to Alaska’s Antitrust and Unfair Trade Practices and Consumer Protection law seeking documents and other information concerning settlement agreements with Actavis and Impax settling the OPANA® ER patent litigation as well as information concerning EPI’s settlement agreement with Actavis settling the Lidoderm patent litigation, as well as information concerning the marketing and sales of Lidoderm.
In February 2016, EPI received a subpoena from the State of South Carolina Office of the Attorney General seeking documents and other information concerning EPI’s settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Lidoderm®.
In December 2014, our subsidiary, Par Pharmaceutical Companies, Inc. (subsequently renamed Endo Generics Holdings, Inc. and referred to in this Note 12. Commitments and Contingencies as Par), received a Subpoena to Testify Before Grand Jury from the Antitrust Division of the DOJ and issued by the U.S. District Court for the Eastern District of Pennsylvania. The subpoena requests documents and information focused primarily on product and pricing information relating to Par’s authorized generic version of Lanoxin (digoxin) oral tablets and Par’s generic doxycycline products, and on communications with competitors and others regarding those products. Par is currently cooperating fully with the investigation.

32

In January 2009, the FTC filed a lawsuit against our subsidiary, Par, in the U.S. District Court for the Central District of California, which was subsequently transferred to the U.S. District Court for the Northern District of Georgia, and which alleged violations of antitrust law arising out of Par’s settlement of certain patent litigation concerning the generic version of AndroGel®. The FTC complaint generally seeks a finding that Par’s settlement agreement violates Section 5(a) of the Federal Trade Commission Act, and a permanent injunction against Par’s ability to engage in certain types of patent settlements in the future. Beginning in February 2009, certain private plaintiffs, including distributors and retailers, filed similar litigation. Generally, the remaining private plaintiff suits seek equitable relief, unspecified damages and costs.
In February 2010, the District Court granted a motion to dismiss the FTC’s claims and granted in part and denied in part a motion to dismiss the claims of the private plaintiffs. In April 2012, the U.S. Court of Appeals for the 11th Circuit affirmed the District Court’s decision on the motion to dismiss the FTC’s claims. In September 2012, the District Court granted a motion for summary judgment against the private plaintiffs’ claims of sham litigation. In July 2013, the Supreme Court of the U.S. reversed the Court of Appeals’ and District Court’s decisions concerning the FTC action and remanded the case to the District Court for further proceedings. In May 2016, those private plaintiffs representing the putative class of indirect purchasers voluntarily dismissed their case against Par with prejudice. Claims by the direct purchasers and the FTC are still pending. We intend to contest this litigation vigorously and to explore all options as appropriate in our best interest.
In February 2015, Par received a CID from the Office of the Attorney General for the State of Alaska seeking production of certain documents and information regarding Par’s settlement of the AndroGel® patent litigation as well as documents produced in the on-going litigation filed by the FTC.
We are currently cooperating with the DOJ, the State of Florida Office of the Attorney General, the State of Alaska Office of the Attorney General and the State of South Carolina Office of the Attorney General in their respective investigations. Investigations and lawsuits similar to these antitrust matters described above may be brought by others. We are unable to predict the outcome of these investigations or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these investigations, if any, but will explore all options as appropriate in our best interest.
In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its subsidiary, Par Sterile Products, LLC, in the U.S. District Court for the District of New Jersey alleging that Par and its subsidiary engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par’s Vasostrict® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of The Sherman Antitrust Act, 15 U.S.C. §§ 1, 2, as well as the antitrust law and common law of the state of New Jersey, alleging that Par and its subsidiary entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages in an unspecified amount, attorney’s fees and costs and injunctive relief and demands a trial by jury. In September 2016, Par and its subsidiary filed a motion to dismiss the case for Fresenius’ failure to properly state a claim under the antitrust laws. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter. We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest.
False Claims Act Litigation
The Attorneys General of Florida, Indiana and Virginia and the U.S. Office of Personnel Management (the USOPM) have issued subpoenas, and the Attorneys General of Michigan, Tennessee, Texas, and Utah have issued CIDs, to our subsidiary, Par, among other companies. The demands generally request documents and information pertaining to allegations that certain of Par’s sales and marketing practices caused pharmacies to substitute ranitidine capsules for ranitidine tablets, fluoxetine tablets for fluoxetine capsules, and two 7.5 mg buspirone tablets for one 15 mg buspirone tablet, under circumstances in which some state Medicaid programs at various times reimbursed the new dosage form at a higher rate than the dosage form being substituted. Par has provided documents in response to these subpoenas to the respective Attorneys General and the USOPM. The aforementioned subpoenas and CIDs culminated in the federal and state law qui tam action brought on behalf of the U.S. and several states by Bernard Lisitza. The complaint was unsealed in August 2011. Lisitza’s corrected second amended complaint generally seeks (i) a finding that defendants violated and be enjoined from future violations of the federal False Claims Act and state false claims acts; (ii) treble damages and maximum civil penalties for each violation of the federal False Claims Act and state false claims acts; (iii) an applicable percentage share of the proceeds; and (iv) expenses, fees, and costs. The U.S. intervened in this action and filed a separate complaint in September 2011, alleging claims for violations of the Federal False Claims Act and common law fraud. The U.S.’s second corrected complaint generally seeks (i) treble damages and civil penalties for violations under the federal False Claims Act and (ii) compensatory and punitive damages for common law fraud. The states of Michigan and Indiana have also intervened as to claims arising under their respective state false claim acts, common law fraud, and unjust enrichment. Michigan’s complaint generally seeks (i) treble damages and civil penalties and (ii) common law compensatory and punitive damages. Indiana’s amended complaint generally seeks treble damages, costs, and attorney’s fees. We intend to vigorously defend this lawsuit. At this time, we are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.

33

Pricing Matters
In March 2016, EPI received a CID from the U.S. Attorney’s Office for the Southern District of New York. The CID requests documents and information regarding contracts with Pharmacy Benefit Managers regarding Frova®. We are currently cooperating with this investigation. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Beginning in January 2016, several complaints, including multiple class action complaints, have been filed in the Philadelphia Court of Common Pleas and in the U.S. District Courts for the Eastern District of Pennsylvania and the District of Rhode Island against us and certain of our subsidiaries, including Par, along with other manufacturers of certain generic pharmaceutical products, seeking compensatory and punitive or treble damages, as well as injunctive relief and alleging that certain marketing and pricing practices by the defendant companies violated state law, including consumer protection law and/or federal and state antitrust laws. The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order in August 2016 transferring certain of these cases as In Re Generic Digoxin and Doxycycline Antitrust Litigation, MDL No. 2724, to the U.S. District Court for the Eastern District of Pennsylvania. Additional similar claims may be brought by other plaintiffs in various jurisdictions.
In December 2015, EPI received Interrogatories and Subpoena Duces Tecum from the State of Connecticut Office of Attorney General requesting information regarding pricing of certain of its generic products, including Doxycycline Hyclate, Amitriptyline Hydrochloride, Doxazosin Mesylate, Methotrexate Sodium and Oxybutynin Chloride. We are currently cooperating with this investigation.
We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Megace ES® (megestrol acetate oral suspension) Cases
In September 2011, our subsidiary, Par Pharmaceutical, Inc. (PPI), along with EDT Pharma Holdings Ltd. (Elan) (now known as Alkermes Pharma Ireland Limited), filed a complaint against TWi Pharmaceuticals, Inc. (TWi) in the U.S. District Court for the District of Maryland alleging infringement of U.S. Patent No. 7,101,576 because TWi filed an ANDA with a Paragraph IV certification seeking FDA approval of a generic version of Megace® ES. A bench trial was held in October 2013, and in February 2014, the District Court issued a decision in favor of TWi, finding all asserted claims of the 7,101,576 patent invalid for obviousness. Par appealed. In August 2014, the District Court issued a preliminary injunction enjoining TWi’s launch of its generic product pending disposition of the appeal. In December 2014, the Federal Circuit reversed the District Court’s decision, remanding for further findings of fact. In March 2015, the District Court issued another preliminary injunction enjoining TWi’s launch of its generic product pending disposition of the case on remand. In July 2015, the District Court issued a new decision in favor of TWi, finding all of the asserted claims invalid, and TWi launched its generic product. PPI appealed again, and in December 2015, the District Court’s decision in favor of TWi was affirmed without opinion. In February 2016, TWi moved the District Court to recover its lost profits, which TWi alleges in the amount of $16 million, resulting from the previous injunctions to which the District Court subjected TWi, as well as attorneys’ fees and costs. PPI opposed TWi’s motion. In September 2016, the District Court denied TWi’s motion for attorneys’ fees and costs and granted in part and denied in part TWi’s motion to recover its lost profits, ordering PPI to pay $12.7 million. We believe that a loss is probable and we have incorporated our best estimate of this loss into our reserve for loss contingencies. It is possible that the outcome of this matter could result in an additional loss above the amount reserved, which could be material.
Securities Related Class Action Litigation
In May 2016, a putative class action entitled Craig Friedman v. Endo International plc Company, Rajiv de Silva and Suketu Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund were appointed lead plaintiffs in the action. In October 2016, a Second Amended Complaint was filed. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with Pharmacy Benefit Managers concerning Frova®. The Second Amended Complaint adds Paul Campanelli as a defendant. The complaint seeks class certification, damages in an unspecified amount and attorney’s fees and costs. We filed a motion to dismiss the case in October 2016. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.

34

On November 7, 2016, a putative class action was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of herself and all similarly situated shareholders, bearing the caption Doris Shasha v. Endo International plc Company, Rajiv Kanishka Liyanaarchchie De Silva and Suketu P. Upadhyay. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act. It alleges that the Company made material false statements in, or omitted material information from, certain of the Company's public disclosures from September 28, 2015 through November 2, 2016, based on news reports of an investigation by the Department of Justice into potential price collusion in the pharmaceutical industry. The complaint seeks class certification, damages in an unspecified amount and attorney's fees and costs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.
Paragraph IV Certifications on OPANA® ER
In late 2012, two patents (U.S. Patent Nos. 8,309,122 and 8,329,216) were issued to EPI covering OPANA® ER (oxymorphone hydrochloride extended-release tablets CII). In December 2012, EPI filed a complaint against Actavis (now Teva) in U.S. District Court for the Southern District of New York for patent infringement based on its ANDA for a non-crush-resistant generic version of OPANA® ER. In May 2013 and June 2013, EPI filed similar suits in the U.S. District Court for the Southern District of New York against the following applicants for non-crush-resistant OPANA® ER: Roxane Laboratories, Inc. (Roxane) and Ranbaxy Laboratories Limited, which was acquired by Sun Pharmaceutical Industries Ltd. (Ranbaxy). Those suits allege infringement of U.S. Patent Nos. 7,851,482, 8,309,122, and 8,329,216. In July 2013, Actavis and Roxane were granted FDA approval to market all strengths of their respective non-crush-resistant formulations of OPANA® ER. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York. In August 2015, the District Court ruled that all defendants infringed the claims of U.S. Patent Nos. 8,309,122 and 8,329,216. The District Court also ruled that the defendants failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid, enjoined the defendants from launching their generic products until the expiration of those patents and directed Actavis to withdraw its generic product within 60 days. In October 2015, the District Court tolled the 60-day period until it decided two pending post-trial motions. In April 2016, the District Court issued an order upholding its August 2015 ruling in EPI’s favor and confirming the prior injunction against the manufacture or sale of the generic version of the non-crush-resistant OPANA® ER currently offered by Actavis and the additional approved but not yet marketed generic version of the product developed by Roxane. The defendants filed appeals to the Court of Appeals for the Federal Circuit. We intend to continue vigorously asserting our intellectual property rights and to oppose any such appeal.
From September 21, 2012 through October 30, 2013, EPI and its partner Grünenthal received Paragraph IV Notices from each of Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals, LLC (Amneal), ThoRx Laboratories, Inc. (ThoRx), Actavis, Impax and Ranbaxy (now Sun Pharmaceutical Industries Ltd.), advising of the filing by each such company of an ANDA for a generic version of the formulation of OPANA® ER designed to be crush-resistant. These Paragraph IV Notices refer to U.S. Patent Nos. 7,851,482, 8,075,872, 8,114,383, 8,192,722, 8,309,060, 8,309,122 and 8,329,216, which variously cover the formulation of OPANA® ER, a highly pure version of the active pharmaceutical ingredient and the release profile of OPANA® ER. EPI filed lawsuits against each of these filers in the U.S. District Court for the Southern District of New York. Each lawsuit was filed within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. We intend, and have been advised by Grünenthal that it too intends, to defend vigorously the intellectual property rights covering the formulation of OPANA® ER designed to be crush-resistant and to pursue all available legal and regulatory avenues in defense of crush-resistant OPANA® ER, including enforcement of the product’s intellectual property rights and approved labeling. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York against the remaining filers. In August 2015, the District Court issued an Opinion holding that all defendants infringed the claims of U.S. Patent Nos. 8,309,060, 8,309,122 and 8,329,216. The Opinion also held that the defendants had shown that U.S. Patent No. 8,309,060 was invalid, but that the defendants had failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid. The District Court also issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent Nos. 8,309,122 and 8,329,216. The time for appealing that Opinion and Order has not yet expired and we expect the defendants to appeal the decision. We intend to continue to vigorously assert our intellectual property and oppose appeals by the defendants. However, there can be no assurance that we and/or Grünenthal will be successful. If we are unsuccessful and Teva, Amneal, ThoRx, Actavis or Impax is able to obtain FDA approval of its product, generic versions of crush-resistant OPANA® ER may be launched prior to the applicable patents’ expirations in 2023. Additionally, we cannot predict or determine the timing or outcome of this defense but will explore all options as appropriate in our best interest. The defendants filed appeals to the Court of Appeals for the Federal Circuit.

35

In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA® ER and a highly pure version of the active pharmaceutical ingredient of OPANA® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal, and Sandoz Inc. based on their ANDAs filed against both the crush-resistant and non-crush-resistant versions of OPANA® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. Beginning July 11, 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029.
We intend to defend vigorously our intellectual property rights and to pursue all available legal and regulatory avenues in defense of both the non-crush-resistant formulation OPANA® ER and the crush-resistant formulation OPANA® ER, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that we will be successful. If we are unsuccessful, competitors that already have obtained, or are able to obtain, FDA approval of their products may be able to launch their generic versions of OPANA® ER prior to the applicable patents’ expirations. Additionally, we cannot predict or determine the timing or outcome of related litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of OPANA® ER and challenge the applicable patents.
Paragraph IV Certification on Fortesta® Gel
In January 2013, EPI and its licensor Strakan Limited received a notice from Watson (now Allergan) advising of the filing by Watson of an ANDA for a generic version of Fortesta® (testosterone) Gel. In February 2013, EPI filed a lawsuit against Watson in the U.S. District Court for the Eastern District of Texas, Marshall division. Because the suit was filed within the 45-day period under the Hatch-Waxman Act for filing a patent infringement action, we believe that it triggered an automatic 30-month stay of approval under the Act. A two-day trial was held on or about February 26 and 27, 2015. In August 2015, the District Court issued an Order holding that the asserted patents are valid and are infringed by Watson’s ANDA. As a result, the District Court ordered that the effective date for the approval of Watson’s ANDA to be the date no sooner than the latest expiration date of the ’913 Patent and the ’865 Patent in November of 2018. Watson filed an appeal in October 2015. In October 2016, the Court of Appeals for the Federal Circuit issued an opinion upholding the District Court’s decision.
We intend, and have been advised by Strakan Limited that it too intends, to defend vigorously Fortesta® Gel and to pursue all available legal and regulatory avenues in defense of Fortesta® Gel, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that we and/or Strakan will be successful. If we and/or Strakan are unsuccessful and Watson is able to obtain FDA approval of its product, Watson may be able to launch its generic version of Fortesta® Gel prior to the applicable patents’ expirations in 2018. Additionally, we cannot predict or determine the timing or outcome of this litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of Fortesta® Gel and challenge the applicable patents.
Paragraph IV Certification on BELBUCA™
In November 2016, we became aware via the FDA's website that FDA’s Office of Generic Drugs had received an ANDA containing a Paragraph IV patent certification with respect to BELBUCA™ (buprenorphine hydrochloride) buccal film in September 2016. A Paragraph IV certification indicates that the generic sponsor believes certain Orange Book listed patents are invalid, unenforceable or not infringed. The FDA does not disclose the identity of the generic sponsor and we have not received the foregoing Paragraph IV patent certification. We intend to vigorously enforce our intellectual property rights relating to BELBUCA™.
Other Proceedings and Investigations
In addition to the above proceedings, proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.

36

NOTE 13. OTHER COMPREHENSIVE (LOSS) INCOME
The following table presents the tax effects allocated to each component of Other comprehensive loss for the three months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized gain (loss) on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain (loss) arising during the period
$
152

 
$
—

 
$
152

 
$
(607
)
 
$
204

 
$
(403
)
Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
146

 
—

 
146

 
(607
)
 
204

 
(403
)
Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
(7,924
)
 
1,729

 
(6,195
)
 
(86,187
)
 
1,235

 
(84,952
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation loss
(7,924
)
 
1,729

 
(6,195
)
 
(60,630
)
 
1,393

 
(59,237
)
Other comprehensive loss
$
(7,778
)
 
$
1,729

 
$
(6,049
)
 
$
(61,237
)
 
$
1,597

 
$
(59,640
)
The following table presents the tax effects allocated to each component of Other comprehensive income (loss) for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized (loss) gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized (loss) gain arising during the period
$
(1,468
)
 
$
613

 
$
(855
)
 
$
2,042

 
$
(731
)
 
$
1,311

Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
(1,474
)
 
613

 
(861
)
 
2,042

 
(731
)
 
1,311

Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
38,782

 
14,177

 
52,959

 
(207,050
)
 
(1,249
)
 
(208,299
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation gain (loss)
38,782

 
14,177

 
52,959

 
(181,493
)
 
(1,091
)
 
(182,584
)
Other comprehensive income (loss)
$
37,308

 
$
14,790

 
$
52,098

 
$
(179,451
)
 
$
(1,822
)
 
$
(181,273
)
The following is a summary of the accumulated balances related to each component of Other comprehensive loss, net of taxes, at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Net unrealized gains
$
954

 
$
1,815

Foreign currency translation loss
(333,099
)
 
(386,020
)
Accumulated other comprehensive loss
$
(332,145
)
 
$
(384,205
)

37

NOTE 14. SHAREHOLDERS' EQUITY
Changes in Shareholder’s Equity
The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2016 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2016
$
5,968,030

 
$
(54
)
 
$
5,967,976

Net (loss) income
(9,210
)
 
16

 
(9,194
)
Other comprehensive income
52,060

 
38

 
52,098

Compensation related to share-based awards
44,567

 
—

 
44,567

Tax withholding for restricted shares
(10,532
)
 
—

 
(10,532
)
Exercise of options
1,952

 
—

 
1,952

Issuance of ordinary shares related to the employee stock purchase plan
4,010

 
—

 
4,010

Other
(16
)
 
—

 
(16
)
Shareholders’ equity at September 30, 2016
$
6,050,861

 
$
—

 
$
6,050,861

The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2015 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2015
$
2,374,757

 
$
33,456

 
$
2,408,213

Net loss
(1,376,579
)
 
(153
)
 
(1,376,732
)
Other comprehensive loss
(180,692
)
 
(581
)
 
(181,273
)
Compensation related to share-based awards
48,537

 
—

 
48,537

Tax withholding for restricted shares
(15,268
)
 
—

 
(15,268
)
Exercise of options
25,068

 
—

 
25,068

Buy-out of noncontrolling interests, net of contributions
(6,876
)
 
(32,732
)
 
(39,608
)
Ordinary shares issued in connection with the Par acquisition
1,325,652

 
—

 
1,325,652

Ordinary shares issued in connection with the Auxilium acquisition
1,519,320

 
—

 
1,519,320

Fair value of equity component of acquired Auxilium Notes
266,649

 
—

 
266,649

Conversion of Auxilium Notes
160,892

 
—

 
160,892

Issuance of ordinary shares related to the employee stock purchase plan
3,328

 
—

 
3,328

Ordinary shares issued
2,300,000

 
—

 
2,300,000

Equity issuance fees
(66,956
)
 
—

 
(66,956
)
Other
18,232

 
—

 
18,232

Shareholders’ equity at September 30, 2015
$
6,396,064

 
$
(10
)
 
$
6,396,054

Share-Based Compensation
As discussed in Note 3. Discontinued Operations and Held for Sale, the operating results of the Company’s AMS business is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. However, as share-based compensation is not material for this business, amounts in this Note 14. Shareholders' Equity have not been adjusted to exclude the impact of this business.

38

The Company recognized share-based compensation expense of $15.0 million and $44.6 million during the three and nine months ended September 30, 2016, respectively, compared to $23.8 million and $86.1 million during the three and nine months ended September 30, 2015, respectively. The share-based compensation expense recognized during the nine months ended September 30, 2015 includes a charge related to the acceleration of Auxilium employee equity awards at closing of $37.6 million. The share-based compensation expense during the three and nine months ended September 30, 2015 includes $11.0 million of expense related to certain AMS equity awards modified in conjunction with the anticipated sale of the business. As of September 30, 2016, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards amounted to $93.9 million. As of September 30, 2016, the weighted average remaining requisite service period of the non-vested stock options was 2.2 years and for non-vested restricted stock units was 2.3 years.
NOTE 15. OTHER (INCOME) EXPENSE, NET
The components of Other (income) expense, net for the three and nine months ended September 30, 2016 and 2015 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Foreign currency loss (gain), net
$
(123
)
 
$
(4,095
)
 
$
2,427

 
$
(24,651
)
Equity (earnings) loss from unconsolidated subsidiaries, net
(2,023
)
 
1,899

 
(539
)
 
3,650

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Legal settlement
—

 
(12,500
)
 
—

 
(12,500
)
Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other miscellaneous, net
(720
)
 
506

 
(1,486
)
 
(1,131
)
Other (income) expense, net
$
(2,866
)
 
$
50,091

 
$
402

 
$
62,589

Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. In addition, the Company incurred $64.3 million and $78.4 million during the three and nine months ended September 30, 2015, respectively, related to unused commitment fees primarily associated with financing for the Par acquisition.
NOTE 16. INCOME TAXES
During the three months ended September 30, 2016, the Company recognized income tax expense of $46.2 million on $145.3 million of loss from continuing operations before income tax, compared to $160.9 million of tax benefit on $964.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the third quarter of 2016, the Company completed a legal entity restructuring. The restructuring resulted in the Company recording a deferred charge of $395.1 million in accordance with applicable accounting guidance. Within the third quarter, the Company recorded net discrete tax expense of $42.6 million primarily related to the amortization of the aforementioned deferred charge, which was partially offset by a favorable return to provision adjustment resulting from filing U.S. federal income tax returns. The tax benefit for the comparable 2015 period was primarily related to benefits resulting from losses from continued operations.
During the nine months ended September 30, 2016, the Company recognized an income tax benefit of $627.8 million on $518.3 million of loss from continuing operations before income tax, compared to $340.5 million of tax benefit on $1,084.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the nine months ended September 30, 2016, the Company completed a legal entity restructuring as part of its continuing integration of our business. This resulted in the realization of a $635.0 million tax benefit arising from an outside basis difference, which was partly offset by a valuation allowance on its U.S. deferred tax assets. The tax benefit for the comparable 2015 period was primarily related to losses from continued operations combined with benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business.

39

NOTE 17. NET LOSS PER SHARE
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Numerator:
 
 
 
 
 
 
 
(Loss) income from continuing operations
$
(191,496
)
 
$
(803,706
)
 
$
109,553

 
$
(744,108
)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests
—

 
(46
)
 
16

 
(153
)
(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders
$
(191,496
)
 
$
(803,660
)
 
$
109,537

 
$
(743,955
)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax
(27,423
)
 
(246,782
)
 
(118,747
)
 
(632,624
)
Net loss attributable to Endo International plc ordinary shareholders
$
(218,919
)
 
$
(1,050,442
)
 
$
(9,210
)
 
$
(1,376,579
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
222,767

 
209,274

 
222,579

 
188,085

Dilutive effect of ordinary share equivalents
—

 
—

 
480

 
—

Dilutive effect of various convertible notes and warrants
—

 
—

 
1

 
—

For diluted per share data—weighted average shares
222,767

 
209,274

 
223,060

 
188,085

Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period. Ordinary share equivalents are measured under the treasury stock method.
For the three months ended September 30, 2016, all stock options and stock awards were excluded from the diluted share calculation because their effect would have been anti-dilutive, as the Company was in a loss position. For the nine months ended September 30, 2016, stock options and stock awards of 5.0 million were excluded from the diluted share calculation because their effect would have been anti-dilutive. All stock options and stock awards were excluded from the diluted share calculation for the three and nine months ended September 30, 2015 because their effect would have been anti-dilutive, as the Company was in a loss position.
Item 2.        Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations describes the principal factors affecting the results of operations, liquidity and capital resources and critical accounting estimates at Endo International plc. This discussion should be read in conjunction with the accompanying quarterly unaudited Condensed Consolidated Financial Statements and our Annual Report on Form 10-K, for the year ended December 31, 2015 (Annual Report). Our Annual Report includes additional information about our significant accounting policies, practices and the transactions that underlie our financial results, as well as a detailed discussion of the most significant risks and uncertainties associated with our financial and operating results. Except for the historical information contained in this Report, including the following discussion, this Report contains forward-looking statements that involve risks and uncertainties. See "Forward-Looking Statements" beginning on page i of this Report.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our” or “us” refer to financial information and transactions of Endo International plc and its consolidated subsidiaries.
RESULTS OF OPERATIONS
Our quarterly results have fluctuated in the past, and may continue to fluctuate. These fluctuations are primarily due to (1) the timing of mergers, acquisitions and other business development activity, (2) the timing of new product launches, (3) purchasing patterns of our customers, (4) market acceptance of our products, (5) the impact of competitive products and products we recently acquired, (6) pricing of our products and (7) litigation-related charges. These fluctuations are also attributable to charges incurred for compensation related to share-based payments, amortization of intangible assets, asset impairment charges, restructuring charges and certain upfront, milestone and other payments made or accrued pursuant to acquisition or licensing agreements.

40

Consolidated Results Review
Total Revenues. Total revenues for the three and nine months ended September 30, 2016 increased 19% to $884.3 million and 26% to $2,768.8 million, respectively, from the comparable 2015 periods. This revenue increase was primarily attributable to revenues related to our September 2015 acquisition of Par. The increases were partially offset by decreased revenues for certain products in our U.S. Branded Pharmaceuticals segment, driven mainly by decreased Voltaren® Gel, Lidoderm®, OPANA® ER and Frova® revenues related to generic competition and decreased revenues from our legacy U.S. Generic Pharmaceuticals segment, driven by a decrease as a result of competitive pressure on commoditized generic products.
Gross margin, costs and expenses. The following table sets forth costs and expenses for the three and nine months ended September 30, 2016 and 2015 (dollars in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
 
$
 
% of Revenue
 
$
 
% of Revenue
 
$
 
% of Revenue
 
$
 
% of Revenue
Cost of revenues
$
557,472

 
63
 
$
442,459

 
59

 
$
1,878,395

 
68
 
$
1,265,583

 
58
Selling, general and administrative
186,735

 
21
 
163,221

 
22

 
558,160

 
20
 
529,290

 
24
Research and development
44,885

 
5
 
21,327

 
3

 
137,166

 
5
 
58,208

 
3
Litigation-related and other contingencies, net
18,256

 
2
 
—

 
—

 
28,715

 
1
 
19,875

 
1
Asset impairment charges
93,504

 
11
 
923,607

 
124

 
263,080

 
10
 
1,000,850

 
46
Acquisition-related and integration items
19,476

 
2
 
(27,688
)
 
(4
)
 
80,201

 
3
 
51,177

 
2
Total costs and expenses*
$
920,328

 
104
 
$
1,522,926

 
204

 
$
2,945,717

 
106
 
$
2,924,983

 
133
__________
*
Percentages may not add due to rounding.
Cost of revenues and gross margin. Cost of revenues for the three and nine months ended September 30, 2016 increased 26% to $557.5 million and 48% to $1,878.4 million, respectively, from the comparable 2015 periods. These increases were primarily attributable to increased costs related to our acquisition of Par and charges to increase excess inventory reserves of approximately $66 million at our U.S. Generic Pharmaceuticals segment due to the underperformance of certain products and the planned discontinuance of several products as part of the 2016 U.S. Generic Pharmaceuticals restructuring initiative announced in May 2016. Gross margins for the three months ended September 30, 2016 decreased to 37% from 41% in the comparable 2015 period and gross margins for the nine months ended September 30, 2016 decreased to 32% from 42% in the comparable 2015 period. These decreases were primarily attributable to the mix of revenue being more heavily weighted toward lower margin generic pharmaceutical product sales as compared to the higher margin branded products, increased intangible asset amortization of $90.0 million and $302.3 million for the three and nine months ended September 30, 2016, respectively, and the charges to increase excess inventory reserves mentioned above.
Selling, general and administrative expenses. Selling, general and administrative expenses for the three and nine months ended September 30, 2016 increased 14% to $186.7 million and 5% to $558.2 million, respectively, from the comparable 2015 periods. These increases were primarily a result of incremental employee, facility and other selling, general and administrative expenses related to the acquisition of Par. The increase during the nine months ended September 30, 2016 was partially offset by a charge during the first quarter of 2015 related to the acceleration of Auxilium employee equity awards at closing of $37.6 million, restructuring charges during the first quarter of 2015 of $26.0 million related to the Auxilium acquisition, and restructuring charges during the third quarter of 2015 of $18.5 million related to the Par acquisition.
Research and development expenses. Research and development expenses for the three and nine months ended September 30, 2016 increased 110% to $44.9 million and 136% to $137.2 million, respectively, from the comparable 2015 periods. The increases were primarily attributable to the acquisition of Par.
Litigation-related and other contingencies, net. Charges for Litigation-related and other contingencies, net for the three and nine months ended September 30, 2016 totaled $18.3 million and $28.7 million, respectively, compared to zero and $19.9 million for the three and nine months ended September 30, 2015, respectively. The Company’s legal proceedings and other contingent matters are described in more detail in Note 12. Commitments and Contingencies of Part I, Item 1.

41

Asset impairment charges. Asset impairment charges for the three and nine months ended September 30, 2016 totaled $93.5 million and $263.1 million, respectively, compared to $923.6 million and $1,000.9 million for the three and nine months ended September 30, 2015, respectively. The pre-tax, non-cash impairment charges of $93.5 million during the third quarter of 2016 were primarily related to a charge of $72.8 million in our U.S. Branded Pharmaceuticals segment relating to our Sumavel® DosePro® product, which resulted from unfavorable formulary changes and a downturn in its performance, and a $16.2 million charge on a definite-lived intangible asset in our International Pharmaceuticals segment relating to a third quarter 2016 decision not to pursue commercialization of a product in certain international markets. The impairment charges of $40.0 million during the three months ended June 30, 2016 resulted from certain market conditions impacting the commercial potential of certain intangible assets in our U.S. Generic Pharmaceuticals segment. These charges are in addition to the $129.6 million impairment charges on certain intangible assets recorded during the three months ended March 31, 2016, including charges of $100.3 million related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects.
The pre-tax, non-cash impairment charges of $923.6 million and $1,000.9 million recorded during the three and nine months ended September 30, 2015, respectively, were primarily related to a third quarter 2015 provisional impairment charge of $680.0 million, representing the difference between the estimated implied fair value of the former UEO reporting unit’s goodwill and its respective net book value. In addition to the goodwill impairment charge, during the third quarter of 2015 the Company also recorded charges of approximately $242.9 million on certain intangible assets primarily from our U.S. Branded Pharmaceuticals and U.S. Generic Pharmaceuticals segments, second quarter 2015 asset impairment charges of $70.2 million on certain intangible assets of our U.S. Generic Pharmaceuticals segment and a first quarter 2015 impairment charge of $7.0 million on certain leasehold improvements associated with Auxilium’s former headquarters.
As a result of a sustained downturn in the testosterone replacement therapy (TRT) market and additional competition and pricing pressure related to certain of our U.S. Generics and Canadian based products, several significant intangible assets are at risk of becoming impaired if we were to experience a decline in future market conditions below our current estimates. Specifically, the excess of undiscounted cash flows over carrying amount for our TESTOPEL, Methotrexate and Canada Base Prescription intangible assets were all less than 5 percent of carrying amount. In addition, any sustained downturns in other areas of our business could result in additional impairments of our definite and indefinite lived assets, which could be material.
Acquisition-related and integration items. Acquisition-related and integration items for the three and nine months ended September 30, 2016 increased 170% to $19.5 million and 57% to $80.2 million, respectively, from the comparable 2015 periods. The increases during the three and nine months ended September 30, 2016 were primarily driven by $11.6 million and $24.8 million of expense, respectively, compared to a benefit of $80.3 million and $83.6 million for the three and nine months ended September 30, 2015, respectively, resulting from changes in the fair value of contingent consideration. The adjustments to contingent consideration were due to changes in market conditions impacting the commercial potential of the underlying products. These increases were partially offset by decreases of $44.7 million and $79.4 million for the three and nine months ended September 30, 2016, respectively, of acquisition-related and integration costs associated with our Auxilium and Par acquisitions, which closed in 2015.
Interest expense, net. The components of Interest expense, net for the three and nine months ended September 30, 2016 and 2015 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Interest expense
$
113,088

 
$
98,701

 
$
343,655

 
$
253,530

Interest income
(904
)
 
(2,255
)
 
(2,759
)
 
(3,334
)
Interest expense, net
$
112,184

 
$
96,446

 
$
340,896

 
$
250,196

Interest expense for the three and nine months ended September 30, 2016 increased 15% to $113.1 million and increased 36% to $343.7 million, respectively, from the comparable 2015 periods. These increases were primarily attributable to an increase in our average total indebtedness to $8.3 billion during the three months ended September 30, 2016 from $7.2 billion in the comparable 2015 period and to $8.4 billion during the nine months ended September 30, 2016 from $6.1 billion in the comparable 2015 period. Our period-over-period average total indebtedness has increased due primarily to the financing of the Par acquisition.
Loss on extinguishment of debt. Loss on extinguishment of debt was zero for the three and nine months ended September 30, 2016 compared to $40.9 million and $41.9 million for the three and nine months ended September 30, 2015, respectively. The 2015 charges were primarily related to the early redemption of the Company’s former 7.00% Senior Notes due 2019 during the third quarter of 2015.

42

Other (income) expense, net. The components of Other (income) expense, net for the three and nine months ended September 30, 2016 and 2015 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Foreign currency loss (gain), net
$
(123
)
 
$
(4,095
)
 
$
2,427

 
$
(24,651
)
Equity (earnings) loss from unconsolidated subsidiaries, net
(2,023
)
 
1,899

 
(539
)
 
3,650

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Legal settlement
—

 
(12,500
)
 
—

 
(12,500
)
Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other miscellaneous, net
(720
)
 
506

 
(1,486
)
 
(1,131
)
Other (income) expense, net
$
(2,866
)
 
$
50,091

 
$
402

 
$
62,589

Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. The Company incurred $64.3 million and $78.4 million during the three and nine months ended September 30, 2015, respectively, related to unused commitment fees primarily associated with financing for the Par acquisition. In addition, during the nine months ended September 30, 2015, the Company recognized an other than temporary impairment of our Litha joint venture investment totaling $18.9 million, reflecting the excess carrying value of this investment over its estimated fair value.
Income tax expense (benefit). During the three months ended September 30, 2016, the Company recognized income tax expense of $46.2 million on $145.3 million of loss from continuing operations before income tax, compared to $160.9 million of tax benefit on $964.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the third quarter of 2016, the Company completed a legal entity restructuring. The restructuring resulted in the Company recording a deferred charge of $395.1 million in accordance with applicable accounting guidance. Within the third quarter, the Company recorded net discrete tax expense of $42.6 million primarily related to the amortization of the aforementioned deferred charge, which was partially offset by a favorable return to provision adjustment resulting from filing U.S. federal income tax returns. The tax benefit for the comparable 2015 period was primarily related to benefits resulting from losses from continued operations.
During the nine months ended September 30, 2016, the Company recognized an income tax benefit of $627.8 million on $518.3 million of loss from continuing operations before income tax, compared to $340.5 million of tax benefit on $1,084.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the nine months ended September 30, 2016, the Company completed a legal entity restructuring as part of its continuing integration of our business. This resulted in the realization of a $635.0 million tax benefit arising from an outside basis difference, which was partly offset by a valuation allowance on its U.S. deferred tax assets. The tax benefit for the comparable 2015 period was primarily related to losses from continued operations combined with benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business.
Under U.S. GAAP, the effective tax rate for the nine months ended September 30, 2016 was primarily determined based on our year-to-date results. The full-year effective tax rate may be significantly different to the extent we experience a change in the jurisdictional mix of earnings during the fourth quarter.
Discontinued operations, net of tax. As a result of our decision to sell our AMS business and wind down our Astora business, which comprises the entirety of our former Devices segment, the operating results of this business are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. The results of our discontinued operations totaled $27.4 million and $118.7 million of loss, net of tax, during the three and nine months ended September 30, 2016, respectively, compared to $246.8 million and $632.6 million of loss, net of tax, in the comparable 2015 periods.
The change in Discontinued operations, net of tax, during the three months ended September 30, 2016 compared to the same period in 2015 was mainly due to a reduction of income tax expense of $228.0 million derived from the valuation allowance recorded on our U.S. deferred tax assets that resulted in no tax benefit on pre-tax losses for the three months ended September 30, 2016. This reduction was partially offset by an increase in charges relating to mesh litigation of $17.7 million during the three months ended September 30, 2016 and a gain on the sale of the Men’s Health and Prostate Health components of approximately $13.6 million recognized during the third quarter of 2015.
The change during the nine months ended September 30, 2016 compared to the same period in 2015 was mainly due to a decrease in charges relating to mesh litigation of $253.6 million, a decrease in asset impairment charges of $203.6 million and a reduction of income tax expense of $126.3 million derived from tax expense recorded as part of the divestiture of the Men’s Health and Prostate Health businesses in the third quarter of 2015, offset partially by a full valuation allowance recorded on the Company’s U.S. net deferred tax assets in 2016, a decrease in income from operations resulting from the sale of the Men’s Health and Prostate Health components in the third quarter of 2015 and a gain on the sale of the Men’s Health and Prostate Health components noted above of approximately $13.6 million during the third quarter of 2015.

43

2016 Outlook
We estimate that our 2016 total revenues will be between $3.87 billion and $4.03 billion. This estimate is based on our expectation of growth for Company revenues from our core products and the full year impact of our 2015 acquisitions, including our acquisition of Par, which closed on September 25, 2015. We consistently apply principles of efficiency to streamline general and administrative expenses, optimize commercial spend and focus research and development efforts onto lower-risk projects and higher-return investments to Endo’s current business. The Company also intends to seek long-term, durable growth both internally and through strategic acquisitions in order to support its objective of transforming Endo into a leading global specialty pharmaceuticals company. There can be no assurance that the Company will achieve these results.
Business Segment Results Review
The three reportable business segments in which the Company operates are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals and (3) International Pharmaceuticals. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income (loss) from continuing operations before income tax, a financial measure not determined in accordance with U.S. GAAP, which we define as loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; excess costs that will be eliminated pursuant to integration plans; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; certain non-cash interest expense; litigation-related and other contingent matters; gains or losses from early termination of debt activities; foreign currency gains or losses on intercompany financing arrangements; and certain other items that the Company believes do not reflect its core operating performance.
Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as Corporate unallocated, including interest expense. The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate costs.
We refer to adjusted income (loss) from continuing operations before income tax in making operating decisions because we believe it provides meaningful supplemental information regarding the Company’s operational performance. For instance, we believe that this measure facilitates its internal comparisons to our historical operating results and comparisons to competitors’ results. The Company believes this measure is useful to investors in allowing for greater transparency related to supplemental information used in our financial and operational decision-making. In addition, we have historically reported similar financial measures to our investors and believe that the inclusion of comparative numbers provides consistency in our current financial reporting. Further, we believe that adjusted income (loss) from continuing operations before income tax may be useful to investors as we are aware that certain of our significant shareholders utilize adjusted income (loss) from continuing operations before income tax to evaluate our financial performance. Finally, adjusted income (loss) from continuing operations before income tax is utilized in the calculation of adjusted diluted income per share, which is used by the Compensation Committee of the Board of Directors in assessing the performance and compensation of substantially all of our employees, including our executive officers.
There are limitations to using financial measures such as adjusted income (loss) from continuing operations before income tax. Other companies in our industry may define adjusted income (loss) from continuing operations before income tax differently than we do. As a result, it may be difficult to use adjusted income (loss) from continuing operations before income tax or similarly named adjusted financial measures that other companies may use to compare the performance of those companies to our performance. Because of these limitations, adjusted income (loss) from continuing operations before income tax is not intended to represent cash flow from operations as defined by U.S. GAAP and should not be used as alternatives to net income as indicators of operating performance or to cash flows as measures of liquidity. The Company compensates for these limitations by providing reconciliations of our segment adjusted income from continuing operations before income tax to our consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP and included in our Condensed Consolidated Statements of Operations.

44

Revenues. The following table displays our revenue by reportable segment for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net revenues to external customers:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
279,843

 
$
304,778

 
$
876,998

 
$
905,198

U.S. Generic Pharmaceuticals
533,691

 
367,933

 
1,682,439

 
1,063,221

International Pharmaceuticals (1)
70,801

 
73,016

 
209,324

 
226,602

Total net revenues to external customers
$
884,335

 
$
745,727

 
$
2,768,761

 
$
2,195,021

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
U.S. Branded Pharmaceuticals. The following table displays the significant components of our U.S. Branded Pharmaceuticals revenues to external customers for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Pain Management:
 
 
 
 
 
 
 
Lidoderm®
$
19,704

 
$
29,689

 
$
66,455

 
$
85,035

OPANA® ER
36,834

 
42,206

 
120,058

 
132,162

Percocet®
33,881

 
31,898

 
103,182

 
100,641

Voltaren® Gel
18,993

 
48,515

 
82,030

 
144,992

 
$
109,412

 
$
152,308

 
$
371,725

 
$
462,830

Specialty Pharmaceuticals:
 
 
 
 
 
 
 
Supprelin® LA
$
19,392

 
$
19,095

 
$
57,855

 
$
53,173

XIAFLEX®
47,695

 
40,000

 
134,159

 
107,918

 
$
67,087

 
$
59,095

 
$
192,014

 
$
161,091

Branded Other Revenues (1)
103,344

 
93,375

 
313,259

 
281,277

Total U.S. Branded Pharmaceuticals (2)
$
279,843

 
$
304,778

 
$
876,998

 
$
905,198

__________
(1)
Products included within Branded Other Revenues in the table above include, but are not limited to, TESTOPEL®, Testim®, Fortesta® Gel, including authorized generic, BELBUCATM, Sumavel® DosePro® and Nascobal® Nasal Spray.
(2)
Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $25.0 million during the three months ended September 30, 2016 or September 30, 2015.
Pain Management
Net sales of Lidoderm® for the three and nine months ended September 30, 2016 decreased 34% to $19.7 million and decreased 22% to $66.5 million from the comparable 2015 periods. These decreases were attributable to volume decreases partially offset by an increase in price. In September 2013 Actavis (now Teva) launched a generic form of Lidoderm®, in May 2014 the Company’s U.S. Generic Pharmaceuticals launched its authorized generic of Lidoderm® and in August 2015 Mylan launched a generic form of Lidoderm®. To the extent additional competitors are able to launch generic versions of Lidoderm®, our revenues could decline further.
Net sales of OPANA® ER for the three and nine months ended September 30, 2016 decreased 13% to $36.8 million and decreased 9% to $120.1 million from the comparable 2015 periods. Net sales continue to be impacted by competing generic versions of the non-crush resistant formulation of OPANA® ER, which launched beginning in early 2013. To the extent additional competitors are able to launch generic versions of the non-crush resistant formulation OPANA® ER, our revenues could decline further. However, in April 2016, the U.S. District Court affirmed a ruling upholding two of the Company’s patents covering OPANA® ER. In addition, in April 2016, the U.S. District Court issued an order upholding its August 2015 ruling in the Company’s favor and confirming the prior injunction against the manufacture or sale of the generic version of non-crush resistant OPANA® ER currently offered by Actavis and the additional approved but not yet marketed generic version of the product developed by Roxane. As a result, the generic product sold by Actavis was removed from the market and other generic versions of the product will not be launched in the near term by other generic companies.

45

Net sales of Percocet® for the three and nine months ended September 30, 2016 increased 6% to $33.9 million and increased 3% to $103.2 million from the comparable 2015 periods. These increases were attributable to price increases, partially offset by volume decreases.
Net sales of Voltaren® Gel for the three and nine months ended September 30, 2016 decreased 61% to $19.0 million and decreased 43% to $82.0 million from the comparable 2015 periods. These decreases were primarily attributable to the March 2016 launch of Amneal Pharmaceuticals LLC’s generic equivalent of Voltaren® Gel and our launch of the authorized generic of Voltaren® Gel in July 2016. Subject to FDA approval, it is possible one or more additional competing generic products could potentially enter the market, which could negatively impact future sales of Voltaren® Gel.
Specialty Pharmaceuticals
Net sales of Supprelin® LA for the three and nine months ended September 30, 2016 increased 2% to $19.4 million and increased 9% to $57.9 million from the comparable 2015 periods. These revenue increases were primarily attributable to volume and price increases.
Net sales of XIAFLEX® for the three and nine months ended September 30, 2016 increased 19% to $47.7 million and increased 24% to $134.2 million from the comparable 2015 periods. These revenue increases were primarily attributable to volume increases in addition to a full period of Auxilium revenues for the nine months ended September 30, 2016.
Branded Other
Net sales of Branded Other products for the three and nine months ended September 30, 2016 increased 11% to $103.3 million and increased 11% to $313.3 million from the comparable 2015 periods. The increase during the three months ended September 30, 2016 was primarily driven by the acquisition of Par branded products, which we acquired on September 25, 2015, partially offset by decreased Frova® revenues related to generic competition. The increase during the nine months ended September 30, 2016 was primarily attributable to the acquisitions of Auxilium, which we acquired on January 29, 2015, and Par, partially offset by decreased Frova® revenues related to generic competition.
U.S. Generic Pharmaceuticals. The following table displays the significant components of our U.S. Generic Pharmaceuticals revenues to external customers for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
U.S. Generic Pharmaceuticals
 
 
 
 
 
 
 
U.S. Generics Base (1)
$
263,431

 
$
252,881

 
$
941,955

 
$
711,392

Sterile Injectables
136,966

 
7,081

 
386,900

 
7,081

New Launches and Alternative Dosages (2)
133,294

 
107,971

 
353,584

 
344,748

Total U.S. Generic Pharmaceuticals
$
533,691

 
$
367,933

 
$
1,682,439

 
$
1,063,221

__________
(1)
U.S. Generics Base includes solid oral-extended release, solid oral-immediate release and pain/controlled substances products.
(2)
New Launches and Alternative Dosages includes liquids, semi-solids, patches, powders, ophthalmics, sprays and new product launches. Products are included in New Launches during the calendar year of launch and the subsequent calendar year such that the period of time any product will be considered a New Launch will range from thirteen to twenty-four months. New Launches contributed $50.3 million and $111.4 million of revenues to the three and nine months ended September 30, 2016, respectively, and $19.9 million and $31.2 million of revenues to the three and nine months ended September 30, 2015, respectively. The table below presents the most significant revenue producing New Launch Products from the respective most recent two calendar launches years:
Year of
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Launch
 
2016
 
2015
 
2016
 
2015
2015
 
- Dutas/Tams Caps
- Pramipexole DHCI
- Propranolol
- Ethacrynate Sodium
- Testosterone Gel Sachets
 
- Propranolol
- Pramipexole DHCI
- Megace ES AG
- Ethacrynate Sodium
- Tolcapone Tabs
 
- Ethacrynate Sodium
- Dutas/Tams Caps
- Propranolol
- Pramipexole DHCI
- Testosterone Gel Sachets
 
- Pramipexole DHCI
- Propranolol
- Tolcapone Tabs
- Megace ES AG
- Ethacrynate Sodium
2016
 
- Diclofenac Gel
- Omeprazole OS
- Levothyroxine
- Frova AG
- Darifenacin HBr ER Tabs
 
N/A - No impact on 2015
 
- Diclofenac Gel
- Darifenacin HBr ER Tabs
- Frova AG
- Omeprazole OS
- Levothyroxine
 
N/A - No impact on 2015

46

Net sales of U.S. Generics Base for the three and nine months ended September 30, 2016 increased 4% to $263.4 million and increased 32% to $942.0 million from the comparable 2015 periods. These increases were attributable to approximately $119.0 million and $478.3 million in revenue during the three and nine months ended September 30, 2016, respectively, as a result of the acquisition of Par, partially offset by a decrease as a result of competitive pressure on commoditized generic products.
Net sales of Sterile Injectables for the three and nine months ended September 30, 2016 increased to $137.0 million and $386.9 million from the comparable 2015 periods. These increases were attributable to the acquisition of Par. Sterile Injectables include net sales of Vasostrict®, the first and only vasopressin injection with a New Drug Application (NDA) approved by the FDA, which were $91.8 million and $248.9 million for the three and nine months ended September 30, 2016, respectively. In June 2016, the U.S. Patent and Trademark Office issued Endo a new Vasostrict® patent, which has an expiration date of January 30, 2035. Any ANDA applicant seeking FDA approval for a generic version of Vasostrict® prior to expiration of the patent has to notify Par of its ANDA filing before it can obtain FDA approval. Any ANDA filer whose application was not received prior to submission of the new patent information would be subject to a 30-month stay of marketing approval by the FDA upon the initiation of Hatch-Waxman litigation by Par against the ANDA filer.
Net sales of New Launches and Alternative Dosages for the three and nine months ended September 30, 2016 increased 23% to $133.3 million and increased 3% to $353.6 million from the comparable 2015 periods. These increases were primarily attributable to launch products from the Par acquisition, partially offset by increased competitive pressure on patches, ophthalmics and other alternative doses. Material products to be launched in fourth quarter 2016 include Ezetimibe tablets (generic version of Zetia®), which is a first-to-file product with an associated brand value of approximately $2.6 billion, and Quetiapine ER tablets (generic version of Seroquel® XR), which is a first-to-file product with an associated brand value of approximately $1.3 billion.
International Pharmaceuticals. Revenues from our International Pharmaceuticals segment for the three and nine months ended September 30, 2016 decreased 3% to $70.8 million and decreased 8% to $209.3 million from the comparable 2015 periods. These decreases were primarily attributable to decreases in Litha revenues as a result of its divestiture of non-core assets during the first quarter of 2016 in addition to unfavorable fluctuations in foreign currency rates, partially offset by increased revenues from Litha’s acquisition of Aspen Holdings in the fourth quarter of 2015.
Adjusted income (loss) from continuing operations before income tax. The following table displays our adjusted income (loss) from continuing operations before income tax by reportable segment for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Adjusted income (loss) from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
131,615

 
$
156,897

 
$
422,816

 
$
484,758

U.S. Generic Pharmaceuticals
$
228,717

 
$
177,961

 
$
655,453

 
$
507,507

International Pharmaceuticals
$
22,077

 
$
18,961

 
$
64,446

 
$
54,729

Corporate unallocated
$
(159,123
)
 
$
(137,180
)
 
$
(473,933
)
 
$
(363,298
)
During the quarter ended December 31, 2015, we realigned certain costs amongst our International Pharmaceuticals segment, U.S. Branded Pharmaceuticals segment and Corporate unallocated costs based on how our chief operating decision maker reviews segment performance. As a result of this realignment, certain expenses included in our consolidated adjusted income (loss) from continuing operations before income tax for the three and nine months ended September 30, 2015 have been reclassified among our various segments to conform to current period presentation. The net impact of these reclassification adjustments increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $0.6 million and $7.5 million, respectively, with an offsetting $8.1 million decrease to International Pharmaceuticals segment costs for the three months ended September 30, 2015 and increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $1.7 million and $21.0 million respectively, with an offsetting $22.7 million decrease to International Pharmaceuticals segment costs for the nine months ended September 30, 2015. The realignment of these expenses did not impact periods prior to 2015.
U.S. Branded Pharmaceuticals. Adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 decreased 16% to $131.6 million and decreased 13% to $422.8 million from the comparable 2015 periods. These decreases are primarily attributable to decreased Voltaren® Gel, Lidoderm®, OPANA® ER and Frova® revenues related to generic competition.

47

U.S. Generic Pharmaceuticals. Adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 increased 29% to $228.7 million and increased 29% to $655.5 million from the comparable 2015 periods. In 2016, revenues and gross margins increased primarily due to the Par acquisition on September 25, 2015. These increases were partially offset by a decrease resulting from competitive pressure on commoditized generic products and charges to increase excess inventory reserves of approximately $42 million at our U.S. Generic Pharmaceuticals segment due to the underperformance of certain products.
International Pharmaceuticals. Adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 increased 16% to $22.1 million and increased 18% to $64.4 million from the comparable 2015 periods. These increases were primarily attributable to an increase in gross margin resulting from the divestiture of certain lower margin products in the first quarter of 2016, increased revenues from Litha’s acquisition of Aspen Holdings and decreased operating expenses, partially offset by unfavorable fluctuations in foreign currency rates.
Corporate unallocated. Corporate unallocated adjusted loss from continuing operations before income tax for the three and nine months ended September 30, 2016 increased 16% to $159.1 million and increased 30% to $473.9 million from the comparable 2015 periods. These increases were primarily attributable to the previously discussed increase in interest expense.
Reconciliation to GAAP. The table below provides reconciliations of our consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Total consolidated loss from continuing operations before income tax
$
(145,311
)

$
(964,645
)

$
(518,254
)

$
(1,084,636
)
Corporate unallocated costs (1)
159,123


137,180


473,933


363,298

Amortization of intangible assets
211,548


121,503


636,061


333,759

Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans
14,208


42,919


111,787


131,783

Upfront and milestone payments to partners
1,770


9,261


5,875


14,063

Separation benefits and other cost reduction initiatives (2)
9,782


22,669


70,412


70,256

Impact of Voltaren® Gel generic competition
—


—


(7,750
)

—

Acceleration of Auxilium employee equity awards at closing
—


—


—


37,603

Certain litigation-related charges, net (3)
18,256


—


28,715


19,875

Asset impairment charges (4)
93,504


923,607


263,080


1,000,850

Acquisition-related and integration items (5)
19,476


(27,688
)

80,201


51,177

Loss on extinguishment of debt
—


40,909


—


41,889

Costs associated with unused financing commitments
—


64,281


—


78,352

Other than temporary impairment of equity investment
—


—


—


18,869

Foreign currency impact related to the remeasurement of intercompany debt instruments
(114
)

(5,693
)

1,558


(23,991
)
Other, net
167


(10,484
)

(2,903
)

(6,153
)
Total segment adjusted income from continuing operations before income tax
$
382,409


$
353,819


$
1,142,715


$
1,046,994

__________
(1)
Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of $(9.0) million and increases of excess inventory reserves of $24.3 million during the three and nine months ended September 30, 2016, respectively, primarily related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative. The adjustment for the three months ended September 30, 2016 resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of $14.8 million and $30.0 million and other restructuring costs of $3.9 million and $16.1 million were recorded for the three and nine months ended September 30, 2016, respectively. Amounts in the comparable 2015 periods include employee separation costs of $20.8 million and $58.1 million, respectively, and a $7.9 million charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium’s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and Selling, general and administrative expense in our Condensed Consolidated Statements of Operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.

48

(3)
These amounts include charges for Litigation-related and other contingencies, net as further described in Note 12. Commitments and Contingencies.
(4)
Asset impairment charges primarily relate to charges to write down intangible assets as further described in Note 9. Goodwill and Other Intangibles and goodwill impairment charges recorded during the third quarter of 2015.
(5)
Acquisition-related and integration items include costs directly associated with previous acquisitions of $7.9 million and $55.4 million for the three and nine months ended September 30, 2016, respectively, compared to $52.6 million and $134.8 million for the comparable 2015 periods. In addition, during the three and nine months ended September 30, 2016, there is a charge for changes in fair value of contingent consideration of $11.6 million and $24.8 million, respectively. During the three and nine months ended September 30, 2015, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of $80.3 million and $83.6 million, respectively.
LIQUIDITY AND CAPITAL RESOURCES
Our principal source of liquidity is cash generated from operations. Our principal liquidity requirements are for working capital for operations, licenses, milestone payments, capital expenditures, debt service payments and acquisitions. The Company’s working capital was $(414.9) million at September 30, 2016 compared to $(21.8) million at December 31, 2015. Working capital at September 30, 2016 includes restricted cash and cash equivalents of $268.9 million held in Qualified Settlement Funds for mesh product liability settlement agreements, which is expected to be paid to qualified claimants within the next twelve months. Working capital at December 31, 2015 included restricted cash and cash equivalents of $579.0 million held in Qualified Settlement Funds for mesh product liability settlement agreements.
We have historically had broad access to financial markets that provide liquidity. Cash and cash equivalents, which primarily consisted of bank deposits, time deposits and money market accounts, totaled $561.6 million at September 30, 2016 compared to $272.3 million at December 31, 2015.
During and beyond 2016, we expect cash generated from operations together with our cash, cash equivalents and the revolving credit facilities to be sufficient to cover cash needs for working capital and general corporate purposes, certain contingent liabilities, payment of contractual obligations, principal and interest payments on our indebtedness, capital expenditures, ordinary share repurchases and any regulatory and/or sales milestones that may become due.
At this time, we cannot accurately predict the effect of certain developments on the rate of sales growth, such as the degree of market acceptance, patent protection and exclusivity of our products, the impact of competition, the effectiveness of our sales and marketing efforts and the outcome of our current efforts to develop, receive approval for and successfully launch our near-term product candidates. Additionally, we may not be successful in implementing, or may face unexpected changes or expenses in connection with our strategic direction, including the potential for opportunistic corporate development transactions. Any of the above could adversely affect our future cash flows. We may need to obtain additional funding for future transactions, to repay our outstanding indebtedness, or for our future operational needs, and we cannot be certain that funding will be available on terms acceptable to us, or at all. Any issuances of equity securities or convertible securities could have a dilutive effect on the ownership interest of our current shareholders and may adversely impact net income per share in future periods. An acquisition may be accretive or dilutive and, by its nature, involves numerous risks and uncertainties. As a result of our acquisition efforts we are likely to experience significant charges to earnings for merger and related expenses (whether or not the acquisitions are consummated) that may include transaction costs, closure costs or costs of restructuring activities.
Borrowings. At September 30, 2016, the Company’s indebtedness includes a credit agreement with combined outstanding principal borrowings of $3,741.5 million and additional availability of approximately $997.4 million under the revolving credit facilities.
The credit agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on capital expenditures, asset sales, mergers and acquisitions, indebtedness, liens, dividends, investments and transactions with the Company’s affiliates. As of September 30, 2016, we were in compliance with all such covenants.
At September 30, 2016, the Company’s indebtedness includes senior notes with aggregate principal amounts totaling $4.7 billion. These notes mature between 2022 and 2025, subject to earlier repurchase or redemption in accordance with the terms of the respective indentures. Interest rates on these notes range from 5.375% to 7.25%. These notes are senior unsecured obligations of the Company’s subsidiaries and are issued or guaranteed on a senior unsecured basis, as applicable, by all of our significant subsidiaries (other than Astora Women's Health Technologies, Grupo Farmacéutico Somar, S.A. de C.V., and Litha Healthcare Group Limited) and certain of our other subsidiaries, except for the 7.25% Senior Notes due 2022, which are issued by Endo Health Solutions Inc. and guaranteed on a senior unsecured basis by the guarantors named in the Fifth Supplemental Indenture relating to such notes.

49

The indentures governing our various senior notes contain affirmative and negative covenants that the Company believes to be usual and customary for senior unsecured indentures. The negative covenants, among other things, restrict the Company’s ability and the ability of its restricted subsidiaries to incur certain additional indebtedness and issue preferred stock, make restricted payments, sell certain assets, agree to any restrictions on the ability of restricted subsidiaries to make payments to us, create certain liens, merge, consolidate, or sell substantially all of the Company’s assets, or enter into certain transactions with affiliates. As of September 30, 2016, we were in compliance with all covenants.
Credit ratings. The Company’s corporate credit ratings assigned by Moody’s Investors Service and Standard & Poor’s are B1 with a negative outlook and B+ with a negative outlook, respectively.
Working capital. The components of our working capital and our liquidity at September 30, 2016 and December 31, 2015 are below (dollars in thousands):
 
September 30, 2016
 
December 31, 2015
Total current assets
$
2,247,436

 
$
3,452,537

Less: total current liabilities
(2,662,302
)
 
(3,474,312
)
Working capital
$
(414,866
)
 
$
(21,775
)
Current ratio
-0.8:1

 
-1.0:1

Working capital decreased by $393 million from December 31, 2015 to September 30, 2016. Since December 31, 2015, our current assets have decreased by $1,205 million. Changes in current assets impacting working capital were largely driven by a $345 million reduction in accounts receivable primarily as a result of less revenues in the third quarter of 2016 compared to the fourth quarter of 2015; a $128 million decrease in inventories resulting from continued amortization of inventory step-up related to our recent business acquisitions and excess inventory reserves recorded during the nine months ended September 30, 2016; and a $311 million net differential between cash distributions made from the Qualified Settlement Funds to mesh-related product liability claimants and cash distributions into the Qualified Settlement Funds. The remaining changes in current assets did not have a significant impact on working capital. Since December 31, 2015, our current liabilities have decreased by $812 million. Changes in current liabilities impacting working capital were driven largely by a decrease in accrued liabilities of approximately $217 million, primarily associated with decreased sales deductions as a result of less gross revenues in the third quarter of 2016 compared to the fourth quarter of 2015. The remaining changes in current liabilities did not have a significant impact on working capital.
The following table summarizes our Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Net cash flow provided by (used in):
 
 
 
Operating activities
$
443,377

 
$
(177,432
)
Investing activities
178,866

 
(5,960,496
)
Financing activities
(334,511
)
 
6,570,546

Effect of foreign exchange rate
1,497

 
(5,260
)
Net increase in cash and cash equivalents
$
289,229

 
$
427,358

Net cash provided by (used in) operating activities. Net cash provided by operating activities was $443.4 million for the nine months ended September 30, 2016 compared to $177.4 million used in operating activities in the comparable 2015 period.
Net cash provided by (used in) operating activities represents the cash receipts and cash disbursements from all of our activities other than investing activities and financing activities. Changes in cash from operating activities reflect, among other things, the timing of cash collections from customers, payments to suppliers, managed care organizations, government agencies, collaborative partners and employees, as well as tax payments and refunds in the ordinary course of business.
The $620.8 million fluctuation in Net cash provided by (used in) operating activities for the nine months ended September 30, 2016 compared to the comparable 2015 period was primarily the result of a $707.3 million federal income tax refund received during the second quarter of 2016, offset partially by the timing of cash collections and cash payments related to our operations.

50

The following table summarizes certain of our significant pre-tax cash outlays and cash receipts impacting Net cash provided by (used in) operating activities for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Payments for mesh-related product liability and other litigation matters
$
931,496

 
$
525,875

Redemption fees paid in connection with debt retirements
—

 
17,496

Unused commitment fees
—

 
78,352

Separation and restructuring payments
73,962

 
59,292

Transaction costs and certain integration charges paid in connection with acquisitions
54,262

 
151,687

U.S. Federal tax refunds received
(712,303
)
 
(70,300
)
Total
$
347,417

 
$
762,402

Net cash provided by (used in) investing activities. Net cash provided by investing activities was $178.9 million for the nine months ended September 30, 2016 compared to $5,960.5 million used in investing activities in the comparable 2015 period.
This $6,139.4 million fluctuation in cash provided by investing activities for the nine months ended September 30, 2016 compared to the comparable 2015 period relates primarily to the cash used for acquisitions in 2015 of $7,514.4 million. In addition, $898.3 million of cash was released from the Qualified Settlement Funds (QSFs) for mesh settlements during the nine months ended September 30, 2016, which was $388.7 million more than cash released from the QSFs during the prior year. These net increases were partially offset by a decrease of $1,584.7 million in proceeds from sale of business, primarily relating to the sale of the Men’s Health and Prostate Health components of the AMS business during the third quarter of 2015, and $587.8 million paid into QSFs for mesh settlements during the nine months ended September 30, 2016, which was $61.0 million more than cash paid into the QSFs during the prior year. Additionally, during the nine months ended September 30, 2015, $40 million of cash was released from the escrow account associated with the acquisition of the remaining outstanding share capital of Litha. Cash payments into QSFs and escrow accounts result in a cash outflow for investing activities. Cash releases from QSFs and escrow accounts result in a cash inflow for investing activities and a corresponding outflow for cash provided by (used in) operating activities. Payments related to our QSFs are further described in Note 12. Commitments and Contingencies of Part I, Item 1.
Net cash (used in) provided by financing activities. Net cash used in financing activities was $334.5 million for the nine months ended September 30, 2016 compared to $6,570.5 million provided by financing activities in the comparable 2015 period.
Items contributing to the $6,905.1 million fluctuation in cash used in financing activities for the nine months ended September 30, 2016 compared to the comparable 2015 period include a decrease in proceeds from the issuance of notes of $2,835.0 million, a decrease in proceeds from the issuance of term loans of $2,800.0 million, a decrease in issuance of ordinary shares of $2,300.0 million, and a decrease in proceeds from draw of revolving debt of $300.0 million, partially offset by a decrease in principal payments on notes of $499.9 million, a decrease in principal payments on term loans of $383.6 million, a decrease in the repurchase of convertible notes of $247.8 million, a decrease in payments for deferred financing fees of $113.9 million, and a decrease in repayments of revolving debt of $75.0 million.
Fluctuations. Our quarterly results have fluctuated in the past and may continue to fluctuate. These fluctuations may be due to the timing of new product launches, purchasing patterns of our customers, market acceptance of our products, the impact of competitive products and pricing, asset impairment charges, restructuring costs, including separation benefits, business combination transaction costs, upfront, milestone and certain other payments made or accrued pursuant to licensing agreements and changes in the fair value of financial instruments and contingent assets and liabilities recorded as part of a business combination. Further, a substantial portion of our total revenues are through three wholesale drug distributors who in turn supply our products to pharmacies, hospitals and physicians. Accordingly, we are potentially subject to a concentration of credit risk with respect to our trade receivables.
Contractual Obligations. As of September 30, 2016, there were no material changes in our contractual obligations from those disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on February 29, 2016.
Inflation. We do not believe that inflation had a material adverse effect on our financial statements for the periods presented.
Off-balance sheet arrangements. We have no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
CRITICAL ACCOUNTING ESTIMATES
Our critical accounting estimates have not changed materially since December 31, 2015, except as described below. For additional discussion of the Company’s critical accounting estimates, see “Critical Accounting Estimates” in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016.

51

As further described in Note 9. Goodwill and Other Intangibles of the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, we initiated an interim goodwill impairment analysis of our U.S. Branded and U.S. Generics reporting units during the second quarter of 2016 as a result of the significant decline in our stock price. The fair values of our reporting units are dependent upon our estimates of future discounted cash flows and other factors. Our estimates of future cash flows include assumptions concerning future operating performance and economic conditions and may differ from actual future cash flows. Estimated future cash flows are discounted to present value using a market participant, weighted average cost of capital. The financial and credit market volatility directly impacts certain inputs and assumptions used to develop the weighted average cost of capital such as the risk-free interest rate, industry beta, debt interest rate, and our market capital structure. Therefore, changes in these assumptions may affect our fair value estimate and the result of the impairment test.
We have not made any substantial changes to our methodology used in our annual impairment test since our previous assessment. Determination of the fair value of a reporting unit is a matter of judgment and involves the use of estimates and assumptions, which are based on management’s best estimates at the time.
We use an income approach (discounted cash flow approach) for the determination of fair value of our reporting units. Our projected cash flows incorporate many assumptions, the most significant of which include variables such as future sales, growth rates, operating margin, and the discount rates applied.
Assumptions related to revenue, growth rates and operating margin are based on management’s annual and ongoing forecasting, budgeting and planning processes and represent our best estimate of the future results of operations across the company as of that point in time. These estimates are subject to many assumptions, such as the economic environment in which our segments operate, demand for our products and competitor actions. The use of different assumptions would increase or decrease our estimated discounted future cash flows and the resulting estimated fair value of our reporting units, and could result in the fair value of a reporting unit being less than its carrying value in the first step of the impairment test. Our analysis indicated the fair values of the U.S. Branded and U.S. Generics reporting units exceeded their respective carrying values; therefore, an impairment charge was not required for the three months ended June 30, 2016. An increase of 50 basis points to our assumed discount rates used in testing any of these reporting units would not have changed the results of our analysis. In addition, a 10% reduction of annual cash flows used in testing any of these reporting units would not have changed the results of our analysis.
During 2016, we have experienced a reduction in pricing expectations leading to higher erosion in comparison to historical patterns in our U.S. Generic Pharmaceuticals business. These items are primarily due to industry and competitive pressures in the sector. Should this trend continue, and the impact be greater than our current expectations, we could experience further deterioration in our U.S. Generic Pharmaceuticals business or be unable to achieve anticipated pricing levels, particularly with respect to our 505(b)(2) products.
In addition, during the third quarter, we have initiated a comprehensive portfolio review. As part of the review, a corporate strategic plan will be formed to maximize the value of our product portfolios by streamlining our operating model and refining our approach to resource allocation. We anticipate completing the portfolio review in the fourth quarter of 2016.
Changes to assumptions used to determine fair value, including, but not limited to, projections of future cash flows and our weighted average cost of capital, or significant declines in our stock price could result in non-cash impairment charges to goodwill or other long-lived assets, which could be material. As of September 30, 2016, our combined goodwill and intangible assets balance is approximately $14.4 billion.
RECENT ACCOUNTING PRONOUNCEMENTS
For discussion of recent accounting pronouncements, refer to Note 2. Recent Accounting Pronouncements in the Condensed Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 3.        Quantitative and Qualitative Disclosures About Market Risk
Market risk is the potential loss arising from adverse changes in the financial markets, including interest rates and foreign currency exchange rates.
Interest Rate Risk
Our exposure to interest rate risk relates primarily to our variable rate indebtedness associated with the term loan portion and revolving credit facilities portion of our credit agreement. To the extent we utilize amounts under our term loans and revolving credit facilities, we would be exposed to additional interest rate risk. At September 30, 2016, our term loans include principal amount of floating-rate debt of $3.7 billion. Borrowings under our Term Loan A facility bear interest at a rate equal to an applicable margin plus London Interbank Offered Rate (LIBOR), while borrowings under our Term Loan B facility bear interest at a rate equal to an applicable margin plus LIBOR, subject to a LIBOR floor of 0.75%. A hypothetical 1% increase in LIBOR over the 0.75% floor would result in $37.4 million of incremental annual interest expense.
As of September 30, 2016 and December 31, 2015, we had no other assets or liabilities with significant interest rate sensitivity.

52

Investment Risk
At September 30, 2016 and December 31, 2015, we had immaterial investments in available-for-sale securities, primarily associated with equity securities of publicly traded companies. Any decline in value below our original investments will be evaluated to determine if the decline in value is considered temporary or other-than-temporary. An other-than-temporary decline in fair value would be included as a charge to earnings.
Foreign Currency Exchange Risk
We operate and transact business in various foreign countries and are therefore subject to risks associated with foreign currency exchange rate fluctuations. The Company manages this foreign currency risk, in part, through operational means including managing foreign currency revenues in relation to same currency costs as well as managing foreign currency assets in relation to same currency liabilities. The Company is also exposed to the potential earnings effects from intercompany foreign currency assets and liabilities that arise from normal trade receivables and payables and other intercompany loans. Additionally, certain of the Company’s subsidiaries maintain their books of record in currencies other than their respective functional currencies. These subsidiaries’ financial statements are remeasured into their respective functional currencies using current or historical exchange rates. Such remeasurement adjustments could have an adverse effect on the Company’s results of operations.
All assets and liabilities of our international subsidiaries, which maintain their financial statements in local currency, are translated to U.S. dollars at period-end exchange rates. Translation adjustments arising from the use of differing exchange rates are included in accumulated other comprehensive income in shareholders’ equity. Gains and losses on foreign currency transactions and short term inter-company receivables from foreign subsidiaries are included in Other (income) expense, net.
Fluctuations in foreign currency rates resulted in a net gain of $0.1 million and a net loss of $2.4 million for the three and nine months ended September 30, 2016, respectively. This compares to a net gain of $4.1 million and a net gain of $24.7 million in the comparable 2015 periods.
Based on the Company’s significant foreign currency denominated intercompany loans existing at September 30, 2016, we estimate that a 10% appreciation or depreciation in the underlying currencies of our foreign currency denominated intercompany loans, relative to the U.S. Dollar, would result in approximately $4.0 million in incremental foreign currency gains or losses, respectively.
Inflation
We do not believe that inflation has had a significant impact on our revenues or operations.
Item 4.        Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as of September 30, 2016. Based on that evaluation, the Company’s Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2016.
Changes in Internal Control over Financial Reporting
The Company acquired certain entities during the year ended December 31, 2015. Particularly as it relates to the Par acquisition, as permitted by the Securities and Exchange Commission, management elected to exclude this acquisition from its assessment of the effectiveness of its internal controls over financial reporting as of December 31, 2015. The Company integrated the Par business into its internal control over financial reporting structure during the nine months ended September 30, 2016. As such, there have been changes during the nine months ended September 30, 2016 associated with the establishment and integration of internal control over financial reporting with respect to Par.

53

PART II. OTHER INFORMATION
Item 1.        Legal Proceedings
The disclosures under Note 12. Commitments and Contingencies of the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q are incorporated into this Part II, Item 1 by reference.
Item 1A.    Risk Factors
Risk factors disclosed in Item 1A. "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016 (Annual Report) and the risk factors disclosed in Item 1A. “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, filed with the Securities and Exchange Commission on May 6, 2016 (Quarterly Report) are incorporated into this document by reference. The risk factors set forth below are the risk factors containing changes from the risk factors previously disclosed in the Company’s Annual Report and the Quarterly Report. Except as set forth below, there have been no material changes to the risk factors disclosed therein.
The pharmaceutical industry is heavily regulated, which creates uncertainty about our ability to bring new products to market and imposes substantial compliance costs on our business.
Governmental authorities such as the FDA impose substantial requirements on the development, manufacture, holding, labeling, marketing, advertising, promotion, distribution and sale of therapeutic pharmaceutical products through lengthy and detailed laboratory and clinical testing and other costly and time-consuming procedures. In addition, before obtaining regulatory approvals for certain generic products, we must conduct limited clinical or other trials to show comparability to the branded products. A failure to obtain satisfactory results in required pre-marketing trials may prevent us from obtaining required regulatory approvals. The FDA may also require companies to conduct post-approval studies and post-approval surveillance regarding their drug products and to report adverse events.
Before obtaining regulatory approvals for the sale of any of our new product candidates, we must demonstrate through preclinical studies and clinical trials that the product is safe and effective for each intended use. Preclinical and clinical studies may fail to demonstrate the safety and effectiveness of a product. Likewise, we may not be able to demonstrate through clinical trials that a product candidate’s therapeutic benefits outweigh its risks. Even promising results from preclinical and early clinical studies do not always accurately predict results in later, large scale trials. A failure to demonstrate safety and efficacy could or would result in our failure to obtain regulatory approvals. Clinical trials can be delayed for reasons outside of our control which can lead to increased development costs and delays in regulatory approval. For example, there is substantial competition to enroll patients in clinical trials and such competition has delayed clinical development of our products in the past. For example, patients may not enroll in clinical trials at the rate expected or patients may drop out after enrolling in the trials or during the trials. In addition, we rely on collaboration partners that may control or make changes in trial protocol and design enhancements, or encounter clinical trial compliance-related issues, which may also delay clinical trials. Product supplies may be delayed or be insufficient to treat the patients participating in the clinical trials, or manufacturers or suppliers may not meet the requirements of the FDA or foreign regulatory authorities, such as those relating to Current Good Manufacturing Practices. We also may experience delays in obtaining, or we may not obtain, required initial and continuing approval of our clinical trials from institutional review boards. We cannot confirm to you that we will not experience delays or undesired results in these or any other of our clinical trials.
We cannot confirm to you that the FDA or foreign regulatory agencies will approve, clear for marketing or certify any products developed by us or that such approval will not subject the marketing of our products to certain limits on indicated use. The FDA or foreign regulatory authorities may not agree with our assessment of the clinical data or they may interpret it differently. Such regulatory authorities may require additional or expanded clinical trials. Any limitation on use imposed by the FDA or delay in or failure to obtain FDA approvals or clearances of products developed by us would adversely affect the marketing of these products and our ability to generate product revenue, which would adversely affect our financial condition and results of operations.
In addition, with respect specifically to pharmaceutical products, the submission of a New Drug Application (NDA) or ANDA to the FDA with supporting clinical safety and efficacy data, for example, does not guarantee that the FDA will grant approval to market the product. Meeting the FDA’s regulatory requirements to obtain approval to market a drug product, which varies substantially based on the type, complexity and novelty of the pharmaceutical product, typically takes years and is subject to uncertainty. The NDA approval process for a new product varies in time, generally requiring a minimum of 10 months following submission of the ANDA to FDA, but could also take several years from the date of application. The timing for the ANDA approval process for generic products is difficult to estimate and can vary significantly. NDA approvals, if granted, may not include all uses (known as indications) for which a company may seek to market a product.

54

Further, once a product is approved or cleared for marketing, failure to comply with applicable regulatory requirements can result in, among other things, suspensions or withdrawals of approvals or clearances, seizures or recalls of products, injunctions against the manufacture, holding, distribution, marketing and sale of a product, and civil and criminal sanctions. Furthermore, changes in existing regulations or the adoption of new regulations could prevent us from obtaining, or affect the timing of, future regulatory approvals or clearances. Meeting regulatory requirements and evolving government standards may delay marketing of our new products for a considerable period of time, impose costly procedures upon our activities and result in a competitive advantage to larger companies that compete against us.
Based on scientific developments, post-market experience, or other legislative or regulatory changes, the current FDA standards of review for approving new pharmaceutical products, or new indications or uses for approved or cleared products, are sometimes more stringent than those that were applied in the past.
Some new or evolving FDA review standards or conditions for approval or clearance were not applied to many established products currently on the market, including certain opioid products. As a result, the FDA does not have as extensive safety databases on these products as on some products developed more recently. Accordingly, we believe the FDA has expressed an intention to develop such databases for certain of these products, including many opioids. In particular, the FDA has expressed interest in specific chemical structures that may be present as impurities in a number of opioid narcotic active pharmaceutical ingredients, such as oxycodone, which based on certain structural characteristics and laboratory tests may indicate the potential for having mutagenic effects. FDA has required, and may continue to require, more stringent controls of the levels of these impurities in drug products for approval.
Also, the FDA may require labeling revisions, formulation or manufacturing changes and/or product modifications for new or existing products containing such impurities. The FDA’s more stringent requirements, together with any additional testing or remedial measures that may be necessary, could result in increased costs for, or delays in, obtaining approval for certain of our products in development. Although we do not believe that the FDA would seek to remove a currently marketed product from the market unless such mutagenic effects are believed to indicate a significant risk to patient health, we cannot make any such assurance.
The Obama administration has also released a comprehensive action plan to reduce prescription drug abuse, which may include proposed legislation to amend existing controlled substances laws to require healthcare practitioners who request Drug Enforcement Administration (DEA) registration to prescribe controlled substances to receive training on opioid prescribing practices as a condition of registration. In addition, state health departments and boards of pharmacy have authority to regulate distribution and may modify their regulations with respect to prescription narcotics in an attempt to curb abuse. In either case, any such new regulations or requirements may be difficult and expensive for us to comply with, may delay our introduction of new products, may adversely affect our total revenues and may have a material adverse effect on our business, results of operations, financial condition and cash flows.
The FDA has the authority to require companies to undertake additional post-approval studies to assess known or signaled safety risks and to make any labeling changes to address those risks. The FDA also can require companies to formulate approved Risk Evaluation and Mitigation Strategies (REMS) to confirm a drug’s benefits outweigh its risks. For example, in 2011, we, along with other manufacturers of long-acting and extended-release opioid drug products, received a letter from the FDA requiring that we develop and submit to the FDA a post-market REMS plan for our OPANA® ER, morphine sulfate ER, and oxycodone ER drug products to require that training is provided to prescribers of these products, and that information is provided to prescribers that they can use in counseling patients about the risks and benefits of opioid drug use. In December 2011, the FDA approved our interim REMS for OPANA® ER, which was subsequently superseded by the class-wide extended-release/long-acting REMS approved in July 2012. The goal of this REMS is to reduce serious adverse outcomes resulting from inappropriate prescribing, misuse and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications. The REMS includes a Medication Guide, Elements to Assure Safe Use and annual REMS Assessment Reports.
The FDA’s exercise of its authority under the FFDCA could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar authority and may impose comparable requirements and costs. Post-marketing studies and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our products. Furthermore, the discovery of significant safety or efficacy concerns or problems with a product in the same therapeutic class as one of our products that implicate or appear to implicate the entire class of products could have an adverse effect on sales of our product or, in some cases, result in product withdrawals. FDA has continuing authority over the approval of an NDA or ANDA and may withdraw approval if, among other reasons, post-marketing clinical or other experience, tests, or data show that a drug is unsafe for use under the conditions upon which it was approved, or if FDA determines that there is a lack of substantial evidence of the drug’s efficacy under the conditions described in its labeling. Furthermore, new data and information, including information about product misuse or abuse at the user level, may lead government agencies, professional societies, practice management groups or patient or trade organizations to recommend or publish guidance or guidelines related to the use of our products, which may lead to reduced sales of our products.

55

The FDA and the DEA have important and complementary responsibilities with respect to our business. The FDA administers an application and post-approval monitoring process to confirm that products that are available in the market are safe, effective and consistently of uniform, high quality. The DEA administers registration, drug allotment and accountability systems to satisfy against loss and diversion of controlled substances. Both agencies have trained investigators that routinely, or for cause, conduct inspections, and both have authority to seek to enforce their statutory authority and regulations through administrative remedies as well as civil and criminal enforcement actions.
The FDA regulates and monitors the quality of drug and device clinical trials to provide human subject protection and to support marketing applications. The FDA may place a hold on a clinical trial and may cause a suspension or withdrawal of product approvals if regulatory standards are not maintained. The FDA also regulates the facilities, processes, and procedures used to manufacture and market pharmaceutical products in the U.S. Manufacturing facilities must be registered with the FDA and all products made in such facilities must be manufactured in accordance with the latest cGMP regulations, which are enforced by the FDA. Compliance with clinical trial requirements and cGMP regulations requires the dedication of substantial resources and requires significant expenditures. In the event an approved manufacturing facility for a particular drug is required by the FDA to curtail or cease operations, or otherwise becomes inoperable, or a third party contract manufacturing facility faces manufacturing problems, obtaining the required FDA authorization to manufacture at the same or a different manufacturing site could result in production delays, which could adversely affect our business, results of operations, financial condition and cash flow.
The FDA is authorized to perform inspections of U.S. and foreign facilities under the FFDCA. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance of a Warning Letter. FDA guidelines also provide for the issuance of Warning Letters for violations of “regulatory significance” for which the failure to adequately and promptly achieve correction may be expected to result in an enforcement action. Finally, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause us to modify certain activities identified during the inspection FDA also may issue Warning Letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection.
Similar to other healthcare companies, during 2015, our facilities, in multiple countries, across the full range of our business units, were subject to routine and new-product related inspections by the FDA, MHRA, HPRA and Health Canada. Some of these inspections resulted in non-critical inspection observations (including FDA Form 483 observations). We have responded to all inspection observations within the required time frame and have implemented, or are continuing to implement, the corrective action plans as agreed with the relevant regulatory agencies.
Many of our core products contain controlled substances. The stringent DEA regulations on our use of controlled substances include restrictions on their use in research, manufacture, distribution and storage. A breach of these regulations could result in imposition of civil penalties, refusal to renew or action to revoke necessary registrations, or other restrictions on operations involving controlled substances. In addition, failure to comply with applicable legal requirements subjects the manufacturing facilities of our subsidiaries and manufacturing partners to possible legal or regulatory action, including shutdown. Any such shutdown may adversely affect their ability to supply us with product and thus, our ability to market affected products. This could have a negative impact on our business, results of operation, financial condition, cash flows and competitive position. See also the risk described under the caption “The DEA limits the availability of the active ingredients used in many of our current products and products in development, as well as the production of these products, and, as a result, our procurement and production quotas may not be sufficient to meet commercial demand or complete clinical trials” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015.
In addition, we are subject to the Federal Drug Supply Chain Security Act (DSCSA). The U.S. government has enacted DSCSA that requires development of an electronic pedigree to track and trace each prescription drug at the salable unit level through the distribution system, which will be effective incrementally over a 10-year period. Compliance with DSCSA and future U.S. federal or state electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens.
We cannot determine what effect changes in regulations or legal interpretations or requirements by the FDA or the courts, when and if promulgated or issued, may have on our business in the future. Changes could, among other things, require different labeling, monitoring of patients, interaction with physicians, education programs for patients or physicians, curtailment of necessary supplies, or limitations on product distribution. These changes, or others required by the FDA or DEA could have an adverse effect on the sales of these products. The evolving and complex nature of regulatory science and regulatory requirements, the broad authority and discretion of the FDA and the generally high level of regulatory oversight results in a continuing possibility that, from time to time, we will be adversely affected by regulatory actions despite our ongoing efforts and commitment to achieve and maintain full compliance with all regulatory requirements.

56

Foreign regulatory requirements vary, including with respect to the regulatory approval process, and failure to obtain regulatory approval or maintain compliance with requirements in foreign jurisdictions would prevent or impact the marketing of our products in those jurisdictions.
We have worldwide intellectual property rights to market many of our products and product candidates and intend to seek approval to market certain of our products outside of the U.S. Approval of a product by the regulatory authorities of foreign countries must be obtained prior to manufacturing or marketing that product in those countries. The approval procedure varies among countries and can involve additional testing and the time required to obtain such approval may differ from that required to obtain FDA approval. The non-U.S. regulatory approval process includes all of the risks associated with obtaining FDA approval set forth herein. Approval by the FDA does not secure approval by the regulatory authorities of any other country, nor does the approval by foreign regulatory authorities in one country secure approval by regulatory authorities in other foreign countries or the FDA.
Outside of the U.S., regulatory agencies generally evaluate and monitor the safety, efficacy and quality of pharmaceutical products and devices and impose regulatory requirements applicable to manufacturing processes, stability testing, record keeping and quality standards, among others. These requirements vary across jurisdiction. In certain countries, including emerging and developing markets, the applicable health care and drug regulatory regimes are continuing to evolve and new requirements may be implemented. Ensuring and maintaining compliance with these evolving requirements is and will continue to be difficult, time-consuming and costly. If we fail to comply with these regulatory requirements or fail to obtain and maintain required approvals, our target market will be reduced and our ability to generate revenue from abroad will be adversely affected.
Item 2.        Unregistered Sales of Equity Securities and Use of Proceeds
There were no purchases or sales of equity securities by the Company during the three months ended September 30, 2016.
Item 3.        Defaults Upon Senior Securities
None.
Item 4.        Mine Safety Disclosures
Not applicable.
Item 5.        Other Information
None.
Item 6.        Exhibits
The information called for by this item is incorporated by reference to the Exhibit Index of this Report.

57

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 
 
ENDO INTERNATIONAL PLC
 
(Registrant)
 
 
 
/s/ PAUL V. CAMPANELLI
Name:
Paul V. Campanelli
Title:
President and Chief Executive Officer
 
(Principal Executive Officer)
 
 
 
/s/ SUKETU P. UPADHYAY
Name:
Suketu P. Upadhyay
Title:
Executive Vice President and Chief Financial Officer
 
(Principal Financial Officer)
Date: November 8, 2016

58

Exhibit Index
Exhibit
No. 
Title
 
 
10.1
Separation Agreement between Endo Health Solutions Inc. and Rajiv De Silva, dated as of September 22, 2016 (Incorporated by reference to Exhibit 10.1 of the Endo International plc Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 28, 2016)
 
 
10.2
Executive Employment Agreement between Endo Health Solutions Inc. and Paul Campanelli, dated as of September 23, 2016 (Incorporated by reference to Exhibit 10.1 of the Endo International plc Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 29, 2016)
 
 
31.1
Certification of the President and Chief Executive Officer of Endo pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
31.2
Certification of the Chief Financial Officer of Endo pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
32.1
Certification of the President and Chief Executive Officer of Endo pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
32.2
Certification of the Chief Financial Officer of Endo pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
101
The following materials from Endo International plc’s Report on Form 10-Q for the quarter ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive (Loss) Income, (iv) the Condensed Consolidated Statements of Cash Flows and (v) the Notes to Condensed Consolidated Financial Statements

 EX-31.1 2 ex3119302016ceo302cert.htm EXHIBIT 31.1 CEO 302 CERT Exhibit
Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Paul V. Campanelli, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Endo International plc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
/S/ PAUL V. CAMPANELLI
Paul V. Campanelli
President and Chief Executive Officer
(Principal Executive Officer)
 
 
Date:
November 8, 2016



 EX-31.2 3 ex3129302016cfo302cert.htm EXHIBIT 31.2 CFO 302 CERT Exhibit
Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Suketu P. Upadhyay, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Endo International plc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
/S/ SUKETU P. UPADHYAY
Suketu P. Upadhyay
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
 
 
Date:
November 8, 2016


 EX-32.1 4 ex3219302016ceo906cert.htm EXHIBIT 32.1 CEO 906 CERT Exhibit
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul V. Campanelli, as President and Chief Executive Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2016 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ PAUL V. CAMPANELLI
Name:
 
Paul V. Campanelli
Title:
 
President and Chief Executive Officer
(Principal Executive Officer)
Date: November 8, 2016
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-32.2 5 ex3229302016cfo906cert.htm EXHIBIT 32.2 CFO 906 CERT Exhibit
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Suketu P. Upadhyay, as Chief Financial Officer of Endo International plc (the Company), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2016 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
 
 
/S/ SUKETU P. UPADHYAY
Name:
 
Suketu P. Upadhyay
Title:
 
Executive Vice President, Chief Financial Officer
(Principal Financial Officer)
Date: November 8, 2016
A signed original of this written statement required by Section 906 has been provided to, and will be retained by, Endo International plc and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 6 endp-20160930.xml XBRL INSTANCE DOCUMENT 0001593034 2016-01-01 2016-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member 2016-01-01 2016-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2016-01-01 2016-09-30 0001593034 2016-11-01 0001593034 2016-09-30 0001593034 2015-12-31 0001593034 2015-07-01 2015-09-30 0001593034 2016-07-01 2016-09-30 0001593034 2015-01-01 2015-09-30 0001593034 2014-12-31 0001593034 2015-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AstoraRestructuringMember 2016-09-30 0001593034 us-gaap:ContractTerminationMember endp:AstoraRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AstoraRestructuringMember 2016-09-30 0001593034 us-gaap:ContractTerminationMember endp:AstoraRestructuringMember 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AstoraRestructuringMember 2015-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AstoraRestructuringMember 2015-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AstoraRestructuringMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AstoraRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:AstoraRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:AstoraRestructuringMember 2015-12-31 0001593034 endp:AstoraRestructuringMember 2016-09-30 0001593034 us-gaap:ContractTerminationMember endp:AstoraRestructuringMember 2015-12-31 0001593034 endp:AstoraRestructuringMember 2016-07-01 2016-09-30 0001593034 endp:AmsMember 2015-08-03 2015-08-03 0001593034 endp:AstoraRestructuringMember 2015-07-01 2015-09-30 0001593034 endp:AmsMember 2015-08-03 0001593034 endp:AstoraRestructuringMember 2016-01-01 2016-03-31 0001593034 endp:AmsMember 2016-01-01 2016-09-30 0001593034 endp:AmsMember 2015-07-01 2015-09-30 0001593034 endp:AmsMember 2016-07-01 2016-09-30 0001593034 endp:AmsMember 2015-01-01 2015-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AstoraRestructuringMember 2016-07-01 2016-09-30 0001593034 us-gaap:ContractTerminationMember endp:AstoraRestructuringMember 2016-07-01 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AstoraRestructuringMember 2016-07-01 2016-09-30 0001593034 endp:AssetImpairmentChargesMember endp:AstoraRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:AssetImpairmentChargesMember endp:AstoraRestructuringMember 2016-07-01 2016-09-30 0001593034 endp:AstoraRestructuringMember 2015-01-01 2015-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 endp:AuxiliumRestructuringMember 2015-12-31 0001593034 us-gaap:SellingGeneralAndAdministrativeExpensesMember endp:USGenericPharmaceuticalsRestructuring2015Member 2016-01-01 2016-09-30 0001593034 endp:InventoryWriteOffsMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 endp:AuxiliumRestructuringMember 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2015Member 2015-09-25 0001593034 endp:USGenericPharmaceuticalsRestructuring2016Member 2016-07-01 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2015Member 2015-12-31 0001593034 endp:USGenericPharmaceuticalsRestructuring2016Member 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2015Member 2016-01-01 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2015Member 2016-07-01 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2015Member 2016-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 endp:AuxiliumRestructuringMember 2015-01-29 0001593034 endp:CharlotteNorthCarolinaFacilityMember endp:USGenericPharmaceuticalsRestructuring2016Member us-gaap:ScenarioForecastMember 2016-10-01 2016-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-07-01 2016-09-30 0001593034 endp:CharlotteNorthCarolinaFacilityMember endp:USGenericPharmaceuticalsRestructuring2016Member us-gaap:ScenarioForecastMember us-gaap:SubsequentEventMember 2016-10-30 2016-12-31 0001593034 endp:AssetImpairmentChargesMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 endp:USGenericPharmaceuticalsRestructuring2016Member 2015-12-31 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AuxiliumRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:AuxiliumRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AuxiliumRestructuringMember 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AuxiliumRestructuringMember 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:AuxiliumRestructuringMember 2016-01-01 2016-09-30 0001593034 endp:EmployeeSeverenceandOtherBenefitRelatedCostsMember endp:AuxiliumRestructuringMember 2015-12-31 0001593034 us-gaap:OtherRestructuringMember endp:AuxiliumRestructuringMember 2015-12-31 0001593034 endp:AuxiliumPharmaceuticalsInc.Member 2015-01-29 2015-06-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member 2015-01-29 2015-01-29 0001593034 endp:VoltarenGelMember 2016-07-01 0001593034 endp:AspenHoldingsMember 2015-10-01 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2015-07-01 2015-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2015-09-25 2015-09-25 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedAndIntegrationItemsMember 2015-01-01 2015-09-30 0001593034 endp:VoltarenGelMember 2016-07-01 2016-07-01 0001593034 endp:AspenHoldingsMember 2015-10-01 2015-10-01 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedAndIntegrationItemsMember 2016-01-01 2016-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2015-09-25 0001593034 endp:OtherAcquisitionsMember 2016-01-01 2016-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2015-01-01 2015-09-30 0001593034 endp:OtherAcquisitionsMember 2016-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:MinimumMember 2015-09-25 2015-09-25 0001593034 endp:AuxiliumPharmaceuticalsInc.Member 2015-01-01 2015-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:MaximumMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2016-07-01 2016-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:InProcessResearchAndDevelopment2018LaunchMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:DevelopedTechnologyOtherNonPartneredGenericInjectibleMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:BupropionMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:VasostrictMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:NeostigmineVialMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:OtherDevelopedTechnologyMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:DevelopedTechnologyOtherPartneredCombinedMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:EphedrineSulphateMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:DevelopedTechnologyOtherNonPartneredGenericNonInjectibleMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember endp:ApisolMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:InProcessResearchAndDevelopment2019LaunchMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:DevelopedTechnologyRightsMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:EzetimibeMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:InProcessResearchAndDevelopment2016LaunchMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:InProcessResearchAndDevelopmentMember endp:OtherInProcessResearchAndDevelopmentMember 2015-09-25 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member 2015-09-25 2015-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:ScenarioPreviouslyReportedMember 2015-09-25 0001593034 endp:ParPharmaceuticalHoldingsInc.Member us-gaap:ScenarioAdjustmentMember 2016-09-30 0001593034 endp:BrandedPharmaceuticalsMember us-gaap:ScenarioAdjustmentMember 2015-01-01 2015-09-30 0001593034 us-gaap:CorporateNonSegmentMember us-gaap:ScenarioAdjustmentMember 2015-07-01 2015-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember endp:InventoryWriteOffsMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-07-01 2016-09-30 0001593034 endp:InternationalPharmaceuticalsMember us-gaap:ScenarioAdjustmentMember 2015-07-01 2015-09-30 0001593034 us-gaap:CorporateNonSegmentMember us-gaap:ScenarioAdjustmentMember 2015-01-01 2015-09-30 0001593034 endp:BrandedPharmaceuticalsMember us-gaap:ScenarioAdjustmentMember 2015-07-01 2015-09-30 0001593034 us-gaap:OtherRestructuringMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember endp:InventoryWriteOffsMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-07-01 2016-09-30 0001593034 endp:InternationalPharmaceuticalsMember us-gaap:ScenarioAdjustmentMember 2015-01-01 2015-09-30 0001593034 endp:GenericPharmaceuticalsMember 2015-07-01 2015-09-30 0001593034 endp:GenericPharmaceuticalsMember 2016-07-01 2016-09-30 0001593034 endp:GenericPharmaceuticalsMember 2015-01-01 2015-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2016-07-01 2016-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2015-07-01 2015-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2016-07-01 2016-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 endp:GenericPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2015-07-01 2015-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2015-01-01 2015-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2015-01-01 2015-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2015-07-01 2015-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2016-07-01 2016-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-09-30 0001593034 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-09-30 0001593034 us-gaap:OperatingSegmentsMember 2015-07-01 2015-09-30 0001593034 us-gaap:OperatingSegmentsMember 2015-01-01 2015-09-30 0001593034 us-gaap:OperatingSegmentsMember 2016-07-01 2016-09-30 0001593034 us-gaap:OperatingSegmentsMember 2016-01-01 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2015-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2016-07-01 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2015-01-01 2015-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2015-07-01 2015-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2015-06-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2016-06-30 0001593034 endp:AcquisitionRelatedContingentConsiderationMember 2014-12-31 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:QualitestMember endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:SumavelDoseProMember endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:QualitestMember endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2016-01-01 2016-09-30 0001593034 endp:SumavelDoseProMember endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:VoltarenGelMember endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:SumavelDoseProMember endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:LehighValleyTechnologiesInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:QualitestMember endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2016-09-30 0001593034 endp:OtherAcquisitionsMember endp:AcquisitionRelatedContingentConsiderationMember 2015-12-31 0001593034 endp:LongTermAvailableForSaleSecuritiesMember 2015-12-31 0001593034 endp:RestrictedCashAndCashEquivalentsMember 2015-12-31 0001593034 us-gaap:MoneyMarketFundsMember 2015-12-31 0001593034 endp:ShortTermAvailableForSaleSecuritiesMember 2015-12-31 0001593034 endp:LongTermAvailableForSaleSecuritiesMember us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 endp:ShortTermAvailableForSaleSecuritiesMember us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 us-gaap:CashAndCashEquivalentsMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member 2016-09-30 0001593034 us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2016-09-30 0001593034 us-gaap:BankTimeDepositsMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel2Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel1Member 2016-09-30 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember 2016-09-30 0001593034 us-gaap:MoneyMarketFundsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember endp:GenericPharmaceuticalsMember 2016-09-30 0001593034 endp:AstoraMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember endp:BrandedPharmaceuticalsMember 2016-09-30 0001593034 endp:AstoraMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:FairValueMeasurementsNonrecurringMember endp:GenericPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember endp:GenericPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:FairValueMeasurementsNonrecurringMember endp:BrandedPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember endp:InternationalPharmaceuticalsMember 2016-09-30 0001593034 endp:AstoraMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember endp:InternationalPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:FairValueMeasurementsNonrecurringMember endp:InternationalPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember endp:InternationalPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember endp:BrandedPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember endp:BrandedPharmaceuticalsMember 2016-09-30 0001593034 endp:AstoraMember us-gaap:FairValueMeasurementsNonrecurringMember 2016-01-01 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember endp:GenericPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:FairValueMeasurementsNonrecurringMember 2016-01-01 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-09-30 0001593034 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001593034 endp:LithaJointVentureInvestmentMember 2016-09-30 0001593034 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001593034 endp:RestrictedCashAndCashEquivalentsMember 2016-09-30 0001593034 us-gaap:FairValueInputsLevel1Member 2015-12-31 0001593034 us-gaap:FairValueInputsLevel2Member 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember 2015-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 us-gaap:FairValueInputsLevel3Member 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember 2015-12-31 0001593034 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationShortTermMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001593034 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2015-12-31 0001593034 us-gaap:EquitySecuritiesMember 2015-12-31 0001593034 endp:AcquisitionRelatedContingentConsiderationLongTermMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001593034 endp:ShortTermAvailableForSaleSecuritiesMember us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 endp:ShortTermAvailableForSaleSecuritiesMember 2016-09-30 0001593034 endp:LongTermAvailableForSaleSecuritiesMember 2016-09-30 0001593034 us-gaap:CashAndCashEquivalentsMember 2016-09-30 0001593034 endp:LongTermAvailableForSaleSecuritiesMember us-gaap:EquitySecuritiesMember 2016-09-30 0001593034 endp:GenericPharmaceuticalsMember 2016-09-30 0001593034 endp:BrandedPharmaceuticalsMember 2015-12-31 0001593034 endp:InternationalPharmaceuticalsMember 2015-12-31 0001593034 endp:GenericPharmaceuticalsMember 2015-12-31 0001593034 endp:BrandedPharmaceuticalsMember 2016-09-30 0001593034 endp:InternationalPharmaceuticalsMember 2016-09-30 0001593034 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-09-30 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-09-30 0001593034 us-gaap:TradeNamesMember 2016-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember 2016-09-30 0001593034 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:LicensingAgreementsMember 2016-01-01 2016-09-30 0001593034 us-gaap:LicensingAgreementsMember 2016-01-01 2016-09-30 0001593034 us-gaap:LicensingAgreementsMember 2016-09-30 0001593034 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:TradeNamesMember 2016-01-01 2016-09-30 0001593034 us-gaap:CustomerRelationshipsMember 2015-12-31 0001593034 us-gaap:DevelopedTechnologyRightsMember 2015-12-31 0001593034 us-gaap:TradeNamesMember 2015-12-31 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0001593034 us-gaap:TradeNamesMember 2016-01-01 2016-09-30 0001593034 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001593034 us-gaap:IndefinitelivedIntangibleAssetsMember 2016-01-01 2016-09-30 0001593034 us-gaap:FiniteLivedIntangibleAssetsMember 2016-01-01 2016-09-30 0001593034 us-gaap:CustomerRelationshipsMember 2016-09-30 0001593034 us-gaap:LicensingAgreementsMember 2015-12-31 0001593034 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:InProcessResearchAndDevelopmentMember 2016-01-01 2016-09-30 0001593034 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:DevelopedTechnologyRightsMember 2016-01-01 2016-09-30 0001593034 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelationshipsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember endp:GenericPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember endp:InternationalPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember endp:XiaflexMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember endp:BrandedPharmaceuticalsMember 2016-01-01 2016-09-30 0001593034 endp:OtherAcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember endp:AstoraMember 2016-01-01 2016-09-30 0001593034 endp:VoltarenGelMember us-gaap:OtherIntangibleAssetsMember 2016-01-01 2016-09-30 0001593034 us-gaap:OtherIntangibleAssetsMember 2015-12-31 0001593034 endp:AstoraMember 2016-01-01 2016-09-30 0001593034 endp:IntangibleAssetsMember endp:GenericPharmaceuticalsMember 2016-01-01 2016-03-31 0001593034 endp:AssetImpairmentChargesMember endp:USGenericPharmaceuticalsRestructuring2016Member 2016-01-01 2016-03-31 0001593034 endp:GoodwillAndIndefiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MinimumMember 2016-01-01 2016-09-30 0001593034 endp:GoodwillAndIndefiniteLivedIntangibleAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:MaximumMember 2016-01-01 2016-09-30 0001593034 endp:IntangibleAssetsMember endp:GenericPharmaceuticalsMember 2016-04-01 2016-06-30 0001593034 us-gaap:TradeNamesMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001593034 us-gaap:DevelopedTechnologyRightsMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001593034 us-gaap:CustomerRelationshipsMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001593034 us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001593034 us-gaap:LicensingAgreementsMember us-gaap:WeightedAverageMember 2016-01-01 2016-09-30 0001593034 endp:VoltarenGelAgreement2015Member 2016-01-01 2016-09-30 0001593034 endp:XiaflexMember 2016-07-01 2016-07-31 0001593034 endp:VoltarenGelAgreementMember 2015-01-01 2015-09-30 0001593034 endp:VoltarenGelAgreementMember 2016-01-01 2016-09-30 0001593034 us-gaap:RevolvingCreditFacilityMember 2015-12-31 0001593034 endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember 2015-12-31 0001593034 endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember 2015-12-31 0001593034 endp:FivePointSevenFiveSeniorNotesDueOnTwoThousandTwentyTwoMember 2016-09-30 0001593034 endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember 2015-12-31 0001593034 endp:SixPointZeroPercentSeniorNotesDueTwoThousandTwentyThreeMember 2016-09-30 0001593034 endp:OtherDebtMember 2016-09-30 0001593034 endp:FivePointThreeSevenFiveSeniorNotesDueOnTwoThousandTwentyThreeMember 2016-09-30 0001593034 endp:A6.00SeniorNotesDue2025Member 2016-09-30 0001593034 endp:A6.00SeniorNotesDue2025Member 2015-12-31 0001593034 endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember 2016-09-30 0001593034 endp:TermLoanFacilityDueTwoThousandNineteenMember 2016-09-30 0001593034 endp:TermLoanFacilityDueTwoThousandNineteenMember 2015-12-31 0001593034 us-gaap:RevolvingCreditFacilityMember 2016-09-30 0001593034 endp:SevenPointTwoFivePercentSeniorNotesDueTwoThousandTwentyTwoMember 2015-12-31 0001593034 endp:OtherDebtMember 2015-12-31 0001593034 endp:TermLoanFacilityDueTwoThousandTwentyTwoMember 2016-09-30 0001593034 endp:TermLoanFacilityDueTwoThousandTwentyTwoMember 2015-12-31 0001593034 us-gaap:RevolvingCreditFacilityMember 2016-04-04 2016-04-04 0001593034 endp:JubilantHollisterStierLaboratoriesLLCMember 2016-04-01 2016-06-30 0001593034 endp:AmericanMedicalSystemsMember endp:VaginalMeshCasesMember 2016-01-01 2016-09-30 0001593034 endp:UnapprovedDrugLitigationMember 2013-09-01 2013-09-30 0001593034 endp:OpanaMember us-gaap:JudicialRulingMember 2015-08-01 2015-08-31 0001593034 endp:AmericanMedicalSystemsMember endp:VaginalMeshCasesMember 2016-09-30 0001593034 endp:NoramcoInc.Member 2015-01-01 2015-09-30 0001593034 endp:OpanaMember us-gaap:SubsequentEventMember 2016-10-01 2016-10-31 0001593034 endp:OpanaMember us-gaap:JudicialRulingMember 2012-01-01 2012-12-31 0001593034 endp:OpanaMember 2012-09-21 2013-10-30 0001593034 endp:NoramcoInc.Member 2016-01-01 2016-09-30 0001593034 endp:TestosteroneCasesMember us-gaap:SubsequentEventMember 2016-11-01 0001593034 endp:ParagraphIVCertificationonFortestaGelMember 2013-02-01 2013-02-28 0001593034 endp:OpanaMember us-gaap:JudicialRulingMember 2015-10-01 2015-10-31 0001593034 endp:MegaceESCasesMember 2016-02-01 2016-02-29 0001593034 endp:VaginalMeshCasesMember 2016-09-30 0001593034 endp:ParPharmaceuticalInc.Member endp:MegaceESCasesMember 2016-09-01 2016-09-30 0001593034 endp:VaginalMeshCasesMember 2016-01-01 2016-06-30 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2016-01-01 2016-09-30 0001593034 endp:VaginalMeshCasesMember 2016-01-01 2016-09-30 0001593034 endp:VaginalMeshCasesMember 2015-12-31 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2016-09-30 0001593034 endp:VaginalMeshCasesMember endp:ProductLiabilityMember 2015-12-31 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2015-07-01 2015-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2015-07-01 2015-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-07-01 2016-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-07-01 2016-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-09-30 0001593034 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2015-01-01 2015-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2015-01-01 2015-09-30 0001593034 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2016-01-01 2016-09-30 0001593034 endp:AmericanMedicalSystemsMember 2015-07-01 2015-09-30 0001593034 endp:RestrictedStockUnitsAndPerformanceStockUnitsMember 2016-01-01 2016-09-30 0001593034 endp:NonVestedStockOptionsMember 2016-01-01 2016-09-30 0001593034 endp:EndoInternationalMember 2015-12-31 0001593034 us-gaap:NoncontrollingInterestMember 2016-09-30 0001593034 endp:EndoInternationalMember 2016-01-01 2016-09-30 0001593034 us-gaap:NoncontrollingInterestMember 2016-01-01 2016-09-30 0001593034 us-gaap:NoncontrollingInterestMember 2015-12-31 0001593034 endp:EndoInternationalMember 2016-09-30 0001593034 us-gaap:NoncontrollingInterestMember 2015-01-01 2015-09-30 0001593034 endp:EndoInternationalMember 2015-01-01 2015-09-30 0001593034 endp:AuxiliumPharmaceuticalsInc.Member endp:EndoInternationalMember 2015-01-01 2015-09-30 0001593034 endp:EndoInternationalMember 2015-09-30 0001593034 endp:ParPharmaceuticalHoldingsInc.Member endp:EndoInternationalMember 2015-01-01 2015-09-30 0001593034 us-gaap:NoncontrollingInterestMember 2014-12-31 0001593034 endp:EndoInternationalMember 2014-12-31 0001593034 us-gaap:NoncontrollingInterestMember 2015-09-30 0001593034 endp:AmericanMedicalSystemsMember 2015-01-01 2015-09-30 0001593034 endp:StockOptionsAndStockAwardsMember 2016-01-01 2016-09-30 xbrli:shares endp:country endp:employee xbrli:pure iso4217:USD xbrli:shares iso4217:USD endp:motion iso4217:USD endp:derivatives endp:patent endp:study_order endp:case endp:company false --12-31 Q3 2016 2016-09-30 10-Q 0001593034 222876797 Large Accelerated Filer Endo International plc ENDP 156897000 177961000 18961000 484758000 507507000 54729000 131615000 228717000 22077000 422816000 655453000 64446000 1244672000 284409000 52600000 134800000 7900000 55400000 1000000 22669000 70256000 9782000 70412000 17496000 0 635000000 395100000 0 0 0 1000 50000000 0 273752000 17705000 20155000 42600000 0.01 0.01 4000000 4000000 4000000 4000000 9787000 19389000 185000 0 0 0 29361000 2203000 24686000 2574000 -1137000 -631000 -2905000 24790000 0 0 0 0 0 0 0 0 0 0 45966000 5324000 -95387000 -7858000 123618000 -211147000 0 -232206000 -7858000 -13201000 -211147000 0 2333000 0 2352000 0 -19000 2 P60D P60D 1100000 0 0 1100000 0 0 0 0 0 -284409000 -16287000 -72814000 -169576000 -16243000 -138456000 -138456000 12008000 26730000 -233843000 12000000 25300000 122714000 99099000 42919000 131783000 14208000 111787000 0 19875000 18256000 28715000 P1Y 12700000 P1Y 8398929000 8302305000 5561000 898288000 P45D P45D 50 P30M P30M 1.00 3 16 19 26730000 16312000 5561000 20264000 23807000 5500000 2800000000 0 7900000 22181000 10569000 7778000 40528000 4900000 0.40 0.06 137180000 363298000 159123000 473933000 578970000 268920000 526785000 587782000 587782000 456000 509563000 898288000 898288000 39608000 6876000 32732000 P6M 9261000 14063000 1770000 5875000 P2Y2M12D 347503000 306096000 1014808000 669815000 8551000 5759000 1162612000 945412000 1815000 954000 -386020000 -333099000 -384205000 -332145000 P11Y P9Y P10Y P7Y P7Y P9Y P8Y P19Y P7Y 8693385000 8733360000 121500000 333800000 211500000 636100000 5693000 23991000 114000 -1558000 15268000 15268000 10532000 10532000 266649000 266649000 48537000 48537000 44567000 44567000 66956000 66956000 23800000 11000000 86100000 11000000 15000000 44600000 16440000 21483000 44800000 121503000 6200000 129200000 333759000 211548000 636061000 -3100000 636061000 0 598853000 37142000 66000 5000000 923607000 923607000 1000850000 1000850000 93504000 93504000 263080000 5041000 263080000 4448000 19350336000 17683502000 3452537000 2247436000 0 0 51939000 55034000 55034000 3889000 51145000 0 0 0 0 0 0 3889000 51145000 167952000 67861000 0 2361000 65500000 100091000 100091000 0 0 0 0 0 0 100091000 2361000 65500000 36522000 0 3855000 3855000 51142000 34000 34000 3000 51145000 2361000 2361000 40488000 0 0 25012000 65500000 2089000 2089000 0 10000 10000 0 0 595000 595000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1766000 1766000 51142000 51100000 24000 24000 3000 51145000 1766000 1766000 40488000 0 0 25012000 65500000 -5.18 -7.42 -7.85 -5.18 -7.42 -7.85 34200000 -1084031000 -1395162000 -1475667000 1053654000 2218596000 3194413000 -27688000 -27688000 51177000 23100000 51177000 19476000 19476000 80201000 0 80201000 2600000000 8140000000 158600000 19700000 1330000000 -80300000 -83605000 -83600000 11600000 24790000 24800000 4500000 142400000 0 -3800000 34691000 148891000 0 148891000 0 0 -114200000 -114200000 -154500000 -700000 -135184000 4879044000 5014228000 0 215612000 215612000 0 31124000 31124000 -13755000 516909000 530664000 -511000 551103000 551614000 30176000 44828000 14652000 -44961000 1048818000 1093779000 -154500000 3472500000 3627000000 118400000 158600000 -1849000 328557000 330406000 9400000 -42916000 1618534000 1661450000 18200000 -92268000 3260510000 3352778000 127800000 158600000 2556000 18613000 16057000 0 8477000 8477000 4744000 261037000 256293000 0 8135654000 8135654000 2719000 2201000 4234000 716000 408753000 836111000 272348000 561577000 0.0001 0.0001 1000000000 1000000000 222124282 222859941 222124282 222859941 22000 22000 -1110050000 -1557271000 -224968000 42850000 -32000 -581000 0 38000 -1110128000 -1558005000 -224968000 42904000 442459000 1265583000 557472000 1878395000 625483000 0 1200000000 700000000 750000000 400000000 1635000000 1017500000 2800000000 1200000000 700000000 750000000 400000000 1635000000 962500000 2779000000 0.0600 0.0575 0.05375 0.0725 0.06 147272000 0 22713000 10088000 10511000 0 12535000 27694000 13831000 49900000 131687000 0 21287000 9026000 9585000 0 11284000 25481000 10221000 44803000 64281000 64281000 78352000 78352000 0 0 0 0 549171000 898288000 -335171000 -613318000 10423000 3733000 871040000 178271000 381952000 716332000 13550000 13550000 0 0 -18775000 -506275000 -27309000 -118633000 -1.18 -3.36 -0.12 -0.53 -1.18 -3.36 -0.12 -0.53 228007000 126349000 0 0 1650000000 11555000 0 -246782000 -632624000 -27309000 -118633000 43705000 282310000 387000 30101000 -5.02 -7.32 -0.98 -0.04 -1.37 -0.09 -5.02 -7.32 -0.98 -0.04 -5260000 1497000 93900000 P2Y3M18D 0 0 18869000 18869000 0 0 0 0 9100000 19878000 0 -40909000 -40909000 -41889000 -41889000 0 0 0 0 0.105 0.09 0.090 0.085 0.220 0.030 -1210000 -1210000 -329000 881000 -80277000 -83605000 11585000 24790000 47900000 214435000 146866000 0 0 4511000 0 0 142355000 146866000 13094000 21668000 8121000 30242000 0 0 0 0 46005000 189082000 142323000 26435000 97003000 18296000 1137000 631000 0 143502000 135796000 18851000 102300000 25196000 0 0 139450000 285797000 P15Y P12Y P12Y P12Y P12Y 1341233000 7858000 818606000 508225000 6544000 1747421000 0 1406610000 334220000 6591000 824062000 546598000 575060000 637623000 725659000 24136000 0 24263000 0 -127000 7427295000 11318000 6731573000 676867000 7537000 7285281000 0 6812151000 465720000 7410000 3472500000 2015800000 312400000 118300000 116400000 230400000 164400000 517900000 556000000 1456700000 118600000 147600000 133300000 283800000 401000000 128600000 243800000 18183000 159000000 4095000 24651000 123000 -2427000 2 13550000 791000 -1785000 -4639000 7299354000 1002776000 5789934000 506644000 7411620000 92268000 1019294000 5865684000 526642000 4875144000 4782876000 7800000 0 19732000 0 0 19732000 8058634000 1676276000 5789934000 592424000 8172000000 1692794000 5865684000 613522000 759280000 673500000 0 85780000 760380000 673500000 0 86880000 93634000 16518000 75750000 1366000 29300000 100300000 40000000 72800000 16200000 274754000 26318000 72814000 169576000 16077000 16300000 100300000 169600000 219654000 3460000 216194000 0 221853000 0 10000000 221900000 55100000 55100000 2200000 224953000 0 21328000 10000000 -803660000 -743955000 -191496000 109537000 46000 153000 0 -16000 -964645000 353819000 -1084636000 1046994000 -145311000 382409000 -518254000 1142715000 -803706000 -744108000 -191496000 109553000 -3.84 -3.96 -0.86 0.49 -3.84 -3.96 -0.86 0.49 -246782000 -632624000 -27423000 -118747000 -246782000 -632624000 -27423000 -118747000 -1899000 -3650000 2023000 539000 -160939000 -340528000 46185000 -627807000 735901000 40429000 -1767000 -35406000 220973000 -342012000 211970000 -616361000 -100372000 -693014000 31823000 -22215000 -238048000 -250746000 30568000 289631000 533441000 588455000 0 0 0 480000 1742880000 1742880000 1437718000 1437718000 2594000 2594000 9170175000 9170175000 8722999000 8722999000 7828942000 6975578000 4900000 1100000 11700000 -96446000 -250196000 -112184000 -340896000 364634000 317035000 752493000 624302000 24900000 32600000 210038000 195830000 177821000 111437000 19350336000 17683502000 3474312000 2662302000 -78000 -11634000 0 0 143502000 78237000 0 0 78237000 65265000 0 0 65265000 0 0 143502000 285797000 177019000 0 0 177019000 108778000 0 0 108778000 0 0 285797000 20215000 0 225000000 0 997400000 12500000 12500000 0 0 8727634000 8426555000 328705000 124250000 8600000000 8000000000 8251657000 8170618000 P3Y 2086176000 1280000000 1201832000 1606726000 1280785000 1200000000 549098000 0 1200000000 19505000 49000 2800000000 16000000 0 19875000 18256000 28715000 2 8000 1140 34000 0 3855000 2361000 -54000 0 427358000 289229000 6570546000 -334511000 -5960496000 178866000 -177432000 443377000 -257597000 -17441000 -1050442000 -1376579000 -218919000 -9210000 -46000 -153000 0 16000 2844969000 0 -50091000 -62589000 2866000 -402000 150 -777199000 -729962000 -35993000 -176956000 79601000 371156000 -84952000 -208299000 -6195000 52959000 -403000 1311000 146000 -861000 -86187000 -607000 -207050000 2042000 -7924000 152000 38782000 -1468000 -84952000 -403000 -208299000 1311000 -6195000 152000 52959000 -855000 -1235000 -204000 1249000 731000 -1729000 -14177000 -613000 -61237000 -60630000 -607000 -179451000 -181493000 2042000 -7778000 -7924000 146000 37308000 38782000 -1474000 -59237000 -182584000 -6195000 52959000 -25715000 -25715000 0 0 -59640000 -59237000 -403000 -181273000 -180692000 -182584000 1311000 -581000 -6049000 -6195000 146000 52098000 52060000 52959000 -861000 38000 0 0 6000 6000 -1597000 -1393000 -204000 1822000 1091000 731000 -1729000 -1729000 0 -14790000 -14177000 -613000 -403000 1311000 152000 -855000 236253000 621450000 134000 55000 7500000 600000 -8100000 21000000 1700000 -22700000 -506000 1131000 720000 1486000 -10484000 -6153000 167000 -2903000 3000000 5700000 13393000 5174000 5743000 5276000 1143000 24412000 6317000 13114000 5274000 31200000 22500000 27300000 13900000 114440000 500000 66956000 0 15268000 10532000 135600000 16200000 14200000 7514425000 30394000 0 19206000 50944000 2182000 88087000 138000 39608000 0 43000 49000 55052000 75568000 1600000000 1588779000 4108000 49832000 702786000 2300000000 0 60000000 0 300000000 0 2835000000 0 17000 0 347000 34000 1959000 14000000 0 2578000 3328000 4010000 25068000 1952000 -1050488000 -1376732000 -1376579000 -153000 -218919000 -9194000 -9210000 16000 0 0 0 0 0 649000 675624000 671618000 1970000 6264000 -25557000 0 -25557000 0 0 6000 0 6000 -25715000 0 -25715000 0 0 6000 0 6000 158000 0 158000 0 0 0 0 0 247760000 0 8931000 4634000 225000000 300000000 225000000 499875000 0 459626000 76000000 21327000 58208000 44885000 137166000 585379000 275745000 30000000 2400000 13300000 159500000 250 0 0 -9000000 0 715000 7000000 769000 285000 3900000 1769000 600000 24300000 21328000 22181000 13400000 33300000 10569000 14315000 16100000 68393000 5229000 13398000 0 5353000 0 0 6910000 0 12263000 17914000 0 8788000 179000 4826000 2502000 5767000 16116000 5946000 10029000 8124000 3400000 6800000 -2341215000 -2350425000 237807000 23413000 745727000 304778000 367933000 73016000 2195021000 905198000 1063221000 226602000 884335000 279843000 533691000 70801000 2768761000 876998000 1682439000 209324000 0 0 0 -7750000 163221000 529290000 186735000 558160000 20800000 58100000 14800000 30000000 48537000 44567000 0 37600000 37603000 0 0 18069899 1519320000 1519320000 1325652000 1325652000 160892000 160892000 3328000 3328000 4010000 4010000 2300000000 2300000000 25068000 25068000 1952000 1952000 5968030000 6050861000 2408213000 2374757000 33456000 6396054000 6396064000 -10000 5967976000 5968030000 -54000 6050861000 6050861000 0 -18232000 -18232000 16000 16000 209274000 188085000 222767000 223060000 209274000 188085000 222767000 222579000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the gross carrying amount of our other intangibles for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalization of payments relating to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Gel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of certain International Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain U.S. Branded Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain U.S. Generic Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain International Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,077</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain Astora intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Removal of fully amortized intangible assets relating to expired or terminated licensing agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(221,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,722,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of other intangible assets held by the Company at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost basis:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions<br clear="none"/>(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments<br clear="none"/>(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other<br clear="none"/>(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total indefinite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships (weighted average life of 15 years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,460</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,858</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames (weighted average life of 12 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology (weighted average life of 12 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,731,573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,891</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216,194</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,812,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total definite-lived intangibles (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,427,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,285,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(233,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,730</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,722,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(508,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(818,606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(598,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406,610</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total definite-lived intangibles</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,341,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,747,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,341,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,747,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,828,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,975,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes intangible assets acquired through the acquisition of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">offset by measurement period adjustments relating to the Par acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes the impairment of certain intangible assets of our </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$169.6 million</font><font style="font-family:inherit;font-size:10pt;">, our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$72.8 million</font><font style="font-family:inherit;font-size:10pt;">, our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;"> and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately </font><font style="font-family:inherit;font-size:10pt;">$16.3 million</font><font style="font-family:inherit;font-size:10pt;">, which is reported as </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Discontinued operations, net of tax</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. See </font><font style="font-family:inherit;font-size:10pt;">Note 3. Discontinued Operations and Held for Sale</font><font style="font-family:inherit;font-size:10pt;"> for further information relating to the Astora wind down.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes the removal of approximately </font><font style="font-family:inherit;font-size:10pt;">$221.9 million</font><font style="font-family:inherit;font-size:10pt;"> of fully amortized intangible assets relating to expired or terminated licensing agreements in our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, including the 2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel agreement, described in </font><font style="font-family:inherit;font-size:10pt;">Note 10. License and Collaboration Agreements</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:10pt;"> Natesto</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, described in </font><font style="font-family:inherit;font-size:10pt;">Note 5. Acquisitions</font><font style="font-family:inherit;font-size:10pt;"> of our Annual Report on Form 10-K for the year ended&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, and STENDRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, described in </font><font style="font-family:inherit;font-size:10pt;">Note 10. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:10pt;"> of our Annual Report on Form 10-K for the year ended&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In addition, </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&amp;D assets of </font><font style="font-family:inherit;font-size:10pt;">$138.5 million</font><font style="font-family:inherit;font-size:10pt;"> were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below provides reconciliations of our consolidated </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which is determined in accordance with U.S. GAAP, to our </font><font style="font-family:inherit;font-size:10pt;">segment adjusted income from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September 30</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consolidated loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(145,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(964,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments to partners</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Gel generic competition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Acceleration of Auxilium employee equity awards at closing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain litigation-related charges, net (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges (4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">923,607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items (5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Costs associated with unused financing commitments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than temporary impairment of equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency impact related to the remeasurement of intercompany debt instruments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,903</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,142,715</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,046,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;">$(9.0) million</font><font style="font-family:inherit;font-size:10pt;"> and increases of excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, primarily related to the 2016 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative. The adjustment for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> and other restructuring costs of </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amounts in the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> periods include employee separation costs of </font><font style="font-family:inherit;font-size:10pt;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$58.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and a </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium&#8217;s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> expense in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. See </font><font style="font-family:inherit;font-size:10pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:10pt;"> for discussion of our material restructuring initiatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These amounts include charges for Litigation-related and other contingencies, net as further described in </font><font style="font-family:inherit;font-size:10pt;">Note 12. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges primarily relate to charges to write down intangible assets as further described in </font><font style="font-family:inherit;font-size:10pt;">Note 9. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:10pt;"> and goodwill impairment charges recorded during the third quarter of 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items include costs directly associated with previous acquisitions of </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$55.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to </font><font style="font-family:inherit;font-size:10pt;">$52.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$134.8 million</font><font style="font-family:inherit;font-size:10pt;"> for the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> periods. In addition, during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there is a charge for changes in fair value of contingent consideration of </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended September 30, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:10pt;">$80.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$83.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amounts of Par Revenue and </font><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font><font style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> from and including </font><font style="font-family:inherit;font-size:10pt;">September&#160;25, 2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90503323836657%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amounts of Auxilium Revenue and Net loss included in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> from and including </font><font style="font-family:inherit;font-size:10pt;">January&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,597</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation of the intangible assets acquired and related amortization periods are as follows:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation (in&#160;millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization period (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Developed Technology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vasostrict</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aplisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Non-Partnered (Generic Non-Injectable)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Partnered (Combined)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nascobal</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Non-Partnered (Generic Injectable)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">In Process Research&#160;&amp; Development (IPR&amp;D):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2019 Launch</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2018 Launch</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ezetimibe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2016 Launch</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ephedrine Sulphate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neostigmine vial</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities held by the Company at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>(Losses)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in restricted cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total other short-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>Gains&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>(Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in restricted cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total other short-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, nor are they indicative of any future results.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited pro forma consolidated results (in thousands, except per share data):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,218,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,395,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, nor are they indicative of any future results.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited pro forma consolidated results (in thousands, except per share data):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,475,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 5. ACQUISITIONS</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each of the acquisitions described below, except for Auxilium, Par and Aspen Holdings, the estimated fair values of the net assets acquired are provisional as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements. Accordingly, the measurement of the assets acquired and liabilities assumed may change upon finalization of the Company&#8217;s valuations and completion of the purchase price allocations, all of which are expected to occur no later than one year from the respective acquisition dates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Auxilium Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">January&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;"> (the Auxilium Acquisition Date), the Company acquired all of the outstanding shares of common stock of Auxilium, a fully integrated specialty biopharmaceutical company emerging as a leader in the men&#8217;s healthcare sector with a strategically focused product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas, in a transaction valued at </font><font style="font-family:inherit;font-size:10pt;">$2.6 billion</font><font style="font-family:inherit;font-size:10pt;">. The Company believed that Auxilium would be highly complementary to its branded pharmaceuticals business with significant opportunities to leverage Auxilium&#8217;s leading presence in men&#8217;s health, as well as the Company&#8217;s R&amp;D capabilities and financial resources, to accelerate the growth of Auxilium&#8217;s XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">and its other products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of Auxilium are included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and the operating results from the Auxilium Acquisition Date are included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> acquisition-related transaction costs associated with the Auxilium acquisition during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized acquisition-related transaction costs associated with the Auxilium acquisition during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> totaling </font><font style="font-family:inherit;font-size:10pt;">$23.1 million</font><font style="font-family:inherit;font-size:10pt;">. These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in </font><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amounts of Auxilium Revenue and Net loss included in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> from and including </font><font style="font-family:inherit;font-size:10pt;">January&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,597</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, nor are they indicative of any future results.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited pro forma consolidated results (in thousands, except per share data):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,218,596</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,395,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Auxilium to reflect factually supportable adjustments that give effect to events that are directly attributable to the Auxilium acquisition assuming the Auxilium acquisition had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. In addition, the adjustments include additional intangible amortization, net of tax, which would have been charged assuming the Company&#8217;s estimated fair value of the intangible assets. The adjustment to the amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> increased the expense by </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition of Par Pharmaceutical Holdings, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">September&#160;25, 2015</font><font style="font-family:inherit;font-size:10pt;"> (Par Acquisition Date), the Company acquired Par, a specialty pharmaceutical company that develops, licenses, manufactures, markets and distributes innovative and cost-effective pharmaceuticals with a focus on high-barrier-to-entry products and first-to-file or first-to-market opportunities, for total consideration of </font><font style="font-family:inherit;font-size:10pt;">$8.14 billion</font><font style="font-family:inherit;font-size:10pt;">, including the assumption of Par debt. The consideration included the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">18,069,899</font><font style="font-family:inherit;font-size:10pt;"> ordinary shares valued at </font><font style="font-family:inherit;font-size:10pt;">$1.33 billion</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of Par are included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The amounts of Par Revenue and </font><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font><font style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> from and including </font><font style="font-family:inherit;font-size:10pt;">September&#160;25, 2015</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands, except per share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90503323836657%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date, including measurement period adjustments since the fair values presented in the Company&#8217;s Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> filed with the Securities and Exchange Commission on February 29, 2016, (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 25, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Measurement period adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 25, 2015<br clear="none"/>(As adjusted)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,755</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets, current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,627,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,014,228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,879,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,048,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,618,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net identifiable assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(92,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,875,144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,135,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,135,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our measurement period adjustments for Par were complete as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. As a result of the measurement period adjustments recorded above, the Company recorded a reduction of </font><font style="font-family:inherit;font-size:10pt;color:#000000;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;"> of expense, </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;related to the amortization of intangible assets and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> related to the amortization of inventory step-up, during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> adjustments of expense recorded during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation of the intangible assets acquired and related amortization periods are as follows:</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation (in&#160;millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization period (in years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Developed Technology:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vasostrict</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aplisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Non-Partnered (Generic Non-Injectable)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Partnered (Combined)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nascobal</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed - Other - Non-Partnered (Generic Injectable)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,015.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">In Process Research&#160;&amp; Development (IPR&amp;D):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2019 Launch</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2018 Launch</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ezetimibe</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D 2016 Launch</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ephedrine Sulphate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Neostigmine vial</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,456.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:80px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the developed technology and IPR&amp;D assets were estimated using a discounted present value income approach. Under this method, an intangible asset&#8217;s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company used cash flows discounted at rates ranging from </font><font style="font-family:inherit;font-size:10pt;">9%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">10.5%</font><font style="font-family:inherit;font-size:10pt;">, which were considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, the assembled workforce of Par and other factors. At the acquisition date, approximately </font><font style="font-family:inherit;font-size:10pt;">$34.2 million</font><font style="font-family:inherit;font-size:10pt;"> of goodwill was expected to be deductible for income tax purposes.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets and inventory step-up.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, nor are they indicative of any future results.</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited pro forma consolidated results (in thousands, except per share data):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053,654</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194,413</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,475,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.85</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These amounts have been calculated after applying the Company&#8217;s accounting policies and adjusting the results of Par to reflect factually supportable adjustments that give effect to events that are directly attributable to the Par acquisition assuming the Par acquisition had occurred on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. In addition, the adjustments include additional intangible amortization, net of tax, that would have been charged assuming the Company&#8217;s estimated fair value of the intangible assets. An adjustment to the amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> increased the expense by </font><font style="font-family:inherit;font-size:10pt;">$44.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$129.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Aspen Holdings</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">October&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutic areas from a subsidiary of Aspen Pharmacare Holdings Ltd, a leading publicly-traded South African company that supplies branded and generic products in more than </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;"> countries, and from GlaxoSmithKline plc (GSK) for total consideration of approximately </font><font style="font-family:inherit;font-size:10pt;">$135.6 million</font><font style="font-family:inherit;font-size:10pt;"> (the Aspen Asset Acquisition). The transaction expanded the Company&#8217;s presence in South Africa.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the net identifiable assets acquired totaled </font><font style="font-family:inherit;font-size:10pt;">$127.8 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in goodwill of </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">, which was assigned to our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. The amount of net identifiable assets acquired in connection with the Aspen Asset Acquisition includes </font><font style="font-family:inherit;font-size:10pt;">$118.4 million</font><font style="font-family:inherit;font-size:10pt;"> of intangible assets to be amortized over an average life of approximately </font><font style="font-family:inherit;font-size:10pt;">19 years</font><font style="font-family:inherit;font-size:10pt;">, and inventory of </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;">. Our measurement period adjustments for Aspen Holdings were complete as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of the Aspen Asset Acquisition are included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. There are no results included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pro forma results of operations have not been presented because the effect of the Aspen Asset Acquisition was not material.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Voltaren</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Gel</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had exclusive U.S. marketing rights to Voltaren&#174; Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. (the </font><font style="font-family:inherit;font-size:10pt;">2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;">). On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement (the </font><font style="font-family:inherit;font-size:10pt;">2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;">) whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and to launch an authorized generic of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel effective July 1, 2016. Pursuant to the </font><font style="font-family:inherit;font-size:10pt;">2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;">, the former 2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement expired on June 30, 2016 in accordance with its terms.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is accounting for this transaction as a business combination as of the effective date in accordance with the relevant accounting literature. The Company acquired the product for consideration of </font><font style="font-family:inherit;font-size:10pt;">$158.6 million</font><font style="font-family:inherit;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;"> and contingent cash consideration with an acquisition-date fair value of </font><font style="font-family:inherit;font-size:10pt;">$142.4 million</font><font style="font-family:inherit;font-size:10pt;">. See </font><font style="font-family:inherit;font-size:10pt;">Note 7. Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of this contingent consideration. See </font><font style="font-family:inherit;font-size:10pt;">Note 10. License and Collaboration Agreements</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of the License and Supply Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary fair values of the net identifiable assets acquired totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$159 million</font><font style="font-family:inherit;font-size:10pt;">, resulting in </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> goodwill. The amount of net identifiable assets acquired in connection with the Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel acquisition includes approximately </font><font style="font-family:inherit;font-size:10pt;">$159 million</font><font style="font-family:inherit;font-size:10pt;"> of identifiable developed technology intangible assets to be amortized over an average life of approximately </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel under business combination accounting effective </font><font style="font-family:inherit;font-size:10pt;">July&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;"> are included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The results included in the accompanying </font><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> were accounted for under the previous license and supply agreement, which was not treated as a business combination. The </font><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> reflects the acquisition of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, effective </font><font style="font-family:inherit;font-size:10pt;">July&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">I</font><font style="font-family:inherit;font-size:10pt;">n addition to the business combinations disclosed above, the Company acquired the rights to commercialize a developed technology asset, which is being treated as a business combination. The asset was acquired during the third quarter of 2016 and was not individually material. Total consideration for this business combination was </font><font style="font-family:inherit;font-size:10pt;">$19.7 million</font><font style="font-family:inherit;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$14.2 million</font><font style="font-family:inherit;font-size:10pt;">, deferred consideration with respect to acquired inventory of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and contingent cash consideration with acquisition-date fair value of </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the net identifiable intangible asset acquired totaled </font><font style="font-family:inherit;font-size:10pt;">$18.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 10. LICENSE AND COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries are generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. In addition, these agreements generally require our subsidiaries to pay royalties on sales of the products arising from these agreements. These agreements generally permit termination by our subsidiaries with no significant continuing obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Novartis AG, Novartis Consumer Health, Inc. and Sandoz, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had exclusive U.S. marketing rights to Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. Effective March 1, 2015, Novartis Consumer Health, Inc. assigned the </font><font style="font-family:inherit;font-size:10pt;">2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;"> to its affiliate, Sandoz, Inc. On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement, the </font><font style="font-family:inherit;font-size:10pt;">2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;">, whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and the exclusive right to launch an authorized generic of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, effective July 1, 2016. Pursuant to the </font><font style="font-family:inherit;font-size:10pt;">2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;">, the former 2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement expired on June 30, 2016 in accordance with its terms. The </font><font style="font-family:inherit;font-size:10pt;">2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement</font><font style="font-family:inherit;font-size:10pt;"> became effective on July 1, 2016 and is accounted for as a business combination as of the effective date. Refer to </font><font style="font-family:inherit;font-size:10pt;">Note 5. Acquisitions</font><font style="font-family:inherit;font-size:10pt;"> for further information. The initial term of the 2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Gel Agreement will expire on June 30, 2023 with an automatic extension of the term for </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year thereafter unless a written notice of non-extension is provided at least </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months in advance of termination. Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel royalties incurred during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$13.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the 2008 Voltaren&#174; Gel Agreement, which was effective through June 30, 2016, the Company agreed (i) to make certain guaranteed minimum annual royalty payments beginning in the fourth year of the 2008 Voltaren&#174; Gel Agreement (2008 Guaranteed Minimum Annual Royalty Payment), (ii) to expend a minimum amount of annual advertising and promotional expenses (A&amp;P Expenditures) on the commercialization of Voltaren&#174; Gel and (iii) to perform a minimum number of face-to-face one-on-one discussions with physicians and other health care practitioners (Details), each subject to certain limitations set forth in the 2008 Voltaren&#174; Gel Agreement, including the requirement that a third party generic equivalent product not be launched. Under the 2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement, the Company agreed to make certain guaranteed minimum annual royalty payments (2015 Guaranteed Minimum Annual Royalty Payment) subject to certain limitations set forth in the 2015 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement, including the requirement that a third party generic equivalent product is not launched. In March 2016, Amneal Pharmaceuticals LLC (Amneal) launched a generic equivalent of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and, therefore, the Company&#8217;s obligations to make the 2008 Guaranteed Minimum Annual Royalty Payment, to expend A&amp;P Expenditures and to perform Details for the remainder of the term of the 2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel Agreement terminated as of the date of the launch of the generic equivalent product by Amneal.&#160;In addition, the Company&#8217;s obligation to make the 2015 Guaranteed Minimum Annual Royalty Payment also terminated.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Out-license Agreement</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were party to an out-licensing agreement with Actelion Pharmaceuticals Ltd. (Actelion) to develop, supply and commercialize XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in Canada and Australia. On July 1, 2016, the parties mutually agreed to terminate the collaboration for Canada and agreed upon certain transition services to be provided by Actelion until approval of the transfer of the drug identification number by the regulatory authority in Canada to the Company. For Australia, the collaboration agreement remains in effect until a new agreement is finalized. In consideration for the rights returned to the Company by Actelion, Endo made a cash payment of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> in July 2016. This transaction was treated as an asset acquisition.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 12. COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturing, Supply and Other Service Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries&#8217; products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. These contracts include agreements with Novartis Consumer Health, Inc., Novartis AG, and Sandoz, Inc. (collectively, Novartis), Teikoku Seiyaku Co. Ltd. (Teikoku), Noramco, Inc. (Noramco), Gr&#252;nenthal GmbH (Gr&#252;nenthal), Sharp Corporation, UPS Supply Chain Solutions, Inc. and Jubilant HollisterStier Laboratories LLC (JHS). If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have an adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the manufacturing and supply agreements described above, we have agreements with&#160;various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant changes made during the nine months ended September 30, 2016 to the agreements listed above and included within our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Noramco, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the Company&#8217;s 2012 agreement with Noramco, the Company made payments to Noramco during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> totaling </font><font style="font-family:inherit;font-size:10pt;">$27.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. These payments are recorded in </font><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font><font style="font-family:inherit;font-size:10pt;"> in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. In July 2016, the Company sent a notice of non-renewal to Noramco which will result in the agreement being terminated as of April 2017. The Company is not subject to any penalties as a result of this termination.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Jubilant HollisterStier Laboratories LLC</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2016, we entered into a new agreement with JHS (JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS agreement is&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#160;years, with automatic renewal provisions thereafter for subsequent&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;from JHS each year, unless JHS is unable to supply XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were not material for any of the periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings and Investigations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries are involved in various claims, legal proceedings, internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including those relating to product liability, intellectual property, regulatory compliance and commercial matters. These and other matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material either individually or in the aggregate, we will disclose such matters. While we cannot predict the outcome of these proceedings and we intend to defend vigorously our position, an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, our reserve for loss contingencies totaled </font><font style="font-family:inherit;font-size:10pt;">$1.28 billion</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$1.20 billion</font><font style="font-family:inherit;font-size:10pt;"> relates to our product liability accrual for vaginal mesh cases. We had previously announced that we had reached master settlement agreements with several of the leading plaintiffs&#8217; law firms to resolve claims relating to vaginal mesh products sold by our AMS subsidiary. The agreements were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Liability</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain of our products and the products of our subsidiaries. These matters are described below in more detail.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability matters are or may be covered in whole or in part under our product liability insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our product liability insurance policies will likely be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Vaginal Mesh Cases. </font><font style="font-family:inherit;font-size:10pt;">In October 2008, the FDA issued a Public Health Notification (October 2008 Public Health Notification) regarding potential complications associated with transvaginal placement of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The notification provides recommendations and encourages physicians to seek specialized training in mesh procedures, to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2011, the FDA issued an update to the October 2008 Public Health Notification regarding mesh to further advise the public and the medical community of the potential complications associated with transvaginal placement of surgical mesh to treat POP and SUI. In the July 2011 update, the FDA stated that adverse events are not rare. Furthermore, the FDA questioned the relative effectiveness of transvaginal mesh as a treatment for POP as compared to non-mesh surgical repair. The July 2011 notification continued to encourage physicians to seek specialized training in mesh procedures, to consider and to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications. In January 2016, the FDA issued a statement reclassifying surgical mesh for transvaginal POP repair from Class II to Class III. Surgical mesh for SUI repair remains a Class II device.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2012, the FDA ordered manufacturers of transvaginal surgical mesh used for POP and of single incision mini-slings for urinary incontinence, such as our AMS subsidiary, to conduct post-market safety studies and to monitor adverse event rates relating to the use of these products. AMS received a total of </font><font style="font-family:inherit;font-size:10pt;">19</font><font style="font-family:inherit;font-size:10pt;"> class-wide post-market study orders regarding its pelvic floor repair and mini-sling products; however, the FDA agreed to place </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> of these study orders on hold for a variety of reasons. AMS commenced </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of these post-market study orders; however, in connection with the wind down of the Astora business, it notified the FDA of its termination of these studies.&#160;The FDA has confirmed closure of these studies.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since 2008, we and certain of our subsidiaries, including AMS and/or Astora, have been named as defendants in multiple lawsuits in the U.S. in various state courts and in a multidistrict litigation (MDL) in the Southern District of West Virginia (MDL No. 2325), in Canada, where various class action and individual complaints are pending, and in other countries alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. Plaintiffs in these suits allege various personal injuries including chronic pain, incontinence and inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and certain plaintiffs&#8217; counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other settlement agreements regarding settling up to approximately </font><font style="font-family:inherit;font-size:10pt;">49,000</font><font style="font-family:inherit;font-size:10pt;"> filed and unfiled mesh claims handled or controlled by the participating counsel for an aggregate total of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.8 billion</font><font style="font-family:inherit;font-size:10pt;">. These MSAs, which were executed at various times since June 2013, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault by us or any of our subsidiaries. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of Qualified Settlement Funds (QSFs) into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation thresholds requiring participation by the majority of claims represented by each law firm party to the MSA. If certain participation thresholds are not met, then we will have the right to terminate the settlement with that law firm. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are included in restricted cash and cash equivalents in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and a dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant shall represent and warrant that liens, assignment rights or other claims that are identified in the claims administration process have been or will be satisfied by the individual claimant. The amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlement, shall be kept confidential by all parties and their counsel.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that valid claims under the MSAs will continue to be settled. However, we intend to vigorously contest pending and future claims that are invalid, for which settlement is not able to be reached or that are in excess of the maximum claim amounts under the MSAs. We are currently aware of approximately </font><font style="font-family:inherit;font-size:10pt;">8,000</font><font style="font-family:inherit;font-size:10pt;"> asserted claims and unasserted claims, which we believe are likely to be asserted, that have not been accrued for because we lack sufficient information to determine whether any potential loss is probable. In addition to these asserted and unasserted claims, which we believe are likely to be asserted, there may be other claims asserted in the future. It is currently not possible to estimate the number or validity of any such future claims.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to evaluate whether a claim is probable of a loss, we must obtain and evaluate certain information pertaining to each individual claim, including but not limited to the following items: the name and social security number of the plaintiff, evidence of an AMS implant, the date of implant, the date the claim was first asserted to AMS, the date that plaintiff&#8217;s counsel was retained, and most importantly, medical records establishing the injury alleged.&#160;Without access to at least this information and the opportunity to evaluate it, we are not in a position to determine its validity or whether a loss is probable. Further, the timing and extent to which we obtain this information and our evaluation thereof, is often impacted by items outside of our control, including, without limitation, the normal cadence of the litigation process and the provision of claim information to us by plaintiff&#8217;s counsel.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to monitor the situation, and, if appropriate, we will make further adjustments to our product liability accrual based on new information. We intend to continue exploring all options as appropriate in our best interests, and depending on developments, there is a possibility that we will suffer adverse decisions or verdicts of substantial amounts, or that we will enter into additional monetary settlements. Any unfavorable outcomes as a result of such litigation or settlements with respect to any asserted or unasserted claims could have a material adverse effect on our business, financial condition, results of operations and cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the date of this report, we believe that the current product liability accrual includes all known claims for which liability is probable and estimable.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in the vaginal mesh QSFs and product liability balance during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Qualified Settlement Funds</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,505</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash contributions to Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">587,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes from Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(898,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(898,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,201,832</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The entire portion of the </font><font style="font-family:inherit;font-size:10pt;">$1.20 billion</font><font style="font-family:inherit;font-size:10pt;"> liability amount shown above is classified as Current portion of legal settlement accrual in the </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Charges related to vaginal mesh product liability for all periods presented are reported in Discontinued operations, net of tax in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to fund the payments under all current settlement agreements over the course of 2016 and 2017. As the funds are disbursed out of the QSFs from time to time, the product liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the product liability accrual and decrease cash and cash equivalents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have been contacted regarding a civil investigation that has been initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and have subsequently received additional subpoenas from other states. We are currently cooperating with this investigation. At this time, we cannot predict or determine the outcome of this investigation or reasonably estimate the amount or range of amounts of fines or penalties, if any, that might result from a settlement or an adverse outcome from this investigation.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Testosterone Cases. </font><font style="font-family:inherit;font-size:10pt;">We and certain of our subsidiaries, including Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), along with other pharmaceutical manufacturers, have been named as defendants in lawsuits alleging personal injury resulting from the use of prescription medications containing testosterone, including Fortesta</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, Delatestryl</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Testim</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, TESTOPEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">and Striant</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Plaintiffs in these suits allege various personal injuries, including pulmonary embolism, stroke and other vascular and/or cardiac injuries and seek compensatory and/or punitive damages, where available. In June 2014, an MDL was formed to include claims involving all testosterone replacement therapies filed against EPI, Auxilium, and other manufacturers of such products, and certain transferable cases pending in federal court were coordinated in the Northern District of Illinois as part of MDL No. 2545. In addition to the federal cases filed against EPI and Auxilium that have been transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545, litigation has also been filed against EPI in the Court of Common Pleas Philadelphia County and in certain other state courts. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545. However, we cannot predict the timing or outcome of any such litigation, or whether any such additional litigation will be brought against us. We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest. As of </font><font style="font-family:inherit;font-size:10pt;">November 1, 2016</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">1,140</font><font style="font-family:inherit;font-size:10pt;"> cases are currently pending against us; some of which may have been filed on behalf of multiple plaintiffs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the U.S. District Court for the Northern District of Illinois entered an order granting defendants&#8217; motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the District Court granted plaintiffs&#8217; motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, a civil class action complaint was filed in the Northern District of Illinois against EPI, Auxilium, and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payors that had paid for certain testosterone products, alleging that the marketing efforts of EPI, Auxilium, and other defendant manufacturers with respect to certain testosterone products constituted racketeering activity in violation of 18 U.S.C. &#167;1962(c), and other civil Racketeer Influenced and Corrupt Organizations Act claims. Further, the complaint alleges that EPI, Auxilium, and other defendant manufacturers violated various state consumer protection laws through their marketing of certain testosterone products and raises other state law claims. In March 2015, defendants filed a motion to dismiss the complaint and plaintiffs responded by filing amended complaints. In February 2016, the District Court granted in part and denied in part defendants&#8217; motion to dismiss. The District Court declined to dismiss plaintiffs&#8217; claims for conspiracy to commit racketeering activity in violation of 18 U.S.C. &#167;1962(d) and claims for negligent misrepresentation. In April 2016, plaintiffs filed a third amended complaint, which defendants moved to dismiss in June 2016. In August 2016, the court denied the motion to dismiss and we filed a response to the third amended complaint in September 2016. In October 2015, a similar civil class action complaint was filed against EPI and other defendant manufacturers in the Northern District of Illinois. Similar litigation may be brought by other plaintiffs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any, but we will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Unapproved Drug Litigation</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, the State of Louisiana filed a Petition for Damages against certain of our subsidiaries, EPI and Generics Bidco I, LLC, and over </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> other pharmaceutical companies alleging the defendants or their subsidiaries marketed products that were not approved by the FDA. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">State of Louisiana v. Abbott Laboratories, Inc., et al</font><font style="font-family:inherit;font-size:10pt;">., C624522 (19th Jud. Dist. La.). The State of Louisiana sought damages, fines, penalties, attorneys&#8217; fees and costs under various causes of action. In October 2015, the District Court ordered judgment for defendants on their exception for no right of action. The State of Louisiana appealed that decision and in October 2016, the Louisiana Court of Appeals, First Circuit, issued a decision affirming the dismissal as to certain counts and reversing the dismissal as to others.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to contest the above case vigorously and to explore other options as appropriate in our best interest. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against us. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Opioid-Related Litigations, Subpoenas and Document Requests</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, Corporation Counsel for the City of Chicago filed suit in Illinois state court against multiple defendants, including our subsidiaries, Endo Health Solutions Inc. (EHSI) and EPI, for alleged violations of city ordinances and other laws relating to defendants&#8217; alleged opioid sales and marketing practices. In June 2014, the case was removed to the U.S. District Court for the Northern District of Illinois. In December 2014, defendants moved to dismiss the Amended Complaint and in May 2015, the District Court issued an order granting that motion in part, dismissing the case as to EHS and EPI. In August 2015, plaintiff filed its Second Amended Complaint against multiple defendants, including EPI and EHSI. In November 2015, defendants moved to dismiss the Second Amended Complaint. In September 2016, the District Court granted in part and denied in part defendants&#8217; motions to dismiss and provided plaintiff an opportunity to amend its complaint. Plaintiff filed the third amended complaint in October 2016.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014 and in June 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, against multiple defendants, including our subsidiaries EHSI and EPI. The complaint asserts violations of California&#8217;s statutory Unfair Competition and False Advertising laws, as well as asserting a claim for public nuisance, based on alleged misrepresentations in connection with sales and marketing of opioids, including OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), abatement, an injunction, and attorneys&#8217; fees and costs. Defendants, which include our subsidiaries, filed various motions attacking the pleadings, including one requesting that the Superior Court refrain from proceeding under the doctrines of primary jurisdiction and equitable abstention. That motion was granted in August 2015, and the case has been stayed pending further proceedings and findings by the FDA. In June 2016, plaintiffs filed a motion to lift the stay and to amend the complaint. Defendants, included EHSI and EPI, opposed that motion. Following a hearing in July 2016, the court provided plaintiffs an opportunity to seek leave to file another amended complaint. In August 2016, plaintiffs filed a renewed motion to lift the stay and amend the complaint. In October 2016, the court granted, in part, plaintiffs&#8217; renewed motion to lift the stay and the plaintiffs filed their third amended complaint.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, a lawsuit was filed in the Chancery Court of the First Judicial District of Hinds County, Mississippi by the State of Mississippi against multiple defendants, including our subsidiaries EHSI and EPI. The complaint alleges violations of Mississippi&#8217;s Consumer Protection Act and various other claims arising out of defendants&#8217; alleged opioid sales and marketing practices. Plaintiff seeks declaratory relief, restitution, civil penalties, abatement, an injunction, and attorneys&#8217; fees and costs. In March 2016, defendants moved to dismiss the complaint.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, our subsidiaries EHSI and EPI received a Request for Information from the State of Tennessee Office of the Attorney General and Reporter seeking documents and information regarding the sales and marketing of opioids, including OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. We are currently cooperating with the State of Tennessee Office of the Attorney General and Reporter in this investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, our subsidiaries EHSI and EPI received a subpoena from the State of New Hampshire Office of the Attorney General seeking documents and information regarding the sales and marketing of opioids, including OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. We were cooperating with the State of New Hampshire Office of the Attorney General in its investigation until we learned that it was being assisted in the investigation by outside counsel hired on a contingent fee basis. The New Hampshire Attorney General initiated an action in the Superior Court for the State of New Hampshire to enforce the subpoena despite this contingent fee arrangement, and we (along with other companies that had received similar subpoenas) responded by filing a motion for protective order to preclude the use of contingent fee counsel. In addition, we filed a separate motion seeking declaratory relief. In March 2016, the Superior Court granted the motion for protective order on the grounds that the contingent fee agreement was invalid as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ultra vires</font><font style="font-family:inherit;font-size:10pt;"> and that the office of the Attorney General had acted outside of its statutory authority in entering into the agreement with the contingent fee counsel. In April 2016, both the New Hampshire Attorney General and the companies that received subpoenas from the New Hampshire Attorney General, including EHSI and EPI, appealed, in part, the March 2016 Superior Court order to the New Hampshire Supreme Court. Those appeals are pending. In April 2016, the New Hampshire Attorney General also entered into a new agreement with outside counsel. In response, the companies that received a subpoena from the New Hampshire Attorney General, including EHSI and EPI, moved to enforce a part of the protective order issued by the Superior Court in March 2016 that is not being appealed by EHSI and EPI. That motion was denied in August 2016.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, EHSI and EPI received a Civil Investigative Demand (CID) from the Department of Justice (DOJ) for the State of Oregon seeking documents and information regarding the sales and marketing of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. We are currently cooperating with the State of Oregon in its investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the County of Suffolk, New York filed suit in New York state court against multiple defendants, including our subsidiaries, EHSI and EPI, for alleged violations of state false and deceptive advertising and other statutes, public nuisance, common law fraud, and unjust enrichment based on opioid sales and marketing practices. The County of Suffolk is seeking compensatory damages, interest, costs, disbursements, punitive damages, treble damages, penalties and attorneys&#8217; fees.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the litigations brought on behalf of the City of Chicago, the People of the State of California, the State of Mississippi and the County of Suffolk, we intend to contest those matters vigorously. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Litigation and Investigations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple direct and indirect purchasers of Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> have filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd., Teikoku Pharma USA, Inc. (collectively, Teikoku) and Actavis plc and certain of its subsidiaries (collectively, Actavis), which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries (collectively, Teva) from Allergan plc (Allergan). Certain of these actions have been asserted on behalf of classes of direct and indirect purchasers, while others are individual cases brought by one or more alleged direct or indirect purchasers. The complaints in these cases generally allege that EPI, Teikoku and Actavis (now Teva) entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the &#8216;529 patent) and other patents. Some of the complaints also allege that Teikoku wrongfully listed the &#8216;529 patent in the Orange Book as related to Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies&#8217; efforts to obtain FDA approval of their versions of Lidoderm</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The cases allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. &#167;&#167; 1, 2) and various state antitrust and consumer protection statutes as well as common law remedies in some states. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys&#8217; fees.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. &#167; 1407, issued an order in April 2014 transferring these cases as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In Re Lidoderm Antitrust Litigation</font><font style="font-family:inherit;font-size:10pt;">, MDL No. 2521, to the U.S. District Court for the Northern District of California. In June 2016, motions for class certification were filed on behalf of classes of direct and indirect purchasers, and EPI, Teikoku and Actavis filed oppositions to those motions in September 2016. Trial is currently scheduled to begin in 2017. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of California as tag-along actions to </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In Re Lidoderm Antitrust Litigation</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple direct and indirect purchasers of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:7pt;"> </font><font style="font-family:inherit;font-size:10pt;">ER have filed cases against our subsidiaries EHSI and EPI, and other pharmaceutical companies, including Penwest Pharmaceuticals Co., which we subsequently acquired, and Impax Laboratories Inc. (Impax), all of which have been transferred and coordinated for pretrial proceedings in the Northern District of Illinois by the Judicial Panel on Multidistrict Litigation. Some of these cases have been filed on behalf of putative classes of direct and indirect purchasers, while others have been filed on behalf of individual retailers or health care benefit plans. These cases generally allege that the agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and EPI&#8217;s introduction of the re-formulation of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER violated antitrust laws. The complaints allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. &#167;&#167; 1, 2), various state antitrust and consumer protection statutes, as well as state common law. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys&#8217; fees. In February 2016, the District Court issued orders (i) denying defendants&#8217; motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants&#8217; motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants&#8217; motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the District Court&#8217;s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers have also filed amended complaints. The defendants successfully moved to dismiss the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. We cannot predict whether or not additional cases similar to those described above will be filed by other plaintiffs or the timing or outcome of any such litigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, our subsidiary, EPI received a CID (the February 2014 CID) from the U.S. Federal Trade Commission (the FTC). The FTC issued a second CID to EPI in March 2014 (the March 2014 CID). The February 2014 CID requested documents and information concerning EPI&#8217;s settlement agreements with Actavis and Impax settling the OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER patent litigation, EPI&#8217;s Development and Co-Promotion Agreement with Impax,</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">and its settlement agreement with Actavis settling the Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation, as well as information concerning the marketing and sales of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:7pt;">. </font><font style="font-family:inherit;font-size:10pt;">The March 2014 CID requested documents and information concerning EPI&#8217;s acquisition of U.S. Patent No. 7,852,482 (the &#8216;482 patent), as well as additional information concerning certain litigation relating to, and the marketing and sales of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. The FTC also issued subpoenas for investigational hearings (similar to depositions) to our employees and former employees. In March 2016, the FTC filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania against us and our subsidiary EPI, as well as against Allergan, Actavis, Impax and Teikoku, alleging generally that the settlement agreements with Actavis, Impax, respectively, constituted, in whole or part, unfair methods of competition in violation Section 5(a) of the FTC Act, 15 U.S.C. &#167; 45(a). The FTC also alleges that one provision of the agreement with Actavis violated Section 7 of the Clayton Act, 15 U.S.C. &#167; 18. The complaint seeks injunctive and declaratory relief and other remedies, including restitution and disgorgement. In June 2016, we joined in the defendants&#8217; motion to sever OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER-related claims from the Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related claims. In July 2016, a motion to dismiss was filed on behalf of all defendants. In October 2016, the District Court granted the defendants&#8217; motion to sever the claims ordering the FTC to file lawsuits for the OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER-related claims separately from the Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related claims. The District Court also denied the defendants&#8217; motion to dismiss as moot. Subsequently in October 2016, the FTC voluntarily sought to dismiss their case against us without prejudice. We filed </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> separate lawsuits relating to OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER-related claims and Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-related claims, with Impax and Watson, respectively, in October 2016 seeking declaratory judgment on the merits of the case.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these matters, if any, but will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, EPI received a CID from the State of Florida Office of the Attorney General issued pursuant to the Florida Antitrust Act of 1980, Section 542.28 and seeking documents and other information concerning EPI&#8217;s settlement agreement with Actavis settling the Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation, as well as information concerning the marketing and sales of Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, EHSI and EPI received a CID for Production of Documents and Information from the State of Alaska Office of Attorney General issued pursuant to Alaska&#8217;s Antitrust and Unfair Trade Practices and Consumer Protection law seeking documents and other information concerning settlement agreements with Actavis and Impax settling the OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER patent litigation as well as information concerning EPI&#8217;s settlement agreement with Actavis settling the Lidoderm patent litigation, as well as information concerning the marketing and sales of Lidoderm.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, EPI received a subpoena from the State of South Carolina Office of the Attorney General seeking documents and other information concerning EPI&#8217;s settlement agreement with Actavis settling the Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation, as well as information concerning the marketing and sales of Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, our subsidiary, Par Pharmaceutical Companies, Inc. (subsequently renamed Endo Generics Holdings, Inc. and referred to in this Note 12. Commitments and Contingencies as Par), received a Subpoena to Testify Before Grand Jury from the Antitrust Division of the DOJ and issued by the U.S. District Court for the Eastern District of Pennsylvania. The subpoena requests documents and information focused primarily on product and pricing information relating to Par&#8217;s authorized generic version of Lanoxin (digoxin) oral tablets and Par&#8217;s generic doxycycline products, and on communications with competitors and others regarding those products. Par is currently cooperating fully with the investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2009, the FTC filed a lawsuit against our subsidiary, Par, in the U.S. District Court for the Central District of California, which was subsequently transferred to the U.S. District Court for the Northern District of Georgia, and which alleged violations of antitrust law arising out of Par&#8217;s settlement of certain patent litigation concerning the generic version of AndroGel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The FTC complaint generally seeks a finding that Par&#8217;s settlement agreement violates Section 5(a) of the Federal Trade Commission Act, and a permanent injunction against Par&#8217;s ability to engage in certain types of patent settlements in the future. Beginning in February 2009, certain private plaintiffs, including distributors and retailers, filed similar litigation. Generally, the remaining private plaintiff suits seek equitable relief, unspecified damages and costs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2010, the District Court granted a motion to dismiss the FTC&#8217;s claims and granted in part and denied in part a motion to dismiss the claims of the private plaintiffs. In April 2012, the U.S. Court of Appeals for the 11</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">th</sup></font><font style="font-family:inherit;font-size:10pt;"> Circuit affirmed the District Court&#8217;s decision on the motion to dismiss the FTC&#8217;s claims. In September 2012, the District Court granted a motion for summary judgment against the private plaintiffs&#8217; claims of sham litigation. In July 2013, the Supreme Court of the U.S. reversed the Court of Appeals&#8217; and District Court&#8217;s decisions concerning the FTC action and remanded the case to the District Court for further proceedings. In May 2016, those private plaintiffs representing the putative class of indirect purchasers voluntarily dismissed their case against Par with prejudice. Claims by the direct purchasers and the FTC are still pending. We intend to contest this litigation vigorously and to explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2015, Par received a CID from the Office of the Attorney General for the State of Alaska seeking production of certain documents and information regarding Par&#8217;s settlement of the AndroGel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> patent litigation as well as documents produced in the on-going litigation filed by the FTC.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently cooperating with the DOJ, the State of Florida Office of the Attorney General, the State of Alaska Office of the Attorney General and the State of South Carolina Office of the Attorney General in their respective investigations. Investigations and lawsuits similar to these antitrust matters described above may be brought by others. We are unable to predict the outcome of these investigations or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these investigations, if any, but will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its subsidiary, Par Sterile Products, LLC, in the U.S. District Court for the District of New Jersey alleging that Par and its subsidiary engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par&#8217;s Vasostrict</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (vasopressin) product.&#160;The complaint alleges violations of Sections 1 and 2 of The Sherman Antitrust Act, 15 U.S.C. &#167;&#167; 1, 2, as well as the antitrust law and common law of the state of New Jersey, alleging that Par and its subsidiary entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product.&#160;Fresenius seeks actual, treble and punitive damages in an unspecified amount, attorney&#8217;s fees and costs and injunctive relief and demands a trial by jury.&#160;In September 2016, Par and its subsidiary filed a motion to dismiss the case for Fresenius&#8217; failure to properly state a claim under the antitrust laws. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter.&#160;We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">False Claims Act Litigation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Attorneys General of Florida, Indiana and Virginia and the U.S. Office of Personnel Management (the USOPM) have issued subpoenas, and the Attorneys General of Michigan, Tennessee, Texas, and Utah have issued CIDs, to our subsidiary, Par, among other companies. The demands generally request documents and information pertaining to allegations that certain of Par&#8217;s sales and marketing practices caused pharmacies to substitute ranitidine capsules for ranitidine tablets, fluoxetine tablets for fluoxetine capsules, and two 7.5 mg buspirone tablets for one 15 mg buspirone tablet, under circumstances in which some state Medicaid programs at various times reimbursed the new dosage form at a higher rate than the dosage form being substituted. Par has provided documents in response to these subpoenas to the respective Attorneys General and the USOPM. The aforementioned subpoenas and CIDs culminated in the federal and state law qui tam action brought on behalf of the U.S. and several states by Bernard Lisitza. The complaint was unsealed in August 2011. Lisitza&#8217;s corrected second amended complaint generally seeks (i) a finding that defendants violated and be enjoined from future violations of the federal False Claims Act and state false claims acts; (ii) treble damages and maximum civil penalties for each violation of the federal False Claims Act and state false claims acts; (iii) an applicable percentage share of the proceeds; and (iv) expenses, fees, and costs. The U.S. intervened in this action and filed a separate complaint in September 2011, alleging claims for violations of the Federal False Claims Act and common law fraud. The U.S.&#8217;s second corrected complaint generally seeks (i) treble damages and civil penalties for violations under the federal False Claims Act and (ii) compensatory and punitive damages for common law fraud. The states of Michigan and Indiana have also intervened as to claims arising under their respective state false claim acts, common law fraud, and unjust enrichment. Michigan&#8217;s complaint generally seeks (i) treble damages and civil penalties and (ii) common law compensatory and punitive damages. Indiana&#8217;s amended complaint generally seeks treble damages, costs, and attorney&#8217;s fees. We intend to vigorously defend this lawsuit. At this time, we are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pricing Matters</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, EPI received a CID from the U.S. Attorney&#8217;s Office for the Southern District of New York. The CID requests documents and information regarding contracts with Pharmacy Benefit Managers regarding Frova</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. We are currently cooperating with this investigation. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in January 2016, several complaints, including multiple class action complaints, have been filed in the Philadelphia Court of Common Pleas and in the U.S. District Courts for the Eastern District of Pennsylvania and the District of Rhode Island against us and certain of our subsidiaries, including Par, along with other manufacturers of certain generic pharmaceutical products, seeking compensatory and punitive or treble damages, as well as injunctive relief and alleging that certain marketing and pricing practices by the defendant companies violated state law, including consumer protection law and/or federal and state antitrust laws. The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. &#167; 1407, issued an order in August 2016 transferring certain of these cases as </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">In Re Generic Digoxin and Doxycycline Antitrust Litigation</font><font style="font-family:inherit;font-size:10pt;">, MDL No. 2724, to the U.S. District Court for the Eastern District of Pennsylvania. Additional similar claims may be brought by other plaintiffs in various jurisdictions.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2015, EPI received Interrogatories and Subpoena Duces Tecum from the State of Connecticut Office of Attorney General requesting information regarding pricing of certain of its generic products, including Doxycycline Hyclate, Amitriptyline Hydrochloride, Doxazosin Mesylate, Methotrexate Sodium and Oxybutynin Chloride. We are currently cooperating with this investigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Megace ES</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> (megestrol acetate oral suspension) Cases</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2011, our subsidiary, Par Pharmaceutical, Inc. (PPI), along with EDT Pharma Holdings Ltd. (Elan) (now known as Alkermes Pharma Ireland Limited), filed a complaint against TWi Pharmaceuticals, Inc. (TWi) in the U.S. District Court for the District of Maryland alleging infringement of U.S. Patent No.&#160;7,101,576 because TWi filed an ANDA with a Paragraph IV certification seeking FDA approval of a generic version of Megace</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;ES. A bench trial was held in October 2013, and in February 2014, the District Court issued a decision in favor of TWi, finding all asserted claims of the 7,101,576 patent invalid for obviousness. Par appealed. In August 2014, the District Court issued a preliminary injunction enjoining TWi&#8217;s launch of its generic product pending disposition of the appeal.&#160;In December&#160;2014, the Federal Circuit reversed the District Court&#8217;s decision, remanding for further findings of fact. In March&#160;2015, the District Court issued another preliminary injunction enjoining TWi&#8217;s launch of its generic product pending disposition of the case on remand.&#160;In July 2015, the District Court issued a new decision in favor of TWi, finding all of the asserted claims invalid, and TWi launched its generic product.&#160;PPI appealed again, and in December 2015, the District Court&#8217;s decision in favor of TWi was affirmed without opinion. In February 2016, TWi moved the District Court to recover its lost profits, which TWi alleges in the amount of </font><font style="font-family:inherit;font-size:10pt;">$16 million</font><font style="font-family:inherit;font-size:10pt;">, resulting from the previous injunctions to which the District Court subjected TWi, as well as attorneys&#8217; fees and costs. PPI opposed TWi&#8217;s motion. In September 2016, the District Court denied TWi&#8217;s motion for attorneys&#8217; fees and costs and granted in part and denied in part TWi&#8217;s motion to recover its lost profits, ordering PPI to pay </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">. We believe that a loss is probable and we have incorporated our best estimate of this loss into our reserve for loss contingencies. It is possible that the outcome of this matter could result in an additional loss above the amount reserved, which could be material.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Related Class Action Litigation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, a putative class action entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Craig Friedman v. Endo International plc Company, Rajiv de Silva and Suketu Upadhyay </font><font style="font-family:inherit;font-size:10pt;">was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the Steamfitters&#8217; Industry Pension Fund and Steamfitters&#8217; Industry Security Benefit Fund were appointed lead plaintiffs in the action. In October 2016, a Second Amended Complaint was filed. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company&#8217;s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney&#8217;s Office for the Southern District of New York regarding contracts with Pharmacy Benefit Managers concerning Frova</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The Second Amended Complaint adds Paul Campanelli as a defendant. The complaint seeks class certification, damages in an unspecified amount and attorney&#8217;s fees and costs. We filed a motion to dismiss the case in October 2016.&#160;We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 7, 2016, a putative class action was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of herself and all similarly situated shareholders, bearing the caption </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Doris Shasha v. Endo International plc Company, Rajiv Kanishka Liyanaarchchie De Silva and Suketu P. Upadhyay</font><font style="font-family:inherit;font-size:10pt;">. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act. It alleges that the Company made material false statements in, or omitted material information from, certain of the Company's public disclosures from September 28, 2015 through November 2, 2016, based on news reports of an investigation by the Department of Justice into potential price collusion in the pharmaceutical industry. The complaint seeks class certification, damages in an unspecified amount and attorney's fees and costs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paragraph IV Certifications on OPANA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> ER</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In late 2012, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> patents (U.S. Patent Nos. 8,309,122 and 8,329,216) were issued to EPI covering OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER (oxymorphone hydrochloride extended-release tablets CII). In December 2012, EPI filed a complaint against Actavis (now Teva) in U.S. District Court for the Southern District of New York for patent infringement based on its ANDA for a non-crush-resistant generic version of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. In May 2013 and June 2013, EPI filed similar suits in the U.S. District Court for the Southern District of New York against the following applicants for non-crush-resistant OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER: Roxane Laboratories, Inc. (Roxane) and Ranbaxy Laboratories Limited, which was acquired by Sun Pharmaceutical Industries Ltd. (Ranbaxy). Those suits allege infringement of U.S. Patent Nos. 7,851,482, 8,309,122, and 8,329,216. In July 2013, Actavis and Roxane were granted FDA approval to market all strengths of their respective non-crush-resistant formulations of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York. In August 2015, the District Court ruled that all defendants infringed the claims of U.S. Patent Nos. 8,309,122 and 8,329,216. The District Court also ruled that the defendants failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid, enjoined the defendants from launching their generic products until the expiration of those patents and directed Actavis to withdraw its generic product within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;">. In October 2015, the District Court tolled the </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">-day period until it decided </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> pending post-trial motions. In April 2016, the District Court issued an order upholding its August 2015 ruling in EPI&#8217;s favor and confirming the prior injunction against the manufacture or sale of the generic version of the non-crush-resistant OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER currently offered by Actavis and the additional approved but not yet marketed generic version of the product developed by Roxane. The defendants filed appeals to the Court of Appeals for the Federal Circuit. We intend to continue vigorously asserting our intellectual property rights and to oppose any such appeal.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From </font><font style="font-family:inherit;font-size:10pt;">September 21, 2012</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">October 30, 2013</font><font style="font-family:inherit;font-size:10pt;">, EPI and its partner Gr&#252;nenthal received Paragraph IV Notices from each of Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals, LLC (Amneal), ThoRx Laboratories, Inc. (ThoRx), Actavis, Impax and Ranbaxy (now Sun Pharmaceutical Industries Ltd.), advising of the filing by each such company of an ANDA for a generic version of the formulation of OPANA</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER designed to be crush-resistant. These Paragraph IV Notices refer to U.S. Patent Nos. 7,851,482, 8,075,872, 8,114,383, 8,192,722, 8,309,060, 8,309,122 and 8,329,216, which variously cover the formulation of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER, a highly pure version of the active pharmaceutical ingredient and the release profile of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. EPI filed lawsuits against each of these filers in the U.S. District Court for the Southern District of New York. Each lawsuit was filed within the </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">-day deadline to invoke a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. We intend, and have been advised by Gr&#252;nenthal that it too intends, to defend vigorously the intellectual property rights covering the formulation of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER designed to be crush-resistant and to pursue all available legal and regulatory avenues in defense of crush-resistant OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER, including enforcement of the product&#8217;s intellectual property rights and approved labeling. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York against the remaining filers. In August 2015, the District Court issued an Opinion holding that all defendants infringed the claims of U.S. Patent Nos. 8,309,060, 8,309,122 and 8,329,216. The Opinion also held that the defendants had shown that U.S. Patent No. 8,309,060 was invalid, but that the defendants had failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid. The District Court also issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent Nos. 8,309,122 and 8,329,216. The time for appealing that Opinion and Order has not yet expired and we expect the defendants to appeal the decision. We intend to continue to vigorously assert our intellectual property and oppose appeals by the defendants. However, there can be no assurance that we and/or Gr&#252;nenthal will be successful. If we are unsuccessful and Teva, Amneal, ThoRx, Actavis or Impax is able to obtain FDA approval of its product, generic versions of crush-resistant OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER may be launched prior to the applicable patents&#8217; expirations in 2023. Additionally, we cannot predict or determine the timing or outcome of this defense but will explore all options as appropriate in our best interest. The defendants filed appeals to the Court of Appeals for the Federal Circuit.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and a highly pure version of the active pharmaceutical ingredient of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal, and Sandoz Inc. based on their ANDAs filed against both the crush-resistant and non-crush-resistant versions of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the &#8216;737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the &#8216;779 patent. Beginning July 11, 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the &#8216;779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to defend vigorously our intellectual property rights and to pursue all available legal and regulatory avenues in defense of both the non-crush-resistant formulation OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and the crush-resistant formulation OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER, including enforcement of the product&#8217;s intellectual property rights and approved labeling. However, there can be no assurance that we will be successful. If we are unsuccessful, competitors that already have obtained, or are able to obtain, FDA approval of their products may be able to launch their generic versions of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER prior to the applicable patents&#8217; expirations. Additionally, we cannot predict or determine the timing or outcome of related litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER and challenge the applicable patents. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paragraph IV Certification on Fortesta</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Gel</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2013, EPI and its licensor Strakan Limited received a notice from Watson (now Allergan) advising of the filing by Watson of an ANDA for a generic version of Fortesta</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (testosterone) Gel. In February 2013, EPI filed a lawsuit against Watson in the U.S. District Court for the Eastern District of Texas, Marshall division. Because the suit was filed within the </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">-day period under the Hatch-Waxman Act for filing a patent infringement action, we believe that it triggered an automatic </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month stay of approval under the Act. A two-day trial was held on or about February 26 and 27, 2015. In August 2015, the District Court issued an Order holding that the asserted patents are valid and are infringed by Watson&#8217;s ANDA. As a result, the District Court ordered that the effective date for the approval of Watson&#8217;s ANDA to be the date no sooner than the latest expiration date of the &#8217;913 Patent and the &#8217;865 Patent in November of 2018. Watson filed an appeal in October 2015. In October 2016, the Court of Appeals for the Federal Circuit issued an opinion upholding the District Court&#8217;s decision.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend, and have been advised by Strakan Limited that it too intends, to defend vigorously Fortesta</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and to pursue all available legal and regulatory avenues in defense of Fortesta</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, including enforcement of the product&#8217;s intellectual property rights and approved labeling. However, there can be no assurance that we and/or Strakan will be successful. If we and/or Strakan are unsuccessful and Watson is able to obtain FDA approval of its product, Watson may be able to launch its generic version of Fortesta</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel prior to the applicable patents&#8217; expirations in 2018. Additionally, we cannot predict or determine the timing or outcome of this litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of Fortesta</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and challenge the applicable patents.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paragraph IV Certification on BELBUCA&#8482;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, we became aware via the FDA's website that FDA&#8217;s Office of Generic Drugs had received an ANDA containing a Paragraph IV patent certification with respect to BELBUCA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8482;</font><font style="font-family:inherit;font-size:10pt;"> (buprenorphine hydrochloride) buccal film in September 2016. A Paragraph IV certification indicates that the generic sponsor believes certain Orange Book listed patents are invalid, unenforceable or not infringed. The FDA does not disclose the identity of the generic sponsor and we have not received the foregoing Paragraph IV patent certification. We intend to vigorously enforce our intellectual property rights relating to BELBUCA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8482;</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Proceedings and Investigations</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the above proceedings, proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 13. OTHER COMPREHENSIVE (LOSS) INCOME</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for gain realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (losses) gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86,187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,924</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,630</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (loss) gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized (loss) gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(855</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for gain realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (losses) gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,959</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,493</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(179,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the accumulated balances related to each component of Other comprehensive loss, net of taxes, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(333,099</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(386,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(332,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(384,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 11. DEBT</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the carrying amounts of the Company&#8217;s total indebtedness at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unamortized Discount and Deferred Loan Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unamortized Discount and Deferred Loan Costs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">7.25% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.75% Senior Notes due 2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,088</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.375% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan A Facility Due 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,221</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,017,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,831</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan B Facility Due 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,779,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Revolving Credit Facility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Other debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,426,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,727,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, less current portion, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,302,305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,398,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of the Company&#8217;s Total long-term debt at&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was&#160;</font><font style="font-family:inherit;font-size:10pt;">$8.0 billion</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$8.6 billion</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Company&#8217;s long-term debt is estimated using the quoted market prices for the same or similar debt issuances. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 4, 2016, the Company paid down the revolving credit facility in the amount of </font><font style="font-family:inherit;font-size:10pt;">$225.0 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have </font><font style="font-family:inherit;font-size:10pt;">$997.4 million</font><font style="font-family:inherit;font-size:10pt;"> of remaining credit available through the revolving credit facilities.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s credit agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on capital expenditures, asset sales, mergers and acquisitions, indebtedness, liens, dividends, investments and transactions with the Company&#8217;s affiliates. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we were in compliance with all such covenants.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 3. DISCONTINUED OPERATIONS AND HELD FOR SALE</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">American Medical Systems</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February 24, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s Board of Directors (Board of Directors) approved a plan to sell the Company&#8217;s American Medical Systems Holdings, Inc. (AMS) business, which comprised the entirety of our former Devices segment. The AMS business was comprised of the Men&#8217;s Health and Prostate Health business as well as the Women&#8217;s Health business (referred to herein as Astora). On August 3, 2015, the Company sold the Men&#8217;s Health and Prostate Health business to Boston Scientific Corporation (Boston Scientific) for </font><font style="font-family:inherit;font-size:10pt;">$1.65 billion</font><font style="font-family:inherit;font-size:10pt;">, with </font><font style="font-family:inherit;font-size:10pt;">$1.60 billion</font><font style="font-family:inherit;font-size:10pt;"> paid upfront in cash and </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash contingent on Boston Scientific achieving certain product revenue milestones in the Men&#8217;s Health and Prostate Health business in 2016.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to selling the Men&#8217;s Health and Prostate Health business in 2015, as of December 31, 2015 and continuing into 2016, the Company was actively pursuing a sale of the Astora business with the Company in active negotiations with multiple potential buyers. The majority of the remaining assets and liabilities of the AMS business, which were related to the Astora business, were classified as held for sale in the Consolidated Balance Sheet as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> in the Company&#8217;s Form 10-K filed with the Securities and Exchange Commission on February 29, 2016. Certain of AMS&#8217;s assets and liabilities, primarily with respect to its product liability accrual related to vaginal mesh cases, the related Qualified Settlement Funds and certain intangible and fixed assets, were not classified as held for sale based on management&#8217;s expectation that these assets and liabilities would remain with the Company.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 24, 2016, the Board of Directors resolved to wind down the Company&#8217;s Astora business as it did not align with the Company&#8217;s strategic direction and to reduce the additional exposure to mesh-related product liability. The Company conducted a wind down process to transition physicians to alternative products during the first quarter of 2016. The Company ceased business operations of Astora on March 31, 2016 and exited its AMS business. As a result, as of </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and periods thereafter, the remaining assets and liabilities of the AMS business, which were related to the Astora business, were no longer classified as held for sale in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. In accordance with applicable accounting guidance, the Company also reclassified the Astora assets and liabilities previously presented as held for sale as of December 31, 2015 to held and used on its </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of the AMS business are reported as </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Discontinued operations, net of tax</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for all periods presented.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the operating results of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Discontinued operations, net of tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation related and other contingencies, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(506,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(246,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Astora wind down initiative announced in the first quarter of 2016, the Company incurred asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$21.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. See below for discussion of our material wind down initiatives.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the </font><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">Purchases of property, plant and equipment</font><font style="font-family:inherit;font-size:10pt;"> of AMS for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from discontinued operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in discontinued investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Astora Restructuring</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Astora wind down process includes a restructuring initiative implemented during the three months ended March 31, 2016, which includes the reduction of the Astora workforce consisting of approximately </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> employees. Under this restructuring initiative, separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Astora restructuring initiative, the Company incurred expenses of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$68.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting of </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;">, asset impairment charges, contract termination charges and other general restructuring costs. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> restructuring expenses related to this initiative during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company anticipates there will be additional pre-tax restructuring expenses of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> related to </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;">, contract termination charges and other restructuring costs. The majority of these actions have been completed as of September&#160;30, 2016 and substantially all cash payments will be made by the end of 2016. These restructuring costs are included in Discontinued operations in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of expenses related to the Astora restructuring initiative is included below for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee separation, retention and other benefit-related costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract termination charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other wind down costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the Astora restructuring initiative totaled </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and is included in </font><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation, Retention and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract Termination Charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 17. NET LOSS PER SHARE</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of basic and diluted net </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(191,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(803,706</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(744,108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Net income (loss) from continuing operations attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(191,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(803,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(743,955</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(246,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,747</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc ordinary shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(218,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,050,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For basic per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ordinary share equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of various convertible notes and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For diluted per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net </font><font style="font-family:inherit;font-size:10pt;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted </font><font style="font-family:inherit;font-size:10pt;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period. Ordinary share equivalents are measured under the treasury stock method.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, all stock options and stock awards were excluded from the diluted share calculation because their effect would have been anti-dilutive, as the Company was in a loss position. For the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, stock options and stock awards of </font><font style="font-family:inherit;font-size:10pt;">5.0 million</font><font style="font-family:inherit;font-size:10pt;"> were excluded from the diluted share calculation because their effect would have been anti-dilutive. All stock options and stock awards were excluded from the diluted share calculation for the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> because their effect would have been anti-dilutive, as the Company was in a loss position.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a nonrecurring basis as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Expense for the Nine Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices&#160;in<br clear="none"/>Active Markets<br clear="none"/>for Identical Assets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Unobservable Inputs<br clear="none"/>(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain Astora property, plant and equipment (NOTE 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,041</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Generics Pharmaceuticals property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Branded Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Generic Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain International Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,243</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain Astora intangible assets (NOTE 3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 7. FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial instruments recorded in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper).&#160;Money market funds are structured to maintain the fund&#8217;s net asset value at&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;">&#160;per unit, which assists in providing adequate liquidity upon demand by the holder.&#160;Money market funds pay dividends that generally reflect short-term interest rates. Thus, only the dividend yield fluctuates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.&#160;These tiers include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in </font><font style="font-family:inherit;font-size:10pt;">Marketable securities</font><font style="font-family:inherit;font-size:10pt;"> in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time of purchase, we classify our marketable securities as either available-for-sale securities or trading securities, depending on our intent at that time. Available-for-sale and trading securities are carried at fair value with unrealized holding gains and losses recorded within other comprehensive income or net income, respectively. The Company reviews unrealized losses associated with available-for-sale securities to determine the classification as a &#8220;temporary&#8221; or &#8220;other-than-temporary&#8221; impairment. A temporary impairment results in an unrealized loss being recorded in other comprehensive income. An impairment that is viewed as other-than-temporary is recognized in net income. The Company considers various factors in determining the classification, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the issuer or investee, and the Company&#8217;s ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity and Cost Method Investments</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has investments that it accounts for using the equity or cost method of accounting totaling </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">. The Company divested a joint venture investment owned through its Litha subsidiary during the three months ended March 31, 2016. The Company classified this joint venture investment as Assets held for sale as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> in its </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to its other equity or cost method investments, which are included in Other Assets in the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company did not recognize any other-than-temporary impairments. The Company considered various factors, including the operating results of its equity method investments and the lack of an unrealized loss position on its cost method investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition-Related Contingent Consideration</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of contingent consideration liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recurring Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">September&#160;30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in <br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other <br clear="none"/>Observable<br clear="none"/>Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>Unobservable<br clear="none"/>Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time deposits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, money market funds include </font><font style="font-family:inherit;font-size:10pt;">$40.5 million</font><font style="font-family:inherit;font-size:10pt;"> in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See </font><font style="font-family:inherit;font-size:10pt;">Note 12. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of our product liability cases.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in <br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other <br clear="none"/>Observable<br clear="none"/>Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>Unobservable<br clear="none"/>Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, money market funds include </font><font style="font-family:inherit;font-size:10pt;">$51.1 million</font><font style="font-family:inherit;font-size:10pt;"> in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See </font><font style="font-family:inherit;font-size:10pt;">Note 12. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of our product liability cases.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts settled</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers (in) and/or out of Level 3</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Measurement period adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value measurement of the contingent consideration obligations was determined using risk-adjusted discount rates ranging from </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">22.0%</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font><font style="font-family:inherit;font-size:10pt;"> related to acquisition-related contingent consideration are included in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> as </font><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items</font><font style="font-family:inherit;font-size:10pt;">, and amounts recorded for the short-term and long-term portions of acquisition related contingent consideration are included in </font><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> and Other liabilities, respectively, in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> by acquisition (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustments and Accretion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments and Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Qualitest acquisition</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Sumavel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Auxilium acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Lehigh Valley Technologies, Inc. acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Voltaren Gel</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">&#160;acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,574</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities held by the Company at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>(Losses)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,012</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in restricted cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,488</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total other short-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:3pt;"><font style="font-family:inherit;font-size:3pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Available-for-sale</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized <br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>Gains&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross <br clear="none"/>Unrealized<br clear="none"/>(Losses)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total included in restricted cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total other short-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonrecurring Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a nonrecurring basis as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Expense for the Nine Months Ended September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices&#160;in<br clear="none"/>Active Markets<br clear="none"/>for Identical Assets<br clear="none"/>(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other<br clear="none"/>Observable Inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br clear="none"/>Unobservable Inputs<br clear="none"/>(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain Astora property, plant and equipment (NOTE 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,041</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Generics Pharmaceuticals property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Branded Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain U.S. Generic Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain International Pharmaceuticals intangible assets (NOTE 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,243</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain Astora intangible assets (NOTE 3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,939</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(284,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> by acquisition (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Adjustments and Accretion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments and Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Qualitest acquisition</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,137</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Sumavel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(631</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Auxilium acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Lehigh Valley Technologies, Inc. acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,389</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,300</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Voltaren Gel</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">&#160;acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,511</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,574</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,196</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes to the Company&#8217;s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;padding-left:9px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,866</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">214,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts settled</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transfers (in) and/or out of Level 3</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:normal;">Measurement period adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value recorded in earnings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,605</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(329</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">881</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">End of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 9. GOODWILL AND OTHER INTANGIBLES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of our goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2015:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,789,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,058,634</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(673,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(759,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,789,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,299,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement period adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation on gross balance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation on accumulated impairment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,692,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,865,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,172,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(673,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(760,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,865,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,411,620</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Intangible Assets</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of other intangible assets held by the Company at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost basis:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquisitions<br clear="none"/>(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments<br clear="none"/>(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other<br clear="none"/>(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total indefinite-lived intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,742,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">676,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">465,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships (weighted average life of 15 years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,318</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,460</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,858</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames (weighted average life of 12 years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology (weighted average life of 12 years)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,731,573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,891</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216,194</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,812,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total definite-lived intangibles (weighted average life of 12 years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,427,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(219,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,285,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170,175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274,754</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(233,843</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,730</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,722,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated amortization:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Effect of Currency Translation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of September 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite-lived intangibles:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(508,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,142</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,147</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334,220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tradenames</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,544</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,591</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Developed technology</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(818,606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(598,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406,610</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Total definite-lived intangibles</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,341,233</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636,061</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,747,421</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,341,233</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(636,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,747,421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other intangibles</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,828,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,975,578</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes intangible assets acquired through the acquisition of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">offset by measurement period adjustments relating to the Par acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes the impairment of certain intangible assets of our </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$169.6 million</font><font style="font-family:inherit;font-size:10pt;">, our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$72.8 million</font><font style="font-family:inherit;font-size:10pt;">, our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;"> and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately </font><font style="font-family:inherit;font-size:10pt;">$16.3 million</font><font style="font-family:inherit;font-size:10pt;">, which is reported as </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Discontinued operations, net of tax</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. See </font><font style="font-family:inherit;font-size:10pt;">Note 3. Discontinued Operations and Held for Sale</font><font style="font-family:inherit;font-size:10pt;"> for further information relating to the Astora wind down.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes the removal of approximately </font><font style="font-family:inherit;font-size:10pt;">$221.9 million</font><font style="font-family:inherit;font-size:10pt;"> of fully amortized intangible assets relating to expired or terminated licensing agreements in our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, including the 2008 Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel agreement, described in </font><font style="font-family:inherit;font-size:10pt;">Note 10. License and Collaboration Agreements</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:10pt;"> Natesto</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, described in </font><font style="font-family:inherit;font-size:10pt;">Note 5. Acquisitions</font><font style="font-family:inherit;font-size:10pt;"> of our Annual Report on Form 10-K for the year ended&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, and STENDRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, described in </font><font style="font-family:inherit;font-size:10pt;">Note 10. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:10pt;"> of our Annual Report on Form 10-K for the year ended&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. In addition, </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&amp;D assets of </font><font style="font-family:inherit;font-size:10pt;">$138.5 million</font><font style="font-family:inherit;font-size:10pt;"> were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> totaled </font><font style="font-family:inherit;font-size:10pt;">$211.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$636.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> totaled </font><font style="font-family:inherit;font-size:10pt;">$121.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$333.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Estimated amortization of intangibles for the five fiscal years subsequent to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">546,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the gross carrying amount of our other intangibles for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalization of payments relating to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Gel acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other acquisitions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,183</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of certain International Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain U.S. Branded Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,814</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain U.S. Generic Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain International Pharmaceuticals intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,077</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of certain Astora intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Removal of fully amortized intangible assets relating to expired or terminated licensing agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(221,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,730</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,722,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the significant decline in the Company&#8217;s stock price, the Company initiated an interim goodwill impairment analysis of our U.S. Branded and U.S. Generics reporting units during the second quarter of 2016. We estimated the fair value of our reporting units through an income approach using a discounted cash flow model.&#160;Our discounted cash flow models are highly reliant on various assumptions, including estimates of future cash flows (including long-term growth rates), discount rate, and expectations about variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for our interim goodwill impairment tests ranged from&#160;</font><font style="font-family:inherit;font-size:10pt;">8.5%</font><font style="font-family:inherit;font-size:10pt;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;">, depending on the overall risk associated with the particular reporting units and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. As a result of this interim analysis, the Company determined that the estimated fair value of our U.S. Branded and U.S. Generics reporting units exceeded their estimated net book value; therefore, an impairment charge was not required for the three months ended June 30, 2016.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Generic Pharmaceuticals Segment</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended March&#160;31, 2016 and June 30, 2016, the Company identified certain market and regulatory conditions impacting the commercial potential of certain indefinite and definite-lived intangible assets in our </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment. Accordingly, we tested these assets for impairment and determined that the carrying value of certain of these assets was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$29.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> during the first and second quarters of 2016, respectively. In addition, during the first quarter of 2016, the Company recognized pre-tax, non-cash asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$100.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to the 2016 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&amp;D projects. See </font><font style="font-family:inherit;font-size:10pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:10pt;"> for discussion of our material restructuring initiatives.</font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Branded Pharmaceuticals Segment </font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of unfavorable formulary changes and generic competition for sumatriptan, the Company has experienced a downturn in the performance of its Sumavel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> DosePro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> product, a needle-free delivery system for sumatriptan acquired from Zogenix, Inc. in 2014. As a result of this underperformance, the Company concluded during the third quarter of 2016 that an impairment assessment was required to evaluate the recoverability of Sumavel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> DosePro</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. After performing this assessment, we recorded a pre-tax, non-cash impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$72.8 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended September 30, 2016, representing a full impairment of the intangible asset.</font></div><div style="line-height:120%;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">International Pharmaceuticals Segment</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended September 30, 2016, the Company determined that it would not pursue commercialization of a product in certain international markets. Accordingly, we tested the definite-lived intangible asset associated with this product for impairment and determined that the carrying value was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charge of </font><font style="font-family:inherit;font-size:10pt;">$16.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the third quarter of 2016.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">NOTE 16. INCOME TAXES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized income tax </font><font style="font-family:inherit;font-size:10pt;">expense</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$46.2 million</font><font style="font-family:inherit;font-size:10pt;"> on </font><font style="font-family:inherit;font-size:10pt;">$145.3 million</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$160.9 million</font><font style="font-family:inherit;font-size:10pt;"> of tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> on </font><font style="font-family:inherit;font-size:10pt;">$964.6 million</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> during the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> period. During the third quarter of 2016, the Company completed a legal entity restructuring. The restructuring resulted in the Company recording a deferred charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$395.1 million</font><font style="font-family:inherit;font-size:10pt;"> in accordance with applicable accounting guidance. Within the third quarter, the Company recorded net discrete tax expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$42.6 million</font><font style="font-family:inherit;font-size:10pt;"> primarily related to the amortization of the aforementioned deferred charge, which was partially offset by a favorable return to provision adjustment resulting from filing U.S. federal income tax returns. The tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> for the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> period was primarily related to benefits resulting from losses from continued operations.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized an income tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$627.8 million</font><font style="font-family:inherit;font-size:10pt;"> on </font><font style="font-family:inherit;font-size:10pt;">$518.3 million</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$340.5 million</font><font style="font-family:inherit;font-size:10pt;"> of tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> on </font><font style="font-family:inherit;font-size:10pt;">$1,084.6 million</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> during the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company completed a legal entity restructuring as part of its continuing integration of our business. This resulted in the realization of a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$635.0 million</font><font style="font-family:inherit;font-size:10pt;"> tax </font><font style="font-family:inherit;font-size:10pt;">benefit</font><font style="font-family:inherit;font-size:10pt;"> arising from an outside basis difference, which was partly offset by a valuation allowance on its U.S. deferred tax assets. The tax benefit for the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> period was primarily related to losses from continued operations combined with benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 8. INVENTORIES</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) The components of inventory shown in the table above are net of allowance for obsolescence.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> inventory, is classified as long-term inventory and is not included in the table above. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$32.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of long-term inventory was included in Other assets in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch, when it is reasonably certain, based on management&#8217;s judgment of reasonably certain future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made once the Company (or its third party development partners) has filed an Abbreviated New Drug Application (ANDA) that has been acknowledged by the U.S. Food and Drug Administration (the FDA) as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be cleared. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the generic drug product being considered, and accordingly, the time frame within which the determination is made varies from product to product. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, or a delay in commercialization, or other potential factors. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$25.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in inventories related to generic products that were not yet available to be sold.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards update (ASU) No. 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No.&#160;2015-14,&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606):&#160;Deferral of the Effective Date,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017 and the Company currently plans to adopt it on January 1, 2018. In March and April 2016, the FASB issued ASU No. 2016-08 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)&#8221;</font><font style="font-family:inherit;font-size:10pt;"> and ASU No. 2016-10 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#8221; </font><font style="font-family:inherit;font-size:10pt;">respectively</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrow-Scope Improvements and Practical Expedients,&#8221; </font><font style="font-family:inherit;font-size:10pt;">which amends certain narrow aspects of Topic 606. The Company is currently evaluating the impact of these standards on the Company&#8217;s consolidated results of operations and financial position, including possible transition alternatives.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#160;(ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively and early application is permitted. The Company is currently evaluating the impact of ASU 2015-11 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued&#160;ASU No. 2016-02, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Improvements to Employee Share-Based Payment Accounting&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (a) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (b) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (c) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (d) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&#8217;s statutory income tax withholding obligation, (e) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (f) electing whether to account for forfeitures of share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-09 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Classification of Certain Cash Receipts and Cash Payments&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-15). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-15 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-15 on the Company&#8217;s consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU No. 2016-16 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company is currently evaluating the impact of ASU 2016-16 on the Company&#8217;s consolidated results of operations and financial position.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 1. BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">Endo International plc</font><font style="font-family:inherit;font-size:10pt;"> and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements</font><font style="font-family:inherit;font-size:10pt;"> of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary to a fair statement of the Company&#8217;s financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and the results of our operations and our cash flows for the periods presented. Operating results for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The year-end Condensed Consolidated Balance Sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was derived from the audited financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise indicated or required by the context, references throughout to &#8220;Endo,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to financial information and transactions of Endo International plc and its subsidiaries.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on branded and generic pharmaceuticals.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 15. OTHER (INCOME) EXPENSE, NET</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Other (income) expense, net</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity (earnings) loss from unconsolidated subsidiaries, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,023</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than temporary impairment of equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs associated with unused financing commitments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other miscellaneous, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net results from the remeasurement of the Company&#8217;s foreign currency denominated assets and liabilities. In addition, the Company incurred </font><font style="font-family:inherit;font-size:10pt;">$64.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$78.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to unused commitment fees primarily associated with financing for the Par acquisition.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 4. RESTRUCTURING</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Restructuring</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2015 U.S Generic Pharmaceuticals Restructuring</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Par Pharmaceutical Holdings, Inc. and its subsidiaries (together herein Par) on </font><font style="font-family:inherit;font-size:10pt;">September&#160;25, 2015</font><font style="font-family:inherit;font-size:10pt;">, we implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment sales, sales support, management activities and staffing, which resulted in separation benefits to certain </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> employees. The cost reduction initiatives included a reduction in headcount of approximately </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> of the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> workforces. Under this restructuring initiative (the 2015 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative), separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the 2015 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative, the Company incurred restructuring expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting of </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;">. The Company does not anticipate any further additional pre-tax restructuring expenses related to </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;">. These actions are expected to be completed by October&#160;31, 2016, with substantially all cash payments made by the end of 2016. In addition, the Company anticipates there will be additional pre-tax restructuring expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;"> related to accelerated depreciation on certain assets. These restructuring costs are allocated to the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, and are primarily included in </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> costs and expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the 2015 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative totaled </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$17.9 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, this liability is included in </font><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 U.S Generic Pharmaceuticals Restructuring</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the ongoing </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> integration efforts, in May 2016 we announced a restructuring initiative to optimize our product portfolio and rationalize our manufacturing sites to expand product margins (the 2016 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative). These measures include certain cost savings initiatives, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility. On October 31, 2016, we entered into a definitive agreement to sell the Charlotte, North Carolina facility for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$14 million</font><font style="font-family:inherit;font-size:10pt;">, subject to purchase price adjustments as defined in the agreement. The Company expects to record an impairment charge during the fourth quarter of 2016 of approximately </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> related to fixed assets associated with the sale. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the 2016 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative, the Company has incurred total restructuring expenses of </font><font style="font-family:inherit;font-size:10pt;">$159.5 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and expects to incur additional restructuring-related expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> consisting of accelerated depreciation, </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;"> and certain other charges. The Company anticipates these actions will be completed by September 2017, with substantially all cash payments made by the end of 2017. Under this restructuring initiative, separation costs will be expensed ratably over the requisite service period, if any.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$13.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$159.5 million</font><font style="font-family:inherit;font-size:10pt;"> recorded during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisted of certain intangible asset impairment charges of </font><font style="font-family:inherit;font-size:10pt;">$100.3 million</font><font style="font-family:inherit;font-size:10pt;"> and charges to increase excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;">$33.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, charges relating to </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.4 million</font><font style="font-family:inherit;font-size:10pt;">, accelerated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> and other charges of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. These charges are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, and are included in Asset impairment charges, Cost of revenues, and </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> costs and expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative totaled </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and is included in </font><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to the accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Auxilium Restructuring</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals LLC hereafter referred to as Auxilium) on </font><font style="font-family:inherit;font-size:10pt;">January&#160;29, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning our sales, sales support, management activities and staffing, which included separation benefits to former Auxilium employees, in addition to the closing of duplicative facilities. The cost reduction initiatives included a reduction in headcount of approximately </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the former Auxilium workforce. For former Auxilium employees that agreed to continue employment with the Company for a merger transition period, the separation costs payable upon completion of their retention period were expensed over their respective retention period. The Company does not anticipate there will be additional material pre-tax restructuring expenses related to this initiative. The Company anticipates that substantially all </font><font style="font-family:inherit;font-size:10pt;">employee separation, retention and other benefit-related costs</font><font style="font-family:inherit;font-size:10pt;"> cash payments relating to this initiative will be made by the end of 2016. The remainder of the cash payments will be made over the remaining lease term of Auxilium&#8217;s former corporate headquarters in Chesterbrook, Pennsylvania. These restructuring costs are included in the </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, and are primarily included in </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> costs and expenses in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The liability related to the Auxilium restructuring initiative totaled </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and is included in </font><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font><font style="font-family:inherit;font-size:10pt;"> and Other liabilities in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</font><font style="font-family:inherit;font-size:10pt;">. Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation, Retention and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the accumulated balances related to each component of Other comprehensive loss, net of taxes, at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(333,099</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(386,020</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(332,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(384,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain (loss) arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for gain realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (losses) gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(403</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,924</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,195</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86,187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,952</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,924</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,630</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,393</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,237</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the tax effects allocated to each component of </font><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.81481481481481%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax Benefit (Expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Before-Tax<br clear="none"/>Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Tax (Expense) Benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net-of-<br clear="none"/>Tax<br clear="none"/>Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (loss) gain on securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized (loss) gain arising during the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,468</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(855</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for gain realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized (losses) gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(861</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,042</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(731</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on foreign currency:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation loss arising during the period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(207,050</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,249</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(208,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: reclassification adjustments for loss realized in net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,959</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,493</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(182,584</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,308</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,790</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(179,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,273</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the carrying amounts of the Company&#8217;s total indebtedness at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unamortized Discount and Deferred Loan Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Principal Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unamortized Discount and Deferred Loan Costs</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">7.25% Senior Notes due 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.75% Senior Notes due 2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,088</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">5.375% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">750,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,481</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">6.00% Senior Notes due 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan A Facility Due 2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">962,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,221</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,017,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,831</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Term Loan B Facility Due 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,779,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,800,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Revolving Credit Facility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:normal;">Other debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,426,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,727,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,272</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less current portion, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt, less current portion, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,302,305</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(131,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,398,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(147,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the operating results of the </font><font style="font-family:inherit;font-size:10pt;font-style:normal;font-weight:normal;">Discontinued operations, net of tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Litigation related and other contingencies, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,705</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,752</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,550</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(506,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126,349</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(246,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides the </font><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">Purchases of property, plant and equipment</font><font style="font-family:inherit;font-size:10pt;"> of AMS for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows from discontinued operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,633</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in discontinued investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a reconciliation of the numerator and denominator of basic and diluted net </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">loss per share</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(191,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(803,706</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(744,108</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Net income (loss) from continuing operations attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(191,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(803,660</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(743,955</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(246,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,747</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(632,624</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Endo International plc ordinary shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(218,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,050,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,210</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For basic per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of ordinary share equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive effect of various convertible notes and warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For diluted per share data&#8212;weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,060</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">September&#160;30, 2016</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in <br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other <br clear="none"/>Observable<br clear="none"/>Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>Unobservable<br clear="none"/>Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,500</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time deposits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,019</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285,797</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, money market funds include </font><font style="font-family:inherit;font-size:10pt;">$40.5 million</font><font style="font-family:inherit;font-size:10pt;"> in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See </font><font style="font-family:inherit;font-size:10pt;">Note 12. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;"> for further discussion of our product liability cases.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at Reporting Date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">December&#160;31, 2015</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in <br clear="none"/>Active Markets<br clear="none"/>for Identical<br clear="none"/>Assets (Level 1)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other <br clear="none"/>Observable<br clear="none"/>Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant <br clear="none"/>Unobservable<br clear="none"/>Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;short-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,265</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related contingent consideration&#8212;long-term</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the carrying amount of our goodwill for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2015:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,676,276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,789,934</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">592,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,058,634</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(673,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(759,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,002,776</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,789,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,299,354</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement period adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation on gross balance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,732</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of currency translation on accumulated impairment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,692,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,865,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,172,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated impairment losses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(673,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(760,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,019,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,865,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,411,620</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in&#160;thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) The components of inventory shown in the table above are net of allowance for obsolescence.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in the vaginal mesh QSFs and product liability balance during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Qualified Settlement Funds</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Product Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,505</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash contributions to Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">587,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes from Qualified Settlement Funds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(898,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(898,288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions to settle disputes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,920</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,201,832</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Other (income) expense, net</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency loss (gain), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity (earnings) loss from unconsolidated subsidiaries, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,023</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,899</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(539</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than temporary impairment of equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal settlement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,500</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs associated with unused financing commitments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other miscellaneous, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">506</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other (income) expense, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date, including measurement period adjustments since the fair values presented in the Company&#8217;s Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> filed with the Securities and Exchange Commission on February 29, 2016, (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 25, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Measurement period adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 25, 2015<br clear="none"/>(As adjusted)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">530,664</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,755</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">516,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets, current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">256,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,037</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,627,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total identifiable assets</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,014,228</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,184</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,879,044</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(511</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,093,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,048,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,057</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,613</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,661,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,618,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net identifiable assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(92,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,260,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,782,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,875,144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,135,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,135,654</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of expenses related to the Astora restructuring initiative is included below for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee separation, retention and other benefit-related costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract termination charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other wind down costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,315</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,393</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation, Retention and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contract Termination Charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Employee Separation, Retention and Other Benefit-Related Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Restructuring Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,353</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,143</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to the accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,398</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes to this accrual during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash distributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability balance as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents selected information for the Company&#8217;s reportable segments for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues to external customers:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">876,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">905,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">367,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,063,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues to external customers</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">884,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,195,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted income from continuing operations before income tax:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,816</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">655,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues generated by our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment are primarily attributable to Canada, Mexico and South Africa.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Attributable to:&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Endo<br clear="none"/>International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Noncontrolling<br clear="none"/>interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br clear="none"/>Shareholders&#8217;<br clear="none"/>Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,968,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,967,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of ordinary shares related to the employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Attributable to:&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Endo<br clear="none"/>International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Noncontrolling<br clear="none"/>interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br clear="none"/>Shareholders&#8217;<br clear="none"/>Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,374,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,408,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,579</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,732</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buy-out of noncontrolling interests, net of contributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued in connection with the Par acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,325,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,325,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued in connection with the Auxilium acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of equity component of acquired Auxilium Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of Auxilium Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of ordinary shares related to the employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity issuance fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,956</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,956</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,396,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,396,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization of intangibles for the five fiscal years subsequent to </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">824,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">725,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">546,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">NOTE 6. SEGMENT RESULTS</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reportable business segments in which the Company operates are: (1)&#160;</font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">, (2) </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> and (3) </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;">. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate segment performance based on each segment&#8217;s </font><font style="font-family:inherit;font-size:10pt;">adjusted income (loss) from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which we define as </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> and before </font><font style="font-family:inherit;font-size:10pt;">certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company&#8217;s operations; excess costs that will be eliminated pursuant to integration plans; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; certain non-cash interest expense; litigation-related and other contingent matters; gains or losses from early termination of debt activities; foreign currency gains or losses on intercompany financing arrangements; and certain other items that the Company believes do not reflect its core operating performance</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company&#8217;s segments and are included in the results below as &#8220;Corporate unallocated.&#8221; The Company&#8217;s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate costs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Branded Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment includes a variety of branded prescription products related to treating and managing pain as well as our urology and men&#8217;s health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, OPANA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> ER, Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Gel, Percocet</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, BELBUCA&#8482;, Aveed</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, Supprelin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> LA, and XIAFLEX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, among others.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Generic Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment focuses on a differentiated product portfolio including high barrier-to-entry products, first-to-file or first-to-market opportunities, which are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women&#8217;s health and cardiovascular disease markets, among others.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Pharmaceuticals</font></div><div style="line-height:120%;padding-top:8px;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women&#8217;s health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents selected information for the Company&#8217;s reportable segments for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenues to external customers:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,843</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">876,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">905,198</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">533,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">367,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,682,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,063,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,801</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,016</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">209,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,602</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net revenues to external customers</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">884,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">745,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,768,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,195,021</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjusted income from continuing operations before income tax:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">422,816</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484,758</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">655,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,446</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues generated by our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment are primarily attributable to Canada, Mexico and South Africa.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we realigned certain costs amongst our </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment, </font><font style="font-family:inherit;font-size:10pt;">U.S. Branded Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment and Corporate unallocated costs based on how our chief operating decision maker reviews segment performance. As a result of this realignment, certain expenses included in our consolidated </font><font style="font-family:inherit;font-size:10pt;">adjusted income (loss) from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> have been reclassified among our various segments to conform to current period presentation. The net impact of these reclassification adjustments increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, with an offsetting </font><font style="font-family:inherit;font-size:10pt;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> decrease to </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment costs for the </font><font style="font-family:inherit;font-size:10pt;">three months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$21.0 million</font><font style="font-family:inherit;font-size:10pt;"> respectively, with an offsetting </font><font style="font-family:inherit;font-size:10pt;">$22.7 million</font><font style="font-family:inherit;font-size:10pt;"> decrease to </font><font style="font-family:inherit;font-size:10pt;">International Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> segment costs for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no material revenues from external customers attributed to an individual country outside of the United States during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below provides reconciliations of our consolidated </font><font style="font-family:inherit;font-size:10pt;">loss from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;">, which is determined in accordance with U.S. GAAP, to our </font><font style="font-family:inherit;font-size:10pt;">segment adjusted income from continuing operations before income tax</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September 30</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total consolidated loss from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(145,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(964,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(518,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,084,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs (1)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473,933</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">333,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111,787</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront and milestone payments to partners</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives (2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,412</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,256</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impact of Voltaren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Gel generic competition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Acceleration of Auxilium employee equity awards at closing</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain litigation-related charges, net (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges (4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">923,607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items (5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,889</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">Costs associated with unused financing commitments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other than temporary impairment of equity investment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,869</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency impact related to the remeasurement of intercompany debt instruments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,903</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,153</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment adjusted income from continuing operations before income tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382,409</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,142,715</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,046,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;">$(9.0) million</font><font style="font-family:inherit;font-size:10pt;"> and increases of excess inventory reserves of </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, primarily related to the 2016 </font><font style="font-family:inherit;font-size:10pt;">U.S. Generic Pharmaceuticals</font><font style="font-family:inherit;font-size:10pt;"> restructuring initiative. The adjustment for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of </font><font style="font-family:inherit;font-size:10pt;">$14.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> and other restructuring costs of </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amounts in the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> periods include employee separation costs of </font><font style="font-family:inherit;font-size:10pt;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$58.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and a </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium&#8217;s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and </font><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font><font style="font-family:inherit;font-size:10pt;"> expense in our </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;">. See </font><font style="font-family:inherit;font-size:10pt;">Note 4. Restructuring</font><font style="font-family:inherit;font-size:10pt;"> for discussion of our material restructuring initiatives.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These amounts include charges for Litigation-related and other contingencies, net as further described in </font><font style="font-family:inherit;font-size:10pt;">Note 12. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset impairment charges primarily relate to charges to write down intangible assets as further described in </font><font style="font-family:inherit;font-size:10pt;">Note 9. Goodwill and Other Intangibles</font><font style="font-family:inherit;font-size:10pt;"> and goodwill impairment charges recorded during the third quarter of 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:18px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition-related and integration items include costs directly associated with previous acquisitions of </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$55.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to </font><font style="font-family:inherit;font-size:10pt;">$52.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$134.8 million</font><font style="font-family:inherit;font-size:10pt;"> for the comparable </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> periods. In addition, during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there is a charge for changes in fair value of contingent consideration of </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended September 30, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of </font><font style="font-family:inherit;font-size:10pt;">$80.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$83.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income and expense are considered corporate items and included in Corporate unallocated. Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards update (ASU) No. 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers&#8221; </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No.&#160;2015-14,&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606):&#160;Deferral of the Effective Date,&#8221;</font><font style="font-family:inherit;font-size:10pt;"> which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017 and the Company currently plans to adopt it on January 1, 2018. In March and April 2016, the FASB issued ASU No. 2016-08 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)&#8221;</font><font style="font-family:inherit;font-size:10pt;"> and ASU No. 2016-10 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,&#8221; </font><font style="font-family:inherit;font-size:10pt;">respectively</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Revenue from Contracts with Customers (Topic 606):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Narrow-Scope Improvements and Practical Expedients,&#8221; </font><font style="font-family:inherit;font-size:10pt;">which amends certain narrow aspects of Topic 606. The Company is currently evaluating the impact of these standards on the Company&#8217;s consolidated results of operations and financial position, including possible transition alternatives.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Measurement of Inventory&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#160;(ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively and early application is permitted. The Company is currently evaluating the impact of ASU 2015-11 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued&#160;ASU No. 2016-02, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Improvements to Employee Share-Based Payment Accounting&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (a) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (b) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (c) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (d) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer&#8217;s statutory income tax withholding obligation, (e) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (f) electing whether to account for forfeitures of share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-09 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on the Company&#8217;s consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15 </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Classification of Certain Cash Receipts and Cash Payments&#8221;</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-15). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-15 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-15 on the Company&#8217;s consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASU No. 2016-16 &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</font><font style="font-family:inherit;font-size:10pt;">&#8221; (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company is currently evaluating the impact of ASU 2016-16 on the Company&#8217;s consolidated results of operations and financial position.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE 14. SHAREHOLDERS' EQUITY</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Shareholder&#8217;s Equity</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Attributable to:&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Endo<br clear="none"/>International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Noncontrolling<br clear="none"/>interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br clear="none"/>Shareholders&#8217;<br clear="none"/>Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at January 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,968,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,967,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (loss) income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,210</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,567</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of ordinary shares related to the employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,050,861</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Attributable to:&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Endo<br clear="none"/>International plc</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-style:normal;font-weight:bold;">Noncontrolling<br clear="none"/>interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total<br clear="none"/>Shareholders&#8217;<br clear="none"/>Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,374,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,408,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,579</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,376,732</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation related to share-based awards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,537</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax withholding for restricted shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,068</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buy-out of noncontrolling interests, net of contributions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued in connection with the Par acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,325,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,325,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued in connection with the Auxilium acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,519,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of equity component of acquired Auxilium Notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">266,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of Auxilium Notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,892</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of ordinary shares related to the employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ordinary shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity issuance fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,956</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,956</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholders&#8217; equity at September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,396,064</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,396,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in </font><font style="font-family:inherit;font-size:10pt;">Note 3. Discontinued Operations and Held for Sale</font><font style="font-family:inherit;font-size:10pt;">, the operating results of the Company&#8217;s AMS business is reported as Discontinued operations, net of tax in the </font><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations</font><font style="font-family:inherit;font-size:10pt;"> for all periods presented. However, as share-based compensation is not material for this business, amounts in this </font><font style="font-family:inherit;font-size:10pt;">Note 14. Shareholders' Equity</font><font style="font-family:inherit;font-size:10pt;"> have not been adjusted to exclude the impact of this business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized share-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$44.6 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to </font><font style="font-family:inherit;font-size:10pt;">$23.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$86.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The share-based compensation expense recognized during the </font><font style="font-family:inherit;font-size:10pt;">nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> includes a charge related to the acceleration of Auxilium employee equity awards at closing of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;">. The share-based compensation expense during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> includes </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;"> of expense related to certain AMS equity awards modified in conjunction with the anticipated sale of the business. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards amounted to </font><font style="font-family:inherit;font-size:10pt;">$93.9 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the weighted average remaining requisite service period of the non-vested stock options was </font><font style="font-family:inherit;font-size:10pt;">2.2</font><font style="font-family:inherit;font-size:10pt;"> years and for non-vested restricted stock units was </font><font style="font-family:inherit;font-size:10pt;">2.3</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div> EX-101.SCH 7 endp-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2405408 - Disclosure - Acquisitions (Aspen Holdings) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Acquisitions (Auxilium Pharmaceuticals, Inc.) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405410 - Disclosure - Acquisitions (Other Acquisition) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405407 - Disclosure - Acquisitions (Par Pharmaceutical Holdings, Inc.) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Acquisitions (Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date) (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2405409 - Disclosure - Acquisitions (Voltaren Gel) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Commitments And Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Commitments And Contingencies (Legal Proceedings and Investigations) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Commitments And Contingencies (Manufacturing, Supply and Other Service Agreements) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Commitments And Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements Of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements Of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements Of Comprehensive (Loss) Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements Of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Debt (Components Of Total Indebtedness) (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Debt (Credit Facility) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Discontinued Operations and Held For Sale link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Discontinued Operations and Held For Sale (Astora Restructuring Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Discontinued Operations and Held For Sale (Cash Flow Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Discontinued Operations and Held For Sale (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Discontinued Operations and Held For Sale (Operating Results of Discontinued Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Discontinued Operations and Held For Sale (Summary of Restructuring Activities) (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Discontinued Operations and Held For Sale (Summary of Restructuring Expenses) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Discontinued Operations and Held For Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair Value Measurements (Financial Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair Value Measurements (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Fair Value Measurements (Summary Of Available-For-Sale Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Goodwill And Other Intangibles link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Goodwill And Other Intangibles (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Goodwill And Other Intangibles (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Goodwill And Other Intangibles (Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Goodwill And Other Intangibles (Schedule Of Estimated Amortization Of Intangibles) (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Goodwill And Other Intangibles (Schedule Of Other Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Goodwill And Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventories (Schedule Of Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - License And Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - License And Collaboration Agreements (Novartis AG, Novartis Consumer Health Inc. and Sandoz) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - License And Collaboration Agreements (XIAFLEX Out-License Agreements) (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Net Loss Per Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Other Comprehensive (Loss) Income (Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Other (Income) Expense, Net (Schedule Of Components Of Other (Income) Expense, Net) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Recent Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Restructuring (Changes to Restructuring Accrual) (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Restructuring (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Segment Results link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Segment Results (Schedule Of Reportable Segments Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Segment Results (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Shareholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Shareholders' Equity (Schedule of Changes in Stockholders' Equity) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 endp-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 endp-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 endp-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Discontinued Operations and Disposal Groups [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] AMS Ams [Member] AMS [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenue Disposal Group, Including Discontinued Operation, Revenue Litigation related and other contingencies, net Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies Disposal Group Including Discontinued Operation, Litigation Related And Other Contingencies Asset impairment charges Impairment of Long-Lived Assets to be Disposed of Gain on sale of business Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Loss from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Discontinued operations, net of tax Disposal Group, Including Discontinued Operation, Operating Income (Loss) Debt Instruments [Abstract] Schedule of long-term debt instruments Schedule of Long-term Debt Instruments [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Schedule of other intangible assets Schedule Of Other Intangible Assets [Table Text Block] Schedule of other intangible assets table text block Schedule of future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of changes in gross carrying amount of other intangible assets Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets [Table Text Block] Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets [Table Text Block] Income Tax Disclosure [Abstract] Income tax expense (benefit) Income Tax Expense (Benefit) Total consolidated loss from continuing operations before income tax Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Deferred tax charge related to restructuring Deferred Tax Liabilities, Deferred Expense, Restructuring Charge Deferred Tax Liabilities, Deferred Expense, Restructuring Charge Discrete tax benefit from amortization of prepaid asset Effective Income Tax Rate Reconciliation, Amortization of Deferred Restructuring Charge, Excess Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Amortization of Deferred Restructuring Charge, Excess Tax Benefit, Amount Discrete tax benefit from outside basis differences Deferred Tax Asset, Outside Basis Difference Deferred Tax Asset, Outside Basis Difference Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Auxilium Pharmaceuticals, Inc. Auxilium Pharmaceuticals, Inc. [Member] Auxilium Pharmaceuticals, Inc. [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Acquisition-Related And Integration Items Acquisition-Related And Integration Items [Member] Acquisition-Related And Integration Items [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Aggregate consideration transferred Business Combination, Consideration Transferred Acquisition-related and integration items Business Combination, Acquisition Related Costs Interest expense Interest Expense Amortization of intangible assets Amortization of Intangible Assets Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Voltaren Gel Voltaren Gel [Member] Voltaren Gel [Member] Payments to acquire business Payments to Acquire Businesses, Gross Contingent consideration Business Combination, Contingent Consideration, Liability Net identifiable assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill Goodwill Finite-lived intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Estimated useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life License And Collaboration Agreements [Abstract] License and Collaboration Agreements Abstract License And Collaboration Agreements [Table] License And Collaboration Agreements [Table] License And Collaboration Agreements [Table] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] XIAFLEX® Xiaflex [Member] Xiaflex [Member] License And Collaboration Agreements [Line Items] License And Collaboration Agreements [Line Items] License And Collaboration Agreements [Line Items] Payments to acquire license rights Payments To Acquire Licensing Rights Payments To Acquire Licensing Rights Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] 2016 US Generic Pharmaceuticals Restructuring US Generic Pharmaceuticals Restructuring 2016 [Member] US Generic Pharmaceuticals Restructuring 2016 [Member] Consideration received Disposal Group, Including Discontinued Operation, Consideration Upfront cash proceeds Proceeds from Divestiture of Businesses Potential milestone payment Disposal Group, Expected Milestone Payment Disposal Group, Expected Milestone Payment Inventory Disclosure [Abstract] INVENTORIES Inventory Disclosure [Text Block] INCOME TAXES Income Tax Disclosure [Text Block] Stockholders' Equity Note [Abstract] Schedule of changes in stockholders' equity Schedule of Stockholders Equity [Table Text Block] Equity [Abstract] OTHER COMPREHENSIVE (LOSS) INCOME Comprehensive Income (Loss) Note [Text Block] DEBT Debt Disclosure [Text Block] Segment Reporting [Abstract] Schedule of reportable segments information Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of reconciliations of consolidated loss from continuing operations before income tax Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block] Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax To Consolidated Income Before Income Tax [Table Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options And Stock Awards Stock Options And Stock Awards [Member] Stock Options And Stock Awards [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares excluded from calculation (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount DISCONTINUED OPERATIONS AND HELD FOR SALE Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill and Other Intangibles [Table]. Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-process research and development In Process Research and Development [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses Licensing Agreements [Member] Customer Relationships Customer Relationships [Member] Tradenames Trade Names [Member] Developed technology Developed Technology Rights [Member] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Indefinite-lived Intangibles Indefinite-lived Intangible Assets [Member] Definite-Lived Intangibles Finite-Lived Intangible Assets [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Weighted Average Weighted Average [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] U.S. Generic Pharmaceuticals Generic Pharmaceuticals [Member] Generic Pharmaceuticals [Member] U.S. Branded Pharmaceuticals Branded Pharmaceuticals [Member] Branded Pharmaceuticals [Member] International Pharmaceuticals International Pharmaceuticals [Member] International Pharmaceuticals [Member] Astora Astora [Member] Astora [Member] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Indefinite-lived intangibles: Indefinite-lived Intangible Assets [Roll Forward] Balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Acquisitions Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Intangible asset impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Other Indefinite-lived Intangible Assets, Other Indefinite-lived Intangible Assets, Other Effect of Currency Translation Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss) Balance Definite-lived intangibles: Finite-lived Intangible Assets [Roll Forward] Balance Finite-Lived Intangible Assets, Gross Impairments Impairment of Intangible Assets, Finite-lived Other Finite-Lived Intangible Assets, Other Finite-Lived Intangible Assets, Other Effect of Currency Translation Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Balance Total other intangibles Intangible Assets, Gross [Roll Forward] Intangible Assets, Gross [Roll Forward] Beginning balance Intangible Assets, Gross (Excluding Goodwill) Impairment of intangible assets Impairment of Intangible Assets (Excluding Goodwill) Other Intangible Assets, Other Intangible Assets, Other Effect of Currency Translation Intangible Assets, Foreign Currency Translation Gain (Loss) Intangible Assets, Foreign Currency Translation Gain (Loss) Ending balance Accumulated amortization: Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward] Finite-Lived Intangible Assets, Accumulated Amortization [Roll Forward] Balance Finite-Lived Intangible Assets, Accumulated Amortization Amortization Impairments Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization Impairment of Intangible Assets, Finite-lived, Effect On Accumulated Amortization Other Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization Finite-Lived Intangible Assets, Other Adjustments, Increase (Decrease) In Accumulated Amortization Effect of Currency Translation Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization Finite-Lived Intangible Assets, Translation Adjustments, Effect On Accumulated Amortization Balance Net other intangibles Intangible Assets, Net (Excluding Goodwill) Intangible life (years) Finite-Lived Intangible Asset, Useful Life LICENSE AND COLLABORATION AGREEMENTS Collaborative Arrangement Disclosure [Text Block] GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] Schedule Of Stockholders' Equity [Table] Schedule Of Stockholders' Equity [Table] Schedule Of Stockholders' Equity [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Endo International plc Endo International [Member] Endo International [Member] Noncontrolling interests Noncontrolling Interest [Member] Par Pharmaceutical Holdings, Inc. Par Pharmaceutical Holdings, Inc. [Member] Par Pharmaceutical Holdings, Inc. [Member] Stockholders' Equity [Line Items] Stockholders' Equity [Line Items] Stockholders' Equity [Line Items] Increase (Decrease) in Shareholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shareholders' equity, beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Compensation related to share-based awards Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Tax withholding for restricted shares Adjustments Related to Tax Withholding for Share-based Compensation Exercise of options Stock Issued During Period, Value, Stock Options Exercised Buy-out of noncontrolling interests, net of contributions Stockholders Equity, Period Decrease, Buy-out of Noncontrolling Interests, Net of Contributions Stockholders Equity, Period Decrease, Buy-out of Noncontrolling Interests, Net of Contributions Ordinary shares issued in connection with acquisitions Stock Issued During Period, Value, Acquisitions Fair value of equity component of acquired Auxilium Notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Conversion of Auxilium Notes Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of ordinary shares related to the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Ordinary shares issued Stock Issued During Period, Value, New Issues Equity issuance fees Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Other Stockholders' Equity, Other Shareholders' equity, ending balance Component of Operating Income [Abstract] OTHER (INCOME) EXPENSE, NET Other Income and Other Expense Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Segment Reconciling Items Segment Reconciling Items [Member] Operating Segments Operating Segments [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Inventory Write-Offs Inventory Write-Offs [Member] Inventory Write-Offs [Member] Other Restructuring Costs Other Restructuring [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total consolidated loss from continuing operations before income tax Corporate unallocated costs Segment Reporting Information, Unallocated Corporate Expense Segment Reporting Information, Unallocated Corporate Expense Amortization of intangible assets Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans Inventory Step-Up And Certain Excess Costs Inventory Step-Up And Certain Excess Costs Upfront and milestone payments to partners Upfront And Milestone Payments To Partners Upfront and milestone payments to partners. Separation benefits and other cost reduction initiatives Cost Reduction Initiatives Cost Reduction Initiatives Impact of Voltaren® Gel generic competition Royalty Expense Acceleration of Auxilium employee equity awards at closing Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Certain litigation-related charges, net Loss Contingency, Loss in Period Asset impairment charges Asset Impairment Charges Acquisition-related and integration items Loss on extinguishment of debt Extinguishment of Debt, Gain (Loss), Net of Tax Costs associated with unused financing commitments Debt Instrument, Unused Borrowing Capacity, Fee Other than temporary impairment of equity investment Equity Method Investment, Other than Temporary Impairment Foreign currency impact related to the remeasurement of intercompany debt instruments Adjustment for Long-term Intercompany Transactions, Gross of Tax Other, net Other Nonrecurring (Income) Expense Severance costs Severance Costs Restructuring expenses Restructuring Charges Remaining lease obligations net of sublease income Provision For Acquired Remaining Lease Obligations Net Of Sublease Income Provision For Acquired Remaining Lease Obligations Net Of Sublease Income Transaction costs Business Combination, Closing Transaction Costs Business Combination, Closing Transaction Costs Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventory, Net Long-term inventory Inventory, Noncurrent Inventories not yet available for sale Inventory, Not Yet Available For Sale, Net Inventory, Not Yet Available For Sale, Net Reconciliation of the numerator and denominator of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Vaginal mesh cases Vaginal Mesh Cases [Member] Vaginal Mesh Cases [Member] Unapproved Drug Litigation Unapproved Drug Litigation [Member] Unapproved Drug Litigation [Member] Megace ES Cases Megace ES Cases [Member] Megace ES Cases [Member] Opana Opana [Member] Opana [Member] Paragraph IV Certification on Fortesta Gel [Member] Paragraph IV Certification on Fortesta Gel [Member] Paragraph IV Certification on Fortesta Gel [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Testosterone cases Testosterone Cases [Member] Testosterone Cases [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] AMS American Medical Systems [Member] American Medical Systems [Member] PPI Par Pharmaceutical, Inc. [Member] Par Pharmaceutical, Inc. [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Reserve for loss contingencies Loss Contingency Accrual Product liability accrual, period expense Loss Contingency Accrual, Product Liability, Gross Number of class-wide post-market study orders received Number Of Class-Wide Post-Market Product Study Orders, Received Number Of Class-Wide Post-Market Product Study Orders, Received Number of class-wide post-market study orders placed on hold by the FDA Number Of Class-Wide Post-Market Product Study Orders, Placed On Hold By FDA Number Of Class-Wide Post-Market Product Study Orders, Placed On Hold By FDA Number of active class-wide post-market study orders Number Of Class-Wide Post-Market Product Study Orders, Active Number Of Class-Wide Post-Market Product Study Orders, Active Loss contingency, claims settled, number Loss Contingency, Claims Settled, Number Settlement amount Loss Contingency, Damages Paid, Value Lawsuits filed Loss Contingency, New Claims Filed, Number Current portion of legal settlement accrual Loss Contingency, Accrual, Current Pending claims, number Loss Contingency, Pending Claims, Number Number of additional pharmaceutical companies named in petitions (over 50) Loss Contingency, Number Of Additional Defendants Named Loss Contingency, Number Of Additional Defendants Named Damages sought per violation Loss Contingency, Damages Sought, Value Damages awarded Litigation Settlement, Awarded Against Entity, Amount Litigation Settlement, Awarded Against Entity, Amount Gain Contingencies [Table] Gain Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Judicial Ruling Judicial Ruling [Member] Gain Contingencies [Line Items] Gain Contingencies [Line Items] Number of patents found infringed upon Gain Contingency, Patents Found Infringed upon, Number Period for generic product to be withdrawn Gain Contingency, Period For Withdrawing Generic Product Gain Contingency, Period For Withdrawing Generic Product Number of post-trial motions Gain Contingency, Number Of Post-Trial Motions Gain Contingency, Number Of Post-Trial Motions Lawsuit filing period Loss Contingency, Lawsuit Filing Period Loss Contingency, Lawsuit Filing Period Stay of approval period, Hatch-Waxman Act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Accounting Policies [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Aspen Holdings Aspen Holdings [Member] Aspen Holdings [Member] Number of countries the company operates in (more than 150) Number of Countries in which Entity Operates Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill, gross, beginning balance Goodwill, Gross Accumulated impairment losses, beginning balance Goodwill, Impaired, Accumulated Impairment Loss Goodwill, beginning balance Measurement period adjustments Goodwill, Purchase Accounting Adjustments Effect of currency translation on gross balance Goodwill, Foreign Currency Translation Gain (Loss) Effect of currency translation on accumulated impairment Goodwill, Accumulated Impairment Loss, Foreign Currency Translation Gain (Loss) Goodwill, Accumulated Impairment Loss, Foreign Currency Translation Gain (Loss) Goodwill, gross, ending balance Accumulated impairment losses, ending balance Goodwill, ending balance Fair Value Disclosures [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Schedule of Trading Securities and Other Trading Assets, Major Types of Trading Securities and Assets [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Trading Securities and Assets [Domain] Major Types of Debt and Equity Securities [Domain] Money market funds Money Market Funds [Member] Equity securities Equity Securities [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Cash and cash equivalents Cash and Cash Equivalents [Member] Restricted cash and cash equivalents Restricted Cash And Cash Equivalents [Member] Restricted Cash And Cash Equivalents [Member] Short-term available for sale securities Short Term Available For Sale Securities [Member] Short Term Available For Sale Securities [Member] Long-term available-for-sale securities Long Term Available For Sale Securities [Member] Long-Term Available-for-Sale Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized (Losses) Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair Value Available-for-sale Securities Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash and cash equivalents Restricted Cash and Cash Equivalents, Current Marketable securities Marketable Securities, Current Accounts receivable Accounts Receivable, Net, Current Inventories, net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income taxes receivable Income Taxes Receivable, Current Assets held for sale (NOTE 3) Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current MARKETABLE SECURITIES Marketable Securities, Noncurrent PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment, Net GOODWILL OTHER INTANGIBLES, NET DEFERRED INCOME TAXES Deferred Tax Assets, Net, Noncurrent OTHER ASSETS Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Current portion of long-term debt Long-term Debt, Current Maturities Income taxes payable Accrued Income Taxes, Current Liabilities held for sale (NOTE 3) Disposal Group, Including Discontinued Operation, Liabilities Total current liabilities Liabilities, Current DEFERRED INCOME TAXES Deferred Tax Liabilities, Net, Noncurrent LONG-TERM DEBT, LESS CURRENT PORTION, NET Long-term Debt, Excluding Current Maturities LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION, NET Loss Contingency, Accrual, Noncurrent OTHER LIABILITIES Other Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES (NOTE 12) Commitments and Contingencies SHAREHOLDERS’ EQUITY: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued Preferred Stock, Value, Issued Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 222,859,941 and 222,124,282 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Endo International plc shareholders’ equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total shareholders’ equity TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Changes in Qualified Settlement Funds accounts and product liability balance Schedule of Loss Contingencies by Contingency [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 7.25% Senior Notes due 2022 Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member] Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member]. 5.75% Senior Notes due 2022 Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member] Five Point Seven Five Senior Notes Due On Two Thousand Twenty Two [Member] 5.375% Senior Notes due 2023 Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member] Five Point Three Seven Five Senior Notes Due On Two Thousand Twenty Three [Member] 6.00% Senior Notes due 2023 Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member] Six Point Zero Percent Senior Notes Due Two Thousand Twenty Three [Member] 6.00% Senior Notes due 2025 6.00% Senior Notes Due 2025 [Member] 6.00% Senior Notes Due 2025 [Member] Term Loan A Facility Due 2019 Term Loan Facility Due Two Thousand Nineteen [Member] Term Loan Facility Due Two Thousand Nineteen [Member] Term Loan B Facility Due 2022 Term Loan Facility Due Two Thousand Twenty Two [Member] Term Loan Facility Due Two Thousand Twenty Two [Member] Other debt Other Debt [Member] Other Debt [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Principal Amount Long-term Debt, Gross Unamortized Discount and Deferred Loan Costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Revolving Credit Facility Long-term Line of Credit Other debt Other Long-term Debt Total long-term debt, net Long-term Debt Less current portion, net Total long-term debt, less current portion, net Long-term Debt, Gross, Noncurrent Long-term Debt, Gross, Noncurrent Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Fair value of long term debt Long-term Debt, Fair Value Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Astora Restructuring Astora Restructuring [Member] Astora Restructuring [Member] Employee separation, retention and other benefit-related costs Employee Severence and Other Benefit Related Costs [Member] Employee Severence and Other Benefit Related Costs [Member] Asset impairment charges Asset Impairment Charges [Member] Asset Impairment Charges [Member] Contract termination charges Contract Termination [Member] Other wind down costs Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Number of positions reduced Restructuring and Related Cost, Number of Positions Eliminated Expected restructuring costs remaining Restructuring and Related Cost, Expected Cost Remaining Restructuring reserve Restructuring Reserve Corporate unallocated Corporate, Non-Segment [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Adjustment Scenario, Adjustment [Member] Total net revenues to external customers Revenues Adjusted income (loss) from continuing operations before income tax Adjusted Income (Loss) Before Income Tax Adjusted income (loss) before income tax. Costs and expenses Other Nonoperating Expense Restructuring and Related Activities [Abstract] Scenario, Forecast Scenario, Forecast [Member] 2015 US Generic Pharmaceuticals Restructuring US Generic Pharmaceuticals Restructuring 2015 [Member] US Generic Pharmaceuticals Restructuring [Member] Auxilium Restructuring Auxilium Restructuring [Member] Auxilium Restructuring [Member] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale, Name [Domain] Long Lived Assets Held-for-sale, Name [Domain] Charlotte, North Carolina Facility Charlotte, North Carolina Facility [Member] Charlotte, North Carolina Facility [Member] Employee Separation, Retention and Other Benefit-Related Costs Asset Impairment Charges Excess Inventory Reserve Write-Offs Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Expected positions eliminated (percent) Restructuring and Related Cost, Expected Positions Eliminated, Percent Restructuring and Related Cost, Expected Positions Eliminated, Percent Expected accelerated depreciation Restructuring and Related Cost, Expected Accelerated Depreciation Restructuring and Related Cost, Expected Accelerated Depreciation Proceeds from sale of property Proceeds from Sale of Property, Plant, and Equipment Expected restructuring costs Restructuring and Related Cost, Expected Cost Restructuring costs incurred Restructuring and Related Cost, Incurred Cost Impairment of intangible assets Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Other charges Other Restructuring Costs Line of Credit Facility [Table] Line of Credit Facility [Table] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Repayments of revolving debt Repayments of Lines of Credit Credit facility, remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Document And Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Ordinary Shares Outstanding Entity Common Stock, Shares Outstanding Contract Termination Charges Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning liability balance Expenses Restructuring Charges, Net Of Asset Impairment Charges Restructuring Charges, Net Of Asset Impairment Charges Cash distributions Payments for Restructuring Ending liability balance Statement of Comprehensive Income [Abstract] CONSOLIDATED NET LOSS OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX: Other Comprehensive Income (Loss), Net of Tax [Abstract] Net unrealized gain (loss) on securities: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax [Abstract] Unrealized gain (loss) arising during the period Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Less: reclassification adjustments for (gain) loss realized in net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Net unrealized gain (loss) on securities: Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Foreign currency translation (loss) gain: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax [Abstract] Foreign currency (loss) gain arising during the period Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Less: reclassification adjustments for loss realized in net loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Foreign currency translation loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax OTHER COMPREHENSIVE (LOSS) INCOME CONSOLIDATED COMPREHENSIVE (LOSS) INCOME Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Less: Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Less: Other comprehensive income (loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Initially Reported Scenario, Previously Reported [Member] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts and other receivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Deferred income tax assets, current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets, Current Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total identifiable assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net identifiable assets acquired Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Income Statement [Abstract] TOTAL REVENUES COSTS AND EXPENSES: Costs and Expenses [Abstract] Cost of revenues Cost of Revenue Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Litigation-related and other contingencies, net Legal Matters and Contingencies Expense Legal Matters and Contingencies Expense OPERATING LOSS FROM CONTINUING OPERATIONS Operating Income (Loss) INTEREST EXPENSE, NET Interest Income (Expense), Net LOSS ON EXTINGUISHMENT OF DEBT OTHER (INCOME) EXPENSE, NET Nonoperating Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX INCOME TAX EXPENSE (BENEFIT) (LOSS) INCOME FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3) Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest CONSOLIDATED NET LOSS Less: Net income (loss) attributable to noncontrolling interests NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC Net Income (Loss) Attributable to Parent NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC: Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Basic (in dollars per share) Earnings Per Share, Basic NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—DILUTED: Earnings Per Share, Diluted [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share Diluted (in dollars per share) Earnings Per Share, Diluted WEIGHTED AVERAGE SHARES: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Net unrealized gain (loss) on securities Accumulated Net Investment Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Net unrealized gain (loss) on foreign currency Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Before Reclassification, Before Tax Amount Other Comprehensive Income (Loss), before Reclassifications, before Tax Before Reclassification, Tax (Expense) Benefit Other Comprehensive Income (Loss) before Reclassifications, Tax Before Reclassification, Net-of-Tax Amount Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification, Before Tax Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Reclassification, Tax (Expense) Benefit Reclassification from AOCI, Current Period, Tax Reclassification, Net-of-Tax Amount Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Before- Tax Amount Other Comprehensive Income (Loss), before Tax Tax Benefit (Expense) Other Comprehensive Income (Loss), Tax SHAREHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Schedule of restructuring reserve by type of cost Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures Disposal Groups, Including Discontinued Operations [Table Text Block] Restructuring and related costs Restructuring and Related Costs [Table Text Block] Expenses Cash payments/distributions Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis] Fair Value, Hierarchy [Axis] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain] Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Time deposits Bank Time Deposits [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Acquisition-related contingent consideration—short-term Acquisition Related Contingent Consideration Short Term [Member] Acquisition Related Contingent Consideration-Short Term [Member] Acquisition-related contingent consideration—long-term Acquisition Related Contingent Consideration Long Term [Member] Acquisition-Related Contingent Consideration-Long Term [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Assets: Fair value of financial assets measured on recurring basis Assets, Fair Value Disclosure, Recurring Liabilities: Liabilities [Abstract] Fair value of financial liabilities measured on recurring basis Liabilities, Fair Value Disclosure, Recurring Numerator: Earnings Per Share Reconciliation [Abstract] Less: Net income (loss) from continuing operations attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest (Loss) income from continuing operations attributable to Endo International plc ordinary shareholders Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] For basic per share data—weighted average shares (shares) Dilutive effect of ordinary share equivalents (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive effect of various convertible notes and warrants (shares) Dilutive Effect Of One Point Seven Five Percentage Of Convertible Senior Subordinated Notes Dilutive Effect Of One Point Seven Five Percentage Of Convertible Senior Subordinated Notes For diluted per share data—weighted average shares (shares) SEGMENT RESULTS Segment Reporting Disclosure [Text Block] 2016 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Schedule of Product Information [Table] Schedule of Product Information [Table] Other Intangible Assets Other Intangible Assets [Member] Other Acquisition Other Acquisitions [Member] Other Acquisitions [Member] Product Information [Line Items] Product Information [Line Items] Capitalization of payments relating to XIAFLEX® Intangible Assets, Capitalization Of Royalties Intangible Assets, Capitalization Of Royalties Acquisition of intangible assets Finite-lived Intangible Assets Acquired Sale of certain International Pharmaceuticals intangible assets Proceeds from Sale of Intangible Assets Impairment of intangible assets Measurement period adjustments relating to acquisitions closed during 2015 Removal of fully amortized intangible assets relating to expired or terminated licensing agreements Effect of currency translation Other Intangible Asset Foreign Currency Translation Adjustment Other Intangible Asset Foreign Currency Translation Adjustment Revenue Business Acquisition, Pro Forma Revenue Net loss attributable to Endo International plc Business Acquisition, Pro Forma Net Income (Loss) Basic net income (loss) income per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted net income (loss) income per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Schedule of tax effects allocated to each component of other comprehensive income Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Schedule of accumulated other comprehensive income (loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of inventory Schedule of Inventory, Current [Table Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Consolidated net loss Adjustments to reconcile consolidated net loss to Net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Inventory step-up Inventory Step Up Inventory Step Up Share-based compensation Share-based Compensation Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts Provision for bad debts Provision for Doubtful Accounts Deferred income taxes Deferred Income Taxes and Tax Credits Net loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Prepayment penalty on long-term debt Debt Instrument, Long Term Debt Prepayment Penalty Debt Instrument, Long Term Debt Prepayment Penalty Asset impairment charges Asset Impairment Charges, Excluding Related To Discontinued Operations Asset Impairment Charges, Excluding Related To Discontinued Operations Gain on sale of business and other assets Gain (Loss) on Disposition of Business Changes in assets and liabilities which (used) provided cash: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Income taxes payable/receivable Increase (Decrease) in Income Taxes Receivable Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of intellectual property and property, plant and equipment Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Proceeds from sale of marketable securities and investments Proceeds from Sale and Maturity of Marketable Securities Proceeds from notes receivable Proceeds from Sale and Collection of Notes Receivable Patent acquisition costs and license fees Payments to Acquire Intangible Assets Proceeds from sale of business, net Increase in restricted cash and cash equivalents Increase in Restricted Cash Decrease in restricted cash and cash equivalents Decrease in Restricted Cash Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of notes Proceeds from Notes Payable Proceeds from issuance of term loans Proceeds from Issuance of Debt, Loans Proceeds from Issuance of Debt, Loans Principal payments on notes Repayments of Notes Payable Principal payments on term loans Repayments of Other Long-term Debt Proceeds from draw of revolving debt Proceeds from Lines of Credit Repayments of revolving debt Principal payments on other indebtedness, net Repayments of Debt Repurchase of convertible senior subordinated notes Repayments of Convertible Debt Sale of AMSH Inc. mandatorily redeemable preferred shares Proceeds from Issuance of Preferred Stock and Preference Stock Deferred financing fees Payments of Financing Costs Payment for contingent consideration Payment On Contingent Consideration Payment On Contingent Consideration Tax benefits of share awards Excess Tax Benefit from Share-based Compensation, Financing Activities Payments of tax withholding for restricted shares Payments Related to Tax Withholding for Share-based Compensation Exercise of options Proceeds from Stock Options Exercised Issuance of ordinary shares related to the employee stock purchase plan Proceeds from Sale of Treasury Stock Issuance of ordinary shares Proceeds from Issuance of Common Stock Payments related to the issuance of ordinary shares Payments of Stock Issuance Costs Cash buy-out of noncontrolling interests Payments to Noncontrolling Interests Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate Effect of Exchange Rate on Cash and Cash Equivalents NET INCREASE IN CASH AND CASH EQUIVALENTS Net Cash Provided by (Used in) Continuing Operations CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash received from income taxes, net Proceeds from Income Tax Refunds Cash paid into Qualified Settlement Funds for mesh legal settlements Settlement Funds, Additions Settlement Funds, Additions Cash paid out of Qualified Settlement Funds for mesh legal settlements Settlement Funds, Payments Settlement Funds, Payments Other cash distributions for mesh legal settlements Other Payments For Legal Settlements Other Payments For Legal Settlements SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Purchases of property, plant and equipment financed by capital leases Capital Lease Obligations Incurred Accrual for purchases of property, plant and equipment Capital Expenditures Incurred but Not yet Paid Acquisition financed by ordinary shares Noncash or Part Noncash Acquisition, Value of Assets Acquired Repurchase of convertible senior subordinated notes financed by ordinary shares Debt Conversion, Original Debt, Amount RECENT ACCOUNTING PRONOUNCEMENTS Significant Accounting Policies [Text Block] Foreign currency loss (gain), net Foreign Currency Transaction Gain (Loss), before Tax Equity (earnings) loss from unconsolidated subsidiaries, net Income (Loss) from Equity Method Investments Other than temporary impairment of equity investment Legal settlement Litigation Settlement, Amount Costs associated with unused financing commitments Other miscellaneous, net Other Nonoperating Income (Expense) Other (income) expense, net RESTRUCTURING Restructuring and Related Activities Disclosure [Text Block] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Developed Technology Vasostrict® Vasostrict [Member] Vasostrict [Member] Aplisol® Apisol [Member] Apisol [Member] Developed - Other - Non-Partnered (Generic Non-Injectable) Developed Technology, Other, Non-Partnered, Generic Non-Injectible [Member] Developed Technology, Other, Non-Partnered, Generic Non-Injectible [Member] Developed - Other - Partnered (Combined) Developed Technology, Other, Partnered, Combined [Member] Developed Technology, Other, Partnered, Combined [Member] Nascobal® Bupropion [Member] Bupropion [Member] Developed - Other - Non-Partnered (Generic Injectable) Developed Technology, Other, Non-Partnered, Generic Injectible [Member] Developed Technology, Other, Non-Partnered, Generic Injectible [Member] Other Developed Technology Other Developed Technology [Member] Other Developed Technology [Member] IPR&D 2019 Launch In Process Research And Development 2019 Launch [Member] In Process Research And Development 2019 Launch [Member] IPR&D 2018 Launch In Process Research And Development 2018 Launch [Member] In Process Research And Development 2018 Launch [Member] Ezetimibe Ezetimibe [Member] Ezetimibe [Member] IPR&D 2016 Launch In Process Research And Development 2016 Launch [Member] In Process Research And Development 2016 Launch [Member] Ephedrine Sulphate Neostigmine Vial [Member] Neostigmine Vial [Member] Neostigmine vial Ephedrine Sulphate [Member] Ephedrine Sulphate [Member] Other IPR&D Other In Process Research And Development [Member] Other In Process Research And Development [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Valuation Amortization period Product Liability Product Liability [Member] Product Liability [Member] Qualified Settlement Funds Settlement Funds [Roll Forward] Settlement Funds [Roll Forward] Balance as of December 31, 2015 Settlement Funds Settlement Funds Cash contributions to Qualified Settlement Funds Cash distributions to settle disputes from Qualified Settlement Funds Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds Settlement Funds, Payments To Plaintiff Counsel From Qualified Settlement Funds Other Settlement Funds, Other Settlement Funds, Other Balance as of September 30, 2016 Product Liability Loss Contingency Accrual [Roll Forward] Balance as of December 31, 2015 Additional charges Loss Contingency Accrual, Provision Cash distributions to settle disputes from Qualified Settlement Funds Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds Loss Contingency Accrual, Payments To Plaintiff Counsel From Qualified Settlement Funds Cash distributions to settle disputes Loss Contingency Accrual, Payments To Plaintiff Counsel Loss Contingency Accrual, Payments To Plaintiff Counsel Balance as of September 30, 2016 Deferred consideration for acquired inventory Business Combination, Deferred Consideration, Acquired Inventory Business Combination, Deferred Consideration, Acquired Inventory Cash flows from discontinued operating activities: Net Cash Provided By (Used In) Operating Activities, Discontinued Operations [Abstract] Net Cash Provided By (Used In) Operating Activities, Discontinued Operations [Abstract] Net loss Depreciation and amortization Disposal Group, Including Discontinued Operation, Depreciation and Amortization Net cash used in discontinued investing activities: Net Cash Provided By (Used In) Investing Activities, Discontinued Operations [Abstract] Net Cash Provided By (Used In) Investing Activities, Discontinued Operations [Abstract] Purchases of property, plant and equipment Euro deferred shares, par value (in dollars per share) Euro Deferred Shares, Par or Stated Value Per Share Euro Deferred Shares, Par or Stated Value Per Share Euro deferred shares, shares authorized Euro Deferred Shares, Shares Authorized Euro Deferred Shares, Shares Authorized Euro deferred shares, shares issued Euro Deferred Shares, Shares Issued Euro Deferred Shares, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Financial assets and liabilities measured at fair value on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Changes to liability for acquisition-related contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of available-for-sale securities Available-for-sale Securities [Table Text Block] Summary of nonrecurring fair value measurements Fair Value Measurements, Nonrecurring [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Voltaren Gel Agreement 2015 Voltaren Gel Agreement 2015 [Member] Voltaren Gel Agreement 2015 [Member] Voltaren Gel Agreement Voltaren Gel Agreement [Member] Voltaren Gel Agreement [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] License agreement term extension period License Agreement Term Extension, Duration License Agreement Term Extension, Duration Termination of agreement notice period Termination Of Agreement Notice Period Termination Of Agreement Notice Period Payments for royalties Payments for Royalties Schedule of components of other (income) expense, net Schedule of Other Nonoperating Income, by Component [Table Text Block] NET LOSS PER SHARE Earnings Per Share [Text Block] Schedule of revenue and net loss of acquired included in Condensed Consolidated Statements of Operations Schedule Of Revenue And Net Loss Of Acquired Included In Condensed Consolidated Statements Of Operations [Table Text Block] Schedule Of Revenue And Net Loss Of Acquired Included In Condensed Consolidated Statements Of Operations [Table Text Block] Schedule of recognized identified assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of valuation of the intangible assets acquired and related amortization periods Schedule Of Valuation Of Intangible Assets Acquired And Related Amortization Periods [Table Text Block] Schedule Of Valuation Of Intangible Assets Acquired And Related Amortization Periods [Table Text Block] Schedule of pro forma consolidated results Business Acquisition, Pro Forma Information [Table Text Block] Revenue Net loss attributable to Endo International plc Basic and diluted net loss per share (in dollars per share) Earnings Per Share, Basic and Diluted Acquisition-related contingent consideration Acquisition Related Contingent Consideration [Member] Acquisition-Related Contingent Consideration [Member] Qualitest acquisition Qualitest [Member] Qualitest [Member] Sumavel acquisition Sumavel DosePro [Member] Sumavel DosePro [Member] Auxilium acquisition Lehigh Valley Technologies, Inc. acquisitions Lehigh Valley Technologies, Inc. [Member] Lehigh Valley Technologies, Inc. [Member] Voltaren Gel® acquisition Other Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Amounts acquired Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Amounts settled Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Transfers (in) and/or out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Measurement period adjustments Liabilities, Fair Value Adjustment Changes in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Effect of currency translation Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Gain (Loss) Included in Other Comprehensive Income (Loss) Fair Value Adjustments and Accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments And Accretion Payments and Other Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements And Effect Of Currency Translation End of period ACQUISITIONS Business Combination Disclosure [Text Block] Minimum Minimum [Member] Maximum Maximum [Member] Ordinary shares issued, shares Stock Issued During Period, Shares, Acquisitions Equity consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Reduction of expenses Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Amortization of intangible assets Amortization of inventory step-up Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Discount rate range (percent) Fair Value Inputs, Discount Rate Goodwill expected to be deductible for income tax purposes Business Acquisition, Goodwill, Expected Tax Deductible Amount Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Noramco, Inc. Noramco, Inc. [Member] Noramco, Inc. [Member] Jubilant HollisterStier Laboratories LLC Jubilant HollisterStier Laboratories LLC [Member] Jubilant HollisterStier Laboratories LLC [Member] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Agreement term Long-term Purchase Commitment, Period Agreement renewal term Long Term Purchase Commitment Renewal Period Purchase commitment, renewal term (in years) FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Amortization Amortization Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill and Indefinite-lived Intangible Assets Goodwill and Indefinite-lived Intangible Assets [Member] Goodwill and Indefinite-lived Intangible Assets [Member] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Intangible Assets Intangible Assets [Member] Intangible Assets [Member] Goodwill [Line Items] Goodwill [Line Items] Net unrealized gains Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Foreign currency translation loss Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated other comprehensive loss Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Paladin Labs Inc. Litha Joint Venture Investment [Member] Litha Joint Venture Investment [Member] Net asset value required to be maintained by money market funds (in dollars per unit) Net asset value required to be maintained by money market funds (Per Unit) Net asset value required to be maintained by money market funds (Per Unit) Joint venture investments Equity Method Investments Available-for-sale securities, amortized cost Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair value, measurements, nonrecurring Fair Value, Measurements, Nonrecurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, plant and equipment Property, Plant, and Equipment, Fair Value Disclosure Asset impairment charges Certain segment intangible assets Finite-Lived And Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Finite-Lived And Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure Total income (expense) from intangible assets Income (Loss) From Intangible Assets, Excluding Goodwill Income (Loss) From Intangible Assets, Excluding Goodwill Total Assets, Fair Value Disclosure Total income (expense) from assets Income (Loss) From Assets Income (Loss) From Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Nonvested Stock Options Non Vested Stock Options [Member] Non Vested Stock Options [Member] Nonvested RSUs Restricted Stock Units And Performance Stock Units [Member] Restricted Stock Units And Performance Stock Units [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation expense Allocated Share-based Compensation Expense Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted average remaining requisite service period, non-vested stock options Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options Weighted average remaining requisite service period, non-vested restricted stock units Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition EX-101.PRE 11 endp-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Nov. 01, 2016
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Trading Symbol ENDP  
Entity Registrant Name Endo International plc  
Entity Central Index Key 0001593034  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Ordinary Shares Outstanding   222,876,797
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
CURRENT ASSETS:    
Cash and cash equivalents $ 561,577 $ 272,348
Restricted cash and cash equivalents 275,745 585,379
Marketable securities 0 34
Accounts receivable 669,815 1,014,808
Inventories, net 624,302 752,493
Prepaid expenses and other current assets 75,568 55,052
Income taxes receivable 40,429 735,901
Assets held for sale (NOTE 3) 0 36,522
Total current assets 2,247,436 3,452,537
MARKETABLE SECURITIES 2,361 3,855
PROPERTY, PLANT AND EQUIPMENT, NET 671,618 675,624
GOODWILL 7,411,620 7,299,354
OTHER INTANGIBLES, NET 6,975,578 7,828,942
DEFERRED INCOME TAXES 3,733 10,423
OTHER ASSETS 371,156 79,601
TOTAL ASSETS 17,683,502 19,350,336
CURRENT LIABILITIES:    
Accounts payable 306,096 347,503
Accrued expenses 945,412 1,162,612
Current portion of legal settlement accrual 1,280,785 1,606,726
Current portion of long-term debt 124,250 328,705
Income taxes payable 5,759 8,551
Liabilities held for sale (NOTE 3) 0 20,215
Total current liabilities 2,662,302 3,474,312
DEFERRED INCOME TAXES 178,271 871,040
LONG-TERM DEBT, LESS CURRENT PORTION, NET 8,170,618 8,251,657
LONG-TERM LEGAL SETTLEMENT ACCRUAL, LESS CURRENT PORTION, NET 0 549,098
OTHER LIABILITIES 621,450 236,253
COMMITMENTS AND CONTINGENCIES (NOTE 12)
SHAREHOLDERS’ EQUITY:    
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued 49 43
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 222,859,941 and 222,124,282 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 22 22
Additional paid-in capital 8,733,360 8,693,385
Accumulated deficit (2,350,425) (2,341,215)
Accumulated other comprehensive loss (332,145) (384,205)
Total Endo International plc shareholders’ equity 6,050,861 5,968,030
Noncontrolling interests 0 (54)
Total shareholders’ equity 6,050,861 5,967,976
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 17,683,502 $ 19,350,336
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Euro deferred shares, par value (in dollars per share) $ 0.01 $ 0.01
Euro deferred shares, shares authorized 4,000,000 4,000,000
Euro deferred shares, shares issued 4,000,000 4,000,000
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 222,859,941 222,124,282
Common stock, shares outstanding 222,859,941 222,124,282
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements Of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
TOTAL REVENUES $ 884,335 $ 745,727 $ 2,768,761 $ 2,195,021
COSTS AND EXPENSES:        
Cost of revenues 557,472 442,459 1,878,395 1,265,583
Selling, general and administrative 186,735 163,221 558,160 529,290
Research and development 44,885 21,327 137,166 58,208
Litigation-related and other contingencies, net 18,256 0 28,715 19,875
Asset impairment charges 93,504 923,607 263,080 1,000,850
Acquisition-related and integration items 19,476 (27,688) 80,201 51,177
OPERATING LOSS FROM CONTINUING OPERATIONS (35,993) (777,199) (176,956) (729,962)
INTEREST EXPENSE, NET 112,184 96,446 340,896 250,196
LOSS ON EXTINGUISHMENT OF DEBT 0 40,909 0 41,889
OTHER (INCOME) EXPENSE, NET (2,866) 50,091 402 62,589
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX (145,311) (964,645) (518,254) (1,084,636)
INCOME TAX EXPENSE (BENEFIT) 46,185 (160,939) (627,807) (340,528)
(LOSS) INCOME FROM CONTINUING OPERATIONS (191,496) (803,706) 109,553 (744,108)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3) (27,423) (246,782) (118,747) (632,624)
CONSOLIDATED NET LOSS (218,919) (1,050,488) (9,194) (1,376,732)
Less: Net income (loss) attributable to noncontrolling interests 0 (46) 16 (153)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC $ (218,919) $ (1,050,442) $ (9,210) $ (1,376,579)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:        
Continuing operations (in dollars per share) $ (0.86) $ (3.84) $ 0.49 $ (3.96)
Discontinued operations (in dollars per share) (0.12) (1.18) (0.53) (3.36)
Basic (in dollars per share) (0.98) (5.02) (0.04) (7.32)
NET LOSS PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—DILUTED:        
Continuing operations (in dollars per share) (0.86) (3.84) 0.49 (3.96)
Discontinued operations (in dollars per share) (0.12) (1.18) (0.53) (3.36)
Diluted (in dollars per share) $ (0.98) $ (5.02) $ (0.04) $ (7.32)
WEIGHTED AVERAGE SHARES:        
Basic (shares) 222,767 209,274 222,579 188,085
Diluted (shares) 222,767 209,274 223,060 188,085
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements Of Comprehensive (Loss) Income (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statement of Comprehensive Income [Abstract]        
CONSOLIDATED NET LOSS $ (218,919) $ (1,050,488) $ (9,194) $ (1,376,732)
Net unrealized gain (loss) on securities:        
Unrealized gain (loss) arising during the period 152 (403) (855) 1,311
Less: reclassification adjustments for (gain) loss realized in net loss (6) 0 (6) 0
Net unrealized gain (loss) on securities: 146 (403) (861) 1,311
Foreign currency translation (loss) gain:        
Foreign currency (loss) gain arising during the period (6,195) (84,952) 52,959 (208,299)
Less: reclassification adjustments for loss realized in net loss 0 25,715 0 25,715
Foreign currency translation loss (6,195) (59,237) 52,959 (182,584)
OTHER COMPREHENSIVE (LOSS) INCOME (6,049) (59,640) 52,098 (181,273)
CONSOLIDATED COMPREHENSIVE (LOSS) INCOME (224,968) (1,110,128) 42,904 (1,558,005)
Less: Net income (loss) attributable to noncontrolling interests 0 (46) 16 (153)
Less: Other comprehensive income (loss) attributable to noncontrolling interests 0 (32) 38 (581)
COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC $ (224,968) $ (1,110,050) $ 42,850 $ (1,557,271)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
OPERATING ACTIVITIES:    
Consolidated net loss $ (9,194) $ (1,376,732)
Adjustments to reconcile consolidated net loss to Net cash provided by (used in) operating activities:    
Depreciation and amortization 716,332 381,952
Inventory step-up 99,099 122,714
Share-based compensation 44,567 48,537
Amortization of debt issuance costs and discount 21,483 16,440
Provision for bad debts 6,264 1,970
Deferred income taxes (613,318) (335,171)
Net loss on disposal of property, plant and equipment 4,639 1,785
Change in fair value of contingent consideration 24,790 (83,605)
Loss on extinguishment of debt 0 41,889
Prepayment penalty on long-term debt 0 (17,496)
Asset impairment charges 284,409 1,244,672
Gain on sale of business and other assets (791) (13,550)
Changes in assets and liabilities which (used) provided cash:    
Accounts receivable 342,012 (220,973)
Inventories 22,215 (31,823)
Prepaid and other assets (289,631) (30,568)
Accounts payable (35,406) (1,767)
Accrued expenses (616,361) 211,970
Other liabilities (250,746) (238,048)
Income taxes payable/receivable 693,014 100,372
Net cash provided by (used in) operating activities 443,377 (177,432)
INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (88,087) (50,944)
Proceeds from sale of intellectual property and property, plant and equipment 2,578 0
Acquisitions, net of cash acquired (30,394) (7,514,425)
Proceeds from sale of marketable securities and investments 34 347
Proceeds from notes receivable 0 17
Patent acquisition costs and license fees (19,206) 0
Proceeds from sale of business, net 4,108 1,588,779
Increase in restricted cash and cash equivalents (588,455) (533,441)
Decrease in restricted cash and cash equivalents 898,288 549,171
Net cash provided by (used in) investing activities 178,866 (5,960,496)
FINANCING ACTIVITIES:    
Proceeds from issuance of notes 0 2,835,000
Proceeds from issuance of term loans 0 2,800,000
Principal payments on notes 0 (499,875)
Principal payments on term loans (76,000) (459,626)
Proceeds from draw of revolving debt 0 300,000
Repayments of revolving debt (225,000) (300,000)
Principal payments on other indebtedness, net (4,634) (8,931)
Repurchase of convertible senior subordinated notes 0 (247,760)
Sale of AMSH Inc. mandatorily redeemable preferred shares 0 60,000
Deferred financing fees (500) (114,440)
Payment for contingent consideration (23,807) (20,264)
Tax benefits of share awards 0 19,878
Payments of tax withholding for restricted shares (10,532) (15,268)
Exercise of options 1,952 25,068
Issuance of ordinary shares related to the employee stock purchase plan 4,010 3,328
Issuance of ordinary shares 0 2,300,000
Payments related to the issuance of ordinary shares 0 (66,956)
Cash buy-out of noncontrolling interests 0 (39,608)
Net cash (used in) provided by financing activities (334,511) 6,570,546
Effect of foreign exchange rate 1,497 (5,260)
NET INCREASE IN CASH AND CASH EQUIVALENTS 289,229 427,358
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 272,348 408,753
CASH AND CASH EQUIVALENTS, END OF PERIOD 561,577 836,111
SUPPLEMENTAL INFORMATION:    
Cash received from income taxes, net 702,786 49,832
Cash paid into Qualified Settlement Funds for mesh legal settlements 587,782 526,785
Cash paid out of Qualified Settlement Funds for mesh legal settlements 898,288 509,563
Other cash distributions for mesh legal settlements 5,561 16,312
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Purchases of property, plant and equipment financed by capital leases 716 4,234
Accrual for purchases of property, plant and equipment 2,201 2,719
Acquisition financed by ordinary shares 0 2,844,969
Repurchase of convertible senior subordinated notes financed by ordinary shares $ 0 $ 625,483
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE 1. BASIS OF PRESENTATION
The accompanying unaudited Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries have been prepared in accordance with United States (U.S.) generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements of Endo International plc and its subsidiaries, which are unaudited, include all normal and recurring adjustments necessary to a fair statement of the Company’s financial position as of September 30, 2016 and the results of our operations and our cash flows for the periods presented. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The year-end Condensed Consolidated Balance Sheet data as of December 31, 2015 was derived from the audited financial statements.
Unless otherwise indicated or required by the context, references throughout to “Endo,” the “Company,” “we,” “our,” or “us” refer to financial information and transactions of Endo International plc and its subsidiaries.
Endo International plc is an Ireland-domiciled, global specialty pharmaceutical company focused on branded and generic pharmaceuticals.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2015.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Recent Accounting Pronouncements
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS
NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017 and the Company currently plans to adopt it on January 1, 2018. In March and April 2016, the FASB issued ASU No. 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” and ASU No. 2016-10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” respectively, which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which amends certain narrow aspects of Topic 606. The Company is currently evaluating the impact of these standards on the Company’s consolidated results of operations and financial position, including possible transition alternatives.
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” (ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively and early application is permitted. The Company is currently evaluating the impact of ASU 2015-11 on the Company’s consolidated results of operations and financial position.
In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company’s consolidated results of operations and financial position.
In March 2016, the FASB issued ASU No. 2016-09 “Improvements to Employee Share-Based Payment Accounting” (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (a) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (b) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (c) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (d) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation, (e) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (f) electing whether to account for forfeitures of share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-09 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on the Company’s consolidated results of operations and financial position.
In August 2016, the FASB issued ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments” (ASU 2016-15). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-15 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-15 on the Company’s consolidated statement of cash flows.
In October 2016, the FASB issued ASU No. 2016-16 “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company is currently evaluating the impact of ASU 2016-16 on the Company’s consolidated results of operations and financial position.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale
 9 Months Ended
Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS AND HELD FOR SALE
NOTE 3. DISCONTINUED OPERATIONS AND HELD FOR SALE
American Medical Systems
On February 24, 2015, the Company’s Board of Directors (Board of Directors) approved a plan to sell the Company’s American Medical Systems Holdings, Inc. (AMS) business, which comprised the entirety of our former Devices segment. The AMS business was comprised of the Men’s Health and Prostate Health business as well as the Women’s Health business (referred to herein as Astora). On August 3, 2015, the Company sold the Men’s Health and Prostate Health business to Boston Scientific Corporation (Boston Scientific) for $1.65 billion, with $1.60 billion paid upfront in cash and $50.0 million in cash contingent on Boston Scientific achieving certain product revenue milestones in the Men’s Health and Prostate Health business in 2016.
In addition to selling the Men’s Health and Prostate Health business in 2015, as of December 31, 2015 and continuing into 2016, the Company was actively pursuing a sale of the Astora business with the Company in active negotiations with multiple potential buyers. The majority of the remaining assets and liabilities of the AMS business, which were related to the Astora business, were classified as held for sale in the Consolidated Balance Sheet as of December 31, 2015 in the Company’s Form 10-K filed with the Securities and Exchange Commission on February 29, 2016. Certain of AMS’s assets and liabilities, primarily with respect to its product liability accrual related to vaginal mesh cases, the related Qualified Settlement Funds and certain intangible and fixed assets, were not classified as held for sale based on management’s expectation that these assets and liabilities would remain with the Company.
On February 24, 2016, the Board of Directors resolved to wind down the Company’s Astora business as it did not align with the Company’s strategic direction and to reduce the additional exposure to mesh-related product liability. The Company conducted a wind down process to transition physicians to alternative products during the first quarter of 2016. The Company ceased business operations of Astora on March 31, 2016 and exited its AMS business. As a result, as of March 31, 2016 and periods thereafter, the remaining assets and liabilities of the AMS business, which were related to the Astora business, were no longer classified as held for sale in the Condensed Consolidated Balance Sheets. In accordance with applicable accounting guidance, the Company also reclassified the Astora assets and liabilities previously presented as held for sale as of December 31, 2015 to held and used on its Condensed Consolidated Balance Sheets.
The operating results of the AMS business are reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented.
The following table provides the operating results of the Discontinued operations, net of tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Revenue
$
387

 
$
43,705

 
$
30,101

 
$
282,310

Litigation related and other contingencies, net
$
17,705

 
$
—

 
$
20,155

 
$
273,752

Asset impairment charges
$
—

 
$
2,200

 
$
21,328

 
$
224,953

Gain on sale of business
$
—

 
$
13,550

 
$
—

 
$
13,550

Loss from discontinued operations before income taxes
$
(27,309
)
 
$
(18,775
)
 
$
(118,633
)
 
$
(506,275
)
Income tax expense
$
—

 
$
228,007

 
$
—

 
$
126,349

Discontinued operations, net of tax
$
(27,309
)
 
$
(246,782
)
 
$
(118,633
)
 
$
(632,624
)

As a result of the Astora wind down initiative announced in the first quarter of 2016, the Company incurred asset impairment charges of $21.3 million during the nine months ended September 30, 2016. See below for discussion of our material wind down initiatives.
The following table provides the Depreciation and amortization and Purchases of property, plant and equipment of AMS for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash flows from discontinued operating activities:
 
 
 
Net loss
$
(118,633
)
 
$
(632,624
)
Depreciation and amortization
$
—

 
$
11,555

Net cash used in discontinued investing activities:
 
 
 
Purchases of property, plant and equipment
$
(138
)
 
$
(2,182
)

Astora Restructuring
The Astora wind down process includes a restructuring initiative implemented during the three months ended March 31, 2016, which includes the reduction of the Astora workforce consisting of approximately 250 employees. Under this restructuring initiative, separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.
As a result of the Astora restructuring initiative, the Company incurred expenses of $1.8 million and $68.4 million during the three and nine months ended September 30, 2016, respectively, consisting of employee separation, retention and other benefit-related costs, asset impairment charges, contract termination charges and other general restructuring costs. There were no restructuring expenses related to this initiative during the three and nine months ended September 30, 2015. The Company anticipates there will be additional pre-tax restructuring expenses of $2.4 million related to employee separation, retention and other benefit-related costs, contract termination charges and other restructuring costs. The majority of these actions have been completed as of September 30, 2016 and substantially all cash payments will be made by the end of 2016. These restructuring costs are included in Discontinued operations in the Condensed Consolidated Statements of Operations.
A summary of expenses related to the Astora restructuring initiative is included below for the three and nine months ended September 30, 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
Employee separation, retention and other benefit-related costs
$
715

 
$
22,181

Asset impairment charges
—

 
21,328

Contract termination charges
769

 
10,569

Other wind down costs
285

 
14,315

Total
$
1,769

 
$
68,393


The liability related to the Astora restructuring initiative totaled $16.1 million as of September 30, 2016 and is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Contract Termination Charges
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
—

 
$
—

 
$
—

 
$
—

Expenses
22,181

 
10,569

 
7,778

 
40,528

Cash distributions
(13,393
)
 
(5,743
)
 
(5,276
)
 
(24,412
)
Liability balance as of September 30, 2016
$
8,788

 
$
4,826

 
$
2,502

 
$
16,116
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring
 9 Months Ended
Sep. 30, 2016
Restructuring and Related Activities [Abstract]  
RESTRUCTURING
NOTE 4. RESTRUCTURING
U.S. Generic Pharmaceuticals Restructuring
2015 U.S Generic Pharmaceuticals Restructuring
In connection with the acquisition of Par Pharmaceutical Holdings, Inc. and its subsidiaries (together herein Par) on September 25, 2015, we implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning the Company’s U.S. Generic Pharmaceuticals segment sales, sales support, management activities and staffing, which resulted in separation benefits to certain U.S. Generic Pharmaceuticals employees. The cost reduction initiatives included a reduction in headcount of approximately 6% of the U.S. Generic Pharmaceuticals workforces. Under this restructuring initiative (the 2015 U.S. Generic Pharmaceuticals restructuring initiative), separation costs are expensed over the requisite service period, if any, while retention is being expensed ratably over the respective retention period.
As a result of the 2015 U.S. Generic Pharmaceuticals restructuring initiative, the Company incurred restructuring expenses of $0.6 million and $5.2 million during the three and nine months ended September 30, 2016, respectively, consisting of employee separation, retention and other benefit-related costs. The Company does not anticipate any further additional pre-tax restructuring expenses related to employee separation, retention and other benefit-related costs. These actions are expected to be completed by October 31, 2016, with substantially all cash payments made by the end of 2016. In addition, the Company anticipates there will be additional pre-tax restructuring expenses of approximately $4.9 million related to accelerated depreciation on certain assets. These restructuring costs are allocated to the U.S. Generic Pharmaceuticals segment, and are primarily included in Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the 2015 U.S. Generic Pharmaceuticals restructuring initiative totaled $10.0 million and $17.9 million at September 30, 2016 and December 31, 2015, respectively. At September 30, 2016, this liability is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
17,914

Expenses
5,229

Cash distributions
(13,114
)
Liability balance as of September 30, 2016
$
10,029


2016 U.S Generic Pharmaceuticals Restructuring
As part of the ongoing U.S. Generic Pharmaceuticals integration efforts, in May 2016 we announced a restructuring initiative to optimize our product portfolio and rationalize our manufacturing sites to expand product margins (the 2016 U.S. Generic Pharmaceuticals restructuring initiative). These measures include certain cost savings initiatives, including a reduction in headcount and the disposal of our Charlotte, North Carolina manufacturing facility. On October 31, 2016, we entered into a definitive agreement to sell the Charlotte, North Carolina facility for proceeds of $14 million, subject to purchase price adjustments as defined in the agreement. The Company expects to record an impairment charge during the fourth quarter of 2016 of approximately $10 million related to fixed assets associated with the sale. The transaction is expected to close in the first quarter of 2017 and is subject to customary closing conditions.
As a result of the 2016 U.S. Generic Pharmaceuticals restructuring initiative, the Company has incurred total restructuring expenses of $159.5 million through September 30, 2016 and expects to incur additional restructuring-related expenses of approximately $30 million consisting of accelerated depreciation, employee separation, retention and other benefit-related costs and certain other charges. The Company anticipates these actions will be completed by September 2017, with substantially all cash payments made by the end of 2017. Under this restructuring initiative, separation costs will be expensed ratably over the requisite service period, if any.
Restructuring charges of $13.3 million and $159.5 million recorded during the three and nine months ended September 30, 2016, respectively, consisted of certain intangible asset impairment charges of $100.3 million and charges to increase excess inventory reserves of $33.3 million during the nine months ended September 30, 2016, charges relating to employee separation, retention and other benefit-related costs of $7.0 million and $13.4 million, accelerated depreciation of $3.4 million and $6.8 million and other charges of $3.0 million and $5.7 million during the three and nine months ended September 30, 2016, respectively. These charges are included in the U.S. Generic Pharmaceuticals segment, and are included in Asset impairment charges, Cost of revenues, and Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative totaled $8.1 million at September 30, 2016 and is included in Accrued expenses in the Condensed Consolidated Balance Sheets. Changes to the accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
—

Expenses
13,398

Cash payments
(5,274
)
Liability balance as of September 30, 2016
$
8,124


Auxilium Restructuring
In connection with the acquisition of Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals LLC hereafter referred to as Auxilium) on January 29, 2015, the Company implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the Company. These measures included realigning our sales, sales support, management activities and staffing, which included separation benefits to former Auxilium employees, in addition to the closing of duplicative facilities. The cost reduction initiatives included a reduction in headcount of approximately 40% of the former Auxilium workforce. For former Auxilium employees that agreed to continue employment with the Company for a merger transition period, the separation costs payable upon completion of their retention period were expensed over their respective retention period. The Company does not anticipate there will be additional material pre-tax restructuring expenses related to this initiative. The Company anticipates that substantially all employee separation, retention and other benefit-related costs cash payments relating to this initiative will be made by the end of 2016. The remainder of the cash payments will be made over the remaining lease term of Auxilium’s former corporate headquarters in Chesterbrook, Pennsylvania. These restructuring costs are included in the U.S. Branded Pharmaceuticals segment, and are primarily included in Selling, general and administrative costs and expenses in the Condensed Consolidated Statements of Operations.
The liability related to the Auxilium restructuring initiative totaled $5.9 million and $12.3 million at September 30, 2016 and December 31, 2015, respectively, and is included in Accrued expenses and Other liabilities in the Condensed Consolidated Balance Sheets. Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
5,353

 
$
6,910

 
$
12,263

Cash distributions
(5,174
)
 
(1,143
)
 
(6,317
)
Liability balance as of September 30, 2016
$
179

 
$
5,767

 
$
5,946
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions
 9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
ACQUISITIONS
NOTE 5. ACQUISITIONS
For each of the acquisitions described below, except for Auxilium, Par and Aspen Holdings, the estimated fair values of the net assets acquired are provisional as of September 30, 2016 and are based on information that is currently available to the Company. Additional information is being gathered to finalize these provisional measurements. Accordingly, the measurement of the assets acquired and liabilities assumed may change upon finalization of the Company’s valuations and completion of the purchase price allocations, all of which are expected to occur no later than one year from the respective acquisition dates.
Auxilium Pharmaceuticals, Inc.
On January 29, 2015 (the Auxilium Acquisition Date), the Company acquired all of the outstanding shares of common stock of Auxilium, a fully integrated specialty biopharmaceutical company emerging as a leader in the men’s healthcare sector with a strategically focused product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas, in a transaction valued at $2.6 billion. The Company believed that Auxilium would be highly complementary to its branded pharmaceuticals business with significant opportunities to leverage Auxilium’s leading presence in men’s health, as well as the Company’s R&D capabilities and financial resources, to accelerate the growth of Auxilium’s XIAFLEX® and its other products.
The operating results of Auxilium are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and the operating results from the Auxilium Acquisition Date are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015.
The Company recognized no acquisition-related transaction costs associated with the Auxilium acquisition during the nine months ended September 30, 2016. The Company recognized acquisition-related transaction costs associated with the Auxilium acquisition during the nine months ended September 30, 2015 totaling $23.1 million. These costs, which related primarily to bank fees, legal and accounting services, and fees for other professional services, are included in Acquisition-related and integration items in the accompanying Condensed Consolidated Statements of Operations.
The amounts of Auxilium Revenue and Net loss included in the Company’s Condensed Consolidated Statements of Operations from and including January 29, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
237,807

Net loss attributable to Endo International plc
$
(257,597
)
Basic and diluted net loss per share
$
(1.37
)

The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on January 1, 2015 for the nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
Revenue
$
2,218,596

Net loss attributable to Endo International plc
$
(1,395,162
)
Basic and diluted net loss per share
$
(7.42
)

These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Auxilium to reflect factually supportable adjustments that give effect to events that are directly attributable to the Auxilium acquisition assuming the Auxilium acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $1.1 million for the nine months ended September 30, 2015. In addition, the adjustments include additional intangible amortization, net of tax, which would have been charged assuming the Company’s estimated fair value of the intangible assets. The adjustment to the amortization expense for the nine months ended September 30, 2015 increased the expense by $6.2 million.
Acquisition of Par Pharmaceutical Holdings, Inc.
On September 25, 2015 (Par Acquisition Date), the Company acquired Par, a specialty pharmaceutical company that develops, licenses, manufactures, markets and distributes innovative and cost-effective pharmaceuticals with a focus on high-barrier-to-entry products and first-to-file or first-to-market opportunities, for total consideration of $8.14 billion, including the assumption of Par debt. The consideration included the Company’s 18,069,899 ordinary shares valued at $1.33 billion.
The operating results of Par are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016. The amounts of Par Revenue and Net loss attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including September 25, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
23,413

Net loss attributable to Endo International plc
$
(17,441
)
Basic and diluted net loss per share
$
(0.09
)

The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date, including measurement period adjustments since the fair values presented in the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016, (in thousands):
 
September 25, 2015
 
Measurement period adjustments
 
September 25, 2015
(As adjusted)
Cash and cash equivalents
$
215,612

 
$
—

 
$
215,612

Accounts and other receivables
530,664

 
(13,755
)
 
516,909

Inventories
330,406

 
(1,849
)
 
328,557

Prepaid expenses and other current assets
31,124

 
—

 
31,124

Deferred income tax assets, current
14,652

 
30,176

 
44,828

Property, plant and equipment
256,293

 
4,744

 
261,037

Intangible assets
3,627,000

 
(154,500
)
 
3,472,500

Other assets
8,477

 
—

 
8,477

Total identifiable assets
$
5,014,228

 
$
(135,184
)
 
$
4,879,044

Accounts payable and accrued expenses
$
551,614

 
$
(511
)
 
$
551,103

Deferred income tax liabilities
1,093,779

 
(44,961
)
 
1,048,818

Other liabilities
16,057

 
2,556

 
18,613

Total liabilities assumed
$
1,661,450

 
$
(42,916
)
 
$
1,618,534

Net identifiable assets acquired
$
3,352,778

 
$
(92,268
)
 
$
3,260,510

Goodwill
4,782,876

 
92,268

 
4,875,144

Net assets acquired
$
8,135,654

 
$
—

 
$
8,135,654


Our measurement period adjustments for Par were complete as of September 30, 2016. As a result of the measurement period adjustments recorded above, the Company recorded a reduction of $3.8 million of expense, $3.1 million related to the amortization of intangible assets and $0.7 million related to the amortization of inventory step-up, during the nine months ended September 30, 2016. There were no adjustments of expense recorded during the three months ended September 30, 2016.
The valuation of the intangible assets acquired and related amortization periods are as follows:
 
Valuation (in millions)
 
Amortization period (in years)
Developed Technology:
 
 
 
Vasostrict®
$
556.0

 
8
Aplisol®
312.4

 
11
Developed - Other - Non-Partnered (Generic Non-Injectable)
230.4

 
7
Developed - Other - Partnered (Combined)
164.4

 
7
Nascobal®
118.3

 
9
Developed - Other - Non-Partnered (Generic Injectable)
116.4

 
10
Other
517.9

 
9
Total
$
2,015.8

 
 
In Process Research & Development (IPR&D):
 
 
 
IPR&D 2019 Launch
$
401.0

 
n/a
IPR&D 2018 Launch
283.8

 
n/a
Ezetimibe
147.6

 
n/a
IPR&D 2016 Launch
133.3

 
n/a
Ephedrine Sulphate
128.6

 
n/a
Neostigmine vial
118.6

 
n/a
Other
243.8

 
n/a
Total
$
1,456.7

 
n/a
Total other intangible assets
$
3,472.5

 
n/a

The fair values of the developed technology and IPR&D assets were estimated using a discounted present value income approach. Under this method, an intangible asset’s fair value is equal to the present value of the incremental after-tax cash flows (excess earnings) attributable solely to the intangible asset over its remaining useful life. To calculate fair value, the Company used cash flows discounted at rates ranging from 9% to 10.5%, which were considered appropriate given the inherent risks associated with each type of asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions.
The goodwill recognized is attributable primarily to strategic and synergistic opportunities related to existing pharmaceutical businesses, the assembled workforce of Par and other factors. At the acquisition date, approximately $34.2 million of goodwill was expected to be deductible for income tax purposes.
Deferred tax assets and liabilities are related primarily to the difference between the book basis and tax basis of identifiable intangible assets and inventory step-up.
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on January 1, 2015 for the three and nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
 
 
Revenue
$
1,053,654

 
$
3,194,413

Net loss attributable to Endo International plc
$
(1,084,031
)
 
$
(1,475,667
)
Basic and diluted net loss per share
$
(5.18
)
 
$
(7.85
)

These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Par to reflect factually supportable adjustments that give effect to events that are directly attributable to the Par acquisition assuming the Par acquisition had occurred on January 1, 2015. These adjustments mainly include adjustments to interest expense and additional intangible amortization. The adjustments to interest expense, net of tax, related to borrowings to finance the acquisition increased the expense by $4.9 million and $11.7 million for the three and nine months ended September 30, 2015, respectively. In addition, the adjustments include additional intangible amortization, net of tax, that would have been charged assuming the Company’s estimated fair value of the intangible assets. An adjustment to the amortization expense for the three and nine months ended September 30, 2015 increased the expense by $44.8 million and $129.2 million, respectively.
Aspen Holdings
On October 1, 2015, the Company acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutic areas from a subsidiary of Aspen Pharmacare Holdings Ltd, a leading publicly-traded South African company that supplies branded and generic products in more than 150 countries, and from GlaxoSmithKline plc (GSK) for total consideration of approximately $135.6 million (the Aspen Asset Acquisition). The transaction expanded the Company’s presence in South Africa.
The fair values of the net identifiable assets acquired totaled $127.8 million, resulting in goodwill of $7.8 million, which was assigned to our International Pharmaceuticals segment. The amount of net identifiable assets acquired in connection with the Aspen Asset Acquisition includes $118.4 million of intangible assets to be amortized over an average life of approximately 19 years, and inventory of $9.4 million. Our measurement period adjustments for Aspen Holdings were complete as of September 30, 2016.
The operating results of the Aspen Asset Acquisition are included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016. There are no results included in the accompanying Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015.
Pro forma results of operations have not been presented because the effect of the Aspen Asset Acquisition was not material.
Voltaren® Gel
The Company had exclusive U.S. marketing rights to Voltaren® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. (the 2008 Voltaren® Gel Agreement). On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement (the 2015 Voltaren® Gel Agreement) whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren® Gel and to launch an authorized generic of Voltaren® Gel effective July 1, 2016. Pursuant to the 2015 Voltaren® Gel Agreement, the former 2008 Voltaren® Gel Agreement expired on June 30, 2016 in accordance with its terms.
The Company is accounting for this transaction as a business combination as of the effective date in accordance with the relevant accounting literature. The Company acquired the product for consideration of $158.6 million, consisting of an upfront payment of $16.2 million and contingent cash consideration with an acquisition-date fair value of $142.4 million. See Note 7. Fair Value Measurements for further discussion of this contingent consideration. See Note 10. License and Collaboration Agreements for further discussion of the License and Supply Agreement.
The preliminary fair values of the net identifiable assets acquired totaled approximately $159 million, resulting in no goodwill. The amount of net identifiable assets acquired in connection with the Voltaren® Gel acquisition includes approximately $159 million of identifiable developed technology intangible assets to be amortized over an average life of approximately 7 years.
The operating results of Voltaren® Gel under business combination accounting effective July 1, 2016 are included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2016. The results included in the accompanying Consolidated Statements of Operations for the three and nine months ended September 30, 2015 were accounted for under the previous license and supply agreement, which was not treated as a business combination. The Consolidated Balance Sheets as of September 30, 2016 reflects the acquisition of Voltaren® Gel, effective July 1, 2016.
Other Acquisition
In addition to the business combinations disclosed above, the Company acquired the rights to commercialize a developed technology asset, which is being treated as a business combination. The asset was acquired during the third quarter of 2016 and was not individually material. Total consideration for this business combination was $19.7 million, consisting of an upfront payment of $14.2 million, deferred consideration with respect to acquired inventory of $1.0 million and contingent cash consideration with acquisition-date fair value of $4.5 million. The fair value of the net identifiable intangible asset acquired totaled $18.2 million.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Results
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
SEGMENT RESULTS
NOTE 6. SEGMENT RESULTS
The reportable business segments in which the Company operates are: (1) U.S. Branded Pharmaceuticals, (2) U.S. Generic Pharmaceuticals and (3) International Pharmaceuticals. These segments reflect the level at which the chief operating decision maker regularly reviews financial information to assess performance and to make decisions about resources to be allocated. Each segment derives revenue from the sales or licensing of its respective products and is discussed in more detail below.
We evaluate segment performance based on each segment’s adjusted income (loss) from continuing operations before income tax, which we define as loss from continuing operations before income tax and before certain upfront and milestone payments to partners; acquisition-related and integration items, including transaction costs, earn-out payments or adjustments, changes in the fair value of contingent consideration and bridge financing costs; cost reduction and integration-related initiatives such as separation benefits, retention payments, other exit costs and certain costs associated with integrating an acquired company’s operations; excess costs that will be eliminated pursuant to integration plans; asset impairment charges; amortization of intangible assets; inventory step-up recorded as part of our acquisitions; certain non-cash interest expense; litigation-related and other contingent matters; gains or losses from early termination of debt activities; foreign currency gains or losses on intercompany financing arrangements; and certain other items that the Company believes do not reflect its core operating performance.
Certain of the corporate general and administrative expenses incurred by the Company are not attributable to any specific segment. Accordingly, these costs are not allocated to any of the Company’s segments and are included in the results below as “Corporate unallocated.” The Company’s consolidated adjusted income from continuing operations before income tax is equal to the combined results of each of its segments less these unallocated corporate costs.
U.S. Branded Pharmaceuticals
Our U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as our urology and men’s health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm®, OPANA® ER, Voltaren® Gel, Percocet®, BELBUCA™, Aveed®, Supprelin® LA, and XIAFLEX®, among others.
U.S. Generic Pharmaceuticals
Our U.S. Generic Pharmaceuticals segment focuses on a differentiated product portfolio including high barrier-to-entry products, first-to-file or first-to-market opportunities, which are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health and cardiovascular disease markets, among others.
International Pharmaceuticals
Our International Pharmaceuticals segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women’s health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs.
The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net revenues to external customers:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
279,843

 
$
304,778

 
$
876,998

 
$
905,198

U.S. Generic Pharmaceuticals
533,691

 
367,933

 
1,682,439

 
1,063,221

International Pharmaceuticals (1)
70,801

 
73,016

 
209,324

 
226,602

Total net revenues to external customers
$
884,335

 
$
745,727

 
$
2,768,761

 
$
2,195,021

 
 
 
 
 
 
 
 
Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
131,615

 
$
156,897

 
$
422,816

 
$
484,758

U.S. Generic Pharmaceuticals
$
228,717

 
$
177,961

 
$
655,453

 
$
507,507

International Pharmaceuticals
$
22,077

 
$
18,961

 
$
64,446

 
$
54,729

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
In 2015, we realigned certain costs amongst our International Pharmaceuticals segment, U.S. Branded Pharmaceuticals segment and Corporate unallocated costs based on how our chief operating decision maker reviews segment performance. As a result of this realignment, certain expenses included in our consolidated adjusted income (loss) from continuing operations before income tax for the three and nine months ended September 30, 2015 have been reclassified among our various segments to conform to current period presentation. The net impact of these reclassification adjustments increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $0.6 million and $7.5 million, respectively, with an offsetting $8.1 million decrease to International Pharmaceuticals segment costs for the three months ended September 30, 2015 and increased U.S. Branded Pharmaceuticals segment and Corporate unallocated costs by $1.7 million and $21.0 million respectively, with an offsetting $22.7 million decrease to International Pharmaceuticals segment costs for the nine months ended September 30, 2015.
There were no material revenues from external customers attributed to an individual country outside of the United States during the three and nine months ended September 30, 2016 or 2015.
The table below provides reconciliations of our consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Total consolidated loss from continuing operations before income tax
$
(145,311
)
 
$
(964,645
)
 
$
(518,254
)
 
$
(1,084,636
)
Corporate unallocated costs (1)
159,123

 
137,180

 
473,933

 
363,298

Amortization of intangible assets
211,548

 
121,503

 
636,061

 
333,759

Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans
14,208

 
42,919

 
111,787

 
131,783

Upfront and milestone payments to partners
1,770

 
9,261

 
5,875

 
14,063

Separation benefits and other cost reduction initiatives (2)
9,782

 
22,669

 
70,412

 
70,256

Impact of Voltaren® Gel generic competition
—

 
—

 
(7,750
)
 
—

Acceleration of Auxilium employee equity awards at closing
—

 
—

 
—

 
37,603

Certain litigation-related charges, net (3)
18,256

 
—

 
28,715

 
19,875

Asset impairment charges (4)
93,504

 
923,607

 
263,080

 
1,000,850

Acquisition-related and integration items (5)
19,476

 
(27,688
)
 
80,201

 
51,177

Loss on extinguishment of debt
—

 
40,909

 
—

 
41,889

Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Foreign currency impact related to the remeasurement of intercompany debt instruments
(114
)
 
(5,693
)
 
1,558

 
(23,991
)
Other, net
167

 
(10,484
)
 
(2,903
)
 
(6,153
)
Total segment adjusted income from continuing operations before income tax
$
382,409

 
$
353,819

 
$
1,142,715

 
$
1,046,994

__________
(1)
Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of $(9.0) million and increases of excess inventory reserves of $24.3 million during the three and nine months ended September 30, 2016, respectively, primarily related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative. The adjustment for the three months ended September 30, 2016 resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of $14.8 million and $30.0 million and other restructuring costs of $3.9 million and $16.1 million were recorded for the three and nine months ended September 30, 2016, respectively. Amounts in the comparable 2015 periods include employee separation costs of $20.8 million and $58.1 million, respectively, and a $7.9 million charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium’s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and Selling, general and administrative expense in our Condensed Consolidated Statements of Operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
These amounts include charges for Litigation-related and other contingencies, net as further described in Note 12. Commitments and Contingencies.
(4)
Asset impairment charges primarily relate to charges to write down intangible assets as further described in Note 9. Goodwill and Other Intangibles and goodwill impairment charges recorded during the third quarter of 2015.
(5)
Acquisition-related and integration items include costs directly associated with previous acquisitions of $7.9 million and $55.4 million for the three and nine months ended September 30, 2016, respectively, compared to $52.6 million and $134.8 million for the comparable 2015 periods. In addition, during the three and nine months ended September 30, 2016, there is a charge for changes in fair value of contingent consideration of $11.6 million and $24.8 million, respectively. During the three and nine months ended September 30, 2015, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of $80.3 million and $83.6 million, respectively.
Interest income and expense are considered corporate items and included in Corporate unallocated. Asset information is not reviewed or included within our internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 7. FAIR VALUE MEASUREMENTS
Financial Instruments
The financial instruments recorded in our Condensed Consolidated Balance Sheets include cash and cash equivalents (including money market funds and time deposits), restricted cash and cash equivalents, accounts receivable, marketable securities, equity and cost method investments, accounts payable and accrued expenses, acquisition-related contingent consideration and debt obligations. Included in cash and cash equivalents and restricted cash and cash equivalents are money market funds representing a type of mutual fund required by law to invest in low-risk securities (for example, U.S. government bonds, U.S. Treasury Bills and commercial paper). Money market funds are structured to maintain the fund’s net asset value at $1.00 per unit, which assists in providing adequate liquidity upon demand by the holder. Money market funds pay dividends that generally reflect short-term interest rates. Thus, only the dividend yield fluctuates. Due to their short-term maturity, the carrying amounts of non-restricted and restricted cash and cash equivalents (including money market funds and time deposits), accounts receivable, accounts payable and accrued expenses approximate their fair values.
Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
•
Level 1—Quoted prices in active markets for identical assets or liabilities.
•
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Marketable Securities
Equity securities consist of investments in the stock of publicly traded companies, the values of which are based on quoted market prices and thus represent Level 1 measurements within the above-defined fair value hierarchy. These securities are not held to support current operations and are therefore classified as non-current assets. Equity securities are included in Marketable securities in our Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015.
At the time of purchase, we classify our marketable securities as either available-for-sale securities or trading securities, depending on our intent at that time. Available-for-sale and trading securities are carried at fair value with unrealized holding gains and losses recorded within other comprehensive income or net income, respectively. The Company reviews unrealized losses associated with available-for-sale securities to determine the classification as a “temporary” or “other-than-temporary” impairment. A temporary impairment results in an unrealized loss being recorded in other comprehensive income. An impairment that is viewed as other-than-temporary is recognized in net income. The Company considers various factors in determining the classification, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the issuer or investee, and the Company’s ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.
Equity and Cost Method Investments
As of September 30, 2016, the Company has investments that it accounts for using the equity or cost method of accounting totaling $9.1 million. The Company divested a joint venture investment owned through its Litha subsidiary during the three months ended March 31, 2016. The Company classified this joint venture investment as Assets held for sale as of December 31, 2015 in its Condensed Consolidated Balance Sheets.
With respect to its other equity or cost method investments, which are included in Other Assets in the Company’s Condensed Consolidated Balance Sheets at September 30, 2016 and December 31, 2015, the Company did not recognize any other-than-temporary impairments. The Company considered various factors, including the operating results of its equity method investments and the lack of an unrealized loss position on its cost method investments.
Acquisition-Related Contingent Consideration
The fair value of contingent consideration liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period, the contingent consideration liability is remeasured at current fair value with changes recorded in earnings. Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs; hence these instruments represent Level 3 measurements within the above-defined fair value hierarchy. See Recurring Fair Value Measurements below for additional information on acquisition-related contingent consideration.
Recurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2016
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant 
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Time deposits
—

 
100,091

 
—

 
100,091

Equity securities
2,361

 
—

 
—

 
2,361

Total
$
67,861

 
$
100,091

 
$
—

 
$
167,952

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
108,778

 
$
108,778

Acquisition-related contingent consideration—long-term
—

 
—

 
177,019

 
177,019

Total
$
—

 
$
—

 
$
285,797

 
$
285,797

At September 30, 2016, money market funds include $40.5 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 12. Commitments and Contingencies for further discussion of our product liability cases.
 
Fair Value Measurements at Reporting Date using:
December 31, 2015
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Equity securities
3,889

 
—

 
—

 
3,889

Total
$
55,034

 
$
—

 
$
—

 
$
55,034

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
65,265

 
$
65,265

Acquisition-related contingent consideration—long-term
—

 
—

 
78,237

 
78,237

Total
$
—

 
$
—

 
$
143,502

 
$
143,502


At December 31, 2015, money market funds include $51.1 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 12. Commitments and Contingencies for further discussion of our product liability cases.
Fair Value Measurements Using Significant Unobservable Inputs
The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Beginning of period
$
135,796

 
$
189,082

 
$
143,502

 
$
46,005

Amounts acquired
146,866

 
47,900

 
146,866

 
214,435

Amounts settled
(8,121
)
 
(13,094
)
 
(30,242
)
 
(21,668
)
Transfers (in) and/or out of Level 3
—

 
—

 
—

 
—

Measurement period adjustments
—

 
(78
)
 
—

 
(11,634
)
Changes in fair value recorded in earnings
11,585

 
(80,277
)
 
24,790

 
(83,605
)
Effect of currency translation
(329
)
 
(1,210
)
 
881

 
(1,210
)
End of period
$
285,797

 
$
142,323

 
$
285,797

 
$
142,323


The fair value measurement of the contingent consideration obligations was determined using risk-adjusted discount rates ranging from 3.0% to 22.0%. Changes in fair value recorded in earnings related to acquisition-related contingent consideration are included in our Condensed Consolidated Statements of Operations as Acquisition-related and integration items, and amounts recorded for the short-term and long-term portions of acquisition related contingent consideration are included in Accrued expenses and Other liabilities, respectively, in our Condensed Consolidated Balance Sheets.
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2016 by acquisition (in thousands):
 
Balance as of December 31, 2015
 
Acquisitions
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2016
Qualitest acquisition
$
1,137

 
$
—

 
$
(1,137
)
 
$
—

 
$
—

Sumavel acquisition
631

 
—

 
(631
)
 
—

 
—

Auxilium acquisition
26,435

 
—

 
2,203

 
(9,787
)
 
18,851

Lehigh Valley Technologies, Inc. acquisitions
97,003

 
—

 
24,686

 
(19,389
)
 
102,300

Voltaren Gel® acquisition
—

 
142,355

 
(2,905
)
 
—

 
139,450

Other
18,296

 
4,511

 
2,574

 
(185
)
 
25,196

Total
$
143,502

 
$
146,866

 
$
24,790

 
$
(29,361
)
 
$
285,797


The following is a summary of available-for-sale securities held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
(Losses) 
 
Fair Value
September 30, 2016
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Total included in cash and cash equivalents
$
25,012

 
$
—

 
$
—

 
$
25,012

Total included in restricted cash and cash equivalents
$
40,488

 
$
—

 
$
—

 
$
40,488

Equity securities
$
—

 
$
—

 
$
—

 
$
—

Total other short-term available-for-sale securities
$
—

 
$
—

 
$
—

 
$
—

Equity securities
$
1,766

 
$
595

 
$
—

 
$
2,361

Long-term available-for-sale securities
$
1,766

 
$
595

 
$
—

 
$
2,361


 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains 
 
Gross
Unrealized
(Losses)
 
Fair Value
December 31, 2015
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Total included in cash and cash equivalents
$
3

 
$
—

 
$
—

 
$
3

Total included in restricted cash and cash equivalents
$
51,142

 
$
—

 
$
—

 
$
51,142

Equity securities
$
24

 
$
10

 
$
—

 
$
34

Total other short-term available-for-sale securities
$
24

 
$
10

 
$
—

 
$
34

Equity securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855

Long-term available-for-sale securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855


Nonrecurring Fair Value Measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis as of September 30, 2016 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2016
 
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Assets:
 
 
 
 
 
 
 
Certain Astora property, plant and equipment (NOTE 3)
$
—

 
$
—

 
$
—

 
$
(5,041
)
Certain U.S. Generics Pharmaceuticals property, plant and equipment
—

 
—

 
649

 
(4,448
)
Certain U.S. Branded Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
—

 
(72,814
)
Certain U.S. Generic Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
45,966

 
(169,576
)
Certain International Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
5,324

 
(16,243
)
Certain Astora intangible assets (NOTE 3)
—

 
—

 
—

 
(16,287
)
Total
$
—

 
$
—

 
$
51,939

 
$
(284,409
)
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories
 9 Months Ended
Sep. 30, 2016
Inventory Disclosure [Abstract]  
INVENTORIES
NOTE 8. INVENTORIES
Inventories consist of the following at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Raw materials (1)
$
195,830

 
$
210,038

Work-in-process (1)
111,437

 
177,821

Finished goods (1)
317,035

 
364,634

Total
$
624,302

 
$
752,493


(1) The components of inventory shown in the table above are net of allowance for obsolescence.
Inventory that is in excess of the amount expected to be sold within one year, which relates primarily to XIAFLEX® inventory, is classified as long-term inventory and is not included in the table above. At September 30, 2016 and December 31, 2015, $32.6 million and $24.9 million, respectively, of long-term inventory was included in Other assets in the Condensed Consolidated Balance Sheets.
The Company capitalizes inventory costs associated with certain generic products prior to regulatory approval and product launch, when it is reasonably certain, based on management’s judgment of reasonably certain future commercial use and net realizable value, that the pre-launch inventories will be saleable. The determination to capitalize is made once the Company (or its third party development partners) has filed an Abbreviated New Drug Application (ANDA) that has been acknowledged by the U.S. Food and Drug Administration (the FDA) as containing sufficient information to allow the FDA to conduct its review in an efficient and timely manner and management is reasonably certain that all regulatory and legal requirements will be cleared. This determination is based on the particular facts and circumstances relating to the expected FDA approval of the generic drug product being considered, and accordingly, the time frame within which the determination is made varies from product to product. The Company could be required to write down previously capitalized costs related to pre-launch inventories upon a change in such judgment, or due to a denial or delay of approval by regulatory bodies, or a delay in commercialization, or other potential factors. As of September 30, 2016 and December 31, 2015, the Company had approximately $25.3 million and $12.0 million, respectively, in inventories related to generic products that were not yet available to be sold.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLES
NOTE 9. GOODWILL AND OTHER INTANGIBLES
Goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2016 were as follows (in thousands):
 
Carrying Amount
 
U.S. Branded Pharmaceuticals
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Balance as of December 31, 2015:
 
 
 
 
 
 
 
Goodwill
$
1,676,276

 
$
5,789,934

 
$
592,424

 
$
8,058,634

Accumulated impairment losses
(673,500
)
 
—

 
(85,780
)
 
(759,280
)
Balance as of December 31, 2015
$
1,002,776

 
$
5,789,934

 
$
506,644

 
$
7,299,354

Measurement period adjustments
16,518

 
75,750

 
1,366

 
93,634

Effect of currency translation on gross balance
—

 
—

 
19,732

 
19,732

Effect of currency translation on accumulated impairment
—

 
—

 
(1,100
)
 
(1,100
)
Balance as of September 30, 2016:
 
 
 
 
 
 
 
Goodwill
$
1,692,794

 
$
5,865,684

 
$
613,522

 
$
8,172,000

Accumulated impairment losses
(673,500
)
 
—

 
(86,880
)
 
(760,380
)
 
$
1,019,294

 
$
5,865,684

 
$
526,642

 
$
7,411,620


Other Intangible Assets
The following is a summary of other intangible assets held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
Cost basis:
Balance as of December 31, 2015
 
Acquisitions
(1)
 
Impairments
(2)
 
Other
(3)
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Total indefinite-lived intangibles
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
676,867

 
$
—

 
$
—

 
$
(211,147
)
 
$
—

 
$
465,720

Customer relationships (weighted average life of 15 years)
11,318

 
—

 
(3,460
)
 
(7,858
)
 
—

 
—

Tradenames (weighted average life of 12 years)
7,537

 
—

 
—

 
—

 
(127
)
 
7,410

Developed technology (weighted average life of 12 years)
6,731,573

 
148,891

 
(216,194
)
 
123,618

 
24,263

 
6,812,151

Total definite-lived intangibles (weighted average life of 12 years)
$
7,427,295

 
$
148,891

 
$
(219,654
)
 
$
(95,387
)
 
$
24,136

 
$
7,285,281

Total other intangibles
$
9,170,175

 
$
34,691

 
$
(274,754
)
 
$
(233,843
)
 
$
26,730

 
$
8,722,999

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2015
 
Amortization
 
Impairments
 
Other
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(508,225
)
 
$
(37,142
)
 
$
—

 
$
211,147

 
$
—

 
$
(334,220
)
Customer relationships
(7,858
)
 
—

 
—

 
7,858

 
—

 
—

Tradenames
(6,544
)
 
(66
)
 
—

 
—

 
19

 
(6,591
)
Developed technology
(818,606
)
 
(598,853
)
 
—

 
13,201

 
(2,352
)
 
(1,406,610
)
Total definite-lived intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Total other intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Net other intangibles
$
7,828,942

 
 
 
 
 
 
 
 
 
$
6,975,578

__________
(1)
Includes intangible assets acquired through the acquisition of Voltaren® Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX®, offset by measurement period adjustments relating to the Par acquisition.
(2)
Includes the impairment of certain intangible assets of our U.S. Generic Pharmaceuticals segment of $169.6 million, our U.S. Branded Pharmaceuticals segment of $72.8 million, our International Pharmaceuticals segment of $16.2 million and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately $16.3 million, which is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016. See Note 3. Discontinued Operations and Held for Sale for further information relating to the Astora wind down.
(3)
Includes the removal of approximately $221.9 million of fully amortized intangible assets relating to expired or terminated licensing agreements in our U.S. Branded Pharmaceuticals segment, including the 2008 Voltaren® Gel agreement, described in Note 10. License and Collaboration Agreements, NatestoTM, described in Note 5. Acquisitions of our Annual Report on Form 10-K for the year ended December 31, 2015, and STENDRA®, described in Note 10. Goodwill and Other Intangibles of our Annual Report on Form 10-K for the year ended December 31, 2015. In addition, $10.0 million of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&D assets of $138.5 million were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.
Amortization expense for the three and nine months ended September 30, 2016 totaled $211.5 million and $636.1 million, respectively. Amortization for the three and nine months ended September 30, 2015 totaled $121.5 million and $333.8 million, respectively. Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2015 is as follows (in thousands):
2016
$
824,062

2017
$
725,659

2018
$
637,623

2019
$
575,060

2020
$
546,598


Changes in the gross carrying amount of our other intangibles for the nine months ended September 30, 2016 were as follows (in thousands):
 
Gross Carrying Amount
December 31, 2015
$
9,170,175

Capitalization of payments relating to XIAFLEX®
12,008

Voltaren® Gel acquisition
159,000

Other acquisitions
18,183

Sale of certain International Pharmaceuticals intangible assets
(1,959
)
Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(72,814
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(169,576
)
Impairment of certain International Pharmaceuticals intangible assets
(16,077
)
Impairment of certain Astora intangible assets
(26,318
)
Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)
(154,500
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(221,853
)
Effect of currency translation
26,730

September 30, 2016
$
8,722,999


Endo tests goodwill and indefinite-lived intangible assets for impairment annually, or more frequently whenever events or changes in circumstances indicate that the asset might be impaired. Our annual assessment is performed as of October 1st.
Goodwill
Given the significant decline in the Company’s stock price, the Company initiated an interim goodwill impairment analysis of our U.S. Branded and U.S. Generics reporting units during the second quarter of 2016. We estimated the fair value of our reporting units through an income approach using a discounted cash flow model. Our discounted cash flow models are highly reliant on various assumptions, including estimates of future cash flows (including long-term growth rates), discount rate, and expectations about variations in the amount and timing of cash flows and the probability of achieving the estimated cash flows. These assumptions are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. The discount rates applied to the estimated cash flows for our interim goodwill impairment tests ranged from 8.5% to 9.0%, depending on the overall risk associated with the particular reporting units and other market factors. We believe the discount rates and other inputs and assumptions are consistent with those that a market participant would use. As a result of this interim analysis, the Company determined that the estimated fair value of our U.S. Branded and U.S. Generics reporting units exceeded their estimated net book value; therefore, an impairment charge was not required for the three months ended June 30, 2016.
Intangible Assets
U.S. Generic Pharmaceuticals Segment
During the three months ended March 31, 2016 and June 30, 2016, the Company identified certain market and regulatory conditions impacting the commercial potential of certain indefinite and definite-lived intangible assets in our U.S. Generic Pharmaceuticals segment. Accordingly, we tested these assets for impairment and determined that the carrying value of certain of these assets was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charges of $29.3 million and $40.0 million during the first and second quarters of 2016, respectively. In addition, during the first quarter of 2016, the Company recognized pre-tax, non-cash asset impairment charges of $100.3 million related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative, which resulted from the discontinuation of certain commercial products and the abandonment of certain IPR&D projects. See Note 4. Restructuring for discussion of our material restructuring initiatives.
U.S. Branded Pharmaceuticals Segment
As a result of unfavorable formulary changes and generic competition for sumatriptan, the Company has experienced a downturn in the performance of its Sumavel® DosePro® product, a needle-free delivery system for sumatriptan acquired from Zogenix, Inc. in 2014. As a result of this underperformance, the Company concluded during the third quarter of 2016 that an impairment assessment was required to evaluate the recoverability of Sumavel® DosePro®. After performing this assessment, we recorded a pre-tax, non-cash impairment charge of $72.8 million during the three months ended September 30, 2016, representing a full impairment of the intangible asset.
International Pharmaceuticals Segment
During the three months ended September 30, 2016, the Company determined that it would not pursue commercialization of a product in certain international markets. Accordingly, we tested the definite-lived intangible asset associated with this product for impairment and determined that the carrying value was no longer fully recoverable, resulting in pre-tax, non-cash asset impairment charge of $16.2 million during the third quarter of 2016.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
License And Collaboration Agreements
 9 Months Ended
Sep. 30, 2016
License And Collaboration Agreements [Abstract]  
LICENSE AND COLLABORATION AGREEMENTS
NOTE 10. LICENSE AND COLLABORATION AGREEMENTS
Our subsidiaries have entered into certain license, collaboration and discovery agreements with third parties for product development. These agreements require our subsidiaries to share in the development costs of such products and the third parties grant marketing rights to our subsidiaries for such products.
The Company and its subsidiaries are generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. In addition, these agreements generally require our subsidiaries to pay royalties on sales of the products arising from these agreements. These agreements generally permit termination by our subsidiaries with no significant continuing obligation.
Novartis AG, Novartis Consumer Health, Inc. and Sandoz, Inc.
The Company had exclusive U.S. marketing rights to Voltaren® Gel through June 30, 2016 pursuant to a License and Supply Agreement entered into in 2008 with and among Novartis AG and Novartis Consumer Health, Inc. Effective March 1, 2015, Novartis Consumer Health, Inc. assigned the 2008 Voltaren® Gel Agreement to its affiliate, Sandoz, Inc. On December 11, 2015, the Company, Novartis AG and Sandoz entered into a new License and Supply Agreement, the 2015 Voltaren® Gel Agreement, whereby the Company licensed exclusive U.S. marketing and license rights to commercialize Voltaren® Gel and the exclusive right to launch an authorized generic of Voltaren® Gel, effective July 1, 2016. Pursuant to the 2015 Voltaren® Gel Agreement, the former 2008 Voltaren® Gel Agreement expired on June 30, 2016 in accordance with its terms. The 2015 Voltaren® Gel Agreement became effective on July 1, 2016 and is accounted for as a business combination as of the effective date. Refer to Note 5. Acquisitions for further information. The initial term of the 2015 Voltaren® Gel Agreement will expire on June 30, 2023 with an automatic extension of the term for one year thereafter unless a written notice of non-extension is provided at least six months in advance of termination. Voltaren® Gel royalties incurred during the nine months ended September 30, 2016 and 2015 were $13.9 million and $22.5 million, respectively.
Under the 2008 Voltaren® Gel Agreement, which was effective through June 30, 2016, the Company agreed (i) to make certain guaranteed minimum annual royalty payments beginning in the fourth year of the 2008 Voltaren® Gel Agreement (2008 Guaranteed Minimum Annual Royalty Payment), (ii) to expend a minimum amount of annual advertising and promotional expenses (A&P Expenditures) on the commercialization of Voltaren® Gel and (iii) to perform a minimum number of face-to-face one-on-one discussions with physicians and other health care practitioners (Details), each subject to certain limitations set forth in the 2008 Voltaren® Gel Agreement, including the requirement that a third party generic equivalent product not be launched. Under the 2015 Voltaren® Gel Agreement, the Company agreed to make certain guaranteed minimum annual royalty payments (2015 Guaranteed Minimum Annual Royalty Payment) subject to certain limitations set forth in the 2015 Voltaren® Gel Agreement, including the requirement that a third party generic equivalent product is not launched. In March 2016, Amneal Pharmaceuticals LLC (Amneal) launched a generic equivalent of Voltaren® Gel and, therefore, the Company’s obligations to make the 2008 Guaranteed Minimum Annual Royalty Payment, to expend A&P Expenditures and to perform Details for the remainder of the term of the 2008 Voltaren® Gel Agreement terminated as of the date of the launch of the generic equivalent product by Amneal. In addition, the Company’s obligation to make the 2015 Guaranteed Minimum Annual Royalty Payment also terminated.
XIAFLEX® Out-license Agreement
We were party to an out-licensing agreement with Actelion Pharmaceuticals Ltd. (Actelion) to develop, supply and commercialize XIAFLEX® in Canada and Australia. On July 1, 2016, the parties mutually agreed to terminate the collaboration for Canada and agreed upon certain transition services to be provided by Actelion until approval of the transfer of the drug identification number by the regulatory authority in Canada to the Company. For Australia, the collaboration agreement remains in effect until a new agreement is finalized. In consideration for the rights returned to the Company by Actelion, Endo made a cash payment of $5.5 million in July 2016. This transaction was treated as an asset acquisition.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt
 9 Months Ended
Sep. 30, 2016
Debt Instruments [Abstract]  
DEBT
NOTE 11. DEBT
The following table presents the carrying amounts of the Company’s total indebtedness at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
7.25% Senior Notes due 2022
$
400,000

 
$
(11,284
)
 
$
400,000

 
$
(12,535
)
5.75% Senior Notes due 2022
700,000

 
(9,026
)
 
700,000

 
(10,088
)
5.375% Senior Notes due 2023
750,000

 
(9,585
)
 
750,000

 
(10,511
)
6.00% Senior Notes due 2023
1,635,000

 
(25,481
)
 
1,635,000

 
(27,694
)
6.00% Senior Notes due 2025
1,200,000

 
(21,287
)
 
1,200,000

 
(22,713
)
Term Loan A Facility Due 2019
962,500

 
(10,221
)
 
1,017,500

 
(13,831
)
Term Loan B Facility Due 2022
2,779,000

 
(44,803
)
 
2,800,000

 
(49,900
)
Revolving Credit Facility
—

 
—

 
225,000

 
—

Other debt
55

 
—

 
134

 
—

Total long-term debt, net
$
8,426,555

 
$
(131,687
)
 
$
8,727,634

 
$
(147,272
)
Less current portion, net
124,250

 
—

 
328,705

 
—

Total long-term debt, less current portion, net
$
8,302,305

 
$
(131,687
)
 
$
8,398,929

 
$
(147,272
)

The total fair value of the Company’s Total long-term debt at September 30, 2016 and December 31, 2015, was $8.0 billion and $8.6 billion, respectively.
The fair value of the Company’s long-term debt is estimated using the quoted market prices for the same or similar debt issuances. Based on this valuation methodology, we determined these debt instruments represent Level 2 measurements within the fair value hierarchy.
Credit Facility
On April 4, 2016, the Company paid down the revolving credit facility in the amount of $225.0 million. As of September 30, 2016, we have $997.4 million of remaining credit available through the revolving credit facilities.
The Company’s credit agreement contains affirmative and negative covenants that the Company believes to be usual and customary for a senior secured credit facility. The negative covenants include, among other things, limitations on capital expenditures, asset sales, mergers and acquisitions, indebtedness, liens, dividends, investments and transactions with the Company’s affiliates. As of September 30, 2016, we were in compliance with all such covenants.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments And Contingencies
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 12. COMMITMENTS AND CONTINGENCIES
Manufacturing, Supply and Other Service Agreements
Our subsidiaries contract with various third party manufacturers, suppliers and service providers to provide raw materials used in our subsidiaries’ products and semi-finished and finished goods, as well as certain packaging, labeling services, customer service support, warehouse and distribution services. These contracts include agreements with Novartis Consumer Health, Inc., Novartis AG, and Sandoz, Inc. (collectively, Novartis), Teikoku Seiyaku Co. Ltd. (Teikoku), Noramco, Inc. (Noramco), Grünenthal GmbH (Grünenthal), Sharp Corporation, UPS Supply Chain Solutions, Inc. and Jubilant HollisterStier Laboratories LLC (JHS). If, for any reason, we are unable to obtain sufficient quantities of any of the finished goods or raw materials or components required for our products or services needed to conduct our business, it could have an adverse effect on our business, financial condition, results of operations and cash flows.
In addition to the manufacturing and supply agreements described above, we have agreements with various companies for clinical development services. Although we have no reason to believe that the parties to these agreements will not meet their obligations, failure by any of these third parties to honor their contractual obligations may have a material adverse effect on our business, financial condition, results of operations and cash flows.
Significant changes made during the nine months ended September 30, 2016 to the agreements listed above and included within our Annual Report on Form 10-K for the year ended December 31, 2015 are as follows:
Noramco, Inc.
Pursuant to the terms of the Company’s 2012 agreement with Noramco, the Company made payments to Noramco during the nine months ended September 30, 2016 and 2015 totaling $27.3 million and $31.2 million, respectively. These payments are recorded in Cost of revenues in our Condensed Consolidated Statements of Operations. In July 2016, the Company sent a notice of non-renewal to Noramco which will result in the agreement being terminated as of April 2017. The Company is not subject to any penalties as a result of this termination.
Jubilant HollisterStier Laboratories LLC
During the second quarter of 2016, we entered into a new agreement with JHS (JHS Agreement). Pursuant to the JHS Agreement, JHS fills and lyophilizes the XIAFLEX® bulk drug substance, which is manufactured by the Company, and produces sterile diluent. The initial term of the JHS agreement is three years, with automatic renewal provisions thereafter for subsequent one-year terms, unless or until either party provides notification prior to expiration of the then current term of the contract. The Company is required to purchase a specified percentage of its total forecasted volume of XIAFLEX® from JHS each year, unless JHS is unable to supply XIAFLEX® within the timeframe established under such forecasts. Amounts purchased pursuant to the JHS Agreement were not material for any of the periods presented.
Legal Proceedings and Investigations
We and certain of our subsidiaries are involved in various claims, legal proceedings, internal and governmental investigations (collectively, proceedings) that arise from time to time in the ordinary course of our business, including those relating to product liability, intellectual property, regulatory compliance and commercial matters. These and other matters that are not being disclosed herein are, in the opinion of our management, immaterial both individually and in the aggregate with respect to our financial position, results of operations and cash flows. If and when such matters, in the opinion of our management, become material either individually or in the aggregate, we will disclose such matters. While we cannot predict the outcome of these proceedings and we intend to defend vigorously our position, an adverse outcome in any of these proceedings could have a material adverse effect on our current and future financial position, results of operations and cash flows.
As of September 30, 2016, our reserve for loss contingencies totaled $1.28 billion, of which $1.20 billion relates to our product liability accrual for vaginal mesh cases. We had previously announced that we had reached master settlement agreements with several of the leading plaintiffs’ law firms to resolve claims relating to vaginal mesh products sold by our AMS subsidiary. The agreements were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault. Although we believe there is a reasonable possibility that a loss in excess of the amount recognized exists, we are unable to estimate the possible loss or range of loss in excess of the amount recognized at this time.
Product Liability
We and certain of our subsidiaries have been named as defendants in numerous lawsuits in various U.S. federal and state courts, as well as in Canada and other countries, alleging personal injury resulting from the use of certain of our products and the products of our subsidiaries. These matters are described below in more detail.
We believe that certain settlements and judgments, as well as legal defense costs, relating to certain product liability matters are or may be covered in whole or in part under our product liability insurance policies with a number of insurance carriers. In certain circumstances, insurance carriers reserve their rights to contest or deny coverage. We intend to contest vigorously any and all such disputes with our insurance carriers and to enforce our rights under the terms of our insurance policies. Accordingly, we will record receivables with respect to amounts due under these policies only when the resolution of any dispute has been reached and realization of the potential claim for recovery is considered probable. Amounts recovered under our product liability insurance policies will likely be less than the stated coverage limits and may not be adequate to cover damages and/or costs relating to claims. In addition, there is no guarantee that insurers will pay claims or that coverage will otherwise be available.
Vaginal Mesh Cases. In October 2008, the FDA issued a Public Health Notification (October 2008 Public Health Notification) regarding potential complications associated with transvaginal placement of surgical mesh to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The notification provides recommendations and encourages physicians to seek specialized training in mesh procedures, to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications.
In July 2011, the FDA issued an update to the October 2008 Public Health Notification regarding mesh to further advise the public and the medical community of the potential complications associated with transvaginal placement of surgical mesh to treat POP and SUI. In the July 2011 update, the FDA stated that adverse events are not rare. Furthermore, the FDA questioned the relative effectiveness of transvaginal mesh as a treatment for POP as compared to non-mesh surgical repair. The July 2011 notification continued to encourage physicians to seek specialized training in mesh procedures, to consider and to advise their patients about the risks associated with these procedures and to be diligent in diagnosing and reporting complications. In January 2016, the FDA issued a statement reclassifying surgical mesh for transvaginal POP repair from Class II to Class III. Surgical mesh for SUI repair remains a Class II device.
In January 2012, the FDA ordered manufacturers of transvaginal surgical mesh used for POP and of single incision mini-slings for urinary incontinence, such as our AMS subsidiary, to conduct post-market safety studies and to monitor adverse event rates relating to the use of these products. AMS received a total of 19 class-wide post-market study orders regarding its pelvic floor repair and mini-sling products; however, the FDA agreed to place 16 of these study orders on hold for a variety of reasons. AMS commenced three of these post-market study orders; however, in connection with the wind down of the Astora business, it notified the FDA of its termination of these studies. The FDA has confirmed closure of these studies.
Since 2008, we and certain of our subsidiaries, including AMS and/or Astora, have been named as defendants in multiple lawsuits in the U.S. in various state courts and in a multidistrict litigation (MDL) in the Southern District of West Virginia (MDL No. 2325), in Canada, where various class action and individual complaints are pending, and in other countries alleging personal injury resulting from the use of transvaginal surgical mesh products designed to treat POP and SUI. Plaintiffs in these suits allege various personal injuries including chronic pain, incontinence and inability to control bowel function and permanent deformities, and seek compensatory and punitive damages, where available.
We and certain plaintiffs’ counsel representing mesh-related product liability claimants have entered into various Master Settlement Agreements (MSAs) and other settlement agreements regarding settling up to approximately 49,000 filed and unfiled mesh claims handled or controlled by the participating counsel for an aggregate total of approximately $2.8 billion. These MSAs, which were executed at various times since June 2013, were entered into solely by way of compromise and settlement and are not in any way an admission of liability or fault by us or any of our subsidiaries. All MSAs are subject to a process that includes guidelines and procedures for administering the settlements and the release of funds. In certain cases, the MSAs provide for the creation of Qualified Settlement Funds (QSFs) into which funds may be deposited pursuant to certain schedules set forth in those agreements. All MSAs have participation thresholds requiring participation by the majority of claims represented by each law firm party to the MSA. If certain participation thresholds are not met, then we will have the right to terminate the settlement with that law firm. In addition, one agreement gives us a unilateral right of approval regarding which claims may be eligible to participate under that settlement. To the extent fewer claims than are authorized under an agreement participate, the total settlement payment under that agreement will be reduced by an agreed-upon amount for each such non-participating claim. Funds deposited in QSFs are included in restricted cash and cash equivalents in the Condensed Consolidated Balance Sheets.
Distribution of funds to any individual claimant is conditioned upon the receipt of documentation substantiating the validity of the claim, a full release and a dismissal of the entire action or claim as to all AMS parties and affiliates. Prior to receiving funds, an individual claimant shall represent and warrant that liens, assignment rights or other claims that are identified in the claims administration process have been or will be satisfied by the individual claimant. The amount of settlement awards to participating claimants, the claims evaluation process and procedures used in conjunction with award distributions, and the negotiations leading to the settlement, shall be kept confidential by all parties and their counsel.
We expect that valid claims under the MSAs will continue to be settled. However, we intend to vigorously contest pending and future claims that are invalid, for which settlement is not able to be reached or that are in excess of the maximum claim amounts under the MSAs. We are currently aware of approximately 8,000 asserted claims and unasserted claims, which we believe are likely to be asserted, that have not been accrued for because we lack sufficient information to determine whether any potential loss is probable. In addition to these asserted and unasserted claims, which we believe are likely to be asserted, there may be other claims asserted in the future. It is currently not possible to estimate the number or validity of any such future claims.
In order to evaluate whether a claim is probable of a loss, we must obtain and evaluate certain information pertaining to each individual claim, including but not limited to the following items: the name and social security number of the plaintiff, evidence of an AMS implant, the date of implant, the date the claim was first asserted to AMS, the date that plaintiff’s counsel was retained, and most importantly, medical records establishing the injury alleged. Without access to at least this information and the opportunity to evaluate it, we are not in a position to determine its validity or whether a loss is probable. Further, the timing and extent to which we obtain this information and our evaluation thereof, is often impacted by items outside of our control, including, without limitation, the normal cadence of the litigation process and the provision of claim information to us by plaintiff’s counsel.
We will continue to monitor the situation, and, if appropriate, we will make further adjustments to our product liability accrual based on new information. We intend to continue exploring all options as appropriate in our best interests, and depending on developments, there is a possibility that we will suffer adverse decisions or verdicts of substantial amounts, or that we will enter into additional monetary settlements. Any unfavorable outcomes as a result of such litigation or settlements with respect to any asserted or unasserted claims could have a material adverse effect on our business, financial condition, results of operations and cash flows.
As of the date of this report, we believe that the current product liability accrual includes all known claims for which liability is probable and estimable.
The following table presents the changes in the vaginal mesh QSFs and product liability balance during the nine months ended September 30, 2016 (in thousands):
 
Qualified Settlement Funds
 
Product Liability
Balance as of December 31, 2015
$
578,970

 
$
2,086,176

Additional charges
—

 
19,505

Cash contributions to Qualified Settlement Funds
587,782

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(898,288
)
 
(898,288
)
Cash distributions to settle disputes
—

 
(5,561
)
Other
456

 
—

Balance as of September 30, 2016
$
268,920

 
$
1,201,832

The entire portion of the $1.20 billion liability amount shown above is classified as Current portion of legal settlement accrual in the September 30, 2016 Condensed Consolidated Balance Sheets. Charges related to vaginal mesh product liability for all periods presented are reported in Discontinued operations, net of tax in our Condensed Consolidated Statements of Operations.
We expect to fund the payments under all current settlement agreements over the course of 2016 and 2017. As the funds are disbursed out of the QSFs from time to time, the product liability accrual will be reduced accordingly with a corresponding reduction to restricted cash and cash equivalents. In addition, we may pay cash distributions to settle disputes separate from the QSFs, which will also decrease the product liability accrual and decrease cash and cash equivalents.
In addition, we have been contacted regarding a civil investigation that has been initiated by a number of state attorneys general into mesh products, including transvaginal surgical mesh products designed to treat POP and SUI. In November 2013, we received a subpoena relating to this investigation from the state of California, and have subsequently received additional subpoenas from other states. We are currently cooperating with this investigation. At this time, we cannot predict or determine the outcome of this investigation or reasonably estimate the amount or range of amounts of fines or penalties, if any, that might result from a settlement or an adverse outcome from this investigation.
Testosterone Cases. We and certain of our subsidiaries, including Endo Pharmaceuticals Inc. (EPI) and Auxilium Pharmaceuticals, Inc. (subsequently converted to Auxilium Pharmaceuticals, LLC and hereinafter referred to as Auxilium), along with other pharmaceutical manufacturers, have been named as defendants in lawsuits alleging personal injury resulting from the use of prescription medications containing testosterone, including Fortesta® Gel, Delatestryl®, Testim®, TESTOPEL® and Striant®. Plaintiffs in these suits allege various personal injuries, including pulmonary embolism, stroke and other vascular and/or cardiac injuries and seek compensatory and/or punitive damages, where available. In June 2014, an MDL was formed to include claims involving all testosterone replacement therapies filed against EPI, Auxilium, and other manufacturers of such products, and certain transferable cases pending in federal court were coordinated in the Northern District of Illinois as part of MDL No. 2545. In addition to the federal cases filed against EPI and Auxilium that have been transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545, litigation has also been filed against EPI in the Court of Common Pleas Philadelphia County and in certain other state courts. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of Illinois as tag-along actions to MDL No. 2545. However, we cannot predict the timing or outcome of any such litigation, or whether any such additional litigation will be brought against us. We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest. As of November 1, 2016, approximately 1,140 cases are currently pending against us; some of which may have been filed on behalf of multiple plaintiffs.
In November 2015, the U.S. District Court for the Northern District of Illinois entered an order granting defendants’ motion to dismiss claims involving certain testosterone products that were approved pursuant to ANDAs, including TESTOPEL®. Plaintiffs filed a motion for reconsideration and clarification of this order. In March 2016, the District Court granted plaintiffs’ motion in part and entered an order permitting certain claims to go forward to the extent they are based on allegations of fraudulent off-label marketing.
In November 2014, a civil class action complaint was filed in the Northern District of Illinois against EPI, Auxilium, and various other manufacturers of testosterone products on behalf of a proposed class of health insurance companies and other third party payors that had paid for certain testosterone products, alleging that the marketing efforts of EPI, Auxilium, and other defendant manufacturers with respect to certain testosterone products constituted racketeering activity in violation of 18 U.S.C. §1962(c), and other civil Racketeer Influenced and Corrupt Organizations Act claims. Further, the complaint alleges that EPI, Auxilium, and other defendant manufacturers violated various state consumer protection laws through their marketing of certain testosterone products and raises other state law claims. In March 2015, defendants filed a motion to dismiss the complaint and plaintiffs responded by filing amended complaints. In February 2016, the District Court granted in part and denied in part defendants’ motion to dismiss. The District Court declined to dismiss plaintiffs’ claims for conspiracy to commit racketeering activity in violation of 18 U.S.C. §1962(d) and claims for negligent misrepresentation. In April 2016, plaintiffs filed a third amended complaint, which defendants moved to dismiss in June 2016. In August 2016, the court denied the motion to dismiss and we filed a response to the third amended complaint in September 2016. In October 2015, a similar civil class action complaint was filed against EPI and other defendant manufacturers in the Northern District of Illinois. Similar litigation may be brought by other plaintiffs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any, but we will explore all options as appropriate in our best interest.
Unapproved Drug Litigation
In September 2013, the State of Louisiana filed a Petition for Damages against certain of our subsidiaries, EPI and Generics Bidco I, LLC, and over 50 other pharmaceutical companies alleging the defendants or their subsidiaries marketed products that were not approved by the FDA. See State of Louisiana v. Abbott Laboratories, Inc., et al., C624522 (19th Jud. Dist. La.). The State of Louisiana sought damages, fines, penalties, attorneys’ fees and costs under various causes of action. In October 2015, the District Court ordered judgment for defendants on their exception for no right of action. The State of Louisiana appealed that decision and in October 2016, the Louisiana Court of Appeals, First Circuit, issued a decision affirming the dismissal as to certain counts and reversing the dismissal as to others.
We intend to contest the above case vigorously and to explore other options as appropriate in our best interest. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions. However, we cannot predict the timing or outcome of any such litigation, or whether any such litigation will be brought against us. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.
Opioid-Related Litigations, Subpoenas and Document Requests
In June 2014, Corporation Counsel for the City of Chicago filed suit in Illinois state court against multiple defendants, including our subsidiaries, Endo Health Solutions Inc. (EHSI) and EPI, for alleged violations of city ordinances and other laws relating to defendants’ alleged opioid sales and marketing practices. In June 2014, the case was removed to the U.S. District Court for the Northern District of Illinois. In December 2014, defendants moved to dismiss the Amended Complaint and in May 2015, the District Court issued an order granting that motion in part, dismissing the case as to EHS and EPI. In August 2015, plaintiff filed its Second Amended Complaint against multiple defendants, including EPI and EHSI. In November 2015, defendants moved to dismiss the Second Amended Complaint. In September 2016, the District Court granted in part and denied in part defendants’ motions to dismiss and provided plaintiff an opportunity to amend its complaint. Plaintiff filed the third amended complaint in October 2016.
In May 2014 and in June 2014, a lawsuit was filed in California Superior Court (Orange County) in the name of the People of the State of California, acting by and through County Counsel for Santa Clara County and the Orange County District Attorney, against multiple defendants, including our subsidiaries EHSI and EPI. The complaint asserts violations of California’s statutory Unfair Competition and False Advertising laws, as well as asserting a claim for public nuisance, based on alleged misrepresentations in connection with sales and marketing of opioids, including OPANA®. Plaintiff seeks declaratory relief, restitution, civil penalties (including treble damages), abatement, an injunction, and attorneys’ fees and costs. Defendants, which include our subsidiaries, filed various motions attacking the pleadings, including one requesting that the Superior Court refrain from proceeding under the doctrines of primary jurisdiction and equitable abstention. That motion was granted in August 2015, and the case has been stayed pending further proceedings and findings by the FDA. In June 2016, plaintiffs filed a motion to lift the stay and to amend the complaint. Defendants, included EHSI and EPI, opposed that motion. Following a hearing in July 2016, the court provided plaintiffs an opportunity to seek leave to file another amended complaint. In August 2016, plaintiffs filed a renewed motion to lift the stay and amend the complaint. In October 2016, the court granted, in part, plaintiffs’ renewed motion to lift the stay and the plaintiffs filed their third amended complaint.
In December 2015, a lawsuit was filed in the Chancery Court of the First Judicial District of Hinds County, Mississippi by the State of Mississippi against multiple defendants, including our subsidiaries EHSI and EPI. The complaint alleges violations of Mississippi’s Consumer Protection Act and various other claims arising out of defendants’ alleged opioid sales and marketing practices. Plaintiff seeks declaratory relief, restitution, civil penalties, abatement, an injunction, and attorneys’ fees and costs. In March 2016, defendants moved to dismiss the complaint.
In September 2014, our subsidiaries EHSI and EPI received a Request for Information from the State of Tennessee Office of the Attorney General and Reporter seeking documents and information regarding the sales and marketing of opioids, including OPANA® ER. We are currently cooperating with the State of Tennessee Office of the Attorney General and Reporter in this investigation.
In August 2015, our subsidiaries EHSI and EPI received a subpoena from the State of New Hampshire Office of the Attorney General seeking documents and information regarding the sales and marketing of opioids, including OPANA® ER. We were cooperating with the State of New Hampshire Office of the Attorney General in its investigation until we learned that it was being assisted in the investigation by outside counsel hired on a contingent fee basis. The New Hampshire Attorney General initiated an action in the Superior Court for the State of New Hampshire to enforce the subpoena despite this contingent fee arrangement, and we (along with other companies that had received similar subpoenas) responded by filing a motion for protective order to preclude the use of contingent fee counsel. In addition, we filed a separate motion seeking declaratory relief. In March 2016, the Superior Court granted the motion for protective order on the grounds that the contingent fee agreement was invalid as ultra vires and that the office of the Attorney General had acted outside of its statutory authority in entering into the agreement with the contingent fee counsel. In April 2016, both the New Hampshire Attorney General and the companies that received subpoenas from the New Hampshire Attorney General, including EHSI and EPI, appealed, in part, the March 2016 Superior Court order to the New Hampshire Supreme Court. Those appeals are pending. In April 2016, the New Hampshire Attorney General also entered into a new agreement with outside counsel. In response, the companies that received a subpoena from the New Hampshire Attorney General, including EHSI and EPI, moved to enforce a part of the protective order issued by the Superior Court in March 2016 that is not being appealed by EHSI and EPI. That motion was denied in August 2016.
In March 2016, EHSI and EPI received a Civil Investigative Demand (CID) from the Department of Justice (DOJ) for the State of Oregon seeking documents and information regarding the sales and marketing of OPANA® ER. We are currently cooperating with the State of Oregon in its investigation.
In August 2016, the County of Suffolk, New York filed suit in New York state court against multiple defendants, including our subsidiaries, EHSI and EPI, for alleged violations of state false and deceptive advertising and other statutes, public nuisance, common law fraud, and unjust enrichment based on opioid sales and marketing practices. The County of Suffolk is seeking compensatory damages, interest, costs, disbursements, punitive damages, treble damages, penalties and attorneys’ fees.
With respect to the litigations brought on behalf of the City of Chicago, the People of the State of California, the State of Mississippi and the County of Suffolk, we intend to contest those matters vigorously. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Antitrust Litigation and Investigations
Multiple direct and indirect purchasers of Lidoderm® have filed a number of cases against our subsidiary EPI and co-defendants Teikoku Seiyaku Co., Ltd., Teikoku Pharma USA, Inc. (collectively, Teikoku) and Actavis plc and certain of its subsidiaries (collectively, Actavis), which was subsequently acquired by Teva Pharmaceuticals Industries Ltd and its subsidiaries (collectively, Teva) from Allergan plc (Allergan). Certain of these actions have been asserted on behalf of classes of direct and indirect purchasers, while others are individual cases brought by one or more alleged direct or indirect purchasers. The complaints in these cases generally allege that EPI, Teikoku and Actavis (now Teva) entered into an anticompetitive conspiracy to restrain trade through the settlement of patent infringement litigation concerning U.S. Patent No. 5,827,529 (the ‘529 patent) and other patents. Some of the complaints also allege that Teikoku wrongfully listed the ‘529 patent in the Orange Book as related to Lidoderm®, that EPI and Teikoku commenced sham patent litigation against Actavis and that EPI abused the FDA citizen petition process by filing a citizen petition and amendments solely to interfere with generic companies’ efforts to obtain FDA approval of their versions of Lidoderm®. The cases allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2) and various state antitrust and consumer protection statutes as well as common law remedies in some states. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees.
The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order in April 2014 transferring these cases as In Re Lidoderm Antitrust Litigation, MDL No. 2521, to the U.S. District Court for the Northern District of California. In June 2016, motions for class certification were filed on behalf of classes of direct and indirect purchasers, and EPI, Teikoku and Actavis filed oppositions to those motions in September 2016. Trial is currently scheduled to begin in 2017. Litigation similar to that described above may also be brought by other plaintiffs in various jurisdictions, and cases brought in federal court will be transferred to the Northern District of California as tag-along actions to In Re Lidoderm Antitrust Litigation.
Multiple direct and indirect purchasers of OPANA® ER have filed cases against our subsidiaries EHSI and EPI, and other pharmaceutical companies, including Penwest Pharmaceuticals Co., which we subsequently acquired, and Impax Laboratories Inc. (Impax), all of which have been transferred and coordinated for pretrial proceedings in the Northern District of Illinois by the Judicial Panel on Multidistrict Litigation. Some of these cases have been filed on behalf of putative classes of direct and indirect purchasers, while others have been filed on behalf of individual retailers or health care benefit plans. These cases generally allege that the agreement reached by EPI and Impax to settle patent infringement litigation concerning multiple patents pertaining to OPANA® ER and EPI’s introduction of the re-formulation of OPANA® ER violated antitrust laws. The complaints allege violations of Sections 1 and 2 of the Sherman Act (15 U.S.C. §§ 1, 2), various state antitrust and consumer protection statutes, as well as state common law. These cases generally seek damages, treble damages, disgorgement of profits, restitution, injunctive relief and attorneys’ fees. In February 2016, the District Court issued orders (i) denying defendants’ motion to dismiss the claims of the direct purchasers, (ii) denying in part and granting in part defendants’ motion to dismiss the claims of the indirect purchasers, but giving them permission to file amended complaints and (iii) granting defendants’ motion to dismiss the complaints filed by certain retailers, but giving them permission to file amended complaints. In response to the District Court’s orders, the indirect purchasers filed an amended complaint to which the defendants filed a renewed motion to dismiss certain claims, and certain retailers have also filed amended complaints. The defendants successfully moved to dismiss the indirect purchaser unjust enrichment claims arising under the laws of the states of California, Rhode Island and Illinois. We cannot predict whether or not additional cases similar to those described above will be filed by other plaintiffs or the timing or outcome of any such litigation.
In February 2014, our subsidiary, EPI received a CID (the February 2014 CID) from the U.S. Federal Trade Commission (the FTC). The FTC issued a second CID to EPI in March 2014 (the March 2014 CID). The February 2014 CID requested documents and information concerning EPI’s settlement agreements with Actavis and Impax settling the OPANA® ER patent litigation, EPI’s Development and Co-Promotion Agreement with Impax, and its settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of OPANA® ER and Lidoderm®. The March 2014 CID requested documents and information concerning EPI’s acquisition of U.S. Patent No. 7,852,482 (the ‘482 patent), as well as additional information concerning certain litigation relating to, and the marketing and sales of OPANA® ER. The FTC also issued subpoenas for investigational hearings (similar to depositions) to our employees and former employees. In March 2016, the FTC filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania against us and our subsidiary EPI, as well as against Allergan, Actavis, Impax and Teikoku, alleging generally that the settlement agreements with Actavis, Impax, respectively, constituted, in whole or part, unfair methods of competition in violation Section 5(a) of the FTC Act, 15 U.S.C. § 45(a). The FTC also alleges that one provision of the agreement with Actavis violated Section 7 of the Clayton Act, 15 U.S.C. § 18. The complaint seeks injunctive and declaratory relief and other remedies, including restitution and disgorgement. In June 2016, we joined in the defendants’ motion to sever OPANA® ER-related claims from the Lidoderm®-related claims. In July 2016, a motion to dismiss was filed on behalf of all defendants. In October 2016, the District Court granted the defendants’ motion to sever the claims ordering the FTC to file lawsuits for the OPANA® ER-related claims separately from the Lidoderm®-related claims. The District Court also denied the defendants’ motion to dismiss as moot. Subsequently in October 2016, the FTC voluntarily sought to dismiss their case against us without prejudice. We filed two separate lawsuits relating to OPANA® ER-related claims and Lidoderm®-related claims, with Impax and Watson, respectively, in October 2016 seeking declaratory judgment on the merits of the case.
We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these matters, if any, but will explore all options as appropriate in our best interest.
In November 2014, EPI received a CID from the State of Florida Office of the Attorney General issued pursuant to the Florida Antitrust Act of 1980, Section 542.28 and seeking documents and other information concerning EPI’s settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Lidoderm®.
In February 2015, EHSI and EPI received a CID for Production of Documents and Information from the State of Alaska Office of Attorney General issued pursuant to Alaska’s Antitrust and Unfair Trade Practices and Consumer Protection law seeking documents and other information concerning settlement agreements with Actavis and Impax settling the OPANA® ER patent litigation as well as information concerning EPI’s settlement agreement with Actavis settling the Lidoderm patent litigation, as well as information concerning the marketing and sales of Lidoderm.
In February 2016, EPI received a subpoena from the State of South Carolina Office of the Attorney General seeking documents and other information concerning EPI’s settlement agreement with Actavis settling the Lidoderm® patent litigation, as well as information concerning the marketing and sales of Lidoderm®.
In December 2014, our subsidiary, Par Pharmaceutical Companies, Inc. (subsequently renamed Endo Generics Holdings, Inc. and referred to in this Note 12. Commitments and Contingencies as Par), received a Subpoena to Testify Before Grand Jury from the Antitrust Division of the DOJ and issued by the U.S. District Court for the Eastern District of Pennsylvania. The subpoena requests documents and information focused primarily on product and pricing information relating to Par’s authorized generic version of Lanoxin (digoxin) oral tablets and Par’s generic doxycycline products, and on communications with competitors and others regarding those products. Par is currently cooperating fully with the investigation.
In January 2009, the FTC filed a lawsuit against our subsidiary, Par, in the U.S. District Court for the Central District of California, which was subsequently transferred to the U.S. District Court for the Northern District of Georgia, and which alleged violations of antitrust law arising out of Par’s settlement of certain patent litigation concerning the generic version of AndroGel®. The FTC complaint generally seeks a finding that Par’s settlement agreement violates Section 5(a) of the Federal Trade Commission Act, and a permanent injunction against Par’s ability to engage in certain types of patent settlements in the future. Beginning in February 2009, certain private plaintiffs, including distributors and retailers, filed similar litigation. Generally, the remaining private plaintiff suits seek equitable relief, unspecified damages and costs.
In February 2010, the District Court granted a motion to dismiss the FTC’s claims and granted in part and denied in part a motion to dismiss the claims of the private plaintiffs. In April 2012, the U.S. Court of Appeals for the 11th Circuit affirmed the District Court’s decision on the motion to dismiss the FTC’s claims. In September 2012, the District Court granted a motion for summary judgment against the private plaintiffs’ claims of sham litigation. In July 2013, the Supreme Court of the U.S. reversed the Court of Appeals’ and District Court’s decisions concerning the FTC action and remanded the case to the District Court for further proceedings. In May 2016, those private plaintiffs representing the putative class of indirect purchasers voluntarily dismissed their case against Par with prejudice. Claims by the direct purchasers and the FTC are still pending. We intend to contest this litigation vigorously and to explore all options as appropriate in our best interest.
In February 2015, Par received a CID from the Office of the Attorney General for the State of Alaska seeking production of certain documents and information regarding Par’s settlement of the AndroGel® patent litigation as well as documents produced in the on-going litigation filed by the FTC.
We are currently cooperating with the DOJ, the State of Florida Office of the Attorney General, the State of Alaska Office of the Attorney General and the State of South Carolina Office of the Attorney General in their respective investigations. Investigations and lawsuits similar to these antitrust matters described above may be brought by others. We are unable to predict the outcome of these investigations or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for these investigations, if any, but will explore all options as appropriate in our best interest.
In July 2016, Fresenius Kabi USA, LLC (Fresenius) filed a complaint against Par and its subsidiary, Par Sterile Products, LLC, in the U.S. District Court for the District of New Jersey alleging that Par and its subsidiary engaged in an anticompetitive scheme to exclude competition from the market for vasopressin solution for intravenous injection in view of Par’s Vasostrict® (vasopressin) product. The complaint alleges violations of Sections 1 and 2 of The Sherman Antitrust Act, 15 U.S.C. §§ 1, 2, as well as the antitrust law and common law of the state of New Jersey, alleging that Par and its subsidiary entered into exclusive supply agreements with one or more active pharmaceutical ingredient (API) manufacturers and that Fresenius has been unable to obtain vasopressin API in order to file an ANDA to obtain FDA approval for its own vasopressin product. Fresenius seeks actual, treble and punitive damages in an unspecified amount, attorney’s fees and costs and injunctive relief and demands a trial by jury. In September 2016, Par and its subsidiary filed a motion to dismiss the case for Fresenius’ failure to properly state a claim under the antitrust laws. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter. We intend to contest the litigation vigorously and to explore all options as appropriate in our best interest.
False Claims Act Litigation
The Attorneys General of Florida, Indiana and Virginia and the U.S. Office of Personnel Management (the USOPM) have issued subpoenas, and the Attorneys General of Michigan, Tennessee, Texas, and Utah have issued CIDs, to our subsidiary, Par, among other companies. The demands generally request documents and information pertaining to allegations that certain of Par’s sales and marketing practices caused pharmacies to substitute ranitidine capsules for ranitidine tablets, fluoxetine tablets for fluoxetine capsules, and two 7.5 mg buspirone tablets for one 15 mg buspirone tablet, under circumstances in which some state Medicaid programs at various times reimbursed the new dosage form at a higher rate than the dosage form being substituted. Par has provided documents in response to these subpoenas to the respective Attorneys General and the USOPM. The aforementioned subpoenas and CIDs culminated in the federal and state law qui tam action brought on behalf of the U.S. and several states by Bernard Lisitza. The complaint was unsealed in August 2011. Lisitza’s corrected second amended complaint generally seeks (i) a finding that defendants violated and be enjoined from future violations of the federal False Claims Act and state false claims acts; (ii) treble damages and maximum civil penalties for each violation of the federal False Claims Act and state false claims acts; (iii) an applicable percentage share of the proceeds; and (iv) expenses, fees, and costs. The U.S. intervened in this action and filed a separate complaint in September 2011, alleging claims for violations of the Federal False Claims Act and common law fraud. The U.S.’s second corrected complaint generally seeks (i) treble damages and civil penalties for violations under the federal False Claims Act and (ii) compensatory and punitive damages for common law fraud. The states of Michigan and Indiana have also intervened as to claims arising under their respective state false claim acts, common law fraud, and unjust enrichment. Michigan’s complaint generally seeks (i) treble damages and civil penalties and (ii) common law compensatory and punitive damages. Indiana’s amended complaint generally seeks treble damages, costs, and attorney’s fees. We intend to vigorously defend this lawsuit. At this time, we are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss for this matter, if any.
Pricing Matters
In March 2016, EPI received a CID from the U.S. Attorney’s Office for the Southern District of New York. The CID requests documents and information regarding contracts with Pharmacy Benefit Managers regarding Frova®. We are currently cooperating with this investigation. We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Beginning in January 2016, several complaints, including multiple class action complaints, have been filed in the Philadelphia Court of Common Pleas and in the U.S. District Courts for the Eastern District of Pennsylvania and the District of Rhode Island against us and certain of our subsidiaries, including Par, along with other manufacturers of certain generic pharmaceutical products, seeking compensatory and punitive or treble damages, as well as injunctive relief and alleging that certain marketing and pricing practices by the defendant companies violated state law, including consumer protection law and/or federal and state antitrust laws. The U.S. Judicial Panel on Multidistrict Litigation, pursuant to 28 U.S.C. § 1407, issued an order in August 2016 transferring certain of these cases as In Re Generic Digoxin and Doxycycline Antitrust Litigation, MDL No. 2724, to the U.S. District Court for the Eastern District of Pennsylvania. Additional similar claims may be brought by other plaintiffs in various jurisdictions.
In December 2015, EPI received Interrogatories and Subpoena Duces Tecum from the State of Connecticut Office of Attorney General requesting information regarding pricing of certain of its generic products, including Doxycycline Hyclate, Amitriptyline Hydrochloride, Doxazosin Mesylate, Methotrexate Sodium and Oxybutynin Chloride. We are currently cooperating with this investigation.
We are unable to predict the outcome of these matters or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for these matters but will explore all options as appropriate in our best interest.
Megace ES® (megestrol acetate oral suspension) Cases
In September 2011, our subsidiary, Par Pharmaceutical, Inc. (PPI), along with EDT Pharma Holdings Ltd. (Elan) (now known as Alkermes Pharma Ireland Limited), filed a complaint against TWi Pharmaceuticals, Inc. (TWi) in the U.S. District Court for the District of Maryland alleging infringement of U.S. Patent No. 7,101,576 because TWi filed an ANDA with a Paragraph IV certification seeking FDA approval of a generic version of Megace® ES. A bench trial was held in October 2013, and in February 2014, the District Court issued a decision in favor of TWi, finding all asserted claims of the 7,101,576 patent invalid for obviousness. Par appealed. In August 2014, the District Court issued a preliminary injunction enjoining TWi’s launch of its generic product pending disposition of the appeal. In December 2014, the Federal Circuit reversed the District Court’s decision, remanding for further findings of fact. In March 2015, the District Court issued another preliminary injunction enjoining TWi’s launch of its generic product pending disposition of the case on remand. In July 2015, the District Court issued a new decision in favor of TWi, finding all of the asserted claims invalid, and TWi launched its generic product. PPI appealed again, and in December 2015, the District Court’s decision in favor of TWi was affirmed without opinion. In February 2016, TWi moved the District Court to recover its lost profits, which TWi alleges in the amount of $16 million, resulting from the previous injunctions to which the District Court subjected TWi, as well as attorneys’ fees and costs. PPI opposed TWi’s motion. In September 2016, the District Court denied TWi’s motion for attorneys’ fees and costs and granted in part and denied in part TWi’s motion to recover its lost profits, ordering PPI to pay $12.7 million. We believe that a loss is probable and we have incorporated our best estimate of this loss into our reserve for loss contingencies. It is possible that the outcome of this matter could result in an additional loss above the amount reserved, which could be material.
Securities Related Class Action Litigation
In May 2016, a putative class action entitled Craig Friedman v. Endo International plc Company, Rajiv de Silva and Suketu Upadhyay was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of himself and all similarly situated shareholders. In August 2016, the Steamfitters’ Industry Pension Fund and Steamfitters’ Industry Security Benefit Fund were appointed lead plaintiffs in the action. In October 2016, a Second Amended Complaint was filed. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act based on the Company’s revision of its 2016 earnings guidance and certain disclosures about its generics business, the integration of Par and its subsidiaries, certain other alleged business issues and the receipt of a CID from the U.S. Attorney’s Office for the Southern District of New York regarding contracts with Pharmacy Benefit Managers concerning Frova®. The Second Amended Complaint adds Paul Campanelli as a defendant. The complaint seeks class certification, damages in an unspecified amount and attorney’s fees and costs. We filed a motion to dismiss the case in October 2016. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.
On November 7, 2016, a putative class action was filed in the U.S. District Court for the Southern District of New York by an individual shareholder on behalf of herself and all similarly situated shareholders, bearing the caption Doris Shasha v. Endo International plc Company, Rajiv Kanishka Liyanaarchchie De Silva and Suketu P. Upadhyay. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Exchange Act. It alleges that the Company made material false statements in, or omitted material information from, certain of the Company's public disclosures from September 28, 2015 through November 2, 2016, based on news reports of an investigation by the Department of Justice into potential price collusion in the pharmaceutical industry. The complaint seeks class certification, damages in an unspecified amount and attorney's fees and costs. We are unable to predict the outcome of this matter or the ultimate legal and financial liability, if any, and at this time cannot reasonably estimate the possible loss or range of loss, if any, for this matter, but will explore all options as appropriate in our best interest and we intend to defend this lawsuit vigorously.
Paragraph IV Certifications on OPANA® ER
In late 2012, two patents (U.S. Patent Nos. 8,309,122 and 8,329,216) were issued to EPI covering OPANA® ER (oxymorphone hydrochloride extended-release tablets CII). In December 2012, EPI filed a complaint against Actavis (now Teva) in U.S. District Court for the Southern District of New York for patent infringement based on its ANDA for a non-crush-resistant generic version of OPANA® ER. In May 2013 and June 2013, EPI filed similar suits in the U.S. District Court for the Southern District of New York against the following applicants for non-crush-resistant OPANA® ER: Roxane Laboratories, Inc. (Roxane) and Ranbaxy Laboratories Limited, which was acquired by Sun Pharmaceutical Industries Ltd. (Ranbaxy). Those suits allege infringement of U.S. Patent Nos. 7,851,482, 8,309,122, and 8,329,216. In July 2013, Actavis and Roxane were granted FDA approval to market all strengths of their respective non-crush-resistant formulations of OPANA® ER. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York. In August 2015, the District Court ruled that all defendants infringed the claims of U.S. Patent Nos. 8,309,122 and 8,329,216. The District Court also ruled that the defendants failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid, enjoined the defendants from launching their generic products until the expiration of those patents and directed Actavis to withdraw its generic product within 60 days. In October 2015, the District Court tolled the 60-day period until it decided two pending post-trial motions. In April 2016, the District Court issued an order upholding its August 2015 ruling in EPI’s favor and confirming the prior injunction against the manufacture or sale of the generic version of the non-crush-resistant OPANA® ER currently offered by Actavis and the additional approved but not yet marketed generic version of the product developed by Roxane. The defendants filed appeals to the Court of Appeals for the Federal Circuit. We intend to continue vigorously asserting our intellectual property rights and to oppose any such appeal.
From September 21, 2012 through October 30, 2013, EPI and its partner Grünenthal received Paragraph IV Notices from each of Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals, LLC (Amneal), ThoRx Laboratories, Inc. (ThoRx), Actavis, Impax and Ranbaxy (now Sun Pharmaceutical Industries Ltd.), advising of the filing by each such company of an ANDA for a generic version of the formulation of OPANA® ER designed to be crush-resistant. These Paragraph IV Notices refer to U.S. Patent Nos. 7,851,482, 8,075,872, 8,114,383, 8,192,722, 8,309,060, 8,309,122 and 8,329,216, which variously cover the formulation of OPANA® ER, a highly pure version of the active pharmaceutical ingredient and the release profile of OPANA® ER. EPI filed lawsuits against each of these filers in the U.S. District Court for the Southern District of New York. Each lawsuit was filed within the 45-day deadline to invoke a 30-month stay of FDA approval pursuant to the Hatch-Waxman legislative scheme. We intend, and have been advised by Grünenthal that it too intends, to defend vigorously the intellectual property rights covering the formulation of OPANA® ER designed to be crush-resistant and to pursue all available legal and regulatory avenues in defense of crush-resistant OPANA® ER, including enforcement of the product’s intellectual property rights and approved labeling. A trial in this case was held from March 2015 through April 2015 in the U.S. District Court for the Southern District of New York against the remaining filers. In August 2015, the District Court issued an Opinion holding that all defendants infringed the claims of U.S. Patent Nos. 8,309,060, 8,309,122 and 8,329,216. The Opinion also held that the defendants had shown that U.S. Patent No. 8,309,060 was invalid, but that the defendants had failed to show that U.S. Patent Nos. 8,309,122 and 8,329,216 were invalid. The District Court also issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent Nos. 8,309,122 and 8,329,216. The time for appealing that Opinion and Order has not yet expired and we expect the defendants to appeal the decision. We intend to continue to vigorously assert our intellectual property and oppose appeals by the defendants. However, there can be no assurance that we and/or Grünenthal will be successful. If we are unsuccessful and Teva, Amneal, ThoRx, Actavis or Impax is able to obtain FDA approval of its product, generic versions of crush-resistant OPANA® ER may be launched prior to the applicable patents’ expirations in 2023. Additionally, we cannot predict or determine the timing or outcome of this defense but will explore all options as appropriate in our best interest. The defendants filed appeals to the Court of Appeals for the Federal Circuit.
In August 2014 and October 2014, the U.S. Patent Office issued U.S. Patent Nos. 8,808,737 and 8,871,779 respectively, which cover a method of using OPANA® ER and a highly pure version of the active pharmaceutical ingredient of OPANA® ER. In November 2014, EPI filed lawsuits against Teva, ThoRx, Actavis, Impax, Ranbaxy, Roxane, Amneal, and Sandoz Inc. based on their ANDAs filed against both the crush-resistant and non-crush-resistant versions of OPANA® ER. Those lawsuits were filed in the U.S. District Court for the District of Delaware alleging infringement of these new patents, which expire in 2027 and 2029, respectively. On November 17, 2015, the District Court held the ‘737 patent invalid for claiming unpatentable subject matter. That patent has been dismissed from all suits and the suits administratively closed as to that patent, subject to appeal at the end of the case on the ‘779 patent. Beginning July 11, 2016, a three-day trial was held in the U.S. District Court for the District of Delaware against Teva and Amneal for infringement of the ‘779 patent. In October 2016, the District Court issued an Opinion holding that the defendants infringed the claims of U.S. Patent No. 8,871,779. The Opinion also held that the defendants had failed to show that U.S. Patent No. 8,871,779 was invalid. The District Court issued an Order enjoining the defendants from launching their generic products until the expiration of U.S. Patent No. 8,871,779 in November 2029.
We intend to defend vigorously our intellectual property rights and to pursue all available legal and regulatory avenues in defense of both the non-crush-resistant formulation OPANA® ER and the crush-resistant formulation OPANA® ER, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that we will be successful. If we are unsuccessful, competitors that already have obtained, or are able to obtain, FDA approval of their products may be able to launch their generic versions of OPANA® ER prior to the applicable patents’ expirations. Additionally, we cannot predict or determine the timing or outcome of related litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of OPANA® ER and challenge the applicable patents.
Paragraph IV Certification on Fortesta® Gel
In January 2013, EPI and its licensor Strakan Limited received a notice from Watson (now Allergan) advising of the filing by Watson of an ANDA for a generic version of Fortesta® (testosterone) Gel. In February 2013, EPI filed a lawsuit against Watson in the U.S. District Court for the Eastern District of Texas, Marshall division. Because the suit was filed within the 45-day period under the Hatch-Waxman Act for filing a patent infringement action, we believe that it triggered an automatic 30-month stay of approval under the Act. A two-day trial was held on or about February 26 and 27, 2015. In August 2015, the District Court issued an Order holding that the asserted patents are valid and are infringed by Watson’s ANDA. As a result, the District Court ordered that the effective date for the approval of Watson’s ANDA to be the date no sooner than the latest expiration date of the ’913 Patent and the ’865 Patent in November of 2018. Watson filed an appeal in October 2015. In October 2016, the Court of Appeals for the Federal Circuit issued an opinion upholding the District Court’s decision.
We intend, and have been advised by Strakan Limited that it too intends, to defend vigorously Fortesta® Gel and to pursue all available legal and regulatory avenues in defense of Fortesta® Gel, including enforcement of the product’s intellectual property rights and approved labeling. However, there can be no assurance that we and/or Strakan will be successful. If we and/or Strakan are unsuccessful and Watson is able to obtain FDA approval of its product, Watson may be able to launch its generic version of Fortesta® Gel prior to the applicable patents’ expirations in 2018. Additionally, we cannot predict or determine the timing or outcome of this litigation but will explore all options as appropriate in our best interest. In addition to the above litigation, it is possible that another generic manufacturer may also seek to launch a generic version of Fortesta® Gel and challenge the applicable patents.
Paragraph IV Certification on BELBUCA™
In November 2016, we became aware via the FDA's website that FDA’s Office of Generic Drugs had received an ANDA containing a Paragraph IV patent certification with respect to BELBUCA™ (buprenorphine hydrochloride) buccal film in September 2016. A Paragraph IV certification indicates that the generic sponsor believes certain Orange Book listed patents are invalid, unenforceable or not infringed. The FDA does not disclose the identity of the generic sponsor and we have not received the foregoing Paragraph IV patent certification. We intend to vigorously enforce our intellectual property rights relating to BELBUCA™.
Other Proceedings and Investigations
In addition to the above proceedings, proceedings similar to those described above may also be brought in the future. Additionally, we are involved in, or have been involved in, arbitrations or various other proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these other proceedings. Currently, neither we nor our subsidiaries are involved in any other proceedings that we expect to have a material effect on our business, financial condition, results of operations and cash flows.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Comprehensive (Loss) Income
 9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
OTHER COMPREHENSIVE (LOSS) INCOME
NOTE 13. OTHER COMPREHENSIVE (LOSS) INCOME
The following table presents the tax effects allocated to each component of Other comprehensive loss for the three months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized gain (loss) on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain (loss) arising during the period
$
152

 
$
—

 
$
152

 
$
(607
)
 
$
204

 
$
(403
)
Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
146

 
—

 
146

 
(607
)
 
204

 
(403
)
Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
(7,924
)
 
1,729

 
(6,195
)
 
(86,187
)
 
1,235

 
(84,952
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation loss
(7,924
)
 
1,729

 
(6,195
)
 
(60,630
)
 
1,393

 
(59,237
)
Other comprehensive loss
$
(7,778
)
 
$
1,729

 
$
(6,049
)
 
$
(61,237
)
 
$
1,597

 
$
(59,640
)
The following table presents the tax effects allocated to each component of Other comprehensive income (loss) for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized (loss) gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized (loss) gain arising during the period
$
(1,468
)
 
$
613

 
$
(855
)
 
$
2,042

 
$
(731
)
 
$
1,311

Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
(1,474
)
 
613

 
(861
)
 
2,042

 
(731
)
 
1,311

Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
38,782

 
14,177

 
52,959

 
(207,050
)
 
(1,249
)
 
(208,299
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation gain (loss)
38,782

 
14,177

 
52,959

 
(181,493
)
 
(1,091
)
 
(182,584
)
Other comprehensive income (loss)
$
37,308

 
$
14,790

 
$
52,098

 
$
(179,451
)
 
$
(1,822
)
 
$
(181,273
)

The following is a summary of the accumulated balances related to each component of Other comprehensive loss, net of taxes, at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Net unrealized gains
$
954

 
$
1,815

Foreign currency translation loss
(333,099
)
 
(386,020
)
Accumulated other comprehensive loss
$
(332,145
)
 
$
(384,205
)
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 14. SHAREHOLDERS' EQUITY
Changes in Shareholder’s Equity
The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2016 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2016
$
5,968,030

 
$
(54
)
 
$
5,967,976

Net (loss) income
(9,210
)
 
16

 
(9,194
)
Other comprehensive income
52,060

 
38

 
52,098

Compensation related to share-based awards
44,567

 
—

 
44,567

Tax withholding for restricted shares
(10,532
)
 
—

 
(10,532
)
Exercise of options
1,952

 
—

 
1,952

Issuance of ordinary shares related to the employee stock purchase plan
4,010

 
—

 
4,010

Other
(16
)
 
—

 
(16
)
Shareholders’ equity at September 30, 2016
$
6,050,861

 
$
—

 
$
6,050,861

The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2015 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2015
$
2,374,757

 
$
33,456

 
$
2,408,213

Net loss
(1,376,579
)
 
(153
)
 
(1,376,732
)
Other comprehensive loss
(180,692
)
 
(581
)
 
(181,273
)
Compensation related to share-based awards
48,537

 
—

 
48,537

Tax withholding for restricted shares
(15,268
)
 
—

 
(15,268
)
Exercise of options
25,068

 
—

 
25,068

Buy-out of noncontrolling interests, net of contributions
(6,876
)
 
(32,732
)
 
(39,608
)
Ordinary shares issued in connection with the Par acquisition
1,325,652

 
—

 
1,325,652

Ordinary shares issued in connection with the Auxilium acquisition
1,519,320

 
—

 
1,519,320

Fair value of equity component of acquired Auxilium Notes
266,649

 
—

 
266,649

Conversion of Auxilium Notes
160,892

 
—

 
160,892

Issuance of ordinary shares related to the employee stock purchase plan
3,328

 
—

 
3,328

Ordinary shares issued
2,300,000

 
—

 
2,300,000

Equity issuance fees
(66,956
)
 
—

 
(66,956
)
Other
18,232

 
—

 
18,232

Shareholders’ equity at September 30, 2015
$
6,396,064

 
$
(10
)
 
$
6,396,054


Share-Based Compensation
As discussed in Note 3. Discontinued Operations and Held for Sale, the operating results of the Company’s AMS business is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for all periods presented. However, as share-based compensation is not material for this business, amounts in this Note 14. Shareholders' Equity have not been adjusted to exclude the impact of this business.
The Company recognized share-based compensation expense of $15.0 million and $44.6 million during the three and nine months ended September 30, 2016, respectively, compared to $23.8 million and $86.1 million during the three and nine months ended September 30, 2015, respectively. The share-based compensation expense recognized during the nine months ended September 30, 2015 includes a charge related to the acceleration of Auxilium employee equity awards at closing of $37.6 million. The share-based compensation expense during the three and nine months ended September 30, 2015 includes $11.0 million of expense related to certain AMS equity awards modified in conjunction with the anticipated sale of the business. As of September 30, 2016, the total remaining unrecognized compensation cost related to all non-vested share-based compensation awards amounted to $93.9 million. As of September 30, 2016, the weighted average remaining requisite service period of the non-vested stock options was 2.2 years and for non-vested restricted stock units was 2.3 years.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other (Income) Expense, Net
 9 Months Ended
Sep. 30, 2016
Component of Operating Income [Abstract]  
OTHER (INCOME) EXPENSE, NET
NOTE 15. OTHER (INCOME) EXPENSE, NET
The components of Other (income) expense, net for the three and nine months ended September 30, 2016 and 2015 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Foreign currency loss (gain), net
$
(123
)
 
$
(4,095
)
 
$
2,427

 
$
(24,651
)
Equity (earnings) loss from unconsolidated subsidiaries, net
(2,023
)
 
1,899

 
(539
)
 
3,650

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Legal settlement
—

 
(12,500
)
 
—

 
(12,500
)
Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other miscellaneous, net
(720
)
 
506

 
(1,486
)
 
(1,131
)
Other (income) expense, net
$
(2,866
)
 
$
50,091

 
$
402

 
$
62,589


Foreign currency loss (gain), net results from the remeasurement of the Company’s foreign currency denominated assets and liabilities. In addition, the Company incurred $64.3 million and $78.4 million during the three and nine months ended September 30, 2015, respectively, related to unused commitment fees primarily associated with financing for the Par acquisition.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes
 9 Months Ended
Sep. 30, 2016
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE 16. INCOME TAXES
During the three months ended September 30, 2016, the Company recognized income tax expense of $46.2 million on $145.3 million of loss from continuing operations before income tax, compared to $160.9 million of tax benefit on $964.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the third quarter of 2016, the Company completed a legal entity restructuring. The restructuring resulted in the Company recording a deferred charge of $395.1 million in accordance with applicable accounting guidance. Within the third quarter, the Company recorded net discrete tax expense of $42.6 million primarily related to the amortization of the aforementioned deferred charge, which was partially offset by a favorable return to provision adjustment resulting from filing U.S. federal income tax returns. The tax benefit for the comparable 2015 period was primarily related to benefits resulting from losses from continued operations.
During the nine months ended September 30, 2016, the Company recognized an income tax benefit of $627.8 million on $518.3 million of loss from continuing operations before income tax, compared to $340.5 million of tax benefit on $1,084.6 million of loss from continuing operations before income tax during the comparable 2015 period. During the nine months ended September 30, 2016, the Company completed a legal entity restructuring as part of its continuing integration of our business. This resulted in the realization of a $635.0 million tax benefit arising from an outside basis difference, which was partly offset by a valuation allowance on its U.S. deferred tax assets. The tax benefit for the comparable 2015 period was primarily related to losses from continued operations combined with benefits resulting from the expected realization of deferred tax assets for certain components of our AMS business.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Share
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
NET LOSS PER SHARE
NOTE 17. NET LOSS PER SHARE
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Numerator:
 
 
 
 
 
 
 
(Loss) income from continuing operations
$
(191,496
)
 
$
(803,706
)
 
$
109,553

 
$
(744,108
)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests
—

 
(46
)
 
16

 
(153
)
(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders
$
(191,496
)
 
$
(803,660
)
 
$
109,537

 
$
(743,955
)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax
(27,423
)
 
(246,782
)
 
(118,747
)
 
(632,624
)
Net loss attributable to Endo International plc ordinary shareholders
$
(218,919
)
 
$
(1,050,442
)
 
$
(9,210
)
 
$
(1,376,579
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
222,767

 
209,274

 
222,579

 
188,085

Dilutive effect of ordinary share equivalents
—

 
—

 
480

 
—

Dilutive effect of various convertible notes and warrants
—

 
—

 
1

 
—

For diluted per share data—weighted average shares
222,767

 
209,274

 
223,060

 
188,085


Basic net loss per share data is computed based on the weighted average number of ordinary shares outstanding during the period. Diluted loss per share data is computed based on the weighted average number of ordinary shares outstanding and, if there is net income from continuing operations attributable to Endo ordinary shareholders during the period, the dilutive impact of ordinary share equivalents outstanding during the period. Ordinary share equivalents are measured under the treasury stock method.
For the three months ended September 30, 2016, all stock options and stock awards were excluded from the diluted share calculation because their effect would have been anti-dilutive, as the Company was in a loss position. For the nine months ended September 30, 2016, stock options and stock awards of 5.0 million were excluded from the diluted share calculation because their effect would have been anti-dilutive. All stock options and stock awards were excluded from the diluted share calculation for the three and nine months ended September 30, 2015 because their effect would have been anti-dilutive, as the Company was in a loss position.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Recent Accounting Pronouncements (Policies)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards update (ASU) No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 represents a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled to receive in exchange for those goods or services. This ASU sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which defers the effective date of ASU 2014-09 by one year, but permits companies to adopt one year earlier if they choose (i.e., the original effective date). As such, ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2017 and the Company currently plans to adopt it on January 1, 2018. In March and April 2016, the FASB issued ASU No. 2016-08 “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Consideration (Reporting Revenue Gross versus Net)” and ASU No. 2016-10 “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” respectively, which clarifies the guidance on reporting revenue as a principal versus agent, identifying performance obligations and accounting for intellectual property licenses. In addition, in May 2016, the FASB issued ASU No. 2016-12 “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” which amends certain narrow aspects of Topic 606. The Company is currently evaluating the impact of these standards on the Company’s consolidated results of operations and financial position, including possible transition alternatives.
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” (ASU 2015-11). ASU 2015-11 states that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public entities, ASU 2015-11 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively and early application is permitted. The Company is currently evaluating the impact of ASU 2015-11 on the Company’s consolidated results of operations and financial position.
In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (ASU 2016-02). ASU 2016-02 establishes the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-02 on the Company’s consolidated results of operations and financial position.
In March 2016, the FASB issued ASU No. 2016-09 “Improvements to Employee Share-Based Payment Accounting” (ASU 2016-09). ASU 2016-09 changes how companies account for certain aspects of share-based payments to employees including: (a) requiring all income tax effects of awards to be recognized in the income statement, rather than in additional paid in capital, when the awards vest or are settled, (b) eliminating the requirement that excess tax benefits be realized before companies can recognize them, (c) requiring companies to present excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity, (d) increasing the amount an employer can withhold to cover income taxes on awards and still qualify for the exception to liability classification for shares used to satisfy the employer’s statutory income tax withholding obligation, (e) requiring an employer to classify the cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation as a financing activity on its statement of cash flows and (f) electing whether to account for forfeitures of share-based payments by (1) recognizing forfeitures of awards as they occur or (2) estimating the number of awards expected to be forfeited and adjusting the estimate when it is likely to change, as is currently required. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-09 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-09 on the Company’s consolidated results of operations and financial position.
In August 2016, the FASB issued ASU No. 2016-15 “Classification of Certain Cash Receipts and Cash Payments” (ASU 2016-15). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period but all of ASU 2016-15 must be adopted in the same period. The Company is currently evaluating the impact of ASU 2016-15 on the Company’s consolidated statement of cash flows.
In October 2016, the FASB issued ASU No. 2016-16 “Intra-Entity Transfers of Assets Other Than Inventory” (ASU 2016-16). ASU 2016-16 states that an entity should recognize the income tax consequences when an intra-entity transfer of an asset other than inventory occurs. ASU 2016-16 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted as long as it is adopted in the first interim period of a fiscal year beginning after December 15, 2016. The Company is currently evaluating the impact of ASU 2016-16 on the Company’s consolidated results of operations and financial position.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Tables)
 9 Months Ended
Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of disposal groups, including discontinued operations, income statement, balance sheet and additional disclosures
The following table provides the operating results of the Discontinued operations, net of tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Revenue
$
387

 
$
43,705

 
$
30,101

 
$
282,310

Litigation related and other contingencies, net
$
17,705

 
$
—

 
$
20,155

 
$
273,752

Asset impairment charges
$
—

 
$
2,200

 
$
21,328

 
$
224,953

Gain on sale of business
$
—

 
$
13,550

 
$
—

 
$
13,550

Loss from discontinued operations before income taxes
$
(27,309
)
 
$
(18,775
)
 
$
(118,633
)
 
$
(506,275
)
Income tax expense
$
—

 
$
228,007

 
$
—

 
$
126,349

Discontinued operations, net of tax
$
(27,309
)
 
$
(246,782
)
 
$
(118,633
)
 
$
(632,624
)
The following table provides the Depreciation and amortization and Purchases of property, plant and equipment of AMS for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
Cash flows from discontinued operating activities:
 
 
 
Net loss
$
(118,633
)
 
$
(632,624
)
Depreciation and amortization
$
—

 
$
11,555

Net cash used in discontinued investing activities:
 
 
 
Purchases of property, plant and equipment
$
(138
)
 
$
(2,182
)
Restructuring and related costs
A summary of expenses related to the Astora restructuring initiative is included below for the three and nine months ended September 30, 2016 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2016
Employee separation, retention and other benefit-related costs
$
715

 
$
22,181

Asset impairment charges
—

 
21,328

Contract termination charges
769

 
10,569

Other wind down costs
285

 
14,315

Total
$
1,769

 
$
68,393
Schedule of restructuring reserve by type of cost
Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Contract Termination Charges
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
—

 
$
—

 
$
—

 
$
—

Expenses
22,181

 
10,569

 
7,778

 
40,528

Cash distributions
(13,393
)
 
(5,743
)
 
(5,276
)
 
(24,412
)
Liability balance as of September 30, 2016
$
8,788

 
$
4,826

 
$
2,502

 
$
16,116

Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
5,353

 
$
6,910

 
$
12,263

Cash distributions
(5,174
)
 
(1,143
)
 
(6,317
)
Liability balance as of September 30, 2016
$
179

 
$
5,767

 
$
5,946

Changes to the accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
—

Expenses
13,398

Cash payments
(5,274
)
Liability balance as of September 30, 2016
$
8,124

Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
17,914

Expenses
5,229

Cash distributions
(13,114
)
Liability balance as of September 30, 2016
$
10,029
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2016
Restructuring and Related Activities [Abstract]  
Schedule of restructuring reserve by type of cost
Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Contract Termination Charges
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
—

 
$
—

 
$
—

 
$
—

Expenses
22,181

 
10,569

 
7,778

 
40,528

Cash distributions
(13,393
)
 
(5,743
)
 
(5,276
)
 
(24,412
)
Liability balance as of September 30, 2016
$
8,788

 
$
4,826

 
$
2,502

 
$
16,116

Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Employee Separation, Retention and Other Benefit-Related Costs
 
Other Restructuring Costs
 
Total
Liability balance as of January 1, 2016
$
5,353

 
$
6,910

 
$
12,263

Cash distributions
(5,174
)
 
(1,143
)
 
(6,317
)
Liability balance as of September 30, 2016
$
179

 
$
5,767

 
$
5,946

Changes to the accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
—

Expenses
13,398

Cash payments
(5,274
)
Liability balance as of September 30, 2016
$
8,124

Changes to this accrual during the nine months ended September 30, 2016 were as follows (in thousands):
 
Total
Liability balance as of January 1, 2016
$
17,914

Expenses
5,229

Cash distributions
(13,114
)
Liability balance as of September 30, 2016
$
10,029
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2016
Auxilium Pharmaceuticals, Inc.  
Business Acquisition [Line Items]  
Schedule of revenue and net loss of acquired included in Condensed Consolidated Statements of Operations
The amounts of Auxilium Revenue and Net loss included in the Company’s Condensed Consolidated Statements of Operations from and including January 29, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
237,807

Net loss attributable to Endo International plc
$
(257,597
)
Basic and diluted net loss per share
$
(1.37
)
Schedule of pro forma consolidated results
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Auxilium had occurred on January 1, 2015 for the nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
Revenue
$
2,218,596

Net loss attributable to Endo International plc
$
(1,395,162
)
Basic and diluted net loss per share
$
(7.42
)
Par Pharmaceutical Holdings, Inc.  
Business Acquisition [Line Items]  
Schedule of revenue and net loss of acquired included in Condensed Consolidated Statements of Operations
The amounts of Par Revenue and Net loss attributable to Endo International plc included in the Company’s Condensed Consolidated Statements of Operations from and including September 25, 2015 to September 30, 2015 are as follows (in thousands, except per share data):
Revenue
$
23,413

Net loss attributable to Endo International plc
$
(17,441
)
Basic and diluted net loss per share
$
(0.09
)
Schedule of recognized identified assets acquired and liabilities assumed
The following table summarizes the fair values of the assets acquired and liabilities assumed at the Par Acquisition Date, including measurement period adjustments since the fair values presented in the Company’s Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on February 29, 2016, (in thousands):
 
September 25, 2015
 
Measurement period adjustments
 
September 25, 2015
(As adjusted)
Cash and cash equivalents
$
215,612

 
$
—

 
$
215,612

Accounts and other receivables
530,664

 
(13,755
)
 
516,909

Inventories
330,406

 
(1,849
)
 
328,557

Prepaid expenses and other current assets
31,124

 
—

 
31,124

Deferred income tax assets, current
14,652

 
30,176

 
44,828

Property, plant and equipment
256,293

 
4,744

 
261,037

Intangible assets
3,627,000

 
(154,500
)
 
3,472,500

Other assets
8,477

 
—

 
8,477

Total identifiable assets
$
5,014,228

 
$
(135,184
)
 
$
4,879,044

Accounts payable and accrued expenses
$
551,614

 
$
(511
)
 
$
551,103

Deferred income tax liabilities
1,093,779

 
(44,961
)
 
1,048,818

Other liabilities
16,057

 
2,556

 
18,613

Total liabilities assumed
$
1,661,450

 
$
(42,916
)
 
$
1,618,534

Net identifiable assets acquired
$
3,352,778

 
$
(92,268
)
 
$
3,260,510

Goodwill
4,782,876

 
92,268

 
4,875,144

Net assets acquired
$
8,135,654

 
$
—

 
$
8,135,654
Schedule of valuation of the intangible assets acquired and related amortization periods
The valuation of the intangible assets acquired and related amortization periods are as follows:
 
Valuation (in millions)
 
Amortization period (in years)
Developed Technology:
 
 
 
Vasostrict®
$
556.0

 
8
Aplisol®
312.4

 
11
Developed - Other - Non-Partnered (Generic Non-Injectable)
230.4

 
7
Developed - Other - Partnered (Combined)
164.4

 
7
Nascobal®
118.3

 
9
Developed - Other - Non-Partnered (Generic Injectable)
116.4

 
10
Other
517.9

 
9
Total
$
2,015.8

 
 
In Process Research & Development (IPR&D):
 
 
 
IPR&D 2019 Launch
$
401.0

 
n/a
IPR&D 2018 Launch
283.8

 
n/a
Ezetimibe
147.6

 
n/a
IPR&D 2016 Launch
133.3

 
n/a
Ephedrine Sulphate
128.6

 
n/a
Neostigmine vial
118.6

 
n/a
Other
243.8

 
n/a
Total
$
1,456.7

 
n/a
Total other intangible assets
$
3,472.5

 
n/a
Schedule of pro forma consolidated results
The following supplemental unaudited pro forma information presents the financial results as if the acquisition of Par had occurred on January 1, 2015 for the three and nine months ended September 30, 2015. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2015, nor are they indicative of any future results.
 
Three Months Ended September 30, 2015
 
Nine Months Ended September 30, 2015
Unaudited pro forma consolidated results (in thousands, except per share data):
 
 
 
Revenue
$
1,053,654

 
$
3,194,413

Net loss attributable to Endo International plc
$
(1,084,031
)
 
$
(1,475,667
)
Basic and diluted net loss per share
$
(5.18
)
 
$
(7.85
)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Results (Tables)
 9 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Schedule of reportable segments information
The following represents selected information for the Company’s reportable segments for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net revenues to external customers:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
279,843

 
$
304,778

 
$
876,998

 
$
905,198

U.S. Generic Pharmaceuticals
533,691

 
367,933

 
1,682,439

 
1,063,221

International Pharmaceuticals (1)
70,801

 
73,016

 
209,324

 
226,602

Total net revenues to external customers
$
884,335

 
$
745,727

 
$
2,768,761

 
$
2,195,021

 
 
 
 
 
 
 
 
Adjusted income from continuing operations before income tax:
 
 
 
 
 
 
 
U.S. Branded Pharmaceuticals
$
131,615

 
$
156,897

 
$
422,816

 
$
484,758

U.S. Generic Pharmaceuticals
$
228,717

 
$
177,961

 
$
655,453

 
$
507,507

International Pharmaceuticals
$
22,077

 
$
18,961

 
$
64,446

 
$
54,729

__________
(1)
Revenues generated by our International Pharmaceuticals segment are primarily attributable to Canada, Mexico and South Africa.
Schedule of reconciliations of consolidated loss from continuing operations before income tax
The table below provides reconciliations of our consolidated loss from continuing operations before income tax, which is determined in accordance with U.S. GAAP, to our segment adjusted income from continuing operations before income tax for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Total consolidated loss from continuing operations before income tax
$
(145,311
)
 
$
(964,645
)
 
$
(518,254
)
 
$
(1,084,636
)
Corporate unallocated costs (1)
159,123

 
137,180

 
473,933

 
363,298

Amortization of intangible assets
211,548

 
121,503

 
636,061

 
333,759

Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans
14,208

 
42,919

 
111,787

 
131,783

Upfront and milestone payments to partners
1,770

 
9,261

 
5,875

 
14,063

Separation benefits and other cost reduction initiatives (2)
9,782

 
22,669

 
70,412

 
70,256

Impact of Voltaren® Gel generic competition
—

 
—

 
(7,750
)
 
—

Acceleration of Auxilium employee equity awards at closing
—

 
—

 
—

 
37,603

Certain litigation-related charges, net (3)
18,256

 
—

 
28,715

 
19,875

Asset impairment charges (4)
93,504

 
923,607

 
263,080

 
1,000,850

Acquisition-related and integration items (5)
19,476

 
(27,688
)
 
80,201

 
51,177

Loss on extinguishment of debt
—

 
40,909

 
—

 
41,889

Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Foreign currency impact related to the remeasurement of intercompany debt instruments
(114
)
 
(5,693
)
 
1,558

 
(23,991
)
Other, net
167

 
(10,484
)
 
(2,903
)
 
(6,153
)
Total segment adjusted income from continuing operations before income tax
$
382,409

 
$
353,819

 
$
1,142,715

 
$
1,046,994

__________
(1)
Corporate unallocated costs include interest expense, net, certain corporate overhead costs, such as headcount and facility expenses and certain other income and expenses.
(2)
Separation benefits and other cost reduction initiatives include decreases of excess inventory reserves of $(9.0) million and increases of excess inventory reserves of $24.3 million during the three and nine months ended September 30, 2016, respectively, primarily related to the 2016 U.S. Generic Pharmaceuticals restructuring initiative. The adjustment for the three months ended September 30, 2016 resulted from the sell-through of certain inventory previously reserved. In addition, employee separation costs of $14.8 million and $30.0 million and other restructuring costs of $3.9 million and $16.1 million were recorded for the three and nine months ended September 30, 2016, respectively. Amounts in the comparable 2015 periods include employee separation costs of $20.8 million and $58.1 million, respectively, and a $7.9 million charge recorded during the nine months ended September 30, 2015, upon the cease use date of Auxilium’s former corporate headquarters, representing the liability for our remaining obligations under the respective lease agreement, net of estimated sublease income. These amounts were primarily recorded as Cost of revenues and Selling, general and administrative expense in our Condensed Consolidated Statements of Operations. See Note 4. Restructuring for discussion of our material restructuring initiatives.
(3)
These amounts include charges for Litigation-related and other contingencies, net as further described in Note 12. Commitments and Contingencies.
(4)
Asset impairment charges primarily relate to charges to write down intangible assets as further described in Note 9. Goodwill and Other Intangibles and goodwill impairment charges recorded during the third quarter of 2015.
(5)
Acquisition-related and integration items include costs directly associated with previous acquisitions of $7.9 million and $55.4 million for the three and nine months ended September 30, 2016, respectively, compared to $52.6 million and $134.8 million for the comparable 2015 periods. In addition, during the three and nine months ended September 30, 2016, there is a charge for changes in fair value of contingent consideration of $11.6 million and $24.8 million, respectively. During the three and nine months ended September 30, 2015, acquisition-related and integration costs are net of a benefit due to changes in the fair value of contingent consideration of $80.3 million and $83.6 million, respectively.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Financial assets and liabilities measured at fair value on recurring basis
The Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
September 30, 2016
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant 
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Time deposits
—

 
100,091

 
—

 
100,091

Equity securities
2,361

 
—

 
—

 
2,361

Total
$
67,861

 
$
100,091

 
$
—

 
$
167,952

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
108,778

 
$
108,778

Acquisition-related contingent consideration—long-term
—

 
—

 
177,019

 
177,019

Total
$
—

 
$
—

 
$
285,797

 
$
285,797

At September 30, 2016, money market funds include $40.5 million in Qualified Settlement Funds to be disbursed to mesh-related product liability claimants. See Note 12. Commitments and Contingencies for further discussion of our product liability cases.
 
Fair Value Measurements at Reporting Date using:
December 31, 2015
Quoted Prices in
Active Markets
for Identical
Assets (Level 1) 
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Equity securities
3,889

 
—

 
—

 
3,889

Total
$
55,034

 
$
—

 
$
—

 
$
55,034

Liabilities:
 
 
 
 
 
 
 
Acquisition-related contingent consideration—short-term
$
—

 
$
—

 
$
65,265

 
$
65,265

Acquisition-related contingent consideration—long-term
—

 
—

 
78,237

 
78,237

Total
$
—

 
$
—

 
$
143,502

 
$
143,502
Changes to liability for acquisition-related contingent consideration
The following table presents changes to the Company’s liability for acquisition-related contingent consideration during the nine months ended September 30, 2016 by acquisition (in thousands):
 
Balance as of December 31, 2015
 
Acquisitions
 
Fair Value Adjustments and Accretion
 
Payments and Other
 
Balance as of September 30, 2016
Qualitest acquisition
$
1,137

 
$
—

 
$
(1,137
)
 
$
—

 
$
—

Sumavel acquisition
631

 
—

 
(631
)
 
—

 
—

Auxilium acquisition
26,435

 
—

 
2,203

 
(9,787
)
 
18,851

Lehigh Valley Technologies, Inc. acquisitions
97,003

 
—

 
24,686

 
(19,389
)
 
102,300

Voltaren Gel® acquisition
—

 
142,355

 
(2,905
)
 
—

 
139,450

Other
18,296

 
4,511

 
2,574

 
(185
)
 
25,196

Total
$
143,502

 
$
146,866

 
$
24,790

 
$
(29,361
)
 
$
285,797

The following table presents changes to the Company’s liability for acquisition-related contingent consideration, which was measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Beginning of period
$
135,796

 
$
189,082

 
$
143,502

 
$
46,005

Amounts acquired
146,866

 
47,900

 
146,866

 
214,435

Amounts settled
(8,121
)
 
(13,094
)
 
(30,242
)
 
(21,668
)
Transfers (in) and/or out of Level 3
—

 
—

 
—

 
—

Measurement period adjustments
—

 
(78
)
 
—

 
(11,634
)
Changes in fair value recorded in earnings
11,585

 
(80,277
)
 
24,790

 
(83,605
)
Effect of currency translation
(329
)
 
(1,210
)
 
881

 
(1,210
)
End of period
$
285,797

 
$
142,323

 
$
285,797

 
$
142,323
Summary of available-for-sale securities
The following is a summary of available-for-sale securities held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
(Losses) 
 
Fair Value
September 30, 2016
 
 
 
 
 
 
 
Money market funds
$
65,500

 
$
—

 
$
—

 
$
65,500

Total included in cash and cash equivalents
$
25,012

 
$
—

 
$
—

 
$
25,012

Total included in restricted cash and cash equivalents
$
40,488

 
$
—

 
$
—

 
$
40,488

Equity securities
$
—

 
$
—

 
$
—

 
$
—

Total other short-term available-for-sale securities
$
—

 
$
—

 
$
—

 
$
—

Equity securities
$
1,766

 
$
595

 
$
—

 
$
2,361

Long-term available-for-sale securities
$
1,766

 
$
595

 
$
—

 
$
2,361


 
Available-for-sale
 
Amortized
Cost
 
Gross
Unrealized
Gains 
 
Gross
Unrealized
(Losses)
 
Fair Value
December 31, 2015
 
 
 
 
 
 
 
Money market funds
$
51,145

 
$
—

 
$
—

 
$
51,145

Total included in cash and cash equivalents
$
3

 
$
—

 
$
—

 
$
3

Total included in restricted cash and cash equivalents
$
51,142

 
$
—

 
$
—

 
$
51,142

Equity securities
$
24

 
$
10

 
$
—

 
$
34

Total other short-term available-for-sale securities
$
24

 
$
10

 
$
—

 
$
34

Equity securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855

Long-term available-for-sale securities
$
1,766

 
$
2,089

 
$
—

 
$
3,855
Summary of nonrecurring fair value measurements
The Company’s financial assets and liabilities measured at fair value on a nonrecurring basis as of September 30, 2016 were as follows (in thousands):
 
Fair Value Measurements at Reporting Date using:
 
Total Expense for the Nine Months Ended September 30, 2016
 
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Assets:
 
 
 
 
 
 
 
Certain Astora property, plant and equipment (NOTE 3)
$
—

 
$
—

 
$
—

 
$
(5,041
)
Certain U.S. Generics Pharmaceuticals property, plant and equipment
—

 
—

 
649

 
(4,448
)
Certain U.S. Branded Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
—

 
(72,814
)
Certain U.S. Generic Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
45,966

 
(169,576
)
Certain International Pharmaceuticals intangible assets (NOTE 9)
—

 
—

 
5,324

 
(16,243
)
Certain Astora intangible assets (NOTE 3)
—

 
—

 
—

 
(16,287
)
Total
$
—

 
$
—

 
$
51,939

 
$
(284,409
)
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2016
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventories consist of the following at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Raw materials (1)
$
195,830

 
$
210,038

Work-in-process (1)
111,437

 
177,821

Finished goods (1)
317,035

 
364,634

Total
$
624,302

 
$
752,493


(1) The components of inventory shown in the table above are net of allowance for obsolescence.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Tables)
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2016 were as follows (in thousands):
 
Carrying Amount
 
U.S. Branded Pharmaceuticals
 
U.S. Generic Pharmaceuticals
 
International Pharmaceuticals
 
Total
Balance as of December 31, 2015:
 
 
 
 
 
 
 
Goodwill
$
1,676,276

 
$
5,789,934

 
$
592,424

 
$
8,058,634

Accumulated impairment losses
(673,500
)
 
—

 
(85,780
)
 
(759,280
)
Balance as of December 31, 2015
$
1,002,776

 
$
5,789,934

 
$
506,644

 
$
7,299,354

Measurement period adjustments
16,518

 
75,750

 
1,366

 
93,634

Effect of currency translation on gross balance
—

 
—

 
19,732

 
19,732

Effect of currency translation on accumulated impairment
—

 
—

 
(1,100
)
 
(1,100
)
Balance as of September 30, 2016:
 
 
 
 
 
 
 
Goodwill
$
1,692,794

 
$
5,865,684

 
$
613,522

 
$
8,172,000

Accumulated impairment losses
(673,500
)
 
—

 
(86,880
)
 
(760,380
)
 
$
1,019,294

 
$
5,865,684

 
$
526,642

 
$
7,411,620
Schedule of other intangible assets
The following is a summary of other intangible assets held by the Company at September 30, 2016 and December 31, 2015 (in thousands):
Cost basis:
Balance as of December 31, 2015
 
Acquisitions
(1)
 
Impairments
(2)
 
Other
(3)
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Indefinite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
In-process research and development
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Total indefinite-lived intangibles
$
1,742,880

 
$
(114,200
)
 
$
(55,100
)
 
$
(138,456
)
 
$
2,594

 
$
1,437,718

Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses (weighted average life of 12 years)
$
676,867

 
$
—

 
$
—

 
$
(211,147
)
 
$
—

 
$
465,720

Customer relationships (weighted average life of 15 years)
11,318

 
—

 
(3,460
)
 
(7,858
)
 
—

 
—

Tradenames (weighted average life of 12 years)
7,537

 
—

 
—

 
—

 
(127
)
 
7,410

Developed technology (weighted average life of 12 years)
6,731,573

 
148,891

 
(216,194
)
 
123,618

 
24,263

 
6,812,151

Total definite-lived intangibles (weighted average life of 12 years)
$
7,427,295

 
$
148,891

 
$
(219,654
)
 
$
(95,387
)
 
$
24,136

 
$
7,285,281

Total other intangibles
$
9,170,175

 
$
34,691

 
$
(274,754
)
 
$
(233,843
)
 
$
26,730

 
$
8,722,999

 
 
 
 
 
 
 
 
 
 
 
 
Accumulated amortization:
Balance as of December 31, 2015
 
Amortization
 
Impairments
 
Other
 
Effect of Currency Translation
 
Balance as of September 30, 2016
Definite-lived intangibles:
 
 
 
 
 
 
 
 
 
 
 
Licenses
$
(508,225
)
 
$
(37,142
)
 
$
—

 
$
211,147

 
$
—

 
$
(334,220
)
Customer relationships
(7,858
)
 
—

 
—

 
7,858

 
—

 
—

Tradenames
(6,544
)
 
(66
)
 
—

 
—

 
19

 
(6,591
)
Developed technology
(818,606
)
 
(598,853
)
 
—

 
13,201

 
(2,352
)
 
(1,406,610
)
Total definite-lived intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Total other intangibles
$
(1,341,233
)
 
$
(636,061
)
 
$
—

 
$
232,206

 
$
(2,333
)
 
$
(1,747,421
)
Net other intangibles
$
7,828,942

 
 
 
 
 
 
 
 
 
$
6,975,578

__________
(1)
Includes intangible assets acquired through the acquisition of Voltaren® Gel and other business combinations in addition to the capitalization of payments relating to XIAFLEX®, offset by measurement period adjustments relating to the Par acquisition.
(2)
Includes the impairment of certain intangible assets of our U.S. Generic Pharmaceuticals segment of $169.6 million, our U.S. Branded Pharmaceuticals segment of $72.8 million, our International Pharmaceuticals segment of $16.2 million and the impairment of certain intangible assets in connection with the wind down of our Astora business, with a net impairment of approximately $16.3 million, which is reported as Discontinued operations, net of tax in the Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016. See Note 3. Discontinued Operations and Held for Sale for further information relating to the Astora wind down.
(3)
Includes the removal of approximately $221.9 million of fully amortized intangible assets relating to expired or terminated licensing agreements in our U.S. Branded Pharmaceuticals segment, including the 2008 Voltaren® Gel agreement, described in Note 10. License and Collaboration Agreements, NatestoTM, described in Note 5. Acquisitions of our Annual Report on Form 10-K for the year ended December 31, 2015, and STENDRA®, described in Note 10. Goodwill and Other Intangibles of our Annual Report on Form 10-K for the year ended December 31, 2015. In addition, $10.0 million of fully amortized assets were removed in connection with the wind down of our Astora business described above. Additionally, certain IPR&D assets of $138.5 million were placed in service and transferred into developed technology, while certain other developed technology assets were removed due to their sale or disposal during the period presented.
Schedule of future amortization expense
Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2015 is as follows (in thousands):
2016
$
824,062

2017
$
725,659

2018
$
637,623

2019
$
575,060

2020
$
546,598
Schedule of changes in gross carrying amount of other intangible assets
Changes in the gross carrying amount of our other intangibles for the nine months ended September 30, 2016 were as follows (in thousands):
 
Gross Carrying Amount
December 31, 2015
$
9,170,175

Capitalization of payments relating to XIAFLEX®
12,008

Voltaren® Gel acquisition
159,000

Other acquisitions
18,183

Sale of certain International Pharmaceuticals intangible assets
(1,959
)
Impairment of certain U.S. Branded Pharmaceuticals intangible assets
(72,814
)
Impairment of certain U.S. Generic Pharmaceuticals intangible assets
(169,576
)
Impairment of certain International Pharmaceuticals intangible assets
(16,077
)
Impairment of certain Astora intangible assets
(26,318
)
Measurement period adjustments relating to acquisitions closed during 2015 (NOTE 5)
(154,500
)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements
(221,853
)
Effect of currency translation
26,730

September 30, 2016
$
8,722,999
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2016
Debt Instruments [Abstract]  
Schedule of long-term debt instruments
The following table presents the carrying amounts of the Company’s total indebtedness at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
 
Principal Amount
 
Unamortized Discount and Deferred Loan Costs
7.25% Senior Notes due 2022
$
400,000

 
$
(11,284
)
 
$
400,000

 
$
(12,535
)
5.75% Senior Notes due 2022
700,000

 
(9,026
)
 
700,000

 
(10,088
)
5.375% Senior Notes due 2023
750,000

 
(9,585
)
 
750,000

 
(10,511
)
6.00% Senior Notes due 2023
1,635,000

 
(25,481
)
 
1,635,000

 
(27,694
)
6.00% Senior Notes due 2025
1,200,000

 
(21,287
)
 
1,200,000

 
(22,713
)
Term Loan A Facility Due 2019
962,500

 
(10,221
)
 
1,017,500

 
(13,831
)
Term Loan B Facility Due 2022
2,779,000

 
(44,803
)
 
2,800,000

 
(49,900
)
Revolving Credit Facility
—

 
—

 
225,000

 
—

Other debt
55

 
—

 
134

 
—

Total long-term debt, net
$
8,426,555

 
$
(131,687
)
 
$
8,727,634

 
$
(147,272
)
Less current portion, net
124,250

 
—

 
328,705

 
—

Total long-term debt, less current portion, net
$
8,302,305

 
$
(131,687
)
 
$
8,398,929

 
$
(147,272
)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments And Contingencies (Tables)
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
Changes in Qualified Settlement Funds accounts and product liability balance
The following table presents the changes in the vaginal mesh QSFs and product liability balance during the nine months ended September 30, 2016 (in thousands):
 
Qualified Settlement Funds
 
Product Liability
Balance as of December 31, 2015
$
578,970

 
$
2,086,176

Additional charges
—

 
19,505

Cash contributions to Qualified Settlement Funds
587,782

 
—

Cash distributions to settle disputes from Qualified Settlement Funds
(898,288
)
 
(898,288
)
Cash distributions to settle disputes
—

 
(5,561
)
Other
456

 
—

Balance as of September 30, 2016
$
268,920

 
$
1,201,832
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Comprehensive (Loss) Income (Tables)
 9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Schedule of tax effects allocated to each component of other comprehensive income
The following table presents the tax effects allocated to each component of Other comprehensive loss for the three months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized gain (loss) on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gain (loss) arising during the period
$
152

 
$
—

 
$
152

 
$
(607
)
 
$
204

 
$
(403
)
Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
146

 
—

 
146

 
(607
)
 
204

 
(403
)
Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
(7,924
)
 
1,729

 
(6,195
)
 
(86,187
)
 
1,235

 
(84,952
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation loss
(7,924
)
 
1,729

 
(6,195
)
 
(60,630
)
 
1,393

 
(59,237
)
Other comprehensive loss
$
(7,778
)
 
$
1,729

 
$
(6,049
)
 
$
(61,237
)
 
$
1,597

 
$
(59,640
)
The following table presents the tax effects allocated to each component of Other comprehensive income (loss) for the nine months ended September 30, 2016 and 2015 (in thousands):
 
Nine Months Ended September 30,
 
2016
 
2015
 
Before-
Tax
Amount
 
Tax Benefit (Expense)
 
Net-of-Tax
Amount
 
Before-Tax
Amount
 
Tax (Expense) Benefit
 
Net-of-
Tax
Amount
Net unrealized (loss) gain on securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized (loss) gain arising during the period
$
(1,468
)
 
$
613

 
$
(855
)
 
$
2,042

 
$
(731
)
 
$
1,311

Less: reclassification adjustments for gain realized in net loss
(6
)
 
—

 
(6
)
 
—

 
—

 
—

Net unrealized (losses) gains
(1,474
)
 
613

 
(861
)
 
2,042

 
(731
)
 
1,311

Net unrealized gain (loss) on foreign currency:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation loss arising during the period
38,782

 
14,177

 
52,959

 
(207,050
)
 
(1,249
)
 
(208,299
)
Less: reclassification adjustments for loss realized in net loss
—

 
—

 
—

 
25,557

 
158

 
25,715

Foreign currency translation gain (loss)
38,782

 
14,177

 
52,959

 
(181,493
)
 
(1,091
)
 
(182,584
)
Other comprehensive income (loss)
$
37,308

 
$
14,790

 
$
52,098

 
$
(179,451
)
 
$
(1,822
)
 
$
(181,273
)
Schedule of accumulated other comprehensive income (loss)
The following is a summary of the accumulated balances related to each component of Other comprehensive loss, net of taxes, at September 30, 2016 and December 31, 2015 (in thousands):
 
September 30, 2016
 
December 31, 2015
Net unrealized gains
$
954

 
$
1,815

Foreign currency translation loss
(333,099
)
 
(386,020
)
Accumulated other comprehensive loss
$
(332,145
)
 
$
(384,205
)
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Schedule of changes in stockholders' equity
The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2016 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2016
$
5,968,030

 
$
(54
)
 
$
5,967,976

Net (loss) income
(9,210
)
 
16

 
(9,194
)
Other comprehensive income
52,060

 
38

 
52,098

Compensation related to share-based awards
44,567

 
—

 
44,567

Tax withholding for restricted shares
(10,532
)
 
—

 
(10,532
)
Exercise of options
1,952

 
—

 
1,952

Issuance of ordinary shares related to the employee stock purchase plan
4,010

 
—

 
4,010

Other
(16
)
 
—

 
(16
)
Shareholders’ equity at September 30, 2016
$
6,050,861

 
$
—

 
$
6,050,861

The following table displays a reconciliation of our beginning and ending balances in shareholders' equity for the nine months ended September 30, 2015 (in thousands):
 
Attributable to: 
 
Endo
International plc
 
Noncontrolling
interests
 
Total
Shareholders’
Equity
Shareholders’ equity at January 1, 2015
$
2,374,757

 
$
33,456

 
$
2,408,213

Net loss
(1,376,579
)
 
(153
)
 
(1,376,732
)
Other comprehensive loss
(180,692
)
 
(581
)
 
(181,273
)
Compensation related to share-based awards
48,537

 
—

 
48,537

Tax withholding for restricted shares
(15,268
)
 
—

 
(15,268
)
Exercise of options
25,068

 
—

 
25,068

Buy-out of noncontrolling interests, net of contributions
(6,876
)
 
(32,732
)
 
(39,608
)
Ordinary shares issued in connection with the Par acquisition
1,325,652

 
—

 
1,325,652

Ordinary shares issued in connection with the Auxilium acquisition
1,519,320

 
—

 
1,519,320

Fair value of equity component of acquired Auxilium Notes
266,649

 
—

 
266,649

Conversion of Auxilium Notes
160,892

 
—

 
160,892

Issuance of ordinary shares related to the employee stock purchase plan
3,328

 
—

 
3,328

Ordinary shares issued
2,300,000

 
—

 
2,300,000

Equity issuance fees
(66,956
)
 
—

 
(66,956
)
Other
18,232

 
—

 
18,232

Shareholders’ equity at September 30, 2015
$
6,396,064

 
$
(10
)
 
$
6,396,054
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other (Income) Expense, Net (Tables)
 9 Months Ended
Sep. 30, 2016
Component of Operating Income [Abstract]  
Schedule of components of other (income) expense, net
The components of Other (income) expense, net for the three and nine months ended September 30, 2016 and 2015 are as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Foreign currency loss (gain), net
$
(123
)
 
$
(4,095
)
 
$
2,427

 
$
(24,651
)
Equity (earnings) loss from unconsolidated subsidiaries, net
(2,023
)
 
1,899

 
(539
)
 
3,650

Other than temporary impairment of equity investment
—

 
—

 
—

 
18,869

Legal settlement
—

 
(12,500
)
 
—

 
(12,500
)
Costs associated with unused financing commitments
—

 
64,281

 
—

 
78,352

Other miscellaneous, net
(720
)
 
506

 
(1,486
)
 
(1,131
)
Other (income) expense, net
$
(2,866
)
 
$
50,091

 
$
402

 
$
62,589
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2016
Earnings Per Share [Abstract]  
Reconciliation of the numerator and denominator of basic and diluted net loss per share
The following is a reconciliation of the numerator and denominator of basic and diluted net loss per share for the three and nine months ended September 30, 2016 and 2015 (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Numerator:
 
 
 
 
 
 
 
(Loss) income from continuing operations
$
(191,496
)
 
$
(803,706
)
 
$
109,553

 
$
(744,108
)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests
—

 
(46
)
 
16

 
(153
)
(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders
$
(191,496
)
 
$
(803,660
)
 
$
109,537

 
$
(743,955
)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax
(27,423
)
 
(246,782
)
 
(118,747
)
 
(632,624
)
Net loss attributable to Endo International plc ordinary shareholders
$
(218,919
)
 
$
(1,050,442
)
 
$
(9,210
)
 
$
(1,376,579
)
Denominator:
 
 
 
 
 
 
 
For basic per share data—weighted average shares
222,767

 
209,274

 
222,579

 
188,085

Dilutive effect of ordinary share equivalents
—

 
—

 
480

 
—

Dilutive effect of various convertible notes and warrants
—

 
—

 
1

 
—

For diluted per share data—weighted average shares
222,767

 
209,274

 
223,060

 
188,085
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Aug. 03, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Upfront cash proceeds       $ 4,108 $ 1,588,779
AMS          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration received $ 1,650,000        
Upfront cash proceeds 1,600,000        
Potential milestone payment $ 50,000        
Asset impairment charges   $ 0 $ 2,200 $ 21,328 $ 224,953
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Operating Results of Discontinued Operations) (Details) - AMS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue $ 387 $ 43,705 $ 30,101 $ 282,310
Litigation related and other contingencies, net 17,705 0 20,155 273,752
Asset impairment charges 0 2,200 21,328 224,953
Gain on sale of business 0 13,550 0 13,550
Loss from discontinued operations before income taxes (27,309) (18,775) (118,633) (506,275)
Income tax expense 0 228,007 0 126,349
Discontinued operations, net of tax $ (27,309) $ (246,782) $ (118,633) $ (632,624)
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Cash Flow Activities) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Net cash used in discontinued investing activities:        
Purchases of property, plant and equipment     $ (88,087) $ (50,944)
AMS        
Cash flows from discontinued operating activities:        
Net loss $ (27,309) $ (246,782) (118,633) (632,624)
Depreciation and amortization     0 11,555
Net cash used in discontinued investing activities:        
Purchases of property, plant and equipment     $ (138) $ (2,182)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Astora Restructuring Narrative) (Details) - Astora Restructuring
 3 Months Ended 9 Months Ended
Sep. 30, 2016
USD ($)
Mar. 31, 2016
employee
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Restructuring Cost and Reserve [Line Items]            
Number of positions reduced | employee   250        
Restructuring expenses $ 1,769,000   $ 0 $ 68,393,000 $ 0  
Expected restructuring costs remaining 2,400,000     2,400,000    
Restructuring reserve $ 16,116,000     $ 16,116,000   $ 0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Summary of Restructuring Expenses) (Details) - Astora Restructuring - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses $ 1,769,000 $ 0 $ 68,393,000 $ 0
Employee separation, retention and other benefit-related costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses 715,000   22,181,000  
Asset impairment charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses 0   21,328,000  
Contract termination charges        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses 769,000   10,569,000  
Other wind down costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring expenses $ 285,000   $ 14,315,000  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Discontinued Operations and Held For Sale (Summary of Restructuring Activities) (Details) - Astora Restructuring
$ in Thousands
 9 Months Ended
Sep. 30, 2016
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning liability balance $ 0
Expenses 40,528
Cash distributions (24,412)
Ending liability balance 16,116
Employee Separation, Retention and Other Benefit-Related Costs  
Restructuring Reserve [Roll Forward]  
Beginning liability balance 0
Expenses 22,181
Cash distributions (13,393)
Ending liability balance 8,788
Contract Termination Charges  
Restructuring Reserve [Roll Forward]  
Beginning liability balance 0
Expenses 10,569
Cash distributions (5,743)
Ending liability balance 4,826
Other Restructuring Costs  
Restructuring Reserve [Roll Forward]  
Beginning liability balance 0
Expenses 7,778
Cash distributions (5,276)
Ending liability balance $ 2,502
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring (Narrative) (Details) - USD ($)
$ in Thousands
 2 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2016
Dec. 31, 2016
Sep. 30, 2016
Mar. 31, 2016
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Sep. 25, 2015
Jan. 29, 2015
Restructuring Cost and Reserve [Line Items]                  
Proceeds from sale of property         $ 2,578 $ 0      
Impairment of intangible assets         274,754        
2015 US Generic Pharmaceuticals Restructuring                  
Restructuring Cost and Reserve [Line Items]                  
Expected positions eliminated (percent)               6.00%  
Restructuring expenses     $ 600   5,229        
Restructuring reserve     10,029   10,029   $ 17,914    
2015 US Generic Pharmaceuticals Restructuring | Selling, general and administrative expenses                  
Restructuring Cost and Reserve [Line Items]                  
Expected accelerated depreciation         4,900        
2016 US Generic Pharmaceuticals Restructuring                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring expenses         13,398        
Restructuring reserve     8,124   8,124   0    
Expected restructuring costs     30,000   30,000        
Restructuring costs incurred     13,300   159,500        
Accelerated depreciation     3,400   6,800        
Other charges     3,000   5,700        
2016 US Generic Pharmaceuticals Restructuring | Employee Separation, Retention and Other Benefit-Related Costs                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring expenses     7,000   13,400        
2016 US Generic Pharmaceuticals Restructuring | Asset Impairment Charges                  
Restructuring Cost and Reserve [Line Items]                  
Impairment of intangible assets       $ 100,300 100,300        
2016 US Generic Pharmaceuticals Restructuring | Excess Inventory Reserve Write-Offs                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring expenses         33,300        
Auxilium Restructuring                  
Restructuring Cost and Reserve [Line Items]                  
Expected positions eliminated (percent)                 40.00%
Restructuring reserve     5,946   5,946   12,263    
Auxilium Restructuring | Employee Separation, Retention and Other Benefit-Related Costs                  
Restructuring Cost and Reserve [Line Items]                  
Restructuring reserve     $ 179   $ 179   $ 5,353    
Scenario, Forecast | 2016 US Generic Pharmaceuticals Restructuring | Charlotte, North Carolina Facility                  
Restructuring Cost and Reserve [Line Items]                  
Asset impairment charges   $ 10,000              
Scenario, Forecast | 2016 US Generic Pharmaceuticals Restructuring | Charlotte, North Carolina Facility | Subsequent Event                  
Restructuring Cost and Reserve [Line Items]                  
Proceeds from sale of property $ 14,000                
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring (Changes to Restructuring Accrual) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
2015 US Generic Pharmaceuticals Restructuring    
Restructuring Reserve [Roll Forward]    
Beginning liability balance   $ 17,914
Expenses $ 600 5,229
Cash payments/distributions   (13,114)
Ending liability balance 10,029 10,029
2016 US Generic Pharmaceuticals Restructuring    
Restructuring Reserve [Roll Forward]    
Beginning liability balance   0
Expenses   13,398
Cash payments/distributions   (5,274)
Ending liability balance 8,124 8,124
2016 US Generic Pharmaceuticals Restructuring | Employee Separation, Retention and Other Benefit-Related Costs    
Restructuring Reserve [Roll Forward]    
Expenses 7,000 13,400
2016 US Generic Pharmaceuticals Restructuring | Other Restructuring Costs    
Restructuring Reserve [Roll Forward]    
Expenses 3,900 16,100
Auxilium Restructuring    
Restructuring Reserve [Roll Forward]    
Beginning liability balance   12,263
Cash payments/distributions   (6,317)
Ending liability balance 5,946 5,946
Auxilium Restructuring | Employee Separation, Retention and Other Benefit-Related Costs    
Restructuring Reserve [Roll Forward]    
Beginning liability balance   5,353
Cash payments/distributions   (5,174)
Ending liability balance 179 179
Auxilium Restructuring | Other Restructuring Costs    
Restructuring Reserve [Roll Forward]    
Beginning liability balance   6,910
Cash payments/distributions   (1,143)
Ending liability balance $ 5,767 $ 5,767
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Auxilium Pharmaceuticals, Inc.) (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 29, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition [Line Items]          
Acquisition-related and integration items   $ 19,476,000 $ (27,688,000) $ 80,201,000 $ 51,177,000
Amortization of intangible assets       636,061,000  
Auxilium Pharmaceuticals, Inc.          
Business Acquisition [Line Items]          
Aggregate consideration transferred $ 2,600,000,000        
Interest expense         1,100,000
Amortization of intangible assets         6,200,000
Auxilium Pharmaceuticals, Inc. | Acquisition-Related And Integration Items          
Business Acquisition [Line Items]          
Acquisition-related and integration items       $ 0 $ 23,100,000
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 5 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]            
Revenue   $ 884,335 $ 745,727   $ 2,768,761 $ 2,195,021
Net loss attributable to Endo International plc   $ (218,919) $ (1,050,442)   $ (9,210) $ (1,376,579)
Auxilium Pharmaceuticals, Inc.            
Business Acquisition, Equity Interests Issued or Issuable [Line Items]            
Revenue       $ 237,807    
Net loss attributable to Endo International plc       $ (257,597)    
Basic and diluted net loss per share (in dollars per share)       $ (1.37)    
Par Pharmaceutical Holdings, Inc.            
Business Acquisition, Equity Interests Issued or Issuable [Line Items]            
Revenue $ 23,413          
Net loss attributable to Endo International plc $ (17,441)          
Basic and diluted net loss per share (in dollars per share) $ (0.09)          
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2015
Auxilium Pharmaceuticals, Inc.    
Business Acquisition, Equity Interests Issued or Issuable [Line Items]    
Revenue   $ 2,218,596
Net loss attributable to Endo International plc   $ (1,395,162)
Basic net income (loss) income per share (in dollars per share)   $ (7.42)
Diluted net income (loss) income per share (in dollars per share)   $ (7.42)
Par Pharmaceutical Holdings, Inc.    
Business Acquisition, Equity Interests Issued or Issuable [Line Items]    
Revenue $ 1,053,654 $ 3,194,413
Net loss attributable to Endo International plc $ (1,084,031) $ (1,475,667)
Basic net income (loss) income per share (in dollars per share) $ (5.18) $ (7.85)
Diluted net income (loss) income per share (in dollars per share) $ (5.18) $ (7.85)
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Sep. 25, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]      
Goodwill $ 7,411,620 $ 7,299,354  
Par Pharmaceutical Holdings, Inc.      
Business Acquisition, Equity Interests Issued or Issuable [Line Items]      
Cash and cash equivalents     $ 215,612
Accounts and other receivables     516,909
Inventories     328,557
Prepaid expenses and other current assets     31,124
Deferred income tax assets, current     44,828
Property, plant and equipment     261,037
Intangible assets     3,472,500
Other assets     8,477
Total identifiable assets     4,879,044
Accounts payable and accrued expenses     551,103
Deferred income tax liabilities     1,048,818
Other liabilities     18,613
Total liabilities assumed     1,618,534
Net identifiable assets acquired     3,260,510
Goodwill     4,875,144
Net assets acquired     8,135,654
Par Pharmaceutical Holdings, Inc. | Initially Reported      
Business Acquisition, Equity Interests Issued or Issuable [Line Items]      
Cash and cash equivalents     215,612
Accounts and other receivables     530,664
Inventories     330,406
Prepaid expenses and other current assets     31,124
Deferred income tax assets, current     14,652
Property, plant and equipment     256,293
Intangible assets     3,627,000
Other assets     8,477
Total identifiable assets     5,014,228
Accounts payable and accrued expenses     551,614
Deferred income tax liabilities     1,093,779
Other liabilities     16,057
Total liabilities assumed     1,661,450
Net identifiable assets acquired     3,352,778
Goodwill     4,782,876
Net assets acquired     $ 8,135,654
Par Pharmaceutical Holdings, Inc. | Adjustment      
Business Acquisition, Equity Interests Issued or Issuable [Line Items]      
Cash and cash equivalents 0    
Accounts and other receivables (13,755)    
Inventories (1,849)    
Prepaid expenses and other current assets 0    
Deferred income tax assets, current 30,176    
Property, plant and equipment 4,744    
Intangible assets (154,500)    
Other assets 0    
Total identifiable assets (135,184)    
Accounts payable and accrued expenses (511)    
Deferred income tax liabilities (44,961)    
Other liabilities 2,556    
Total liabilities assumed (42,916)    
Net identifiable assets acquired (92,268)    
Goodwill 92,268    
Net assets acquired $ 0    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) - Par Pharmaceutical Holdings, Inc.
$ in Millions
Sep. 25, 2015
USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 3,472.5
In-process research and development  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 1,456.7
In-process research and development | IPR&D 2019 Launch  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 401.0
In-process research and development | IPR&D 2018 Launch  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 283.8
In-process research and development | Ezetimibe  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 147.6
In-process research and development | IPR&D 2016 Launch  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 133.3
In-process research and development | Ephedrine Sulphate  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 128.6
In-process research and development | Neostigmine vial  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 118.6
In-process research and development | Other IPR&D  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 243.8
Developed Technology  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation 2,015.8
Developed Technology | Vasostrict®  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 556.0
Amortization period 8 years
Developed Technology | Aplisol®  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 312.4
Amortization period 11 years
Developed Technology | Developed - Other - Non-Partnered (Generic Non-Injectable)  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 230.4
Amortization period 7 years
Developed Technology | Developed - Other - Partnered (Combined)  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 164.4
Amortization period 7 years
Developed Technology | Nascobal®  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 118.3
Amortization period 9 years
Developed Technology | Developed - Other - Non-Partnered (Generic Injectable)  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 116.4
Amortization period 10 years
Developed Technology | Other Developed Technology  
Acquired Finite-Lived Intangible Assets [Line Items]  
Valuation $ 517.9
Amortization period 9 years
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Par Pharmaceutical Holdings, Inc.) (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 25, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Business Acquisition [Line Items]          
Amortization of intangible assets       $ (636,061,000)  
Minimum          
Business Acquisition [Line Items]          
Discount rate range (percent)       3.00%  
Maximum          
Business Acquisition [Line Items]          
Discount rate range (percent)       22.00%  
Par Pharmaceutical Holdings, Inc.          
Business Acquisition [Line Items]          
Aggregate consideration transferred $ 8,140,000,000        
Ordinary shares issued, shares 18,069,899        
Equity consideration $ 1,330,000,000        
Reduction of expenses   $ 0   $ 3,800,000  
Amortization of intangible assets     $ (44,800,000) 3,100,000 $ (129,200,000)
Amortization of inventory step-up       $ 700,000  
Goodwill expected to be deductible for income tax purposes $ 34,200,000        
Interest expense     $ 4,900,000   $ 11,700,000
Par Pharmaceutical Holdings, Inc. | Minimum          
Business Acquisition [Line Items]          
Discount rate range (percent) 9.00%        
Par Pharmaceutical Holdings, Inc. | Maximum          
Business Acquisition [Line Items]          
Discount rate range (percent) 10.50%        
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Aspen Holdings) (Narrative) (Details)
$ in Thousands
Oct. 01, 2015
USD ($)
country
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Business Acquisition [Line Items]      
Goodwill   $ 7,411,620 $ 7,299,354
Aspen Holdings      
Business Acquisition [Line Items]      
Number of countries the company operates in (more than 150) | country 150    
Payments to acquire business $ 135,600    
Net identifiable assets acquired 127,800    
Goodwill 7,800    
Intangible assets $ 118,400    
Estimated useful life 19 years    
Inventories $ 9,400    
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Voltaren Gel) (Narrative) (Details) - USD ($)
Jul. 01, 2016
Sep. 30, 2016
Dec. 31, 2015
Business Acquisition [Line Items]      
Goodwill   $ 7,411,620,000 $ 7,299,354,000
Voltaren Gel      
Business Acquisition [Line Items]      
Aggregate consideration transferred $ 158,600,000    
Payments to acquire business 16,200,000    
Contingent consideration 142,400,000    
Net identifiable assets acquired 158,600,000    
Goodwill 0    
Finite-lived intangible assets acquired $ 158,600,000    
Estimated useful life 7 years    
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.5.0.2
Acquisitions (Other Acquisition) (Narrative) (Details) - Other Acquisition
$ in Millions
 9 Months Ended
Sep. 30, 2016
USD ($)
Business Acquisition [Line Items]  
Aggregate consideration transferred $ 19.7
Payments to acquire business 14.2
Deferred consideration for acquired inventory 1.0
Contingent consideration 4.5
Net identifiable assets acquired $ 18.2
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Results (Schedule Of Reportable Segments Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Segment Reporting Information [Line Items]        
Total net revenues to external customers $ 884,335 $ 745,727 $ 2,768,761 $ 2,195,021
Corporate unallocated | Adjustment        
Segment Reporting Information [Line Items]        
Costs and expenses   7,500   21,000
U.S. Branded Pharmaceuticals        
Segment Reporting Information [Line Items]        
Total net revenues to external customers 279,843 304,778 876,998 905,198
Adjusted income (loss) from continuing operations before income tax 131,615 156,897 422,816 484,758
U.S. Branded Pharmaceuticals | Adjustment        
Segment Reporting Information [Line Items]        
Costs and expenses   600   1,700
U.S. Generic Pharmaceuticals        
Segment Reporting Information [Line Items]        
Total net revenues to external customers 533,691 367,933 1,682,439 1,063,221
Adjusted income (loss) from continuing operations before income tax 228,717 177,961 655,453 507,507
International Pharmaceuticals        
Segment Reporting Information [Line Items]        
Total net revenues to external customers 70,801 73,016 209,324 226,602
Adjusted income (loss) from continuing operations before income tax $ 22,077 18,961 $ 64,446 54,729
International Pharmaceuticals | Adjustment        
Segment Reporting Information [Line Items]        
Costs and expenses   $ (8,100)   $ (22,700)
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Segment Reporting Information [Line Items]        
Total consolidated loss from continuing operations before income tax $ (145,311) $ (964,645) $ (518,254) $ (1,084,636)
Amortization of intangible assets     636,061  
Acceleration of Auxilium employee equity awards at closing       37,600
Asset impairment charges 93,504 923,607 263,080 1,000,850
Acquisition-related and integration items 19,476 (27,688) 80,201 51,177
Loss on extinguishment of debt 0 40,909 0 41,889
Costs associated with unused financing commitments 0 64,281 0 78,352
Other than temporary impairment of equity investment 0 0 0 18,869
Severance costs 14,800 20,800 30,000 58,100
Remaining lease obligations net of sublease income       7,900
Transaction costs 7,900 52,600 55,400 134,800
Change in fair value of contingent consideration 11,600 (80,300) 24,790 (83,605)
2016 US Generic Pharmaceuticals Restructuring        
Segment Reporting Information [Line Items]        
Restructuring expenses     13,398  
2016 US Generic Pharmaceuticals Restructuring | Inventory Write-Offs        
Segment Reporting Information [Line Items]        
Restructuring expenses     33,300  
2016 US Generic Pharmaceuticals Restructuring | Other Restructuring Costs        
Segment Reporting Information [Line Items]        
Restructuring expenses 3,900   16,100  
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Corporate unallocated costs 159,123 137,180 473,933 363,298
Amortization of intangible assets 211,548 121,503 636,061 333,759
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans 14,208 42,919 111,787 131,783
Upfront and milestone payments to partners 1,770 9,261 5,875 14,063
Separation benefits and other cost reduction initiatives 9,782 22,669 70,412 70,256
Impact of Voltaren® Gel generic competition 0 0 (7,750) 0
Acceleration of Auxilium employee equity awards at closing 0 0 0 37,603
Certain litigation-related charges, net 18,256 0 28,715 19,875
Asset impairment charges 93,504 923,607 263,080 1,000,850
Acquisition-related and integration items 19,476 (27,688) 80,201 51,177
Loss on extinguishment of debt 0 40,909 0 41,889
Costs associated with unused financing commitments 0 64,281 0 78,352
Other than temporary impairment of equity investment 0 0 0 18,869
Foreign currency impact related to the remeasurement of intercompany debt instruments (114) (5,693) 1,558 (23,991)
Other, net 167 (10,484) (2,903) (6,153)
Segment Reconciling Items | 2016 US Generic Pharmaceuticals Restructuring | Inventory Write-Offs        
Segment Reporting Information [Line Items]        
Restructuring expenses (9,000)   24,300  
Operating Segments        
Segment Reporting Information [Line Items]        
Total consolidated loss from continuing operations before income tax $ 382,409 $ 353,819 $ 1,142,715 $ 1,046,994
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Narrative) (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
USD ($)
$ / derivatives
Dec. 31, 2015
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Net asset value required to be maintained by money market funds (in dollars per unit) | $ / derivatives 1.00  
Minimum    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Discount rate range (percent) 3.00%  
Maximum    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Discount rate range (percent) 22.00%  
Restricted cash and cash equivalents    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Available-for-sale securities, amortized cost $ 40,488 $ 51,142
Paladin Labs Inc.    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Joint venture investments $ 9,100  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Financial Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Assets:    
Fair value of financial assets measured on recurring basis $ 167,952 $ 55,034
Liabilities:    
Fair value of financial liabilities measured on recurring basis 285,797 143,502
Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 108,778 65,265
Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 177,019 78,237
Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 65,500 51,145
Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis 100,091  
Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 2,361 3,889
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Assets:    
Fair value of financial assets measured on recurring basis 67,861 55,034
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 65,500 51,145
Quoted Prices in Active Markets for Identical Assets (Level 1) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis 0  
Quoted Prices in Active Markets for Identical Assets (Level 1) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 2,361 3,889
Significant Other Observable Inputs (Level 2)    
Assets:    
Fair value of financial assets measured on recurring basis 100,091 0
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Other Observable Inputs (Level 2) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis 100,091  
Significant Other Observable Inputs (Level 2) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Unobservable Inputs (Level 3)    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Liabilities:    
Fair value of financial liabilities measured on recurring basis 285,797 143,502
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—short-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 108,778 65,265
Significant Unobservable Inputs (Level 3) | Acquisition-related contingent consideration—long-term    
Liabilities:    
Fair value of financial liabilities measured on recurring basis 177,019 78,237
Significant Unobservable Inputs (Level 3) | Money market funds    
Assets:    
Fair value of financial assets measured on recurring basis 0 0
Significant Unobservable Inputs (Level 3) | Time deposits    
Assets:    
Fair value of financial assets measured on recurring basis 0  
Significant Unobservable Inputs (Level 3) | Equity securities    
Assets:    
Fair value of financial assets measured on recurring basis $ 0 $ 0
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) - Acquisition-related contingent consideration - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period $ 135,796 $ 189,082 $ 143,502 $ 46,005
Amounts acquired 146,866 47,900 146,866 214,435
Amounts settled (8,121) (13,094) (30,242) (21,668)
Transfers (in) and/or out of Level 3 0 0 0 0
Measurement period adjustments 0 (78) 0 (11,634)
Changes in fair value recorded in earnings 11,585 (80,277) 24,790 (83,605)
Effect of currency translation (329) (1,210) 881 (1,210)
Fair Value Adjustments and Accretion     24,790  
Payments and Other     (29,361)  
End of period 285,797 $ 142,323 285,797 $ 142,323
Qualitest acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     1,137  
Amounts acquired     0  
Fair Value Adjustments and Accretion     (1,137)  
Payments and Other     0  
End of period 0   0  
Sumavel acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     631  
Amounts acquired     0  
Fair Value Adjustments and Accretion     (631)  
Payments and Other     0  
End of period 0   0  
Auxilium acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     26,435  
Amounts acquired     0  
Fair Value Adjustments and Accretion     2,203  
Payments and Other     (9,787)  
End of period 18,851   18,851  
Lehigh Valley Technologies, Inc. acquisitions        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     97,003  
Amounts acquired     0  
Fair Value Adjustments and Accretion     24,686  
Payments and Other     (19,389)  
End of period 102,300   102,300  
Voltaren Gel® acquisition        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     0  
Amounts acquired     142,355  
Fair Value Adjustments and Accretion     (2,905)  
Payments and Other     0  
End of period 139,450   139,450  
Other        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning of period     18,296  
Amounts acquired     4,511  
Fair Value Adjustments and Accretion     2,574  
Payments and Other     (185)  
End of period $ 25,196   $ 25,196  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Summary Of Available-For-Sale Securities) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Cash and cash equivalents    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 25,012 $ 3
Gross Unrealized Gains 0 0
Gross Unrealized (Losses) 0 0
Fair Value 25,012 3
Restricted cash and cash equivalents    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 40,488 51,142
Gross Unrealized Gains 0 0
Gross Unrealized (Losses) 0 0
Fair Value 40,488 51,142
Short-term available for sale securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0 24
Gross Unrealized Gains 0 10
Gross Unrealized (Losses) 0 0
Fair Value 0 34
Long-term available-for-sale securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 1,766 1,766
Gross Unrealized Gains 595 2,089
Gross Unrealized (Losses) 0 0
Fair Value 2,361 3,855
Money market funds    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 65,500 51,145
Gross Unrealized Gains 0 0
Gross Unrealized (Losses) 0 0
Fair Value 65,500 51,145
Equity securities | Short-term available for sale securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 0 24
Gross Unrealized Gains 0 10
Gross Unrealized (Losses) 0 0
Fair Value 0 34
Equity securities | Long-term available-for-sale securities    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 1,766 1,766
Gross Unrealized Gains 595 2,089
Gross Unrealized (Losses) 0 0
Fair Value $ 2,361 $ 3,855
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Asset impairment charges $ (93,504) $ (923,607) $ (263,080) $ (1,000,850)
Fair value, measurements, nonrecurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total income (expense) from assets     (284,409)  
Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Asset impairment charges     (4,448)  
Total income (expense) from intangible assets     (169,576)  
Fair value, measurements, nonrecurring | U.S. Branded Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total income (expense) from intangible assets     (72,814)  
Fair value, measurements, nonrecurring | International Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total income (expense) from intangible assets     (16,243)  
Fair value, measurements, nonrecurring | Astora        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Asset impairment charges     (5,041)  
Total income (expense) from intangible assets     (16,287)  
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total 0   0  
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Generic Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 0   0  
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Branded Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | International Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Astora        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 0   0  
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total 0   0  
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | U.S. Generic Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 0   0  
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | U.S. Branded Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | International Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | Astora        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 0   0  
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3)        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Total 51,939   51,939  
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | U.S. Generic Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 649   649  
Certain segment intangible assets 45,966   45,966  
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | U.S. Branded Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 0   0  
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | International Pharmaceuticals        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Certain segment intangible assets 5,324   5,324  
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | Astora        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Property, plant and equipment 0   0  
Certain segment intangible assets $ 0   $ 0  
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventories (Schedule Of Inventories) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials $ 195,830 $ 210,038
Work-in-process 111,437 177,821
Finished goods 317,035 364,634
Total 624,302 752,493
Long-term inventory 32,600 24,900
Inventories not yet available for sale $ 25,300 $ 12,000
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
USD ($)
Goodwill [Roll Forward]  
Goodwill, gross, beginning balance $ 8,058,634
Accumulated impairment losses, beginning balance (759,280)
Goodwill, beginning balance 7,299,354
Measurement period adjustments 93,634
Effect of currency translation on gross balance 19,732
Effect of currency translation on accumulated impairment (1,100)
Goodwill, gross, ending balance 8,172,000
Accumulated impairment losses, ending balance (760,380)
Goodwill, ending balance 7,411,620
U.S. Branded Pharmaceuticals  
Goodwill [Roll Forward]  
Goodwill, gross, beginning balance 1,676,276
Accumulated impairment losses, beginning balance (673,500)
Goodwill, beginning balance 1,002,776
Measurement period adjustments 16,518
Effect of currency translation on gross balance 0
Effect of currency translation on accumulated impairment 0
Goodwill, gross, ending balance 1,692,794
Accumulated impairment losses, ending balance (673,500)
Goodwill, ending balance 1,019,294
U.S. Generic Pharmaceuticals  
Goodwill [Roll Forward]  
Goodwill, gross, beginning balance 5,789,934
Accumulated impairment losses, beginning balance 0
Goodwill, beginning balance 5,789,934
Measurement period adjustments 75,750
Effect of currency translation on gross balance 0
Effect of currency translation on accumulated impairment 0
Goodwill, gross, ending balance 5,865,684
Accumulated impairment losses, ending balance 0
Goodwill, ending balance 5,865,684
International Pharmaceuticals  
Goodwill [Roll Forward]  
Goodwill, gross, beginning balance 592,424
Accumulated impairment losses, beginning balance (85,780)
Goodwill, beginning balance 506,644
Measurement period adjustments 1,366
Effect of currency translation on gross balance 19,732
Effect of currency translation on accumulated impairment (1,100)
Goodwill, gross, ending balance 613,522
Accumulated impairment losses, ending balance (86,880)
Goodwill, ending balance $ 526,642
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Schedule Of Other Intangible Assets) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
Dec. 31, 2015
Indefinite-lived intangibles:      
Balance   $ 1,742,880  
Acquisitions   34,691  
Intangible asset impairment   (55,100)  
Other   (138,456)  
Effect of Currency Translation   2,594  
Balance $ 1,437,718 1,437,718  
Definite-lived intangibles:      
Balance   7,427,295  
Acquisitions   34,691  
Impairments   (219,654)  
Other   (95,387)  
Effect of Currency Translation   24,136  
Balance 7,285,281 7,285,281  
Total other intangibles      
Beginning balance   9,170,175  
Impairment of intangible assets   (274,754)  
Other   (233,843)  
Effect of Currency Translation   26,730  
Ending balance 8,722,999 8,722,999  
Accumulated amortization:      
Balance   (1,341,233)  
Amortization   (636,061)  
Impairments   0  
Other   232,206  
Effect of Currency Translation   (2,333)  
Balance (1,747,421) (1,747,421)  
Net other intangibles 6,975,578 6,975,578 $ 7,828,942
Astora      
Definite-lived intangibles:      
Impairments   (10,000)  
Total other intangibles      
Impairment of intangible assets   (16,300)  
U.S. Generic Pharmaceuticals      
Total other intangibles      
Impairment of intangible assets   (169,600)  
U.S. Branded Pharmaceuticals      
Definite-lived intangibles:      
Impairments   $ (221,900)  
Total other intangibles      
Impairment of intangible assets (72,800)    
International Pharmaceuticals      
Total other intangibles      
Impairment of intangible assets (16,200)    
Weighted Average      
Accumulated amortization:      
Intangible life (years)   12 years  
Indefinite-lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   $ (114,200)  
Definite-lived intangibles:      
Acquisitions   (114,200)  
Definite-Lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   148,891  
Definite-lived intangibles:      
Acquisitions   148,891  
Licenses      
Definite-lived intangibles:      
Balance   676,867  
Impairments   0  
Other   (211,147)  
Effect of Currency Translation   0  
Balance 465,720 465,720  
Accumulated amortization:      
Balance   (508,225)  
Amortization   (37,142)  
Impairments   0  
Other   211,147  
Effect of Currency Translation   0  
Balance (334,220) $ (334,220)  
Licenses | Weighted Average      
Accumulated amortization:      
Intangible life (years)   12 years  
Licenses | Definite-Lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   $ 0  
Definite-lived intangibles:      
Acquisitions   0  
Customer Relationships      
Definite-lived intangibles:      
Balance   11,318  
Impairments   (3,460)  
Other   (7,858)  
Effect of Currency Translation   0  
Balance 0 0  
Accumulated amortization:      
Balance   (7,858)  
Amortization   0  
Impairments   0  
Other   7,858  
Effect of Currency Translation   0  
Balance 0 $ 0  
Customer Relationships | Weighted Average      
Accumulated amortization:      
Intangible life (years)   15 years  
Customer Relationships | Definite-Lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   $ 0  
Definite-lived intangibles:      
Acquisitions   0  
Tradenames      
Definite-lived intangibles:      
Balance   7,537  
Impairments   0  
Other   0  
Effect of Currency Translation   (127)  
Balance 7,410 7,410  
Accumulated amortization:      
Balance   (6,544)  
Amortization   (66)  
Impairments   0  
Other   0  
Effect of Currency Translation   19  
Balance (6,591) $ (6,591)  
Tradenames | Weighted Average      
Accumulated amortization:      
Intangible life (years)   12 years  
Tradenames | Definite-Lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   $ 0  
Definite-lived intangibles:      
Acquisitions   0  
Developed technology      
Definite-lived intangibles:      
Balance   6,731,573  
Impairments   (216,194)  
Other   123,618  
Effect of Currency Translation   24,263  
Balance 6,812,151 6,812,151  
Accumulated amortization:      
Balance   (818,606)  
Amortization   (598,853)  
Impairments   0  
Other   13,201  
Effect of Currency Translation   (2,352)  
Balance (1,406,610) $ (1,406,610)  
Developed technology | Weighted Average      
Accumulated amortization:      
Intangible life (years)   12 years  
Developed technology | Definite-Lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   $ 148,891  
Definite-lived intangibles:      
Acquisitions   148,891  
In-process research and development      
Indefinite-lived intangibles:      
Balance   1,742,880  
Intangible asset impairment   (55,100)  
Other   (138,456)  
Effect of Currency Translation   2,594  
Balance $ 1,437,718 1,437,718  
In-process research and development | Indefinite-lived Intangibles      
Indefinite-lived intangibles:      
Acquisitions   (114,200)  
Definite-lived intangibles:      
Acquisitions   $ (114,200)  
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]            
Amortization $ 211,500     $ 121,500 $ 636,100 $ 333,800
Goodwill [Line Items]            
Impairment of intangible assets         274,754  
2016 US Generic Pharmaceuticals Restructuring | Asset Impairment Charges            
Goodwill [Line Items]            
Impairment of intangible assets     $ 100,300   100,300  
U.S. Generic Pharmaceuticals            
Goodwill [Line Items]            
Impairment of intangible assets         $ 169,600  
U.S. Generic Pharmaceuticals | Intangible Assets            
Goodwill [Line Items]            
Impairment of intangible assets   $ 40,000 $ 29,300      
U.S. Branded Pharmaceuticals            
Goodwill [Line Items]            
Impairment of intangible assets 72,800          
International Pharmaceuticals            
Goodwill [Line Items]            
Impairment of intangible assets $ 16,200          
Minimum            
Goodwill [Line Items]            
Discount rate range (percent)         3.00%  
Maximum            
Goodwill [Line Items]            
Discount rate range (percent)         22.00%  
Goodwill and Indefinite-lived Intangible Assets | Significant Unobservable Inputs (Level 3) | Minimum            
Goodwill [Line Items]            
Discount rate range (percent)         8.50%  
Goodwill and Indefinite-lived Intangible Assets | Significant Unobservable Inputs (Level 3) | Maximum            
Goodwill [Line Items]            
Discount rate range (percent)         9.00%  
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Schedule Of Estimated Amortization Of Intangibles) (Details)
$ in Thousands
Sep. 30, 2016
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2016 $ 824,062
2017 725,659
2018 637,623
2019 575,060
2020 $ 546,598
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.5.0.2
Goodwill And Other Intangibles (Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
Definite-lived intangibles:    
Beginning balance   $ 9,170,175
Impairment of intangible assets   (274,754)
Measurement period adjustments relating to acquisitions closed during 2015   34,691
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements   (219,654)
Ending balance $ 8,722,999 8,722,999
International Pharmaceuticals    
Definite-lived intangibles:    
Impairment of intangible assets (16,200)  
U.S. Branded Pharmaceuticals    
Definite-lived intangibles:    
Impairment of intangible assets (72,800)  
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements   (221,900)
U.S. Generic Pharmaceuticals    
Definite-lived intangibles:    
Impairment of intangible assets   (169,600)
Other Intangible Assets    
Definite-lived intangibles:    
Beginning balance   9,170,175
Measurement period adjustments relating to acquisitions closed during 2015   (154,500)
Effect of currency translation   26,730
Ending balance $ 8,722,999 8,722,999
Other Intangible Assets | International Pharmaceuticals    
Definite-lived intangibles:    
Sale of certain International Pharmaceuticals intangible assets   (1,959)
Impairment of intangible assets   (16,077)
Other Intangible Assets | U.S. Branded Pharmaceuticals    
Definite-lived intangibles:    
Impairment of intangible assets   (72,814)
Removal of fully amortized intangible assets relating to expired or terminated licensing agreements   (221,853)
Other Intangible Assets | U.S. Generic Pharmaceuticals    
Definite-lived intangibles:    
Impairment of intangible assets   (169,576)
Other Intangible Assets | Voltaren Gel    
Definite-lived intangibles:    
Acquisition of intangible assets   159,000
Other Intangible Assets | Other Acquisition    
Definite-lived intangibles:    
Acquisition of intangible assets   18,183
Other Intangible Assets | XIAFLEX®    
Definite-lived intangibles:    
Capitalization of payments relating to XIAFLEX®   12,008
Other Intangible Assets | Astora    
Definite-lived intangibles:    
Impairment of intangible assets   $ (26,318)
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.5.0.2
License And Collaboration Agreements (Novartis AG, Novartis Consumer Health Inc. and Sandoz) (Narrative) (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Voltaren Gel Agreement 2015    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
License agreement term extension period 1 year  
Termination of agreement notice period 6 months  
Voltaren Gel Agreement    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Payments for royalties $ 13.9 $ 22.5
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.5.0.2
License And Collaboration Agreements (XIAFLEX Out-License Agreements) (Details)
$ in Millions
 1 Months Ended
Jul. 31, 2016
USD ($)
XIAFLEX®  
License And Collaboration Agreements [Line Items]  
Payments to acquire license rights $ 5.5
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Components Of Total Indebtedness) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Debt Instrument [Line Items]    
Unamortized Discount and Deferred Loan Costs $ (131,687) $ (147,272)
Total long-term debt, net 8,426,555 8,727,634
Less current portion, net 124,250 328,705
Total long-term debt, less current portion, net 8,302,305 8,398,929
Fair value of long term debt 8,000,000 8,600,000
Revolving Credit Facility    
Debt Instrument [Line Items]    
Unamortized Discount and Deferred Loan Costs 0 0
Revolving Credit Facility 0 225,000
7.25% Senior Notes due 2022    
Debt Instrument [Line Items]    
Principal Amount 400,000 400,000
Unamortized Discount and Deferred Loan Costs $ (11,284) (12,535)
Interest rate (as a percent) 7.25%  
5.75% Senior Notes due 2022    
Debt Instrument [Line Items]    
Principal Amount $ 700,000 700,000
Unamortized Discount and Deferred Loan Costs $ (9,026) (10,088)
Interest rate (as a percent) 5.75%  
5.375% Senior Notes due 2023    
Debt Instrument [Line Items]    
Principal Amount $ 750,000 750,000
Unamortized Discount and Deferred Loan Costs $ (9,585) (10,511)
Interest rate (as a percent) 5.375%  
6.00% Senior Notes due 2023    
Debt Instrument [Line Items]    
Principal Amount $ 1,635,000 1,635,000
Unamortized Discount and Deferred Loan Costs $ (25,481) (27,694)
Interest rate (as a percent) 6.00%  
6.00% Senior Notes due 2025    
Debt Instrument [Line Items]    
Principal Amount $ 1,200,000 1,200,000
Unamortized Discount and Deferred Loan Costs $ (21,287) (22,713)
Interest rate (as a percent) 6.00%  
Term Loan A Facility Due 2019    
Debt Instrument [Line Items]    
Principal Amount $ 962,500 1,017,500
Unamortized Discount and Deferred Loan Costs (10,221) (13,831)
Term Loan B Facility Due 2022    
Debt Instrument [Line Items]    
Principal Amount 2,779,000 2,800,000
Unamortized Discount and Deferred Loan Costs (44,803) (49,900)
Other debt    
Debt Instrument [Line Items]    
Unamortized Discount and Deferred Loan Costs 0 0
Other debt $ 55 $ 134
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Credit Facility) (Narrative) (Details) - USD ($)
$ in Thousands
 9 Months Ended
Apr. 04, 2016
Sep. 30, 2016
Sep. 30, 2015
Line of Credit Facility [Line Items]      
Repayments of revolving debt   $ 225,000 $ 300,000
Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Repayments of revolving debt $ 225,000    
Credit facility, remaining borrowing capacity   $ 997,400  
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments And Contingencies (Manufacturing, Supply and Other Service Agreements) (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Noramco, Inc.      
Long-term Purchase Commitment [Line Items]      
Payments for royalties   $ 27.3 $ 31.2
Jubilant HollisterStier Laboratories LLC      
Long-term Purchase Commitment [Line Items]      
Agreement term 3 years    
Agreement renewal term 1 year    
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments And Contingencies (Legal Proceedings and Investigations) (Narrative) (Details)
$ in Thousands
 1 Months Ended 9 Months Ended 12 Months Ended 13 Months Ended
Oct. 31, 2016
case
Sep. 30, 2016
USD ($)
Feb. 29, 2016
USD ($)
Oct. 31, 2015
motion
Aug. 31, 2015
Sep. 30, 2013
company
Feb. 28, 2013
Sep. 30, 2016
USD ($)
study_order
case
Dec. 31, 2012
patent
Oct. 30, 2013
Nov. 01, 2016
case
Dec. 31, 2015
USD ($)
Loss Contingencies [Line Items]                        
Reserve for loss contingencies   $ 1,280,000           $ 1,280,000        
Current portion of legal settlement accrual   1,280,785           1,280,785       $ 1,606,726
Vaginal mesh cases | AMS                        
Loss Contingencies [Line Items]                        
Product liability accrual, period expense   1,200,000           $ 1,200,000        
Number of class-wide post-market study orders received | study_order               19        
Number of class-wide post-market study orders placed on hold by the FDA | study_order               16        
Number of active class-wide post-market study orders | study_order               3        
Loss contingency, claims settled, number | case               49,000        
Settlement amount               $ 2,800,000        
Lawsuits filed | case               8,000        
Testosterone cases | Subsequent Event                        
Loss Contingencies [Line Items]                        
Pending claims, number | case                     1,140  
Vaginal mesh cases                        
Loss Contingencies [Line Items]                        
Current portion of legal settlement accrual   1,200,000           $ 1,200,000        
Unapproved Drug Litigation                        
Loss Contingencies [Line Items]                        
Number of additional pharmaceutical companies named in petitions (over 50) | company           50            
Megace ES Cases                        
Loss Contingencies [Line Items]                        
Damages sought per violation     $ 16,000                  
Megace ES Cases | PPI                        
Loss Contingencies [Line Items]                        
Damages awarded   $ 12,700                    
Opana                        
Gain Contingencies [Line Items]                        
Lawsuit filing period                   45 days    
Stay of approval period, Hatch-Waxman Act                   30 months    
Opana | Subsequent Event                        
Loss Contingencies [Line Items]                        
Lawsuits filed | case 2                      
Opana | Judicial Ruling                        
Gain Contingencies [Line Items]                        
Number of patents found infringed upon | patent                 2      
Period for generic product to be withdrawn       60 days 60 days              
Number of post-trial motions | motion       2                
Paragraph IV Certification on Fortesta Gel [Member]                        
Gain Contingencies [Line Items]                        
Lawsuit filing period             45 days          
Stay of approval period, Hatch-Waxman Act             30 months          
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments And Contingencies (Details) - USD ($)
$ in Thousands
 6 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Qualified Settlement Funds      
Cash contributions to Qualified Settlement Funds   $ 587,782 $ 526,785
Product Liability      
Balance as of September 30, 2016   1,280,000  
Vaginal mesh cases      
Qualified Settlement Funds      
Balance as of December 31, 2015 $ 578,970 578,970  
Cash contributions to Qualified Settlement Funds   587,782  
Cash distributions to settle disputes from Qualified Settlement Funds (898,288)    
Other   456  
Balance as of September 30, 2016   268,920  
Vaginal mesh cases | Product Liability      
Product Liability      
Balance as of December 31, 2015 $ 2,086,176 2,086,176  
Additional charges   19,505  
Cash distributions to settle disputes from Qualified Settlement Funds   (898,288)  
Cash distributions to settle disputes   (5,561)  
Balance as of September 30, 2016   $ 1,201,832  
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before- Tax Amount $ (7,778) $ (61,237) $ 37,308 $ (179,451)
Tax Benefit (Expense) 1,729 1,597 14,790 (1,822)
OTHER COMPREHENSIVE (LOSS) INCOME (6,049) (59,640) 52,098 (181,273)
Net unrealized gain (loss) on securities        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before Reclassification, Before Tax Amount 152 (607) (1,468) 2,042
Before Reclassification, Tax (Expense) Benefit   204 613 (731)
Before Reclassification, Net-of-Tax Amount 152 (403) (855) 1,311
Reclassification, Before Tax Amount (6) 0 (6) 0
Reclassification, Tax (Expense) Benefit 0 0 0 0
Reclassification, Net-of-Tax Amount (6) 0 (6) 0
Before- Tax Amount 146 (607) (1,474) 2,042
Tax Benefit (Expense) 0 204 613 (731)
OTHER COMPREHENSIVE (LOSS) INCOME 146 (403) (861) 1,311
Net unrealized gain (loss) on foreign currency        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Before Reclassification, Before Tax Amount (7,924) (86,187) 38,782 (207,050)
Before Reclassification, Tax (Expense) Benefit 1,729 1,235 14,177 (1,249)
Before Reclassification, Net-of-Tax Amount (6,195) (84,952) 52,959 (208,299)
Reclassification, Before Tax Amount 0 25,557 0 25,557
Reclassification, Tax (Expense) Benefit 0 158 0 158
Reclassification, Net-of-Tax Amount 0 25,715 0 25,715
Before- Tax Amount (7,924) (60,630) 38,782 (181,493)
Tax Benefit (Expense) 1,729 1,393 14,177 (1,091)
OTHER COMPREHENSIVE (LOSS) INCOME $ (6,195) $ (59,237) $ 52,959 $ (182,584)
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other Comprehensive (Loss) Income (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Equity [Abstract]    
Net unrealized gains $ 954 $ 1,815
Foreign currency translation loss (333,099) (386,020)
Accumulated other comprehensive loss $ (332,145) $ (384,205)
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.5.0.2
Shareholders' Equity (Schedule of Changes in Stockholders' Equity) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Shareholders' equity, beginning balance     $ 5,967,976 $ 2,408,213
Net (loss) income $ (218,919) $ (1,050,488) (9,194) (1,376,732)
Other comprehensive (loss) income (6,049) (59,640) 52,098 (181,273)
Compensation related to share-based awards     44,567 48,537
Tax withholding for restricted shares     (10,532) (15,268)
Exercise of options     1,952 25,068
Buy-out of noncontrolling interests, net of contributions       (39,608)
Fair value of equity component of acquired Auxilium Notes       266,649
Conversion of Auxilium Notes       160,892
Issuance of ordinary shares related to the employee stock purchase plan     4,010 3,328
Ordinary shares issued       2,300,000
Equity issuance fees       (66,956)
Other     (16) 18,232
Shareholders' equity, ending balance 6,050,861 6,396,054 6,050,861 6,396,054
Par Pharmaceutical Holdings, Inc.        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Ordinary shares issued in connection with acquisitions       1,325,652
Auxilium Pharmaceuticals, Inc.        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Ordinary shares issued in connection with acquisitions       1,519,320
Endo International plc        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Shareholders' equity, beginning balance     5,968,030 2,374,757
Net (loss) income     (9,210) (1,376,579)
Other comprehensive (loss) income     52,060 (180,692)
Compensation related to share-based awards     44,567 48,537
Tax withholding for restricted shares     (10,532) (15,268)
Exercise of options     1,952 25,068
Buy-out of noncontrolling interests, net of contributions       (6,876)
Fair value of equity component of acquired Auxilium Notes       266,649
Conversion of Auxilium Notes       160,892
Issuance of ordinary shares related to the employee stock purchase plan     4,010 3,328
Ordinary shares issued       2,300,000
Equity issuance fees       (66,956)
Other     (16) 18,232
Shareholders' equity, ending balance 6,050,861 6,396,064 6,050,861 6,396,064
Endo International plc | Par Pharmaceutical Holdings, Inc.        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Ordinary shares issued in connection with acquisitions       1,325,652
Endo International plc | Auxilium Pharmaceuticals, Inc.        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Ordinary shares issued in connection with acquisitions       1,519,320
Noncontrolling interests        
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Shareholders' equity, beginning balance     (54) 33,456
Net (loss) income     16 (153)
Other comprehensive (loss) income     38 (581)
Buy-out of noncontrolling interests, net of contributions       (32,732)
Shareholders' equity, ending balance $ 0 $ (10) $ 0 $ (10)
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.5.0.2
Shareholders' Equity (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 15.0 $ 23.8 $ 44.6 $ 86.1
Acceleration of Auxilium employee equity awards at closing       37.6
Unrecognized compensation cost $ 93.9   $ 93.9  
AMS        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense   $ 11.0   $ 11.0
Nonvested Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted average remaining requisite service period, non-vested stock options     2 years 2 months 12 days  
Nonvested RSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Weighted average remaining requisite service period, non-vested restricted stock units     2 years 3 months 18 days  
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.5.0.2
Other (Income) Expense, Net (Schedule Of Components Of Other (Income) Expense, Net) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Component of Operating Income [Abstract]        
Foreign currency loss (gain), net $ (123) $ (4,095) $ 2,427 $ (24,651)
Equity (earnings) loss from unconsolidated subsidiaries, net (2,023) 1,899 (539) 3,650
Other than temporary impairment of equity investment 0 0 0 18,869
Legal settlement 0 (12,500) 0 (12,500)
Costs associated with unused financing commitments 0 64,281 0 78,352
Other miscellaneous, net (720) 506 (1,486) (1,131)
Other (income) expense, net $ 2,866 $ (50,091) $ (402) $ (62,589)
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.5.0.2
Income Taxes (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ 46,185 $ (160,939) $ (627,807) $ (340,528)
Total consolidated loss from continuing operations before income tax (145,311) $ (964,645) (518,254) $ (1,084,636)
Deferred tax charge related to restructuring 395,100   395,100  
Discrete tax benefit from amortization of prepaid asset 42,600      
Discrete tax benefit from outside basis differences $ 635,000   $ 635,000  
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Numerator:        
(LOSS) INCOME FROM CONTINUING OPERATIONS $ (191,496) $ (803,706) $ 109,553 $ (744,108)
Less: Net income (loss) from continuing operations attributable to noncontrolling interests 0 (46) 16 (153)
(Loss) income from continuing operations attributable to Endo International plc ordinary shareholders (191,496) (803,660) 109,537 (743,955)
Loss from discontinued operations attributable to Endo International plc ordinary shareholders, net of tax (27,423) (246,782) (118,747) (632,624)
NET LOSS ATTRIBUTABLE TO ENDO INTERNATIONAL PLC $ (218,919) $ (1,050,442) $ (9,210) $ (1,376,579)
Denominator:        
For basic per share data—weighted average shares (shares) 222,767 209,274 222,579 188,085
Dilutive effect of ordinary share equivalents (shares) 0 0 480 0
Dilutive effect of various convertible notes and warrants (shares) 0 0 1 0
For diluted per share data—weighted average shares (shares) 222,767 209,274 223,060 188,085
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.5.0.2
Net Loss Per Share (Narrative) (Details)
shares in Millions
 9 Months Ended
Sep. 30, 2016
shares
Stock Options And Stock Awards  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from calculation (shares) 5.0
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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a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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 357 401 1 false 109 0 false 12 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.endo.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.endo.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements Of Operations (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements Of Operations (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements Of Comprehensive (Loss) Income (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncomeUnaudited Condensed Consolidated Statements Of Comprehensive (Loss) Income (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements Of Cash Flows (Unaudited) Sheet http://www.endo.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements Of Cash Flows (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.endo.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 2102100 - Disclosure - Recent Accounting Pronouncements Sheet http://www.endo.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 8 false false R9.htm 2103100 - Disclosure - Discontinued Operations and Held For Sale Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSale Discontinued Operations and Held For Sale Notes 9 false false R10.htm 2104100 - Disclosure - Restructuring Sheet http://www.endo.com/role/Restructuring Restructuring Notes 10 false false R11.htm 2105100 - Disclosure - Acquisitions Sheet http://www.endo.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2106100 - Disclosure - Segment Results Sheet http://www.endo.com/role/SegmentResults Segment Results Notes 12 false false R13.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.endo.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2108100 - Disclosure - Inventories Sheet http://www.endo.com/role/Inventories Inventories Notes 14 false false R15.htm 2109100 - Disclosure - Goodwill And Other Intangibles Sheet http://www.endo.com/role/GoodwillAndOtherIntangibles Goodwill And Other Intangibles Notes 15 false false R16.htm 2110100 - Disclosure - License And Collaboration Agreements Sheet http://www.endo.com/role/LicenseAndCollaborationAgreements License And Collaboration Agreements Notes 16 false false R17.htm 2111100 - Disclosure - Debt Sheet http://www.endo.com/role/Debt Debt Notes 17 false false R18.htm 2112100 - Disclosure - Commitments And Contingencies Sheet http://www.endo.com/role/CommitmentsAndContingencies Commitments And Contingencies Notes 18 false false R19.htm 2113100 - Disclosure - Other Comprehensive (Loss) Income Sheet http://www.endo.com/role/OtherComprehensiveLossIncome Other Comprehensive (Loss) Income Notes 19 false false R20.htm 2114100 - Disclosure - Shareholders' Equity Sheet http://www.endo.com/role/ShareholdersEquity Shareholders' Equity Notes 20 false false R21.htm 2115100 - Disclosure - Other (Income) Expense, Net Sheet http://www.endo.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 21 false false R22.htm 2116100 - Disclosure - Income Taxes Sheet http://www.endo.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2117100 - Disclosure - Net Loss Per Share Sheet http://www.endo.com/role/NetLossPerShare Net Loss Per Share Notes 23 false false R24.htm 2202201 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://www.endo.com/role/RecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://www.endo.com/role/RecentAccountingPronouncements 24 false false R25.htm 2303301 - Disclosure - Discontinued Operations and Held For Sale (Tables) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables Discontinued Operations and Held For Sale (Tables) Tables http://www.endo.com/role/DiscontinuedOperationsAndHeldForSale 25 false false R26.htm 2304301 - Disclosure - Restructuring (Tables) Sheet http://www.endo.com/role/RestructuringTables Restructuring (Tables) Tables http://www.endo.com/role/Restructuring 26 false false R27.htm 2305301 - Disclosure - Acquisitions (Tables) Sheet http://www.endo.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.endo.com/role/Acquisitions 27 false false R28.htm 2306301 - Disclosure - Segment Results (Tables) Sheet http://www.endo.com/role/SegmentResultsTables Segment Results (Tables) Tables http://www.endo.com/role/SegmentResults 28 false false R29.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.endo.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.endo.com/role/FairValueMeasurements 29 false false R30.htm 2308301 - Disclosure - Inventories (Tables) Sheet http://www.endo.com/role/InventoriesTables Inventories (Tables) Tables http://www.endo.com/role/Inventories 30 false false R31.htm 2309301 - Disclosure - Goodwill And Other Intangibles (Tables) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesTables Goodwill And Other Intangibles (Tables) Tables http://www.endo.com/role/GoodwillAndOtherIntangibles 31 false false R32.htm 2311301 - Disclosure - Debt (Tables) Sheet http://www.endo.com/role/DebtTables Debt (Tables) Tables http://www.endo.com/role/Debt 32 false false R33.htm 2312301 - Disclosure - Commitments And Contingencies (Tables) Sheet http://www.endo.com/role/CommitmentsAndContingenciesTables Commitments And Contingencies (Tables) Tables http://www.endo.com/role/CommitmentsAndContingencies 33 false false R34.htm 2313301 - Disclosure - Other Comprehensive (Loss) Income (Tables) Sheet http://www.endo.com/role/OtherComprehensiveLossIncomeTables Other Comprehensive (Loss) Income (Tables) Tables http://www.endo.com/role/OtherComprehensiveLossIncome 34 false false R35.htm 2314301 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.endo.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.endo.com/role/ShareholdersEquity 35 false false R36.htm 2315301 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.endo.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.endo.com/role/OtherComprehensiveLossIncome 36 false false R37.htm 2317301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.endo.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.endo.com/role/NetLossPerShare 37 false false R38.htm 2403402 - Disclosure - Discontinued Operations and Held For Sale (Narrative) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleNarrativeDetails Discontinued Operations and Held For Sale (Narrative) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 38 false false R39.htm 2403403 - Disclosure - Discontinued Operations and Held For Sale (Operating Results of Discontinued Operations) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleOperatingResultsOfDiscontinuedOperationsDetails Discontinued Operations and Held For Sale (Operating Results of Discontinued Operations) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 39 false false R40.htm 2403404 - Disclosure - Discontinued Operations and Held For Sale (Cash Flow Activities) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleCashFlowActivitiesDetails Discontinued Operations and Held For Sale (Cash Flow Activities) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 40 false false R41.htm 2403405 - Disclosure - Discontinued Operations and Held For Sale (Astora Restructuring Narrative) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleAstoraRestructuringNarrativeDetails Discontinued Operations and Held For Sale (Astora Restructuring Narrative) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 41 false false R42.htm 2403406 - Disclosure - Discontinued Operations and Held For Sale (Summary of Restructuring Expenses) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleSummaryOfRestructuringExpensesDetails Discontinued Operations and Held For Sale (Summary of Restructuring Expenses) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 42 false false R43.htm 2403407 - Disclosure - Discontinued Operations and Held For Sale (Summary of Restructuring Activities) (Details) Sheet http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleSummaryOfRestructuringActivitiesDetails Discontinued Operations and Held For Sale (Summary of Restructuring Activities) (Details) Details http://www.endo.com/role/DiscontinuedOperationsAndHeldForSaleTables 43 false false R44.htm 2404402 - Disclosure - Restructuring (Narrative) (Details) Sheet http://www.endo.com/role/RestructuringNarrativeDetails Restructuring (Narrative) (Details) Details http://www.endo.com/role/RestructuringTables 44 false false R45.htm 2404403 - Disclosure - Restructuring (Changes to Restructuring Accrual) (Details) Sheet http://www.endo.com/role/RestructuringChangesToRestructuringAccrualDetails Restructuring (Changes to Restructuring Accrual) (Details) Details http://www.endo.com/role/RestructuringTables 45 false false R46.htm 2405402 - Disclosure - Acquisitions (Auxilium Pharmaceuticals, Inc.) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsAuxiliumPharmaceuticalsIncNarrativeDetails Acquisitions (Auxilium Pharmaceuticals, Inc.) (Narrative) (Details) Details http://www.endo.com/role/AcquisitionsTables 46 false false R47.htm 2405403 - Disclosure - Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) Sheet http://www.endo.com/role/AcquisitionsScheduleOfRevenueAndIncomeAndNetLossIncludedInConsolidatedStatementsOfOperationsDetails Acquisitions (Schedule Of Revenue And Income And Net Loss Included In Consolidated Statements of Operations) (Details) Details http://www.endo.com/role/AcquisitionsTables 47 false false R48.htm 2405404 - Disclosure - Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) Sheet http://www.endo.com/role/AcquisitionsScheduleOfProFormaConsolidatedResultsDetails Acquisitions (Schedule Of Pro Forma Consolidated Results) (Details) Details http://www.endo.com/role/AcquisitionsTables 48 false false R49.htm 2405405 - Disclosure - Acquisitions (Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date) (Details) Sheet http://www.endo.com/role/AcquisitionsScheduleOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails Acquisitions (Schedule Of Fair Values Of The Assets Acquired And Liabilities Assumed At The Acquisition Date) (Details) Details http://www.endo.com/role/AcquisitionsTables 49 false false R50.htm 2405406 - Disclosure - Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) Sheet http://www.endo.com/role/AcquisitionsScheduleOfValuationOfIntangibleAssetsAcquiredAndRelatedAmortizationPeriodsDetails Acquisitions (Schedule Of Valuation Of The Intangible Assets Acquired And Related Amortization Periods) (Details) Details http://www.endo.com/role/AcquisitionsTables 50 false false R51.htm 2405407 - Disclosure - Acquisitions (Par Pharmaceutical Holdings, Inc.) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsParPharmaceuticalHoldingsIncNarrativeDetails Acquisitions (Par Pharmaceutical Holdings, Inc.) (Narrative) (Details) Details http://www.endo.com/role/AcquisitionsTables 51 false false R52.htm 2405408 - Disclosure - Acquisitions (Aspen Holdings) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsAspenHoldingsNarrativeDetails Acquisitions (Aspen Holdings) (Narrative) (Details) Details http://www.endo.com/role/AcquisitionsTables 52 false false R53.htm 2405409 - Disclosure - Acquisitions (Voltaren Gel) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsVoltarenGelNarrativeDetails Acquisitions (Voltaren Gel) (Narrative) (Details) Details http://www.endo.com/role/AcquisitionsTables 53 false false R54.htm 2405410 - Disclosure - Acquisitions (Other Acquisition) (Narrative) (Details) Sheet http://www.endo.com/role/AcquisitionsOtherAcquisitionNarrativeDetails Acquisitions (Other Acquisition) (Narrative) (Details) Details http://www.endo.com/role/AcquisitionsTables 54 false false R55.htm 2406402 - Disclosure - Segment Results (Schedule Of Reportable Segments Information) (Details) Sheet http://www.endo.com/role/SegmentResultsScheduleOfReportableSegmentsInformationDetails Segment Results (Schedule Of Reportable Segments Information) (Details) Details http://www.endo.com/role/SegmentResultsTables 55 false false R56.htm 2406403 - Disclosure - Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) Sheet http://www.endo.com/role/SegmentResultsScheduleOfReconciliationsOfConsolidatedAdjustedIncomeLossBeforeIncomeTaxDetails Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) Details http://www.endo.com/role/SegmentResultsTables 56 false false R57.htm 2407402 - Disclosure - Fair Value Measurements (Narrative) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements (Narrative) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 57 false false R58.htm 2407403 - Disclosure - Fair Value Measurements (Financial Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements (Financial Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 58 false false R59.htm 2407404 - Disclosure - Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails Fair Value Measurements (Financial Liabilities Measured At Fair Value On Recurring Basis Using Significant Unobservable Inputs) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 59 false false R60.htm 2407405 - Disclosure - Fair Value Measurements (Summary Of Available-For-Sale Securities) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsSummaryOfAvailableForSaleSecuritiesDetails Fair Value Measurements (Summary Of Available-For-Sale Securities) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 60 false false R61.htm 2407406 - Disclosure - Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) Sheet http://www.endo.com/role/FairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnNonrecurringBasisDetails Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) Details http://www.endo.com/role/FairValueMeasurementsTables 61 false false R62.htm 2408402 - Disclosure - Inventories (Schedule Of Inventories) (Details) Sheet http://www.endo.com/role/InventoriesScheduleOfInventoriesDetails Inventories (Schedule Of Inventories) (Details) Details http://www.endo.com/role/InventoriesTables 62 false false R63.htm 2409402 - Disclosure - Goodwill And Other Intangibles (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfChangesInCarryingAmountOfGoodwillDetails Goodwill And Other Intangibles (Schedule Of Changes In The Carrying Amount Of Goodwill) (Details) Details http://www.endo.com/role/GoodwillAndOtherIntangiblesTables 63 false false R64.htm 2409403 - Disclosure - Goodwill And Other Intangibles (Schedule Of Other Intangible Assets) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfOtherIntangibleAssetsDetails Goodwill And Other Intangibles (Schedule Of Other Intangible Assets) (Details) Details http://www.endo.com/role/GoodwillAndOtherIntangiblesTables 64 false false R65.htm 2409404 - Disclosure - Goodwill And Other Intangibles (Narrative) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesNarrativeDetails Goodwill And Other Intangibles (Narrative) (Details) Details http://www.endo.com/role/GoodwillAndOtherIntangiblesTables 65 false false R66.htm 2409405 - Disclosure - Goodwill And Other Intangibles (Schedule Of Estimated Amortization Of Intangibles) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfEstimatedAmortizationOfIntangiblesDetails Goodwill And Other Intangibles (Schedule Of Estimated Amortization Of Intangibles) (Details) Details http://www.endo.com/role/GoodwillAndOtherIntangiblesTables 66 false false R67.htm 2409406 - Disclosure - Goodwill And Other Intangibles (Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets) (Details) Sheet http://www.endo.com/role/GoodwillAndOtherIntangiblesScheduleOfChangesInGrossCarryingAmountOfOtherIntangibleAssetsDetails Goodwill And Other Intangibles (Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets) (Details) Details http://www.endo.com/role/GoodwillAndOtherIntangiblesTables 67 false false R68.htm 2410401 - Disclosure - License And Collaboration Agreements (Novartis AG, Novartis Consumer Health Inc. and Sandoz) (Narrative) (Details) Sheet http://www.endo.com/role/LicenseAndCollaborationAgreementsNovartisAgNovartisConsumerHealthIncAndSandozNarrativeDetails License And Collaboration Agreements (Novartis AG, Novartis Consumer Health Inc. and Sandoz) (Narrative) (Details) Details http://www.endo.com/role/LicenseAndCollaborationAgreements 68 false false R69.htm 2410402 - Disclosure - License And Collaboration Agreements (XIAFLEX Out-License Agreements) (Details) Sheet http://www.endo.com/role/LicenseAndCollaborationAgreementsXiaflexOutLicenseAgreementsDetails License And Collaboration Agreements (XIAFLEX Out-License Agreements) (Details) Details http://www.endo.com/role/LicenseAndCollaborationAgreements 69 false false R70.htm 2411402 - Disclosure - Debt (Components Of Total Indebtedness) (Details) Sheet http://www.endo.com/role/DebtComponentsOfTotalIndebtednessDetails Debt (Components Of Total Indebtedness) (Details) Details http://www.endo.com/role/DebtTables 70 false false R71.htm 2411403 - Disclosure - Debt (Credit Facility) (Narrative) (Details) Sheet http://www.endo.com/role/DebtCreditFacilityNarrativeDetails Debt (Credit Facility) (Narrative) (Details) Details http://www.endo.com/role/DebtTables 71 false false R72.htm 2412402 - Disclosure - Commitments And Contingencies (Manufacturing, Supply and Other Service Agreements) (Narrative) (Details) Sheet http://www.endo.com/role/CommitmentsAndContingenciesManufacturingSupplyAndOtherServiceAgreementsNarrativeDetails Commitments And Contingencies (Manufacturing, Supply and Other Service Agreements) (Narrative) (Details) Details http://www.endo.com/role/CommitmentsAndContingenciesTables 72 false false R73.htm 2412403 - Disclosure - Commitments And Contingencies (Legal Proceedings and Investigations) (Narrative) (Details) Sheet http://www.endo.com/role/CommitmentsAndContingenciesLegalProceedingsAndInvestigationsNarrativeDetails Commitments And Contingencies (Legal Proceedings and Investigations) (Narrative) (Details) Details http://www.endo.com/role/CommitmentsAndContingenciesTables 73 false false R74.htm 2412404 - Disclosure - Commitments And Contingencies (Details) Sheet http://www.endo.com/role/CommitmentsAndContingenciesDetails Commitments And Contingencies (Details) Details http://www.endo.com/role/CommitmentsAndContingenciesTables 74 false false R75.htm 2413402 - Disclosure - Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) Sheet http://www.endo.com/role/OtherComprehensiveLossIncomeScheduleOfTaxEffectsAllocatedToEachComponentOfOtherComprehensiveIncomeDetails Other Comprehensive (Loss) Income (Schedule Of Tax Effects Allocated To Each Component Of Other Comprehensive Income) (Details) Details http://www.endo.com/role/OtherComprehensiveLossIncomeTables 75 false false R76.htm 2413403 - Disclosure - Other Comprehensive (Loss) Income (Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://www.endo.com/role/OtherComprehensiveLossIncomeAccumulatedOtherComprehensiveIncomeLossDetails Other Comprehensive (Loss) Income (Accumulated Other Comprehensive Income (Loss)) (Details) Details http://www.endo.com/role/OtherComprehensiveLossIncomeTables 76 false false R77.htm 2414402 - Disclosure - Shareholders' Equity (Schedule of Changes in Stockholders' Equity) (Details) Sheet http://www.endo.com/role/ShareholdersEquityScheduleOfChangesInStockholdersEquityDetails Shareholders' Equity (Schedule of Changes in Stockholders' Equity) (Details) Details http://www.endo.com/role/ShareholdersEquityTables 77 false false R78.htm 2414403 - Disclosure - Shareholders' Equity (Narrative) (Details) Sheet http://www.endo.com/role/ShareholdersEquityNarrativeDetails Shareholders' Equity (Narrative) (Details) Details http://www.endo.com/role/ShareholdersEquityTables 78 false false R79.htm 2415402 - Disclosure - Other (Income) Expense, Net (Schedule Of Components Of Other (Income) Expense, Net) (Details) Sheet http://www.endo.com/role/OtherIncomeExpenseNetScheduleOfComponentsOfOtherIncomeExpenseNetDetails Other (Income) Expense, Net (Schedule Of Components Of Other (Income) Expense, Net) (Details) Details http://www.endo.com/role/OtherComprehensiveLossIncomeTables 79 false false R80.htm 2416401 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.endo.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.endo.com/role/IncomeTaxes 80 false false R81.htm 2417402 - Disclosure - Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) Sheet http://www.endo.com/role/NetLossPerShareReconciliationOfNumeratorAndDenominatorOfBasicAndDilutedNetLossPerShareDetails Net Loss Per Share (Reconciliation Of The Numerator And Denominator Of Basic And Diluted Net Loss Per Share) (Details) Details http://www.endo.com/role/NetLossPerShareTables 81 false false R82.htm 2417403 - Disclosure - Net Loss Per Share (Narrative) (Details) Sheet http://www.endo.com/role/NetLossPerShareNarrativeDetails Net Loss Per Share (Narrative) (Details) Details http://www.endo.com/role/NetLossPerShareTables 82 false false All Reports Book All Reports endp-20160930.xml endp-20160930.xsd endp-20160930_cal.xml endp-20160930_def.xml endp-20160930_lab.xml endp-20160930_pre.xml true true ZIP 100 0001593034-16-000082-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001593034-16-000082-xbrl.zip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�CRXK]-QNKT^93THZT%9CSO[[CW?FKX0 M+@@7>X\+,A64[[/LK%WSTZ_/*3V[$4D@S
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

    V%X'&K6DRW/SUWVR%!_>XP! M30VDAC3!T' $'44>(<$08 3M$C?$05+-EK[;SJR(>[M'BQW"XJ?9O+@+V>UT MN2K"=XM5!;73XFP/3NAKRR\?_[GV\BJ9W.ACC7ELNW)/".VTW=;.->.0SVS6 M)6^0=6$Q5F)?7>N-6 YN5H.?8I2 $B6M$Q(X)25AA+H&(_.>Q15D. VV%(%H M5;WAR;Y-SR(]L!OC)'R\_DL3^-/E7NN21! ,3,)[SVN"H=YR3N/G>J/Z@4B8YYCRQZ])+NS*]_ M $J49,>6 1"@F*F>.7%L1UA[;6#MC8VW,S'B,KX?1P2YD.W-&$9?@'+&!&:R M$ 47+"<*IY0HD=&N+ MT+Y^+ 6MI.ZA[!*^K%"EP%F.$)&"W5J?7_W=54-T<$K*=& M\T',BFJGF&.MJ9Z2VK>JZN6@<0AJ1/M\*JL]F!RPMOH$)<(RQ237Y)=4I2J5 M&>U0Z@PY3UTD>6ALD05[Y+55-S<.5EV-YL&+UUZ%D&F2B04U6JM,Q**4M5E 1VV]PS\Q)7GUJK;1N1JZV=%L2HMUK3 MV*M4$93!8"6*4=0EW.L1UF2.0^9Z6V%7?W!DQ59V_E'57^Y->>.K5KTOU?OM MP^=J=7/7MKR^V6[6F^G2G%(\E#\*!@I*$94I(:40 )BG)/8P*,#$K1P;O/GH M]=E_R.M?_M.<$*._RX_T%[FKMKH^%!J>=CO]NBC?;L+604WV6),=6)-%[N F M)W@O7Y9U9?:,+D9STC@$,YYYS4"=/8[$[A;9.*"$RU324BBB\TN,TH/,4RPL MG\R)TW9T<=VON[>)WYF+_X>@.:R>AN8-'>BK<^P,[5_0PZI'+ZD]U+ M.P=A>8A4=!3Z^1J;[@K:VR^CUM#^UMFI:" 6;764SF;;AVW[$N&->820-P^/ MJ^J^6J[KK]6Q!GIK#C!/6WJ M!&O2@DV>H'VVS/%'B_GUV>4 ?K#3UXNYP$UK:KJH_T<+QA=M4'?G4+-,UM5LNZHW=?7ZQ4*CR2SY=K6JEK-O=/[_MCOP/4#C IIS:BS+ ) 2XAS"H@.=8>IT#XN]@]Y%G.P<^,;N7__@M[\KHHN!% MR7@]$E[>1X&+:._J976]J1[6$RA214F)1"I47N8X)P1T," M481"FGWCXRJF M&=Q)"SQ.1V=TJA[8/+]2FR^/MLI[ MKNW=TW4?J]EBNE[7=_7L]$4[00[P*MG_0$-,Z$.S/7-Q[06<8Z?&H_&+FS*_J<97R>>7O;8^_$1;,*Q, M]^'ZC&0/XL)QR/,+NE6CHDFYL$\$D?&SZCXCR#?P87;Q5T_K&0[ M&=E?K-TYC2C3AS>H2B8IS8DJD,"RH*0H,GRHQ$!:N!Q;C(G#*??VN$CN-;'6 M ']N[GX>,/>V=TTTM8[BE0$S[^,A]M%+M\6;?$,X\(<5<7=+^RNY)[NV*UE8-_918 1.LTK)CRW8W>3B5WU_&J_9KM)=O97AM_;UED'Q>>3BM^YUF. %F&%].%P^'M9O(TC' M+U6S">F,R-FXL\]''":BFQXA%_?D/UP9OYT&<)YR)8F2/,M@EJ*L++JV,RE8 MV(*]38N#E.9_CKC]Q8K64,7VT(S&*JN/L'C>MTSN0OTXI#.P3OZ0Y6>,@9NXLV5_;^O-M_?-IC+7 M5"^:]58+:/77AFGS_SE1-%<(I(+E)59%CDC&Z\^KTE:O_+Y%__^WZ]K_<]"P@R7;*=AEV MW33N%*.FM469&)C)$6?RAT&:M% '/BMB3>$9X0OOAG%(8 2[FM@=V%$69_?5 M?+NH;NX^5NO-:CO;;%?U\HO^2[7Z6K%OM_K3;NYXL]X0IH @S@J0" C,% M4I3#C.9 0,8 *EP6F'S:-P=C* ((Z@X-2Y./1#[=[/QC0 M^ZNNDLM)K3N_YT0WHK=&(K\Q+7PNQ-'9=)=D'08>F_5T\[S1Y\6V5 M]2Z)_K31LUESYIM-]6"959_NJVI#EW,ZG]?FUZ:+8VQ9'RW).#7'#%DNBS25 MD*99!@75)E%*"TJ%GZ0/AQ\(,UT !<,,P+0H6[VE\Q4]YU9_Q5\GEG?K(V]B?3Y3R9'AAH/V=/@6]L M&5'7# M\PBQAIAO:3@?JW9]TV08)RA@"1572I$BYP C E5Q4$_)(0TPUWJU;08%U)-- MH*@J(<6RY*PT\PLJ0)X[OE3CM:?O-*>\VH!J'<=8_( M<[;W"-NITYC"BQ63[O.FWCX9FZP'MLYNOA2(1?N-?R=M\_OIZDNUGA0 F!W7 M.9)8 %E@"&E1<%FF90$1 MBM@/]B$R4C2IB'C1!1D'# BIR5.452E1G)\SQZ MK7Z_WOBZ"D;:@O4]%V>W4O6@;AS#J9\)WVUMZLV'[<#X,/UF4IZU:E9/6IT@ M#'**LXQ"EM)"<$QIV@T.0 5W.V7V:C,EP"D!)$4BI3#'YHU%)5)$&)5Z#.;< M8XG>;8#PZ?H^>=S#^S]ZQKR[\LZDA<..F=K,ZCK'3WXPF<&]S&T-J M6J]^GRZVU;MZ^KE>M+>@_UI-S3QA?K/\:&Y&7^U?;5K_MFP^FTJA29*NEX_; MC?ZQ9DG_JW8JLKM!'Q(""EQRFK),<"(R36H*@( 0Y04#3J_9#PXN$G2R9:>]IC/YPQCC&U]ZNL4Q:@SG M#_]8< #V%K%QE?PL53;Z'(;KD:EN(*->T]*0G#DKY'[4[^87W\$0S<.T7DZP MA$!W'8SU7+TL%&20'#!PECMN#0W;]H^BESMS?!4SC)L%S3[M1"YK_'W;F#6T#ZMZIJ6R7B9TMC&'7'Z=KOY9;=;FP:'D>JY] M4\^FBX2NU^:;/[46))GC::)>=#M*8F2F_1/('3 =H7847NC)GC,\V:A>#W9' MIG%]+'E-T7JSTT>_\GV+*)6Y*A#"A$B><5 @10^*B;*LKW[9MA-[9V/]9=D> MQ5]N]I=$W#PKP1WD*@\@5];L^LM5#&)#R54^(KG*O>3*E=WQRI6S)19RY<=. M'[D"^Q:+5&*.5*J* N8H59S"M&LQ*X336\A]VAE0KKY?+3A(%0@@5=;,^DM5 M#%)#2148D50!+ZER97>\4N5LB854^;%C*U5LNOSG;?U0B>JQ6=>;=??:(*62 M9)AEYJBC;B.%6.X; S1'3DF59Q.1!;]!A 24M7 M!^E"BO,R,V?$IB>5X]"9OD8T0;N7F[KP]BC EVJYT5^MZ_G^/,#N$%^[F(!S M5J:,E )2)'( )=9UZ[(W7;B]&\MLN8< 29/$![.Q_JL80;@V$Z8AJ773:/Z M,AM%K]XD[(QTA2-['"H6T)XF5K<,HFVFU7TMGQ4I%XR*G"JF9 :R''<9&X L M50&TS:&U2VG;;OAY+38&H+B7M$5B-Y"TV1$[I+(=^7)7-@^N1ZUL/O;8*9LW M4V\I6[61_WM;K]OSF(?S0R_"^'3?K#:WU>IAGT%24J:YA.8Z'$1XEA>E M%!T6P%5IHW9Q$416P!/[(0QLH?. MB^5XG.,FH">03XY2OB*J+>S$X'Y[DCND:^;-;&MV#K3_^@=PT1.\45SULXNK MGD5!PU,;VU("TC:R]6+NA6@WC"J>D%$RHF>L='SW=\".%1U\3O:)C+SZ==T'L-E-ZGLIZ5R^K M=L/ZI""LA'E!2RH +S$ >7% R2GSVZ@Z$+;((?5T=\!^ZVK?\YO&MMU) =\3 M D.YW7%;QP@][K\59$!GQ]U$$L8K-AM/!O;_.(J4%[/^M0TN%_&";>3:@:.? MUYO5=+:90"$X(EBI3.2RX&6*Q6'N2#EG;H?-'#_<14>\3I/M\/S[L./^*0EG MAJTG6^,8=;[@FR ]QJ?/'\;G\;C@861.6$E*!"%065&"C,B\$-W9)" S#GW& M0:\&HX^--M1^;0_T-7?)7;V<:A&:+I+I+NP^G(3=U2'L?C8*YI8SA2#?+@T: MF'7'(D0+[BHY.4=Y!'AUS&PNH57G*'M3OX+P/29-"V/0BSH7D"M;[3LY1'U0 M69&EYB8X!$1&\[)0*"7=R0 <\%=9IL^GQ]YQG@"Z?70'XXL.W&*S9.;&IT> MK?^CPS/P_.@%1LZ(31_^QJ$NO2QHPO4F;_TXJUXJ+PDNJ!8N 03%D@)&#K,5 M_1U/3>G5YA"5J18";PD;6U9E29Z=V@6A?W0*&,:J MUU4Q(&NV2BFGJZ7^]/6':O7I?MJV=U+7.<@T1[ H*5 02$8 R1G3*!3!:59@ MD95.K^ $:C*R3K[?/IBUF6;EF(V%(M1.\2[ I9O@=0 3C3!I(7Y7Z[Y0)F=' MW1FY"\S].-0NM%%-U/[JIG7'QW25MGNW$KO5:([/HM#-[BYL4^:^;=YK:/J7 M-'WZ0[](_>N;;Y-"9)@+RA3B%&(" ,[4 5JICH]ZVPOB(+BLAOBSE[\]9K'5 M>OWOR?MJTSW<]=/"O%6=F(ZVWU-D+#MYXBN9GMB6;)ID^<0Z_3E:O"OG5TV& M\;6=2(_'OUX2_N35\9TGCS:# "AUK)@(I"7))"$6$E5*)M"1=PTAPY))3!V@N:H;O<1\+%XO+?.O_)B[MB5O@?_U@%A"!^/,6X,8O?9\#(<\[91Z!]5 M_>5^4\WI5XWF2_5^:S;IW]RU%:SUS7:SWDR7N[=V%UO]:\?J?;LG\KC6662\ M((K! L@BIQ1JI!TXB@KI$H(&@A0Y_HAJV3SHP.%>9A_*)7;A883><(L-G0') MWH)D9X*) 3LCDA,KQE+!#\/ZF8@PL%O'$0Z&-KJYZ%"*$PC,GOG9I"RSE$@D M:<%XH217)"\/P4AQ$$/O[5J.O<>D6;6[16:)#M^[*4$RGVZF^\/#?W9B,]V+ MS7HG,3_M_GS]!MJ+JDC+; "QQI%-=^_NTI7*]W_=R^)3 @&6%%*"YQ#"2#6>>@A!V4ELKIW9T X ML5,\H]/F78_J[JZ:M;/*I\6"I/KO;?UUNC!@WY: BSG-NDXP)G\Y%P@Z\,D. M?9?\/2\!')PJ#TYM?_/GS\:J9&]64!!(".33:/3I5YU M)>^VG1*" TRGRM)\A^T'KBV]QJY[=:FWG\8QP8AFG5V%*1"+MN/]4_7%Q-+# MVN6QAGU;_;5AFIA_3G1#NDE)4IRG!:>84"@Y51(PJ I(J-O5#C8M2D:! +S( MLKR G)PX)!*P04L,3'W7!2E MTRU0'H4/,XH<;_F+3+V=-HZ(=3?9W '_N46>'*$GW0TXI^B3/7RS34[+ZF](CN,H^']5T]7MG\U$Y47**95*-YY1 M5A!8R$X]4H"<=K;Y(0IT-;JW.S9@U><]M,"EV]=6/J,#.-O827C]&(^JM[JS51$HL18I! M"8FBD/"24-4) : R8JI\Q)!E(LTS")A4 *:4R%2H@J,<$8Y*6(O#NKQ5T;7 M7#NRHZEN<)Z'TUT#??3*:T"&U5XGC_VPZNMF97_]]6 UG@(K/5PF!9>\R 73 M?Q+=-LB%.$R802J=WDGVA&#NVX2HX+D4%.90IX4\+P4I< XH(T/DO"2V_MI1 M'4M^@[,\F/H:Y&,77X,QJ/8ZN>M'E5XW(WLKKP>G$857_^Z$@DSJ>6_.\Q0A MHE*E1-ZI 4VITT%N3P@*LTRH3.),$)BBC H),@5S!3*A)^6QK_#,TSR-+KQ6 M5$<3WM L#R>\^M^,7GCU[X857A=W_;#"ZV1D?^%UY]1Z_\'LOIIO%]7-W8=5 M,]_.-M?+NV;UT"*X-3NJ)XB)O"@DA)#BG)2\A!@+@GDA"\0(8"X:V[^UR'+: M 32[B_<0DQ.,R1\M2L='MP)P;+D;85!Z'?E J9P6PI*,BY8UZ+(L=/!O#[M1-:S M%MKW:8N;?O7BT4ZYAJ+03;->8<_YP=8P8G6&HS,R%8+9<0A4$$N:\/W.X:Q8 MV]S)0[!=4\*<7"Y%3@!B:2HER2D1A )"]9R:0ZMY;*\&!I&A$UP.QW2\.3NO M/(/1Y2,YIY!\GO'VYLSAB-(0W/D=-?+AT.ZHT"LVOR"_02@:P=&=WB8T ;N, M6_KW?;+Y[O T*2YS (E"1%%>(B0($'RO[9CAW*EPV*>=R+K[XD3KG>_CT;T( MM&(+9<>2!02QIPO<[ASSP><;)IX_U9KK85_YN M[CXVWZ8+\PK0)!.,2H!1CB!0,.6$%JIK'*:XL,X,PS496;.> C/EHL?=10[K M9%4MINTQEDV3_-]KJM[)__NO_Y+AXC\<4J. U%LDF)=AW4W=7EC4>.:#F[OD M /0R5#ODI9>AW"]3#42]7?)J30X$8PJHG:&WT6UA<[>7 8/1/DXLNBP)KVXQ!V4+X=9 M_ZRJYNWMX9^F9M'I.8))S@D3A$M$H))"0('SM%-:(O*L>[;->OK?MT&KP?CT M/3;'9>WI;N%U5JTVTWKY[-&&#_=3/>F95=M-/9LNUGVU,(0'K*L%@U#O6S1H MP>U>5^@\8+\4%ZMV\ 9CYTL(H>@>AP:&-.C[@D)8KJPOK7UXG-8K,Q7YODGY MUVRQ-9>9_-(T\S_KQ6*""IE2"7-:XC++,T)4<<# "80^+U@&!> AC1Y/51XQ MN^6"<>XK=2'PS'"-XXAQC-Q(MCV_<#0B@[;CF6W7];):KWGS\+G>A6RM+5_U MU,7$[I."Y;5.N>KI@LYFS=:\F/*E?4GE<5%M*CK_?]OUQMAQM&(]$4IFB).2 M^768I1VZSOLOAC#Y5_+6:F@M36GEXK%9U,T^F!Z1/JY+3TT5' M<]&*G@/-M^;-]D2/=CBLD$1SR1G1N7PW&(= C8"'9FP#-%PBF75761"]OMZ/=,?7P<. Y-"6Z5 M0[KCSYK]QKAG;:IF5=5?EGR[6E7+V;?;U72Y7K0*=92A"=$H",X@ D@KCVR6PIA^&,&2;'P;O]N4&)]1 MU_G^Z39)G:5;ZM)"42& 80$,D 9)HB80X&F90X$9M!E]V*(]B*' MN#T,MU6((#S:+4,,3:%;G.K0G6Z(OC)'\)(68/(6NU%+$VF?B'8RN$EKVO-L>GGB><(5E*7)KK77A!BPSGN&L_Y1+ZU2+[MQN]MF@> M5U]H),GTV;-J M^NCGAO&KI*==#EK9A[D>BMDU+Z>K9;W\LOY0K;HW[LS+IY"*DD-6%"1#.A.% M !Z$N\"<]Q;.?LU'U\\61K+48[;>CUFCIG_K_G9\%^:G>IG,F\5BNEH?O^OX MMFAX[WC+ZG!N":NN'5[SSM?NG="KI,5\<94]RZB;V(9QSF@U-Y!Y;TMO2!XC M*/#^J:!) 0D!6893JDB&RQPK< @%#+D]51&A^ M1_@8W.I7;X(;DG6/0#.;;1^V"Z-^#J@P!Z( $J5$Y#KV8B@8@&7W$'"]_*HSW6;U;;<)9/.L>4%@3J6.0X 6&@IUA]17L/ORZZK, U+K M+\$'D%?[;6F;$>GL>0:M!#60$\:FG*',>E4B@_)FK84;+!\NKY7B^;/ M-?V\WJRFL\T$RAS($A=0I*44$)$4Z/\HSR5#+$>V-=5>;40#[!P_-@.JO?5QC35GKR:5W/V[;=U._=] MK%;MN1PZV]1?:W,AT &(*M,"J!3P,LM25*(BI5D'I$B5TX.Z$9J/G'3WU^U\2RF^O?[^^O9:?_MTMZ8C!N9V\79AN-]$S&Y]:K>O@)I^_)3\9Q#K; M^UMR )T<45],$-V)/2.3$;TT#O&,:6 S6(]WO@?HKMZT6[4DTN)=X#QG!0-% MF2F6PJX!#'*K.S0]/C:R,/)FN6X6]7S:+;Z;^MG@M\GLR3@SNCP8&\>H\0'^ M_2TP?K;;]O+C<93U;6.*Z[%2\;5P')(4PS:B"92HSI:3( "8=5 $$ M<1DO%P$8>>2=V&361E>=5FMAWWM_M.F>OSM<<(9%02E"*6Y*#D6 /"NKHC3'%&' M%QW>Z/2X*&+A"Y+9BX@1W)7A#;T)T!$JN=GA42W7NRZ*%$,T+0#+ M(4T)Q%(>"B-:?-/2<5NV7R/Q=UD;7#]_-L#:[6\=,L?M$YX46B[&QN?.<1GV MA#1N0UJ+[4&H(3ZZKH24IW+/> MK'7&)^IU>[7E>@(1H!P*LVV"IZ8RBU+9-0_RS.KVN."-QJY>GN TVQOFU>=- M4J_76XW7E##7YNR'G@/-]X =ZY#!J+>L+5Z"=<=ZX3/"A2'\NB.<'P@_8!VX M\&?)X+EB7F@GC$,"PYOUO.@6AS>')=+=];^J68EF^WESM^UN_5U/L)X'"\&E M *JDH$"J4-EA)IR[[3KIU5!D.3Q@2^Z:5?)Y.F\%T?W)DQY,VBG=8"2ZJ=M3 M_CI@28=L\ 7I5SDZOT3=G]IQ:%884[Y?Q@[%CWV1_ZY:KDTK7@OV=QOT;;@FLS+_U5LL M;/7KEVF]-(NF-\O=ZT]:0A^KU>;;!]TE-_*_M_5C>XJL).)H,W&UTHCY"2QQTF,WH7&O3/YL66=JKJL)@8E'*+ M)=C!N?;,"TT][@#S*C% $X-T5ZH[<<(>[*4H=UC;O13U?NN^ 5U@MS#L0,]K MB\8Q&![!@G(4LYK(/=,A[+3O.QQ?.N+WT]67ZOB:X\>JO8C@MFF+K^;YLVTU MW^]Q;);K"162(RY!5LH2Y8@)R,H.D.2THM_2>OUNZA7R4'\,D>?7+;)*?XDZ,!(W*60V0;D=/\@EUD MY]D%P'XLOA83!_+-",+D4)8VP_?\?H6N[MK0B9!0(4%5SDHBBD+FM.BVTI89 MR)3'NYS>;7E,U#P>XFR++'I^MI[N;G/YW-W!:^I8NYO/WGA//###?L6KL*Q& M*%=U "];GNI0.!2DG)D=9PG*W8PWBDZ>O%B_)+R8C5'6AW/J8;TA9V\7<@-;H+7@4Q^ZF#^K;VI M]W!"= _U8L=#[5D\HX<17#$.A8QAV//'F6-QYZ^BW1:0C]6LJK^:*\DF/$T+ M""7G,LL4!H)FM#LY4$H.@-MZ9I FHQ?I.TSF(H ]J+Z:Z,.LKQK&HC2D#AXH M_O@VQ0/)W_>T.0E?#];'*GE]3'I3['KSY2]SW>DHG0=-,B1!4118SZ YP BB MDS:I*-*^^N;25G1A.P'35]"<./15LN#DA90P&S('DJX3*$Z:Y\-Q'U(/.U_LX;8^V;TZ0,_[9""1M&'523V# MNFFLLAK6R#?U-@*G_:?#'Z;?VOP4%)AE6.0$IK(0(LUU#.C:+5+N^-Y8__9< MAKC7&??#+.UQARC4+-B:T+Y3X!A,AIW_?GB#V8$GOWLX7C-?5[+'*GG>]EC/ M>?V8ZB5DJZW.K8[U_TG!@.!9(0L.86G>7,&'.WH)!L#QDHX@30XA9P934NVB M2N\LT8?6'HH6D\]0HM;R>P)R!+KVC#97:?-E?<3JYFV2C<#UXZO'"K!)$ \K M**<(J.*( I 5F.2$P"QGO#MK3V">.[WF';+=R&O N[G7PF(LQF?8>V%W$'+# MK.RV=!_7=TB:UT5(L#ZAT^K ZR$',_==[/;_Q-NN=>3:_]UDF@DAUTQ.3FF/YZ% MWQ?9#UK$>K/K;0_8Z>2%R'>32H\WNL;Z,-<9R8S@BG&H M9@S#O!_@G/=2S:'H#JJ>!]!C>(_'G5AW00WAI5$+:Q #[00V')?6UW?N MSLJO;QLZ^^]MO:J>W-U"E_/C]2U%03.,,U%@CE$!0)8=E3Y7@+I-VP,V''_+ MC_[^O9X_K /?+Q62?#NE'9IUO]M ]R#-RV=[F(?;I:YVUTM=M;1?Z(XI>Q+/ MJ&D$3XQ#16,8]OPJT5C<.5QZ/*NJ^5IIZU^X\NH) D@@$HP(SC K05% AM"A MN(!RZK;J';+EZ(O?'=C$])+#B>9ZN:D6BVJVV4X7!S5MQ[.?M,:Z!-B6YW.# M/(*W1C+*8UCV_8W!D=CSSHZZ0\;56F=P-WN9'?9J.GB&U2':'Z]=7[:NU>J"WM;WI'F//S*@7\9ZY473&@V5' M1Z17[0.RFOQVBDK?(G^8_.@,D2X94@A_C$0]HYCV5I84CC_?/$E+]J_3S795 M;[[=W/TZ7?VSVI@%F$_5S'S/E!/+O&1%@4G&L<",*H%E=UD;(4"FCB]&!&X] MXYHC MXN0(^;*)ZIN,.J2KX;PS$MF-9]\;J6MH)GL(,&_:R5?[6M#[9O-D(1Q#DB*8 MYH5.GKF>*4L$NK>V*<*8]%3?/DT/*KU+ \[[*H;0I'M+ZU!\!]'5(UBCK"W< MBVW8<>/235%#.&6TU-!R'WI6 Z^5&=^I:M[@_(4AH(72C!2R*'"#! M:9[CKETA6>IQ56'_1CTF_AYW%G[0_\Z4ZXY%@),G(!?UK#V;>U>Y;M\)P+GG MS#\.S\&F^T=X%SGG_"9=+I-Z;ZI'HH'A['EK^MZ3*9^44=3M>K1.7$\N6-3) MJE"*PKQ@:2I+)A!'E+"NY9+E3GMM0K1WD7EY=S-K6^^\7'[R"F>624E?QDJJGNGH;(IV$X*X( 7/ 4M-AD-$RKM;82@16>F1 M:GBW-4R&<=C=7R_UM*P#N%]A6.Z_,$N%7_7@="Z'^1-MEU_$);??<0E-Z!%4 MNVIPF;,1S[DYHU^]Z1R':/4WXY7C#CUYL7]=]97FD%(EYQE*2X%9H3 "97?\ MEA9 %&ZOJGHV$CDEZ'#%$21_:NT$:1!6W03IE-"+"M)KW)P1I-YTCD.0^IOQ MW;.I07@)?VA@(AA39K^((BG%"*62FJGJI?3Y>SE PFI MI#)33"*$,J(RD)>'*_$8@)G3,Q<1FH^< *KK]_0]CW'@JA?GO51S*+J#JN*N+6/6]7[T-7?FV>1WS72YGB">YD)QB5-9 M\*S@>4:[7<"LA(55Y2Y(0Q?3H8UY+GQA,#H\;-N;UO."-#BC?43I^H1,@\X\ MPSXPFP[O _)JM]#O_W8M7O']PT67A#UH.2-X"7>8*8T$3J76X+YL7K<[QS9 M[XWKXHG(.8)(\;S(F.1"8H(/\01+PMS.IWDWX[%@["KNM4[I'\WATF[O5+/T M23#]F;1+,.-2Z*7E1TC'3;@723!?X^9,@MF;SG$DF/W-: )W,W_]:6\@?= "C25&00TNY8%I,98KY5.;=6!IT.SU?3/\T@6U5?F\574UB?GQM> MH0EU+\[%X[+/1+A%U9[$;W%=KC[WA![+ IT?I>.0I0!VG"G1]6'&)X5ZVAY. MRQ*5)<^A4A2GIC+8[>3C&4:.5Z?[MQ,]=7H:[RVE*'JDMQU*_8D=QU *8,>9 MZ-Z'&9^AU"80(,<9X:F@)$L!*4K)47=HA@,]BCWVSCNWX3%Z?$[EO3C[V#U9 M6B_-0*KF;Y]?"<2J^^PC'),!)AR7G6 XS"F<6!N?R+C!/Z,M'CSX2 IOEE^K MU<8?=2^JE^;S^Q9BG1EW5YXH+ <0H1-<%Q:D9PQ9:I,OK^.3*6]+SBA6 M/W9\*AW=FI2Y5W'_^/&G33/[)UW.=]^H] _;[TP8S"E&3&!,%".\$%QV91>> M2JE\RR !(42ND7S:G_JEOW[Z3_.JT+\E#]/EW/3(>O%-3U#F5?707@3UV!F2 MK.^GJSZ;FD+ZQ[VJNE,S=WAWVJW-RK,D$,,Z P@VF10H(HE:K;.< Y!;C'73/.;0V3 M8XIN--\=MGO[7RCCSJ>E?$;EL-_U,5H2CSOE6U27N33F.3?G]*TOG2-1L-YF MO'(S3$]>[':,[MJZ6>KTU!Q$TE_KK];UO'T)JEE.\@RG*"\EH"PMRQPPD';7 M;0D*T]Q!BL(T.%!Q;0?-PV.U7+< 7CA"-4$XV!6M+ LGTS^EJ[IB[1G:(78(['E^XA9<=;O,*=+)' MOK]\UF#_^;,!GYRBOWKQ5.FP"7,OKL]DUI(3B605/_ M5L\W6E'^/$)OIP,GUT%Y58"C>B>>'L.?>N0@"F_!]/O36W!&Y7WW9K:5RDBM*L@$1* MA2'G,"^Z5CG/1)]':%S;BJQ@IPO6NQU2JV_[I%&GD8=<9G-?)=7#XZ+Y5E7) MNAVAAQU7YJ74?L_3.//OH7F1J>^E>/N-'1VZ2V\->($K6[GKP?((Q:Z/-6^^ M)-N'I7Y[K72>^- L=^WJ%@N>99@!S '-.*2=> MW24L/J5]1.R4VQV^2\O8BWPY;V;RX7I\4M;3'JLM2OY,N>]&:EOIFMYM/:"2 MIDQ_-"4,9207JLRZK?;"/&;8:T>21WL#EP*?)6MU,*GKQ;E;P2\>S[UW+NUF MI0>1N^CVI>])LMK"U(/;D0A:$%->W->9&UK>&9DIX6@(DB MA<0H!656*@DIHB([++_ DO81,L\6AY&R]H;=S]MO/S?;S>Y"SJ79UZ0_=6'* MY_529WS5N6$7A6PW!8M)<._'^]X_)?3Z34(CO]WW$E462M:3XW%I65]C7GVR M+P!'X6]NGZ1IR;)4":$R)A1$6&MJ!X (C@.\>N'3K-.\L\>K%\>7+D[?OSAN M* _\ZH67!^P$[T+DNXF?Q[WM8[VL_8PN1G#%.#0RAF'>E[([]R_'NKIIM M;N[D7[-[W76KCSIYNED:3.:1:?V'/+[@-1%88H(8HV4N\@S(#!3@D(YR[+:I M,63#L9=96ZPF)[QK5E7]99E4>]3)2L-VW,88E'$[M;P8V6YZ>>2Y YH8I.;2 M#MX]*]=^(2V>E8NS)=&!R',[$&/X8QRB&<>TY_L+X_'7,^G<[5'?:NF^>=SO M3U]/B(19)HCB*2Z8XB+/#X_C2DHX"Y!U>K4;.^V4M\GU>_Y1TD]2?Y%P^ND_ M$_I>[+Z0?__M^G?Z3KZ__10DV?1COE>V&9WTH.GF$6URA#N*?/,E'MT3SE[> M&(=X1K',+N4,P)ZM=+ZLTU3#6JV^:0"_3Q?;:I*5!4),Y!@"D0H 2GAX(5.F M5&83#;-NYI\VT]7&3CK#M.LR?I]#M*]%OB:55PF3OUR_?V^>7;M1R0?Y\?I& M##N(K6@\,WS#NF$< S>P34W,CAMCL.9ERDI09BPE& ">4UYV%ZG+'()\/UCE MTO)>SC"MN@_5#F"(@2KU=_]7#U%;^G^D(6IMD]<0=6/,=HA^VCX^+JKV4/3" M %"+YL_KY5VS>FC#^.$Y/P4$@QF%*N,H([C4@M%-A"1DI=->JU!M1J[>;B_=\6C.5.ZA77!CZ3.2;/>4^G([#OT*8\JYG:3]^+&Z3.I3M=GL M1%*9)NA\7N\J+1C(C'$F> X%+,HBSXI#9H@(8I.OU>IS8W5_E'<;+F/I%(Z; M/CU.:U./W#3)W[?317U7FPLJ#Y"3%G-[5OFATK^]J+[H#&-]^+G+,YK^9)\7 MKN%8=DS*GK%XE1Q0#<*:PY51@[#G=U64#XMV5T2]9O0+^AV&I!%<"=7?AB9D MM_&7ZFYGVX275#<#,LZ+G*=4L)1W>W(E*Y35X#0R11+8BO=\'.[!,VQ/M MKM)1..XKTAVH(2CSE^@HU(52Z#P:4,WJG=&?8_OKBPBTW=T[ MK\VU2Y^WNYLK@FAS?YXM1'I0BMW4>L?NX1"#!I>TZ$Y"X;!T.@CXH+3Z*7DO M>NTT_2T67A/W8.R-0.7#V=+$Z%_N"]*FMFQ.$^DOKY=?J[6Y%I8NYR]LFQ;U M>K9HUMM5=2Q 7\S=V*0SBSG$4P(M"OVS7" M=@/NS1U=KZO-NOV^QI5-@,PA5P56/$.L+!A+\2$UE9G;_8-Q$$37T / )[EA MKTN[(OG"3D$O[P8W.>WF\XVIA*XVA_G]">:KI$7=OK[;XDXZX .?W_.A]HS4 MQG75.'0WLHW/3_<-P*BM(IM'O'=O>J]UTS>K^HM6E(7Y+GUHMLM--A$%XH3+ M4BI48E,=SEFWPTYQ 9PNNN[?6F2E_5@=KJS6XWAV\I3]NEK6>O2OMY]WJFON M45PV&YU5!5/D +ZP4]]AW>"FM 9%<@1WE73P$O.3JV2'<%A)?9.O,_(9CNMQ M2&5 >YI8O=+Q:%;]95G?U3,]"=635=-2O?SRH5G4L[I:WU9_;=C"7%=+&%(R M+;$JE$J)AL%*I@G$G*6I8@5U.IEEUR1K;\?E$!LUZPRMVK=3O^:*"*)S$F:L1)*#G-!&,@1S0NIDU"BD,?- MLR&;MQJPO:^AW2-.9GO(R4*#3'[ZHN'^S>,$5U#^[?1Q<,Z]1++CN8.9G.!, M#-#D)P-5<_ZY16O.?@TKE@X\GE',&-X8AVQ&L:R)WY?=!'1W+,VT9 ZIF=(Y*!3CKM5#-,FQYZZ2:5 M.V#)3]5TM=0A;?VWG5:V!S:WYJ[IM0YR\W8ZK>?6ZWI>3U>UUSG80$ZPT\\! MV?=2SOU9V)T\[MC>>V*',CF!.:QB6C%W1BO#,C\.E0QL4Q.SKSK>7?MB:^VV MU-O[Z?*V>GAL5M/5M^N'QVF],C^;0,@44&699@K!HJ J+SN)SEFN,QRK8[81 M ;B,6J\SN+LMUQL-+]ET^)+Z -"4)JO=8*X/%@U\QZHSJV=&=$07C6-XQS3P M^:VKL;FT'?COZLU^^\UQN_FNCCKC>K]N33;TOSN 9K5JOF3ST9X=/'Z4S+I:JJ"0"LS!DSVP$+112$*!-= M\YRDT"WK"-9L]%RC?<0JF:[7S:QN9V%_UIM[/3-K7R$YOCJB,\B'^A+3!5LF MWUB""^J,<0S/\&:]L" 7@3?;H=LF+>^;9;.[ZWCY93>/:?>NK:N)*HI<"H4 MAZ@0HM B00YI2TJ%6Q;1L['HF<1N2O!0KV?50O^@:K8^)9*^E-IE%4-PV>.D M\"FR[LZPG_;@_C:LN)UGZHRD!:)X'$(6RI@F2C=TWN'Z2GL%SS.2%20' J4E M):*@/$="I$"R3&'D],"$=RM.6P;( M"B@$P9PJ"7@)!>%.V\2] '"!RU*S ;B@$.6\+%,"68F*$N?ZS]@O8'V4GVX_ M_L9O?_MX_?X7M[P@#M]VV<+%J7;+(9[ ;0\M[0&_=J;[8OMX?(@]HXY1_30. MX8QK8C-@OW?<_U,OZTWUSMQ(?+W\^;A ML]D%73?+VZG^[0F'$A9<_Y<)@+!2.6*RP(B4 @.EL-/VR!!X"H)$5I8YPC*% M@&I/_;DM2P,Z=AS185"+GV]Q&IQM^P+[UVJA M)P?SVVIVOVP6S9=O'^LO]YOUK]7#YVHU(3SC>8IDC@NA",UR6(J]CA0XEZ5K M7?U\:QBA0M(",(G;30Q,0LZ% (SF*DV14U[H54X_ $R."(DB6KFS1_GZX;2TZ8CG7_\EP\5_.-S;Z$[2^0PF M/C]NN<@12O+'#HQE5NC)CL,MEE%9\KNUTH4MNTLJGQOY@I#V(V,$EU#Z8V]" M= <'2:2/];I9[#^_Y Q@10 !#$%&9)H5N.O+2$NPM1P^^=0T5X2#M "8<:B4 M'BC('$?3"5,!N:(DLA32QX4!XZR#;LQ8:& T4MST;P?#1_O<&''0O6C,^&F> M+4-V>G=JW&M:YT7 "'3.#W?3U_4.^O9"EMFM9YIIWK+2,[Y?*OU'/=/?NE[^ MOVK6WE.P1X04YI*(#&49TM.O F("]KT<(E) :T7LB0,04B %TA2R%/(2,4$X MXV4ILP??3)9?WPFRU<[5UT]]=15\KVGVEJ<1T"([3&'$#(BS_D%G2$\:!>P^E'Y M6H@;R$$C"(I#6=H,W_T#!-X#G%U=M9KO(5"8@9P0)EF)*,Y@5NC_VXL!+H'5 MNI=7PX(5BE&,"=(*A+*"8)4J";(<9CD1,/;TY*70>A)6.[ A JDW]3TBYQ"L M!PR5)R+; 0X9&+T]$" 2#N&)"*'/RR/] MTK3+E&MKZ$CSB4]3;-)G:%X<\J M6+&MN459]]E]$P4"5&50Z FH8)SA,F5=41=*H*RVP+WXP3G'F6*H++F&BR2@ M4O"2%ZP$1 # G)[\] @V[Z?K6?-YZEX,!.@)<4IEWTT@4D0)(0JP#+*2B)++@G6= M7DF>QZB3?0RBQ; (E3!OMXP@[ UBIF<-K">O]L_VOH"I MF_*7+.6I8$10E&54*3WPNX'.*+"/F&^TD\*4I@("JF=)$(FT)$2P7,J29(PJ MP2,'Q5T@=-K-%YY*B]@V((MNX>MU GU"4U\F79_D'8;1/@_R^C'K\![OJQ2\ M%A\"$3>"$!#*DN]>X@W%CI607R\_K)I9M5Y_K-:5_A?W=#G? S"=3KN=O)MN ME[/[/01S;P,7&&"1H[S0@01FW+ ]3+90TTZK(D& MFYR@/>7=)S@$=X!#M+BD(_S"1W"'V,441Z)>"S*Q^!Y!U(EF6C- ?PT:E\HG M$$"6 \&X2K%"*<,,J'^G-76Z.9.1+0/D2DE"P$4!P>B@I2V1^R>_[! M',LTS\LTR_(+* 8Z#E#ES8Q$K8M+B%@L.2'Q4 MWID:!Q6/29&?2CM09:>_STQ\35]]F1B!?GI#;P+TA*!Y.7HBP1S %#&*19IC M2FEF7HON.GJJWH<_ MJ[CTOFK6F_K+0[VL?J^GW9E+@DM!*&(9%"1'$A=,' YAE53:9^#_=N"3KGH19A)'X7+D% MBQ,\B0'D$PT\V7+0_/BL^2F[.WMVTOVBO:\)=#]R1B##/0UH@G44EU)')R^= MNG15%*%'I6K!BC *L)RS2 M;#XGL7?UG/;XKYIAEVF^+V4VE9 !V'*LB'P7?[Q*([Z1EFU^MG?2D: 0BV]N$)F"7<=U,^48.W1T/RQ '2BF&S2!@PIRI/&0<@J=N M&ROMVM0ML8)@(CB@$.D!B4N%"I[C5 +]K=A9[FXGVZ&>XKH?,!"O%@)](4K= M-'O/IL5TW7<#9B#"73=C#D]\GXV901S@L$_3BIVS>S;#\CN":!'#JN_V[.WS/7 K_3\>UZ4SVL)[C,1"ISFD%4"II*QHM#^5+ TJI.[]6PP)1Q M3(EDLM 97EGJR71*]+1%A]ACB M'G +1D')CW)/L@N1+\AG5'^,XP;E.*8U _1GG^0484 M4%(03KOA"W26X_Z^Q1L-\A)#QA 3("\ASK,2PEPRK1NPH%S(V+OB?Y\NMFWZ MC6G7ZO5]$OUV[JZVR[> MU7>5%@)!=&*%@$I)FC.F\ZER/QI1#NTN0 \"!!8P@T25698AR+.,92F6"*F" M<4ZEBI[C/#2K3?T_NU=&'JM5W?ZT6]Z4[%(<)SIC-EJ3-DDI<,9@ P"%4J]?^SPBKH]OG\R*-W MCRHYP'(HR/@R9E'M&H LM\G$=SSY5+!\"7.H5@U G%]ERH- NPK4RQ:_5FWJ MR<\(*DM]+6C"]18'=?U4;3:+RG0;M5W.UQ^;Q4(UJS^GJ_E$8H@H3+%2 &4R M8_KO>=<:$]S^HO >;416V;]OIXOZKJ[FR1%CTH)T4(\^%%I([D#LN@OP.QZ*?!OFS:"?'KIK\FQ@'(&H$@A["B"=N%_(5Y CCB MBBB$ &.0($@X@ET3$I=TLIOB?=I,5QMW37[SXUT&P7,DUN. 3?5?9Y5Y,[.Y M2T0U:\-> K(KLXT8^JO*V^RY"W%0ROJI;TQB_#4V*$%AA#6LDEK*IS4/X]-, M>^AGA-+1?A]UI/-Y;3K&>H)4GBK]'Y*20@DIP87LVLH ;Y)JWT+D5-6/EW? M)]J5FU7]>=LB2C9-XI'(>G7Y PV6?=^=MO$- @\;SHP&7T9\AL6'Z3?S]?JV M^;"8ULM-?7?'F^UR72V4MOC09YZ/5UCDA9 IB '&:"4DOP 3'];39;5%_,> M_:W?4(J$RFKA&N?^-YN-IP0C"CA99H+F>&<8I#+[-@.MK\$R^O3(Z>[+0A_K;5D MR#W\A2>G;S0;ABG_(!.>L5 QXSQS7MK??J2EE+L1,SYE=L1_1FA]F/ JIN8" M,UZ4*4^+C,F"Y%B*K@F:961?3)7+N4WAWZN#N9FO^UFN7?->LT;G94LOU3+V3)U2U#J!C=\.EJ]4U_T^PYKR:,"8ESG.GF >*9GEV5 MN&N[A$C8+X*&;7?4JZ,#CL9GO#F/2%_>QSPJO6VR&IG]&.LW.G6H_5JOS3Q0 M *(R18H\0S0K\K)4@AY2=HC%Y&NU^MSTRS'L6W,9C:? K$=BMX:C(^+L?KKZ M4EE6@X/1V2?%B,-CF 3C*CF@&X.<'< X"YD[R6.6, ]KK,3+ER6K.?\K3?K5 M9MA[+HD.BBX_YTKH\/ZUZ)"/#Z?AM;F@=9+A_6L M0T5[M![VJX0/[6F[XF)(DE^K3%[$D2,H:U[&[N;20RABUC A&:<%@45JRB(% MQZG@>PQ(?TL>-DM%2 K>;-LC\$>(^1&5_VWV(\3M,+0/&9LOZH&(\36H)P:- MH0/'R%!QT)KP'S#6V=O6)YXY,ABV?)XJ@8&2.10(@IPK2K*\:SL7-+5=]@[; MZ@^T'OXCUX+Y* M#G?\78_+.0[)Z#B51G.677KJ3=UK>6I\7XP@81W R&;0_NWTD,_&U!+: M!:%Y-6???EN;%F\>6Q#++W2VJ;_6F[I:BWH]:R/YMIKO?ZS1TL_KS6HZVTP0 MR N22UB0#*9<"D$)DH!#EJNT0 H[O/TS$*+(^^':$LW=HOESO_8R/T&;-)TU M.IIVYOR[TP,Y0[G-(JJ.TF-N05:;D+0.ZXQ(V+?D)V.'UN:_)0=3DJ,M6M9/ M/7HT)_FC,\CMR:.A/.KT2M((/>O[L-*P'K9]EBD,P:_%[\$=.()P/KS-S26' MC%N]2C?ZV*RGBU]6S?;Q>CE;;.<:U(M0#I#UKS4/E9G*3Z!(,\H!S*1$%,L, M%3CO0&4EDBX[VB-#B1S>C9XL-(YA*UC].#M3VAK(&>.H>0UE;'.1#A]-$$3U MN*IF]6YRLIR?WG,\R3E*0:IG)Q IS@5/%D P)P!A[,Y$5H?YO#-!_W]^^FZ:O[!7B6/!FX[4Z@ZP,-.$^R)/#,5B."-<:3[,0QKHO=DA[1=;E=-MZC\Z7ZJ M._"'Z:I9?=J8;MYNNOI0K=H?3+CBH@2 (BAXQ@DL]/\ JCAC2F&&K2XI<6TS M [ HTUPWD /(2L(@$EC_#:4*%RC/(J?>!FDR[S9EK%NL>LQ.5\E7 S/YR63C MS6(Q7:W- UZ[W_B;0ZX6DGZ+_/I"S+MET"WIAYTPG_:D:Z!ZN"<[J$F+-=%@ M=S^_$.,.^>^%F/?+<$-ZP"Y[M:?GM?PT L$CR$!C6-7$[9:]@L_N?^EV<]^L MZO^IYA,,,B)2(IB"@ JB,.#T. 8AZA%TOFNK)"70Z3#-RE)!R3-SOAVG%!<% MT=\NRXL$F]V?R?0 LY?6N?/K%56B4ALBFNS^3.BE6.T5.:*R&S)BV+/L&R6> M4V$?';Q)'&54\+?F?#3HR5*O*'"]7F]UB\A\>,XIEPC10A*L*.K&DA*(]HX M^W:X$"E/48IQRB EJ7F8O.1I(9#B ,+8CP&?5?^ZA1A HVPY[:'Z$>@,J/C7 M0S,90.DC,!I!Y=]@MI_"[S[<5=T=B1NQLKM:8J/J7NS85H=Y\_#0+#]MFMD_ M]8SBYL49!HD>FR% 8P0!*(L2U,& M3V69JSR56>P'HW<0D[7!&*J(%)1NNUT]0S/M)OY[DC_M2 Y2L@A39[>@[4R! M/23IXZBL![6HB==%O67ON]29RY(57.A\.>.R0%G*R\/XRV'FM"7Z7#LT+QC' M*=0920%YJIC^7ZK3%(8)ST 6.Y%]*G.>Y8L@?#KK650J^^B8]T0ZN'993+A# M$CLZK?*WY'6-ZLF.MS;M$\ RPT4FD,20)!%Z=4X8 MBLV1BH^K%6\)CQ9GRED+Y\V,K4Y]F]]5\NZAN[M2T7K4S1;I>5YLU M75'=5G]MF";GGQ.D,"K, MO5028)#)K,"R@&4!F$X.:*FDVV,+8;$Q@?6,"WFQ\71CN1A;T@RW21WVN)]F4R/^U5G6/+96.8F MFP.[V$YGQ^M;-V'N[#";6XTENUK;54*/+CXQ)^GL,4X]6)2T)B5_M$8EQJJD M-6O@5ZR"NN1,%+B,Z\<1-BYD>S.&P><6F [(+ #]MFP^KZO55X/K>OFXW>@? M:W_H?]4N\QVA4H1HCA'$4@@FRKSDDG3B)7/,7?+N* SA 1CDC'"2J@S6L*S M(H>0F%4+J5#T?/U>_ZUJ;\KN M.WXXV&Z_9EH9]7U:)=59AUMU9NGEZ!Z!:= M+N-GNR U>A>[Q:K3^&09E*Z24[N2UK#DJ647CULQO'0F?%VT4XPCBEV6@F9$ M@]0MIM&OTWIAVE;-ZM-T47TRX%K QY8)1P) *9A45!"2 9;Q3KJ$PE:GP%W: MRU( 4\#3DH(,0@Y()CE),Y)1DL&"QBY0?]H^/$Q7WTSZ/.W0_JPCSL]KC3=9 M'P"[!94@1-O%B*$Y=I-\^CVG1X 75VX+[LX(<4CFQZ&K02UJXO53STQ^-\[%+EE^RHY M17MQ$?7@U":[C>"A<8AL5 M?RTVCL>E>Y^=FQ^7GQLS5OU9TM3(S_K9?T^5< MPYJ]\N-;_=7:W+2CI_IMCY]DE!%X2E%K=V3N/ SW5.@*+094ZHDB["[0C62,59UE,] MK"<*"0%I(=)4$(8X0D1WDSW$-$=63Y]=!%CT_?'!R@3&IJ0URK$Z-*RC[>I" MH_6Q6Z :V+V1MOJ'<\79HP$7\/@XRC^7,?V[HP<7X]]JFO"NGE7+=76(?;?5 MZD'^M='?,R\^;'<[#R<BVFX]8$?+:U"0LFR.8I00VJ(G6\QPBA6EH_VCTS=VA^??-1@/ZT KB M)!,RI1S#G&. LS)E:9H?9DR%L#KX'ZJMR#'B!&&[Q_(POI8M2/<0$8)>B_@P M,+-NP>&4U)N[$]':X4L^7()4AZ@P,+E^(:$GR7;AX&TF7HL% 3D<02 (:4T3 MIZ?Y/=*BFM7'YMMT83:Z3BCG-,URF.H8DYIK_E!^F)<(0%.7,I17 Y'%OL/4 M'ME:=:CFV6;[':[.26!.2U 7F14DI*SE+#=[I>T MX(0!I[OOXB 8(F>J?^:!$GIY"3'>:KY/.WY #[XEOH[9" M+:>KI6YWW=UX>G)W28$5Q7G&N0X*C!=EFF*@D\^<4I2JPNELI7\KD07WO;Q- MWMU\^I1\D!^33_])/THW->U!GYUB#L.-7UVZ0K 1">X!TL;1?A=;:9++2Q;75T;VY2[^TUCXX?+$Y.34Z.-K>9U,%JAZK? M:*BW*YN7OR]K5]/CWF M7N-0<1X-Z/AUZS'V(KMB^%!.>JVD/KI.,H+"_/@X:<8\K'U+>N8>H"]+_J:KZ_$F]OQ=.K\?3/M#3,GZ%4O'V4&D(*TU0RP$I$.Y0TIT[7RPV- M;=#TJS-(>Z2SZ' I:B>-SV]'G>[,\BT-#N1AUZ+A^)SK7TX\VI(EN0J6G M?CV]?6YOT8B*C$%\8E5^'-;[XYCA7\SZ5TN6E_""8S7!7"*R7T6_U@GI\DNM MV_X.X\?=S9STH5EMZO]I?W^WR/X\G.*T0#G/\K(LS"UW!&:\Z+ 6F%G>TWU9 MC"Z:YG5?]ZFT?>UL,W_9W%=)?;#PQ<#5W9$Z/3%SO]?*KT(P= =PJ@B,V//^ M%8"#4>8O1[.^BV=F;KX#6['W%/Z#^;OT2/<)VYAW7 MVS/U"SE\5#/S2W'P\DS\HAZQG7FS[;I>5NL=HMV]XA]6C6I6#]/KY9WYX^E] MO) @2LH"",R( @IDX&3^7V1.*[>AVQYPYORX:I(687OC^J%$J/_U=N%Z#61P M%]A-?2_)OELRT"%-3J!>)1ILTJ)-3N!>?/+JR.J9R6DL_XQC\AG-NF:87NZF MLONB['H" ,Y448*TR$ *<\Y2P03!O) X]>?WU6:WF\PL,$P(34L@BQ03SD0F($E!WK61%RESZ]1N MGQV]9[_OMB5,-YM5_7F[:>/+IDGDUVAVKF"Z2Q\5LV!'PA*LSP\"/ MTW&,!4_L38A>U6^_H[E/>*93?%$OMAOSJ+* (M61),M!63(DFI M]VTK5^PX(='Q_CI MFV/[J[ 43LLR(U 2( HB(02*YXB:K0,"X\+^QL#0#4?6O1.X@9YGBT._Q:K" M)9EWD\ 3I(=R[Q%K\@2LS^6$P=EWJ.A?T@M^A?K3(=#?&W9E=T>67JNFQR)[ M!$7R:*8U W16AT#U]^UT46^J=7@!T^BJH@ZXY M^C(Q CWUAMX$Z DN.Y>V#].OU4)H>JB'V6RHR4V99Z[45RIL]P^ M\H*UKV[]Z,/,"!2T'_XF5!]Q*8)L_ZH7]?;AP_UT]3"=5=M-/9LNUM?+V;_M M&\6"%5!D>59@ FB1%8RPKM$29\1!6/LW%EUE.XA6,FLYD7O+ZE>G;L'H&L'0 M"&A,$Z5+N=P77-W77^Y_GRX6U;?;:G:_;!;-E[HZ;56!E)>ITF-4XCS#**5% MVK4J! (.HR9 :]&'S0YCL@.9G**\,L<0_^UT.+GL40[!M$42,S#%;BG-F]QZ MY#@A>'6Y*7A8?CVO">[-L^4MP6^2\5I "$CC"")"2&N:.)W-[ZFI[NF4E'#" M4SWO%8 42J&"B,/,MZ30(02X?WATQ3]]V>=?_R7#Q7\$3)F^L_>U$>%/S @& M0 _PK[S>X\6!5?=N;]XZJ86O]TT50@*8285+7A"J>%8>FY)2(H=.[MM$]*[> M NO9HU\Q[K5^W9>+$?3NWB8T ?N&VZ:GP\OJ)^/VXTY\+F@JJNGASA[NSZ_[N[MN:V<2S]/K\"C]U5SBP)$+R\3!6(RTRFG,O& M24]M]8-*D6E;.[+HI61W/+]^P:MHQY(!$"#IKJYV.8XC?.<[X'<.#X #4*V$ M-Y95VX%D7M8W#E36@:?F#;B[:II9$X6Z^ARL[K?5-]^R3<;D1=_+(O+A:!QZ"-$1!"A-$ M>#WTE[0&#Q=4#2=+J-'R!%FRAS"I=$DF7OT?-EW MXX32@?/F3Q=7A_+A+LA:\91VQ&W EI7J?ZWW-S]AW#T%N7MJ4FOU8_59"X0C MGJ2<10D*2$!2GJ;=,A-"[4F]J%FZ)NMX\S#7<\D\(>TZ86PMGL6UV3L^RD8=K;5GSM1>+/I'Y60 M-LE\F%D8FX:#8Z%K0H^X#E='H'Z6#_G-H,= :^C7CUFIL< MA"QK,^-M1RU[-%@*7);],E'LNLCV^TW=3GS!"!)1Z!,O@@*F- R2*&X!0X+3 MQ3:[+D^+31*_=( J:6%2:V'?)NT8MJM 31O"M#PX21"S[KKYA;&>B6\ZD/7L M&"^4FUKL=SNKN1KR<=LO_ XHAR3@,7(HS!)XR , M6L0\Y:*-:%\G>RW3@FL0U[[JOZ!UD,K./[^6_6G^*R] ?K\O*XOG67F>"DT: M\?1 S8\)MY!O@'=70UUOE MZ\"3R_^]W^U+[ M!4X_*_Q@E(0M1'/J\7:OC.%7KSF1I*,.\1818Q$3 ?2]B*?53&I/NA2,.4C+AJ_+Q?Z@>__(.N:*YH3=KD$Z:Q ]Q^R0I_4@>GU&"7UH,?BEM_O5P\:K\ M$7]M_KR%E/^X.\=[ ; PI>81WF;(B]N7 VN>&S?H_@R[.H5&\]N[(KO)MKOU M0];OO\VY)T(_%CQ)L!_Z(DVZMQ[AZ;V S-( QZ&87UUEJZIL5MJ0;5>/8%^^ M56XT&LO.FK]1(_&$OI\Z*!^+Q!4!X D#H*:@^>VW&*+U_.P\6CN:=G^FP.V* M(BVEV2U*K*J?8V($.0H#1'T$HB21"1!M_^$ MIHEZ<_>9X!WMF%JO5K:KKF?H,&JT(YH):2JMHF8"]2T%Y-Y;NA-;/)H]:;91SOO)![S7%NS*!SS-P8R>?[) ],I.SL=9+(ZY?W M3U>T>77_>GAS7Q#*J9<2DL8"BE @A.)N826-$JRQKVC>AHRSX^CS\O&0;)UN M3?66)H%AZC4+\.,G8_^RO ^WBJ=-!>[3%6A) %]U*W#S=M30G&T61DR7Q,:^N!*H^?-LK"I8X&*4K@9Y' M5'4JO=^MM]EN1_/;[^OZLG*VWJTV>0G\:_9CGTJ>_[V( ^%!$J*$,)XB+PX0 M#B@1'-$P"7&J>"N4YJ"^"!%*A4A\3C!'9:L^+%(((44L]. (EYC0__[V_N+] MU_>?/E[H+9S;HE5MJ7L"/O5>OUJ H(<0'"""WTN0H$(YI.R*]E[N>A MI[:-RIW.5SW%^[#>KF_O;YO&URB-8B8S/D\.D20X#6E"I,Q"PL,@P%1KM]'3 M3_;2&,.0X0@AC--8*G;$B!\0+R%A%/JN.YXT8/1D2Y,;-75R1XN>"#4XM*\? ML2,T3U@XH2=F;,U#-@RQYS;FBZ8(+'_TQDB]D,8>HWY,D)<&%/(D;B=Z&%.N M)0)//CF$).48(AG3.4X\0I*8,QJQB 0H\2%W+0(U&$T1T.-&402_'(PQ!EE,(HII%'21T*PJ:&!=83YK_JBG*1:I5M.;:5C6TZ(*(ZA!@AHEJ&&> M@1KH&2 J]_TYT2IE!D_HF'TOS$/C'-B5NYZ_@^M"5(ZVEL16?V@/JA?9)9=@ M]H_OMU)BLMU^5X,FV\ORF[+4M? "WV=>ZA-!*!,B]M,@:1]IF<=II5+WJ M##PQ!/0L.0.-+SMC6E4O]Y:T]DQ>V#)UA%[UR[F[YQ$")K'\]3K:2.P/"".? MB_Q!!J]\N]R\WU[EQ6WUT_=;&,6A,*8 M!WXZ)MR"LTV*DY*RNL!2':<))>$C@12BH7B/E5P;S R0_/. ^ MBPD.I5T"A;%48 D",YJJW=DUL!ERAZ\,6NL.(5A6$,=5H]-TG5 12SS/X^FW M94SN9"Y.F;F^WS[(KWGQN"A/H?"$B/(N$:IZ@)H0+PB9 M8&GB01PS3J@D-$4>]!$5OF?2\=P@-_WY26_P@=T^NWMW?S=EGJKAURD24\N^ MG%DFVEGWEC//SHC14DW]23&/Z#(Y"TZ325.O:&](KW>>EONM2C1?I"HO0A'Y MB(=>+,HK0P@*(0\:[2KW7#"CEDLOC!/'+);O[3 2(<<"DC1(0^$)'$'F<8BU M>E(;%-Q;+$!F[)G\LKW.P"]WF?SE[?YXTQK[;*I%@K&(U%/S7L.*&M<9Z&@M MH4VTU_YGCE1VS ]@=AZ2:,628[O7![.CFVKWEC7;"XT^%^M51C85S_+'?\_S MRS_6FPW_<9>MRG1R^8/5I_AJ!2(%#.6I P+1!*LM?_:0/Y:B%6!M\0(]CGXGH'+#B>0 M(4OFUU4KK_WR![B[+^YRXTKP2.[4RZOGYTG#;+IGR!EH,9^!%C60L,$!-ZB! M3Y,H6^%<(3T>U[?SB 3V7XD%9[" \KW'N3;ZZ]9<=L"DVG[[;I*O;]6"Z!1 MP@B*0RH"CL,08D1PZ"'$<,""F&.]BP\&CN4X$I3PWLE_=]O=A D.",'O%<;C M.V/=L*LFXV,2JR?,PSAUAD=:L>7X1@E665'6,EAJ9%7?+ M8O_X<7F;D1_KW<*#\I,)#*1J$E]^12@-FJ%P&D1:2:_1 (X5JX\)E*# [R4L M39$RHTY-F9RSIB='VH0Y4:"72#DA.X,XG(?6##,AMSBG]%3E2W;7J!BY+K*L M7MY^.CK+;Y?K[0(2"I%\^_(]CA+H(R[3M79\(E*D(S7V1AU??VI@F@IDD68U M69J&X<%:]1JY3M1*F:L3$F:?[WGHF@.[\6-ZN\O?;U5^;(V>D M_'0J/!11SX]#+Q!!-XC OM*1+\./=JQE#:!R_73U5XUN= 8C1$Z(G MS+Q^1-0*11J=]-Q29=;B3I,RM6YS/QGZ@N .9&0&_=D&@,^MS H-??SG_?>U M]/O^'_EFL]Y)T;G8K[-"ZHX<7!*XSG;GY[09GG(

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end